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SUMMARY 
 
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with multiple genetic 
aberrations and limited treatment options, with EGFR inhibitor erlotinib being the only clinically 
proven targeted therapy with marginal benefit in survival when combined with gemcitabine. 
Better targeted treatment strategies as well as predictive biomarkers remain unmet needs for 
clinical research in pancreatic cancer. This study first explores the protein and genetic 
mechanisms of primary (de novo) and acquired erlotinib resistance in PDAC using 5 primary 
PDAC cell lines as well as 2 sub-cultured erlotinib resistance lines. It then utilizes multiple in 
vitro assays and synergy analyses to examine 4 horizontal combined blockade combinations 
of the Epidermal Growth Factor Receptor (EGFR)/ Insuling Growth Factor Receptor (IGF1R), 
EGFR/ Phosphoinositide 3-kinase (PI3K), EGFR/ PI3K/ mammalian target of rapamycin 
(mTOR) and Methyl ethyl ketone (MEK)/ PI3K/mTOR tyrosine kinase inhibitors (TKI). Finally, 
the study took the two best combinations and established its pre-clinical efficacy using two 
robust in vivo primary patient xenograft models. 
 
In summary, this project found that the PI3K/Akt/mTOR (PAM) pathway was over-expressed 
in primary erlotinib resistance, and was further over-activated via the downstream mTOR 
pathway in acquired erlotinib resistance. This occurred in both genetic and protein expression 
levels. This, in turn, suggested that combined blockade of EGFR and PAM pathway could 
possibly overcome erlotinib resistance. Indeed, the combined blockade of these two pathways 
significantly down-regulated downstream signalling of each pathway more than each drug 
alone. Erlotinib (ERL) acts synergistically with PI3K inhibitor BYL-719 (BYL) and dual 
PI3K/mTOR inhibitor BEZ-235 (BEZ), with superior effect observed in downstream compared 
to upstream blockades. Of note, treatment of erlotinib resistant cell lines with PI3K inhibitor-
based combination caused significant G1 cell cycle arrest, inhibition of colony formation, and 
15 
 
necrosis and apoptosis, more so compared to parent cell lines. Erlotinib plus BYL (PI3K 
inhibitor), and erlotinib plus BEZ (dual PI3K/mTOR inhibitor) were taken forward to in-vivo 
study. In primary patient-derived tumor subrenal capsule and subcutaneous xenografts, 
Erlotinib plus BYL significantly reduced tumor volume (P=0.005). Strong pEGFR and pAkt 
immunostaining (2+/3+) was correlated with high and low responses respectively to both 
erlotinib and erlotinib plus BYL. 
 
Overall, the research project has been successful in demonstrating the efficacy of co-inhibition 
of EGFR/ PI3K pathway in PDAC, and is leading to an ongoing phase I/ II study proposal of 
erlotinib plus BYL in metastatic PDAC in second-line setting. Importantly, this study captured 
the principle of oncogenic dependence or addiction. Despite their molecular and genetic 
heterogeneity, PDAC cells appear to have a propensity to escape and depend on a specific 
pathway (PI3K/Akt) in the face of drug pressure (erlotinib), which renders them hypersensitive 
to EGFR/PI3K co-inhibition. This suggests that oncogenic dependence can be targeted, and 
identifies pEGFR and pAkt as candidate biomarkers for further translational research. This 
may be a step in advance in personalising treatment for up to 70% PDAC patients with over-
activated PAM pathway. 
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1.1 Epidemiology of Pancreatic Cancer 
1.1.1 Incidence and Survival 
Worldwide, pancreatic cancer is the 12th most common cancer, with an age-standardised rate 
of 4.4 / 100,000 people. The incidence of pancreatic cancer is almost 3 times higher in the 
developed countries than under-developed countries, with standardised rate if 10.7/ 100,000 
in Australian and 12.2/ 100,000 in the United States.2,3 In Australia, the incidence rate of 
pancreatic cancer is steadily increasing over the last 30 years. Crude incidence rate in 
Australia has increased by 50% from 6 per 100,000 (1972) to 11 per 100,000 people (2007), 
with 2546 patients diagnosed in 2009 (figure 1.1). The increase in incidence trend is not 
simply a consequence of improved diagnostics. It has been hypothesised that the increased 
incidence may be related to the aging population, as well as the epidemic of smoking. Smoking 
in males peaked in 1940s and in females peaked in 1970s, and the long term effects are 
thought to affect pancreatic cancer incidence after a lag time of 30-40 years.4 
Most pancreatic cancer patients have a short survival, such that mortality rate is almost 
equivalent to incidence rate worldwide (4.2/ 100,000). The resulting 5-year prevalence rate is 
relatively lower compared to other cancers, at 2.7/ 100,000.5 In Australia, mortality trend also 
closely juxtaposes the incidence trend (figure 1.2), with 2248 deaths in Australia in 2009.4,6 
Similarly, in the US over the last 70 years there is a steady rise in pancreatic cancer mortality 
proportional to incidence trends (figure 1.3). Pancreatic cancer contributes to the top five 
causes of cancer mortality in Australia, with a 5-year relative survival of only 4.6%, and 75% 
of patients dead within 1 year of diagnosis.2,4,6 Unfortunately, the poor prognosis has not 
changed over the years, with 5-year survival of 2% (1975-77), 3% (1984-86) and 5% (1996-
2003).7 With the little progress in treating this deadly cancer over the last half century, 
combined with the rising incidence of this disease, pancreatic cancer is becoming a serious 
public health problem. 
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Figure 1.1: Crude incidence and mortality rates of pancreatic cancer, 1972-2006. From Creigton 
et al. (2010) Pancreatic Cancer in NSW.4 
  
Figure 1.2: Number of pancreatic cancer cases and deaths by year by sex in Australia (2012) 
AIHW.6 
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Figure 1.3: Age standardised mortality rate of selected cancers in males and females in US, 
1930-2004. From Jemal et al. (2008) Global Cancer Statistics.7  
 
1.1.2 Causes of Pancreatic cancer 
The causes of pancreatic cancer have yet to be fully elucidated. However, there are a number 
of risk factors that may predispose to the development of pancreatic cancer. 
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Age and gender: The risk of pancreatic cancer increases with age. The median age of 
diagnosis of pancreatic cancer is 66 years old for males and 71 for females. The risk of men 
and women aged 80-84 years-old diagnosed with pancreatic cancer is 10 and 15 times higher 
than those aged 50-54 years-old, respectively (Figure 1.4).4 As well as being a risk factor, 
age is also an important prognostic factor. The mortality rate for the 80-84 year age group is 
11 and 17-fold higher than the 50-54 age group (Figure 1.4).4 Pancreatic cancer more 
commonly affects males, which is particularly the case in developed countries (Figure 1.5).5 
Males are found to have 30% higher incidence of pancreatic cancer than females. There is no 
strong evidence suggesting hormonal or reproductive factors are protective for women. On 
the other hand, the higher incidence in males is more likely due to smoking habits.4 
 
 
Figure 1.4: Incidence and mortality rates of pancreatic cancer by age in NSW. From Creigton et 
al. (2010) Pancreatic Cancer in NSW.4 
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Figure 1.5: Incidence of Pancreatic Cancer worldwide. From GLOBOCAN (2008)5 
 
Figure 1.6: Incidence of Pancreatic Cancer by continents. From GLOBOCAN (2008)5 
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Geography and race: Pancreatic cancer has an uneven distribution around the world. By 
continents, Asia and Europe together contribute 70% of the burden of pancreatic cancer 
worldwide (Figure 1.6). Approximately 60% of pancreatic cancer occurs in developed 
countries. The age standardised rates for males and females are 3 and 5 per 100,000 higher 
in developed than developing countries (Figure 1.5).5,8 Smoking habits in developed, 
industrialised countries over the last 3-4 decades have been attributed to the higher incidence 
of pancreatic cancer, but other factors may include genetic polymorphism by race and lower 
access to diagnostic facilities in underdeveloped countries.9,10  
Hereditary factors: Pancreatic cancer is estimated to be inheritable in 5-10% of cases.9 
Hereditary pancreatitis is passed on in an autosomal dominant inheritance with incomplete 
inheritance. The risk of pancreatic cancer is increased by 50- to 60-fold, and is typically 
diagnosed in clusters of family with early onset pancreatic cancer (20 years old) 11,12 BRCA 
mutation carriers are also at risk of developing pancreatic cancer, with a 2-fold increase in risk 
for BRCA-1 and 3-4-fold increase in risk for BRCA-2 carriers. These patients present a decade 
earlier than those without family history, and have a male predominance of 2:1 ratio.13 
Lifestyle risk factors: Smoking is clearly a risk factor for developing pancreatic cancer. A 
large cohort study in 1993 of 17,633 men found a dose-response effect of smoking, with a 4-
fold higher risk for current heavy smokers (RR 3.9, CI= 1.5- 10.3).14 In Australia, the cancer 
prevention study by the Australian Institute of Health and Welfare (AIHW) found that both male 
and female smokers had a 2.3-fold relative risk of developing pancreatic cancer, with a 
population attributable risk of 17% and 12% respectively.15 No difference is found between 
tobacco smokers or chewers, suggesting that pancreatic cancer is caused by both ingesting 
and inhaling tobacco.16 Consumers of more than 10 alcohol units per month were also found 
to have an increased risk of pancreatic cancer, by 3-fold.14 It is currently thought that alcohol 
only becomes a risk factor if it leads to chronic pancreatitis.17 The role of diet has been 
extensively investigated in pancreatic cancer. Caloric restriction and antioxidants have been 
suggested to confer a protective effect, but the challenge has been the difficulty validating 
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these in large-scale cohort studies and obtaining accurate diet exposure data.9,18 Insulin 
resistance or diabetes may increase the risk of pancreatic cancer, but may also be secondary 
to pancreatic cancer, so it is unclear at this stage whether it is a true causative factor.17 
Chronic pancreatitis: Chronic pancreatitis, like other chronic inflammatory conditions such 
as chronic gastritis, has been implicated as a precursor to pancreatic cancer. Probably less 
than 5% of pancreatic cancer is attributed to chronic pancreatitis.19 Chronic pancreatitis may 
be related to chronic alcoholism, cystic fibrosis; but can be hereditary or idiopathic.9 Patients 
with alcoholic or idiopathic pancreatitis have a 15-fold increased risk of pancreatic cancer.19  
Overall then, after taking into account of the attributable risk factors of smoking (10-15%), 
chronic pancreatitis (5%) and family history (5-10%), there still remain 70-80% of cases where 
no apparent causes are found. There is therefore an urgent need to understand more about 
the aetiology and biology of this very aggressive tumour type. 
 
 
1.2 Tumour Biology in Pancreatic cancer 
1.2.1 Multiple genetic alterations in Pancreatic cancer 
For a long time, it has been known that pancreatic ductal adenocarcinoma is one of the most 
complex cancers with extensive genetic and molecular alterations.20,21 Chromosomal 
aberrations are more complicated than those of other cancer types, with losses in multiple 
chromosomal arms including 1p, 3p, 4q, 6q, 8p, 9p, 12q, 17q, 18q and 21q as well as gains 
in 8q and 20q.22 As well as these, loss of heterozygosity (LOH) has also been identified 
between 6q and 17p, 12q and 18q, and 12q, 17p and 18q.23 On the gene level, significant 
alterations have been detected in oncogenes (K-Ras), tumour suppressor genes (P53, P16, 
DCC), over-expression of growth factors (EGF, TGF, FGF) and their receptors (EGFR, TGF-
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 receptors).21 Some of these- K-Ras, GNAS, telomere shortening- are identified early in the 
pancreatic carcinogenesis pathways; while others such as P53, SMAD4 loss and inactivation 
of DUSP6 are later events (Figure 1.7).23,24 Telomere shortening and reduction in signal, in 
particular, has been demonstrated in 96% of pancreatic intraepithelial neoplasia (PanIN), but 
not in inflammatory or atrophic lesions, suggesting it as one of the earliest events in pancreatic 
carcinogensis.25 Furthermore, epigenetic alterations involving methylation-induced silencing 
of biologically relevant genes are also common in pancreatic cancer. Among these are 
silencing of P16 (14-33% of cases), Hedgehog interacting protein (40-50%) and SPARC (88-
94% of cases).26 
 
Figure 1.7: Pancreatic carcinogenesis. From Simone and Maitra (2013) Molecular genetics of 
Pancreatic cancer.24 
 
 
To unravel the complexity of cancer genome, the International Cancer Genome Consortium 
(ICGC) was set up in 2008 following the launch of the Cancer Genome Project in UK and The 
Cancer Genome Atlas in US. This is a large-scale global initiative that aims at identifying a full 
range of somatic mutations and high-definition cataloguing of genomic abnormalities in 50 
different cancer types.27 The pancreatic cancer arm of the ICGC has been led by a network of 
institutions in Australia and Canada. The Australian Pancreatic Cancer Genome Initiative 
(APGI) currently has 11 active clinical sites and over 150 clinical and scientific staff involved. 
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It has been tasked with the prospective accrual of 400 patients with primary resected tumours 
and performing deep genome sequencing with complete clinical annotation. Additional 
integrated projects that arise from this global program include xenograft experiments, pathway 
analyses, epidemiological and clinical trial programs such as the IMPaCT trial.27,28 
In a seminal paper published in Nature, Biankin et al. published the first 142 cases of the APGI 
program.29 By using a combination of deep sequencing and capturing system on 142 stage I 
and II PDAC and correlating these information with  detailed clinical-pathological phenotypes 
–of which 99 had adequate cellularity to be informative, the group identified 16 significantly 
mutated genes, including some known mutations (K-Ras, P53, CDKN2A, SMAD4, MLL3, 
TGFBR2, ARID1A and SF3B1); and uncovering novel mutations in chromatin modification 
(EPC1, ARID2), DNA damage repair (ATM), and axonal guidance genes (ROBO2, 3). 
Importantly, the detailed analysis identified 2016 non-silent mutations and 1628 copy-number 
variations with an average of 26 mutations detected per patient, suggesting substantial 
heterogeneity (table 1.1).29 Using two independent sleeping beauty mutagenesis models and 
a short hairpin RNA (shRNA) screen, the investigators further confirmed the functional 
relevance of K-Ras, P53, CDKN2A and SMAD4 mutations, implying their putative roles as 
driver mutations. The pathways identified to be significant included G1/S checkpoint, 
apoptosis, angiogenesis and TGF- signalling in this study.29 
 
Table 1.1: mutations found on genome wide sequencing of 99 patients. From Biankin (2012) 
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.29 
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As for metastatic pancreatic cancer, genomic signature is less known, possibly because of the 
challenges in acquiring sufficient tissue for fine needle aspirate (FNA) or endoscopic 
ultrasound (EUS) biopsy. Campbell et al. was able to sequence multiple metastases from 10 
PDAC patients by means of autopsy study, and they found that it had a distinctive pattern of 
genomic instability characterised by deletions (22%) and fold-back inversions (16%).30 This, 
in turn, suggests that a significant disruption in the G1-S cell cycle and repair mechanism.30 In 
another study from Nature, Yachida’s group studied both the primary and secondaries of 8 
pancreatic cancer patients at autopsy. They found that all parental clones already 
accumulated the common driver (“founder”) mutations (K-Ras, P53, SMAD4); and metastases 
had additionally acquired 20-30 highly varied passenger (“progressor”) mutations.31 
 
 
1.2.2 Clonal heterogeneity, driver mutations and actionable targets 
Gene sequencing studies have thus far identified the extreme complexity of pancreatic cancer. 
To complicate further, cancer is increasingly recognised as an evolutionary process. The 
concept of clonal heterogeneity was actually proposed in 1976, and described the evolutionary 
process where clones acquire “successive somatic mutations that allow for sequential 
selection of fitter subclones” (Figure 1.8).32 However, it is only until now when single cell 
sequencing technologies become available that this concept can be tested. A number of major 
studies with deep sequencing multiple tissues from the same patient/ cell line have been 
published in the last few years, and they invariably identified significant variations arising in 
subclonal populations from a single cancer cell.30,31,33-35 In the most famous publication from 
Nature, Swanton’s group performed multiple gene sequencing on 8-10 core biopsy sites of 
nephrectomy and metastatectomy specimen in 4 renal cell carcinoma patients. They identified 
128 somatic mutations by multi-region sequencing, but only 40 of which (or 31%) could be 
detected across all regions. In addition, 26 of the 30 tumour sampling specimens had divergent 
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allelic-imbalance profile, and ploidy heterogeneity was also observed. This suggested that 
there was extensive intra-tumoural heterogeneity, and that a single biopsy could only capture 
55% of all mutations detected in the entire tumour.35 The issue of intra-tumoural heterogeneity 
therefore poses a considerable challenge to the use of targeted therapies, because the 
decision to targeted treatment often hinges on the concept of discovering “actionable targets” 
from limited core or FNA biopsy, which may not represent the whole picture if there is 
significant intra-tumoural heterogeneity.32 
 
Figure 1.8: clonal expansion in primary and metastatic tumour. From Caldas (2012) Cancer 
sequencing unravels clonal evolution.32 
 
Whilst intra-tumoural heterogeneity may be challenging, it “may not be insurmountable barrier 
to cancer therapy if treatments can be designed to target mutations present in all cells”.32 
There is now a plethora of literature demonstrating the significance of “founder or driver 
mutations”. In Campbell et al’s study, eight rearrangements were found in all PDAC 
metastases of one patient and not in the primary tumour.30 In Yachida’s study, the vast majority 
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of homozygous mutations (89%) already existed in the parental clone of PDAC, and 
deleterious mutations were more commonly found in parent than subclones (12.6% vs. 
8.1%).31 These findings have significant therapeutic implications. Whilst extensive gene 
alterations make it difficult to differentiate “driver mutations” from “passenger mutations”,36 
there is an intrinsic order to these genetic alteration; clonal ordering can be tracked by 
phylogenetic tree, and suggests that identifying common mutations at the trunk of the 
phylogenetic tree to be a strategy to develop more robust biomarkers and therapy.35 
Importantly, these driver mutations can now be mapped to distinctive molecular pathways by 
means of integrative genomic analyses platforms.37-39 In fact, by means of complex 
bioinformatics models, the Cancer Genome Atlas network has now catalogued 291 high-
confidence drivers among 11 tumour types. Only 2 high-confidence genes (P53 and PIK3CA) 
and 51 other gene have protein affecting mutations universally in more than 10% of pan-
cancer samples. Of note, these genes are found to originate from 5 distinct pathways: 
chromatin remodelling, mRNA processing, cell signalling/ proliferation, cell adhesion and DNA 
repair/ cell cycle.38 Using this approach, a median of only 4 protein affecting mutations is found 
among the 11 cancer types, where at least 1 of these are high confidence genes in 94% of 
tumour types.38 In other words, in most tumour types there are potentially many gene 
mutations, some driver mutations but only a few protein-affecting mutations; and these are 
probably the real actionable targets that matter. 
In summary, with the rapidly expanding field of genomics science propelled by the advent of 
gene sequencing and bioinformatics technology, we are only beginning to understand the 
extensive tumour complexity and heterogeneity. Yet, within these considerable changes, gene 
mutations occur in an orderly evolutionary process, and protein-affecting mutations are likely 
finite. Importantly, these genetic changes appear to conform to common molecular pathways. 
This suggests that studying specific pathway activation to determine actionable targets may 
be a more optimal strategy to overcome a disease with such extensive genetic alterations. 
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1.2.3   Core molecular pathways in pancreatic cancer 
In the early 2000s, K-Ras, CDKN2A/P16, P53 and SMAD4 have been identified as the core 
molecular pathways in pancreatic ductal adenocarcinoma, also known as the “big 4 mountains 
of the genomic landscape.20,24,40 Through the advances in gene sequencing and bioinformatics 
technology, 12 core biological pathways are now identified as core signalling in PDAC (Figure 
1.9).24,41 Importantly, many of these pathways are well-established hallmarks of cancer as 
identified by Hanahan and Weinberg.42 It is impossible for this thesis to cover the scope of all 
the core signalling pathways. Thus, only the pertinent signalling pathways will be described 
here. 
Growth Signalling (K-Ras and PI3K): Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR 
pathways are signalling cascades of phosphorylating kinases that play critical roles in cancer 
growth and proliferation.43 K-Ras is an important member of a multi-gene Ras family (Ki-Ras, 
N-Ras, H-Ras), and is particularly important for PDAC carcinogenesis. It has been shown that 
K-Ras somatic mutations (usually at codon 12, 13 or 61) are present in increasing rates in 
advanced stages of pancreatic intra-epithelial neoplasia (PanIN)- the precursor of PDAC- from 
30-38% (PanIA), 31-44% (PanIB), 73% (PanIN2) to 83% (PanIN3); and are prevalent in over 
90% of PDAC.20 Furthermore, K-Ras is also responsible in promoting and continuing tumour 
growth. K-Ras activates downstream signalling Raf (B-Raf, Raf-1, A-Raf), ERK and MEK.43 
Activated ERK can translocate into cell nucleus, regulate transcription factors, altered gene 
expression with the end results of promoting cell growth (Figure 1.10). This so-called 
mitogenic-activated protein kinases (MAPKs) pathway is constitutively activated by mutated 
K-Ras through the intrinsic binding of GTPs.23 K-Ras codon 12 mutation has been shown to 
be negatively prognostic in advanced PDAC, predicting for higher stage, liver metastases and 
a survival of 3.9 (K-Ras mutant) versus 10.2 months (K-Ras wild type) (HR 7.39, P<0.001).44 
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Figure 1.9 Core signalling pathways in pancreatic cancer. From Simone and Maitra (2013) 
Molecular genetics of Pancreatic cancer.24 The highlighted pathways will be described in more detail.  
 
PI3K/Akt/mTOR –often abbreviated as the PAM pathway- are an integral pathway in cell 
growth and survival, responsible for important cellular functions such as protein synthesis, cell 
cycle progression, proliferation and survival.45,46 In cancer, multiple components of the 
pathway is known to be disrupted, including PIK3CA, AKT, PTEN mutations, PIK3CA, AKT1, 
AKT2 gene amplifications, and loss of tumour suppressor gene expression (PTEN).47 The 
PI3K family consists of three classes. Class I PI3-kinase is highly over-expressed in 70% of 
pancreatic ductal adenocarcinoma.48 Class I PI3K isoforms are activated by interacting with 
Ras and p85 regulatory units.45 Once activated, PI3K catalyses the transformation of 
phosphatidylinositol 4,5-bisphosphate to phosphatidylinositol 3,4,5-trisphosphate, which in 
turn recruits PKB/Akt to the cellular surface. Akt is activated by dual binding of PDK1 to Thr308 
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and PDK2 to Ser473 regulatory binding sites, which in turn relieves the inhibitor effect of TSC-
1 and TSC-2 on mTORC-1 and -2 complexes. mTORC-1 complex is one of the major 
components of the translational machinery in cancer. It up-regulates direct downstream S6 
and 4EBP-1, which are intricately involved in cell cycle and mRNA translation.49,50 Other 
downstream signals activated by the PI3K/Akt system include GSK-3, cyclin-D1, Forkhead 
and BAD, which together regulate a wide range of cellular processes (Figure 1.10).45,51,52 
PI3K, particularly the class IB isoform (p110γ) is over-expressed in 70% of PDAC.48 Akt, the 
direct downstream signal of the PI3K complex, is also consistently activated in PDAC cell 
lines.53 Close to half of PDAC patients had high total Akt-2 (43%) and phosphorylated Akt 
(46%) in a study of 65 patients.54 High pAkt expression has also be shown to be an 
independently negative prognostic marker, with 5 year survival of 57% for patients with low 
pAkt expression in the tumour versus 14% for those with high expression (P<0.05).54 
Critical to the function of these two pathways is the myriad of upstream regulators including 
epidermal growth factor receptor (EGFR), insulin growth factor receptor (IGF1R) and many 
others (HGF, HER2, HGF, VEGF-R, PDGF-R, Kit); as well as the significant interaction at 
multiple levels of these signalling pathways.43,47 EGFR is involved in an autocrine positive 
feedback loop with the Ras and Raf, as well as the PAM pathway leading to altered 
transcription of genes such as HCCR.55,56 Whilst EGFR mutation is rare (<5%) and typically 
silent in PDAC, it is over-expressed in >40% of PDAC.57-60 IGF1R, on the other hand, is over-
expressed in 50% of PDAC61, and it also mediates growth and survival via both MAPK and 
PAM pathways.62 Importantly, cross-talks have also been demonstrated between these cell 
surface receptors,61,63 possibly through EGFR-IGF1R heterodimerization or survivin 
expression.64 Cross-talks also exist on multiple levels between the MAPK and PAM pathways, 
with interactions reported for K-Ras/ GSK3 (a downstream effector of Akt), K-Ras/ PTEN via 
TGF-, and K-Ras/ PI3K and PDK1.65-68 The multiple interactions and feedback loops certainly 
add a layer of complexity to the biology of these pathways, and suggest that these signalling 
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cascades should be viewed as a “signalling network” rather than a “simple linear, unidirectional 
cascade”.56 
 
Figure 1.10 MAPK and PAM pathways. From Jin and Esteva (2008) Cross-talk between the HER 
and insulin-like growth factor receptor signalling pathway.52 
 
Epithelial-mesenchymal transition (TGF- and SMAD-4): Epithelial-mesenchymal 
Transition (EMT) is a normal development and embryogenesis process that is hijacked by 
cancer cells for migration and progression.69 It is a complicated process that is facilitated by 
TGF-β through either SMAD-4 dependent or SMAD-4 independent (non-canonical) pathway, 
via transcription factors such as SNAIL, SLUG, ZEB1 and TWIST.70 Other factors that help 
orchestrate this process included growth factors and cytokines, miRNAs as well as interaction 
with microenvironment.71 This eventually leads to a loss of E-cadherin and gain of vimentin, 
which transform an epithelial to spindle-shaped mesenchymal cell morphology.72 The central 
players of this process are SMAD-4, a family of cytoplasmic transcription factors that are 
directly activated by serine phosphorylation at their cognate receptors; and TGF-β, which 
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functions as tumour suppressor normally but may paradoxically induce proliferation in cancer, 
particularly in the later stages of cancer.73 
EMT appears to be a central pathophysiologic mechanism in PDAC. Nearly 80% of PDAC 
tumours have active expression of the EMT transcription factors SNAIL or SLUG.74 In PDAC 
with functional SMAD-4, TGFβ binds to a type 2 TGFβ-receptor (TβRII), which phosphorylates 
the SMAD2 and SMAD3 via ALK5. These in turn form heterodimers with SMAD-4, which 
mediates EMT, proliferation, migration and invasion.72 In 55% of PDAC with deleted or 
inactivated SMAD-4, typically in more advanced stages, the anti-proliferative properties of 
TGF-β may be lost, which confers survival advantage to the cell.75 (Figure 1.11). That said, 
TGF-β may continue to have an inhibitory effect on cell proliferation via SMAD-4 independent 
inhibition of ERK.76 EMT can still occur in SMAD-4 deleted tumours, but this occurs through 
MAPK, PI3K, NF-κb, Hedgehog and other non-canonical pathways.72,77,78 Importantly, 
Ras/Raf/ERK is not only a crucial activating step by TGF-β in either pathway for EMT,79 K-
Ras itself is also known to constitutively induce EMT in transfection experiments.80 To 
complicate this further, even among the K-Ras mutant cell lines, only those that became 
independent to K-Ras lost expression of E-cadherin gained vimentin and became 
mesenchymal in morphology, whereas others that remained addicted to K-Ras continued to 
display epithelial morphology.81  
Aside from tumour migration, EMT has long been implicated in cancer stem cells and drug 
resistance in PDAC.82 EMT and drug resistance appeared to go hand in hand. Cancer cells 
that have undergone EMT are more drug resistant; and cells that survived in the presence of 
a drug are more likely to undergo EMT.72 EMT has been studied in the context of erlotinib 
resistance. In NSCLC, a multigene signature of EMT was found to be a determinant of erlotinib 
resistance in 42 cell lines.83 In PDAC, an animal model that utilised 11 cell lines had found that 
mesenchymal cell lines were much more resistant to erlotinib also.84 EMT may not be 
exclusively a marker of EGFR inhibitor resistance. It is also found to be involved in gemcitabine 
resistance in PDAC,85 and IGF1R inhibitor resistance in PDAC and hepatocellular 
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carcinoma.86,87 At this stage, it is thought that EMT may be reversible. Down-regulation of EMT 
related pathways such as NOTCH and ZEB/Rho with SiRNA appeared to at least partially 
reverse EMT.88,89 Clinical trials targeting NOTCH, Wnt and Hedgehog pathways are now 
underway in pancreatic cancer.90 
 
Figure 1.11: SMAD pathway. From Maier et al. (2010) Epithelial-mesenchymal transition in 
pancreatic carcinoma.72 
 
Desmoplasia (Hedgehog): The Hedgehog (Hh) pathway consists of the ligand receptor 
Patched1 (PTCH) with 3 known ligands: Sonic Hedgehog (SHh), Indian Hedgehog and Desert 
Hedgehog. When a ligand binds the PTCH, this releases the normal repressive activity it has 
on the transmembrane protein Smoothened (SMO), leading to activation of a number of 
transcription factors such as GLI1 and HIP resulting in the transcription of genes.91 Current 
evidence suggests that Hh is a downstream target of K-Ras, with NF- suggested as an 
intermediary between Ras and Hh.91 Hh activation is actually important for the normal 
development of the gastrointestinal system during embryogenesis; with the exception being 
the pancreas, where the down-regulation of Hh is critical for the normal development of 
pancreas in embryos and functioning of pancreas in adults.91   
The association between Hh and tumourigenesis in PDAC was first described in PDAC in two 
papers in Nature simultaneously in 2003.92,93 In a genomic analysis of 24 pancreatic cancers 
in 2008, hedgehog pathway is found to be up-regulated in 67-100% of PDAC.41 SHh is also 
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found to be increased by 46-fold in PDAC stem cells which occupy the invasive front of 
pancreatic cancer.94 Importantly, Hh has been demonstrated to be an important stimulating 
factor of desmoplasia in vivo, a reaction referring to the recruitment of fibroblasts, endothelial 
cells and many stromal cells. This is a particularly important feature in PDAC as this results in 
enrichment in the tumour microenvironment and creating barrier to delivery of therapeutic 
drugs to the tumour cells.91 The reaction appears to be dependent on the paracrine system 
between tumour cells and microenvironment. In an experiment of co-transplanting SHh-
positive human tumour cells and mouse fibroblasts, SMO knockout mice fibroblasts have been 
shown to be lead to smaller tumours than SMO- wild type fibroblasts.95 In another experiment, 
inhibition of the Hh pathway practically abrogates the metastatic potential of PDAC without 
affecting tumour volume. Active efforts are continuing to research the therapeutic potentials of 
combining Hh antagonists with chemotherapy to improve drug delivery in PDAC.94 
 
Figure 1.12: Sonic Hedgehog pathway. From Kelleher (2010) Hedgehog signalling therapeutics 
in pancreatic cancer.94 
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JAK Pathway: Janus Kinase (JAK)/ Signals Transducers and Activators of Transcription 
(STAT) pathway is a key signalling process of multiple cytokines and growth factors regulating 
numerous developmental and homeostatic processes.96,97 It consists of 3 families of genes, 
including 4 members in the JAK or Janus family, 7 in the STAT family and 8 genes within the 
Suppressors of Cytokine Signaling (SOCS) family.96-98 The binding of extracellular ligand to 
the receptor leads to intracellular JAKs phosphorylating each other, and STATS molecules 
dimerizing with each other; the STAT molecules then enter the nucleus and regulate 
transcription.97 The SOCS molecules, on the other hand, act as negative feedback 
suppressing JAK/STAT pathway activation.97 (Figure 1.13) Although the canonical JAK/ STAT 
pathway is relatively direct, it is also known to cross-talk with the MAPK and PAM pathways 
across multiple levels.98 Since 2005, several JAK2 mutations and translocations have been 
described to be the mechanism of leukemia and myeloproliferative disorders.99,100 Aside from 
haematological cancers, the JAK/ STAT pathway has also been implicated in the progression 
of pancreatic cancer;41,101 and STAT3 over-expression has been shown to be obligatory for 
the development of acinar-to-ductal metaplasia- an early event of PDAC initiation.102 Recently, 
pancreatic cancer-induced cachexia is found to be dependent on JAK2.103 There is now 
emerging interest to target JAK1/2 and STAT3 in PDAC.101,102 In a randomised phase II study 
recently reported in ASCO 2014, JAK1/2 inhibitor ruloxitinib was explored in the second-line 
setting of metastatic pancreatic cancer patients. 127 patients were randomised to receive 
either ruloxitinib 15mg BD plus capecitabine 1000mg/ m2 days 1-14 every 3 weeks, or placebo 
plus capecitabine with the same dose. The primary endpoint was overall survival (OS), with 
secondary endpoints of PFS and overall response rate (ORR).104 Whilst the primary analysis 
was negative, in subgroup analysis patients with high CRP (>13 mg/L) were seen to have 
superior OS (HR 0.47, P=0.01). Ruloxitinib is now being investigated in a multi-centred 
international phase III study in metastatic pancreatic cancer patients who either fail first-line 
or are intolerable to first-line chemotherapy. 
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Figure 1.13: JAK/ STAT Pathway. From Harrison (2012) the JAK/ STAT Pathway.96 
 
1.3 Treatment Options in Advanced and Metastatic PDAC 
1.3.1   Chemotherapies and Targeted therapies 
Despite numerous clinical trials and extensive research in advanced and metastatic pancreatic 
cancer, treatments remain limited and prognosis is unchanged at 6-12 months. Aside from 
complete resection, all other treatment can only be regarded as palliative. In this next section, 
the key trials in the area of chemotherapy and targeted therapies are summarised (table 1.2). 
Chemoradiotherapy is usually reserved for locally advanced disease, and remains 
controversial due to a number of negative trials including ESPAC-1 and LAP-07.105 It has little 
relevance to the background of this thesis, so it will not be discussed here.  
Study Setting/ Pt Treatment Response PFS OS 
Burris et al. 
(1998)106 
First-Line  
(n=126) 
Gemcitabine vs. 
5FU 
5 vs. 0% 2.3 vs. 0.9m 
(P=0.0002) 
5.6 vs. 4.4m 
(P=0.003) 
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Tempero et al. 
(2003)107 
First-Line (n=96) FDR Gem vs. 
Gemcitabine # 
6 vs. 9% 3.4 vs. 1.9m 
(P=0.68) 
8.0 vs. 5.0m 
(P=0.013)  
Moore et al. 
(2007)108 
First-Line 
(n=569) 
Gem-erlotinib vs. 
Gem 
9 vs. 8% 3.8 vs. 3.6m 
(HR 0.77, 
P=0.004) 
6.2 vs. 5.9m 
(HR 0.82, 
P=0.038) 
Cunningham et 
al. 
(2009)109 
First-Line 
(n=533) 
Gem-CAP vs. 
Gemcitabine 
19 vs. 12% 
(P=0.03) 
5.3 vs. 3.8m 
(HR 0.78, 
P=0.004) 
7.1 vs. 6.2m (HR 
0.86, P=0.08)* 
Conroy et al. 
(2010)110 
First-Line 
(n=342) 
FOLFIRNOX vs. 
Gem 
32 vs. 9% 
(P<0.001) 
6.4 vs. 3.3m 
(HR 0.47, 
P<0.001) 
11.1 vs. 6.8m 
(HR 0.57, 
P<0.001) 
Von Hoff et 
al.(2013)111 
First-Line 
(n=842) 
Gem-Abraxane 
vs. Gem 
23 vs. 7% 
(P<0.0001) 
5.5 vs. 3.7m 
(HR 0.69, 
P<0.0001) 
8.5 vs. 6.7m 
(HR 0.72, 
P<0.0001)  
Jacobs et al. 
(2004)112  
Second-Line 
(n=46) 
OFF vs. BSC^ - 5.3 vs. 2.5m (P 
not reported) 
4.8 vs. 2.3m 
(P=0.008) 
Oettle et al. 
(2005)113 
Second-Line 
(n=168) 
OFF vs. FF - 3.3 vs. 2.2m 
(P=0.012) 
6.5 vs. 3.3m 
(P=0.014) 
Table 1.2: Randomised clinical trials of chemotherapies and targeted therapy with positive 
results in overall survival. #FDR (Fixed dose rate): 10mg/m2/ minute, *Meta-analysis of 3 studies 
with n=935 showed significant OS benefit (HR 0.86, P=0.02).109 ^OFF: Oxaliplatin-5FU- folinic acid 
(similar to FOLFOX). BSC= best supportive care 
Chemotherapy: In 1998, the landmark randomised controlled trial compared gemcitabine 
(given 7 out of 8 weeks) against the previous standard 5-FU in advanced pancreatic cancer 
in 126 patients. The primary endpoint of the trial was actually clinical benefit, a composite 
endpoint of debilitating symptoms and signs of pain, weight loss and functional impairment.106 
This was fulfilled by demonstrating 24% patients on gemcitabine deriving clinical benefit, 
compared to only 6% on 5-FU (P=0.002). In addition, gemcitabine significantly improved PFS 
(P=0.0002) and OS (P=0.003) compared to 5FU. Whilst gemcitabine resulted in higher rates 
of grade 3-4 neutropenia (26% vs. 5%, P<0.001), no serious infections were observed in either 
group, and both treatments were otherwise reasonably well tolerated.106 Gemcitabine was 
therefore accepted as the new standard of care since the late 1990s. Over the next 10 years, 
efforts were invested to improve median OS beyond 6 months. Tempero et al. researched on 
more efficient ways of drug delivery. The fixed dose rate (FDR) gemcitabine, given at 
10mg/m2/ min, resulted in a linear and higher serum accumulation of the active compound, 
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and led to a significant improvement of median (P=0.013), 1-year (P=0.014) and 2-year 
survivals (P=0.007).107 However, the FDR strategy could not be widely adopted due to a 
doubling of grade 3-4 neutropenia, leukopenia and thrombocytopenia to a rate of around 
40%.107 Others have researched on gemcitabine-based combinations to provide additional 
benefits to gemcitabine alone. The phase III trials on Gem + 5FU and Gem + cisplatin 
unfortunately did not show significant benefit in OS and only marginal benefit in PFS.114,115 In 
2009, Cunningham et al. reported the large GEM-CAP study of 533 patients from 75 hospitals 
in the UK. Gemcitabine plus capecitabine- an oral pro-drug of 5FU, resulted in a significant 
improvement in PFS (P=0.004) and a strong trend to improvement in OS (P=0.08). 
Cunningham et al. combined with the results of 2 other RCT in a meta-analysis, and reported 
a significant benefit in OS (HR 0.86, P=0.02) with no statistical heterogeneity (I2 =0%). Yet, 
even then the median survival still remains at 7.1 months. It was only until the ACCORD-11 
trial by Conroy et al. and MPACT trial by Von Hoff et al. reported in the last 3 years that the 
landscape of chemotherapy in metastatic pancreatic cancer has started to change. The 
ACCORD-11 trial studied a potent 3-drug combination of 5FU, oxaliplatin and irinotecan in 
342 patients at 48 French centres. For the first time, clinical trial was stopped early due to 
benefit instead of futility. A clinical meaningful benefit of +3.1 (to 6.4 m) and +4.3 months (to 
11.1 m) in median PFS and OS was demonstrated in addition to statistical significance (both 
P<0.001), and fewer patients had worsened quality of life at 6 months (HR 0.47, P<0.001).110 
There were initial concerns over the significantly higher rates of grade 3 and 4 neutropenia 
(46 vs. 21%), diarrhoea (13 vs. 2%) and sensory neuropathy (9 vs. 0%); but subsequent real-
life data showed that the protocol could be safely given in its modified version (without bolus 
5FU) without compromising its efficacy.116 In early 2013, the MPACT trial comparing 
gemcitabine + abraxane was also reported, showing a significant improvement of PFS and 
OS of +1.8 (to 5.5 m) and +2.8 (to 8.8 m) respectively.111 Abraxane has a therapeutic 
advantage over other chemotherapies, since it is designed as paclitaxel chemotherapy bound 
in albumin. The albumin coating allows it to bypass the demoplastic structures shielding the 
tumour and reach the tumour micro-environment readily, and in vivo it is shown to cause 
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stromal collapse and thereby increasing drug bioavailability.94 Importantly, the combination is 
well tolerated and patients could receive 75-80% of the proposed dose intensity.111 Therefore, 
both FOLFIRINOX and Gem-abraxane can now be considered as acceptable standards for 
patients who are of good performance status.117 
Second-line treatment options in PDAC are very limited, with no existing standard of care. 
Many advanced pancreatic cancer patients are poor candidates for clinical trials after failing 
first-line treatment. As a result, most second-line clinical trials are either retrospective or single 
arm phase II trials only, with small sample size of 15-25 in phase II series.118,119 Most 
chemotherapy regimens can only produce a response rate of 0-20%, and the progression free 
and overall survivals are consistently around 1-2 months and 3-4 months respectively 
regardless of the agents.118 There are few available phase III trials in second line setting. 
Oxaliplatin plus 5-FU/ Folinic acid (OFF) improves survival from 13 weeks to 26 weeks over 
best supportive care (BSC) (P=0.008), and 3.3 to 6.5 months over FF (P=0.014); and 
Rubitecan, which significantly improves PFS (from 1.6 to 1.9m, P=0.003) but not OS (from 3.0 
to 3.6m, P=0.63).112,113,120 Another trial recently reported is the AIO-PK0104 trial, which 
randomised advanced or metastatic patients to gemcitabine +erlotinib versus capecitabine+ 
erlotinib first-line, with planned cross-over to the arm without erlotinib second-line, in a 1:1 
ratio with non-inferiority design. Focusing on the second-line analysis, 51% of patients were 
able to receive salvage therapy. In a post-hoc analysis, gemcitabine appears to be superior to 
capecitabine in second-line with time to treatment failure 2 cross over (TT2c) of 2.5 vs. 2.0 m 
(P=0.00005).121 Clearly some patients may benefit from salvage therapy, and there is thus a 
great need in clinical trial research to establish a standard in the second-line setting. 
Targeted therapies: There has been emerging interest in the use of targeted therapies in 
cancer treatment. Targeted therapies exploit the fact that some cancers are addicted to certain 
aberrant molecular pathways for growth and metastases. By blocking the dominant pathway 
in a particular cancer, targeted therapies result in remarkable control of tumour and promote 
tumour kill when used in combination with chemotherapy.122 In pancreatic cancer, the only 
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targeted therapy with proven efficacy to date is EGFR tyrosine kinase inhibitor (TKI) erlotinib 
in the PA.3 trial. In this trial, gemcitabine plus erlotinib delays progression by 23% (P=0.004) 
and improves overall survival by 18% (P=0.038). However, the absolute benefit is exceedingly 
small, with +0.2 months and +10 days in median PFS and OS.108  
The development of other targeted therapies including bevacizumab (vascular endothelin 
growth factor inhibitor), cetuximab (epidermal growth factor inhibitor), tipifarnib (K-Ras 
inhibitor) and marimastat (matrix metalloproteinase inhibitor) has all been disappointing.123-126 
The latest failure to add to this growing list is ganitumab (IGF1R inhibitor). A phase II trial was 
reported in 2010, randomizing patients to gemcitabine + conatumumab (death receptor 5 
agonist), or gemcitabine + ganitumab (IGF1R inhibitor, Amgen) or gemcitabine + placebo. 
This resulted in superior median PFS for Gem+ ganitumumab (5.1 m) and Gem+ 
conatumumab (4.0 m) compared to Gem + placebo (2.1 m), with a borderline significant P-
value of 0.072 and 0.082 respectively. The study was not powered for analysis of OS, which 
was not significantly different between the 3 arms at this stage (Gem+ G: 8.7 vs. 5.9m, P=0.12; 
Gem+ C: 7.5 vs. 5.9m, P=0.59).127,128 The promising results in phase II setting prompted a 
large multi-centre, double-blinded phase III trial development. Unfortunately, in Aug 2012, 
AMGEN released a statement announcing termination of its phase III trial in PDAC for 
futility.129 Currently, there are a number of ongoing phase I/II trials examining the possible 
utility of novel targeted therapies including Ras, Src, KIT, Hedgehog and proteasome 
inhibitors.130,131 However, with the repeated occurrence of promising phase II data only to be 
rejected by disappointing phase III trial results, investigators must start to look at novel 
combination of targeted therapies, addressing drug resistance and selecting patients by 
biomarkers in order to continue forward in this area of unmet need.132-134  
 
1.3.2  Comparison of EGFR Drug Clinical Trials in PDAC, CRC and NSCLC 
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As discussed, EGFR tyrosine kinase inhibitors erlotinib is the only proven targeted therapy in 
PDAC to date. However, the small clinical benefit observed in OS and the challenge in finding 
a predictive biomarker have made it difficult to implement erlotinib in routine clinical practice. 
On the other hand, EGFR inhibitors and antibodies have well established roles in metastatic 
NSCLC and CRC. By comparing the difference in the trials of these cancer types, the aim was 
to explore better strategies to continue development of these drugs in PDAC. EGFR TKI 
erlotinib and gefitinib have been studied across different solid tumours, but the bulk of phase 
III studies were conducted in metastatic non-small cell lung cancer (NSCLC). At the time of 
preparing this thesis, the promising data of afatinib has just started to emerge in NSCLC with 
EGFR mutation, and it certainly corresponds well with other gefitinib and erlotinib studies.135 
EGFR antibodies cetuximab and panninitumab have mainly been studied in metastatic 
colorectal cancer (CRC). Whereas the emphasis in NSCLC and CRC clinical trials is to select 
EGFR treatment by predictive biomarkers, the focus of phase III studies in PDAC has only 
been incorporating EGFR inhibitors/ antibodies into standard chemotherapy in unselected 
population thus far. Table 1.3 summarises the important randomised controlled clinical trials 
in these three cancers using EGFR inhibitor or antibody: 
Clinical 
Trial 
Cancer 
type 
Line of 
Rx 
Experimental Comparator RR 
(EGFRi/ab
) 
PFS OS 
PA.3 
(2007)108 
mPDAC 
1
st
 
Erlotinib + 
gemcitabine 
Gemcitabine RR 9% SD 
49% 
3.8 v 3.6m 
(HR 0.77, 
P=0.004) 
6.2 v 5.9m 
(HR=0.82, 
P=0.038) 
AIO-
PK0104 
(2013)121 
mPDAC 1st / 2nd  Erlotinib + 
capecitabine 
 
Gemcitabine 
Erlotinib + 
Gemcitabine 
 
Capecitabin
e 
RR 16% 
SD 38% 
TTF2 4.2 v 
4.2m (HR 
1.00, P=1.0) 
6.2 v 6.9m 
(HR 1.02, 
P=0.90) 
AVITA 
(2008)136 
mPDAC 
1
st
 
Erlotinib+ 
gemcitabine + 
bevacizumab 
Erlotinib + 
gemcitabine 
RR 14% 
SD 67% 
4.6 v 3.6m 
(HR 0.73, 
P=0.0002) 
7.1 v 6.0m 
(HR=0.89, 
P=0.21) 
SWOG 
S0205 
(2010)124 
mPDAC 
1
st
 
Cetuximab + 
gemcitabine 
Gemcitabine RR 14% 
SD 37% 
3.4 v 3.0m 
(HR=1.07, 
P=0.006) 
6.2 v 5.9m 
(HR=1.06, 
P=0.23) 
NCT00079
066 
(2008)137 
mCRC 2nd or 
later 
Cetuximab + 
irinotecan 
Irinotecan RR 13% in 
K-Ras WT 
3.7 v 1.9m 
in K-Ras 
WT (HR 
9.5 v 4.8m  
K-Ras WT 
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0.40, 
P<0.001) 
(HR 0.55, 
P<0.001) 
CRYSTAL 
(2009)138 
mCRC 1st Cetuximab + 
FOLFIRI 
FOLFIRI RR 59% in 
K-Ras WT 
9.9 v 8.7m 
in K-Ras 
WT (HR 
0.70, 
P=0.001) 
23.5 v 
20.0m in K-
Ras WT 
(HR 0.80, 
P=0.0093) 
Peters et 
al. 
(2009)139 
mCRC 2nd or 
later 
Pannitumuab+ 
FOLFIRI 
FOLFIRI RR 35% in 
K-Ras WT 
5.9 v 3.9m    
K-Ras WT  
(HR 0.73, 
P=0.004) 
14.5 v 
12.5m  K-
Ras WT 
(HR 0.85, 
P=0.12)  
BR.21 
(2005)140 
mNSCLC 2nd/3rd Erlotinib Placebo RR 9% SD 
34% 
2.2 v 1.8m 
(HR 0.61, 
P<0.001) 
6.7 v 4.7m 
(HR 0.70, 
P<0.001) 
FLEX 
(2009)141,14
2 
mNSCLC 1st Chemotherap
y 
Chemo + 
Cetuximab 
RR 36%  
 
4.8 v 4.8m 
(HR 0.94, 
P=0.39) 
11.3 v 
10.1m (HR 
0.87, 
P=0.044)* 
SATURN 
(2010)143  
mNSCLC Mainte
nance 
Erlotinib Placebo RR 12% 
SD 58% 
3.1 v 2.8m 
(HR 0.71, 
P<0.0001) 
12.0 v 
11.0m 
(P=0.009) 
IPASS 
(2010)144 
mNSCLC 
1
st
 
Gefitinib Carboplatin/ 
Paclitaxel 
RR 43% HR 0.48, 
P<0.0001 in 
EGFR mut 
21.9 vs 21.6 
(HR 1.00, 
P=0.99) in 
EGFR mut 
OPTIMAL 
(2010)145,14
6 
mNSCLC 
(EGFR 
mut) 
1
st
 
Erlotinib Carboplatin/ 
Gemcitabine 
RR 58% 
SD 22% 
13.1 v 4.6m 
(HR=0.16, 
P<0.0001) 
HR 1.065 
(P=0.68) 
EURTAC 
(2012)147 
mNSCLC 
(EGFR 
mut) 
1
st
 
Erlotinib Carboplatin/ 
Gemcitabine 
RR 82% 
SD 14% 
9.4 v 5.2m 
(HR 0.37, 
P<0.0001) 
19.3 v 
19.5m 
(P=0.87) 
 
Table 1.3: List of EGFR inhibitors (erlotinib, gefitinib) and EGFR antibody (cetuximab, 
pannitumumab) trials in PDAC, CRC and NSCLC. Bolded indicates significant difference observed 
(P<0.05). *The updated analysis of the FLEX trial stratified by EGFR expression shows a more 
significant benefit in OS with tumours of high EGFR expression (HR 0.73, P=0.011).TTF denotes time 
to treatment failure  
There is certainly a discernible difference in EGFR treatment response rate in patients with 
tumours selected by a positive predictive marker compared to the unselected population. In 
clinical trials that study NSCLC patients with EGFR mutation such as OPTIMAL and EURTAC, 
and in a clinical trial (IPASS) that has a concentrated proportion of patients with EGFR 
mutation, the response rate (RR=CR/PR) ranges from 43% to 82%.144-147 If disease control 
rate (DCR =CR/PR + SD) is considered, this is even as high as 96% (EURTAC).147 Likewise, 
the RR of cetuximab approaches 60% in the first-line setting in the selected group of patients 
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with K-Ras WT tumours.137 In the setting where these drugs are used in an unselected 
population, the response rates are much lower, in the order of 8-30% (ISEL, INTACT-2), 12% 
(SATURN) and 9% (BR.21) in first-, maintenance and second-line settings in lung 
cancer.143,148-150 In unselected population in PDAC, the response rate of erlotinib is even lower. 
In the PA.3 trial, the response rate of gemcitabine plus erlotinib is 8.6% which is no different 
to the 8.0% with gemcitabine alone. DCR between gemcitabine and gemcitabine plus erlotinib 
are higher but not significantly different (58% vs. 49%, P=0.07).108 Similarly, in the phase III 
AVITA trial, the combination of erlotinib, bevacizumab and gemcitabine yields a response rate 
only slightly higher at 14% compared to 9% in the arm of gemcitabine plus erlotinib (P=0.057) 
and no difference in DCR 62 vs. 59%.151 Finally, the AIO-PK0104 trial demonstrates that 
gemcitabine +erlotinib appears more active than capecitabine+ erlotinib first-line (16% vs. 
5%), and both chemo agents alone have low response in second-line (gem: 6%, cap: 3%). 
The DCR is higher in gemcitabine+ erlotinib at 51% compared to capecitabine+ erlotinib at 
38%.121 From these studies, gemcitabine is likely the main active drug; erlotinib and 
bevacizumab only add slightly more stable disease and partial response respectively. 
Currently the exact response rate of erlotinib alone cannot be determined, since there have 
not been any RCTs with erlotinib only compared to placebo.  
With regards also to PFS analysis, there have been proven significant delays in progression 
in phase III trials of all 3 cancers. The only clinical trial with no demonstrable PFS benefit was 
the FLEX trial, which compared chemotherapy with chemotherapy plus cetuximab. That said, 
the time to treatment failure in the FLEX trial was significantly better with the combination 
therapy (HR 0.86, P=0.015).142 Importantly, subgroup analyses of the EGFR mutation positive 
NSCLC and K-Ras WT CRC showed a much greater magnitude of PFS advantage of EGFR 
therapy compared to control with HR as great as 0.16 (P<0.0001) in the OPTIMAL study.145 
For PDAC trials, gemcitabine plus erlotinib or cetuximab demonstrated superior PFS than the 
respective comparator arm, but the absolute magnitude of PFS benefit appeared to be small, 
in the order of 0.4 to 1.0 months.108,124,136 The AIO trial suggests that gemcitabine with erlotinib 
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may be superior to capecitabine with erlotinib (Time to failure first-line: 3.2 vs. 2.2 m, 
P=0.003).121 In all treatment arms, however, the median PFS reported remains between 3-5 
months, far less than that observed in first-line NSCLC and CRC trials.  
5 phase III trials actually shows an overall survival (OS) advantage for these targeted therapies 
despite PFS advantage in all trials  (NCT00079066, CRYSTAL, PA.3, BR.21, 
SATURN).108,137,138,140,143 The absolute benefit in OS is appreciable in the mCRC trial selected 
for K-Ras WT, but in the NSCLC and PDAC trials the magnitude of OS difference in modest 
at best, in the order of 0.3 months (PA.3) and 2.0 months (BR.21). It has been argued- 
especially in the first-line NSCLC trials- that OS is a less reliable endpoint than PFS, as 
patients often receive multiple lines of therapies after end of study. Since EGFR inhibitors are 
available as an option in the second or third-line setting, and a fair proportion of patients who 
did not receive the experimental treatment end up being treated with it after first-line, any 
potential OS advantages may have been diluted by this cross-over effect. For the PDAC trials, 
only BR.21 reports a significant difference in OS, and median OS are all consistently at the 
realms of 5-7 months. 
In summary, EGFR therapy is clearly active in some cancers. Whilst there are probably 
mechanistic difference between EGFR inhibitors and EGFR antibodies, all these drugs appear 
to stabilise disease and have the capability of delaying progression. Although cross-trial 
comparison is not statistically sound, it appears that these therapies are consistently more 
active in first-line than subsequent lines settings in advanced and metastatic NSCLC and 
CRC. Only few clinical trials actually resulted in significant OS benefit, which may be because 
of cross-over of EGFR inhibitors in the case of NSCLC trials. In general, the median survivals 
of PDAC regardless of experimental treatment are much shorter than the other two cancers, 
probably reflecting the aggressive nature of PDAC, poorer functional status of these patients, 
more treatment-related complications necessitating dose modifications, and a lack of second- 
and subsequent-line therapy.108,118 Importantly, the above comparison elucidated a much 
more favourable outcome when these targeted drugs can be applied on selected populations 
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(EGFR inhibitors in EGFR mutated NSCLC or EGFR antibodies in K-Ras mutation WT CRC). 
Together, this suggests a strong need to discover predictive markers for EGFR drugs in 
advanced PDAC so that it can be used upfront. 
1.3.3   Resistance in EGFR targeted treatment in Cancer 
Before turning to describing strategies to optimise targeted therapies in cancer, the 
unavoidable problem with targeted drugs- drug resistance- must be explored. Although these 
drugs were active initially, cancers soon developed resistance to these drugs, probably due to 
the multiple collateral pathways present.152 A plethora of translational studies examine the 
different types of resistance in NSCLC, but increasingly also in other cancer types including 
colorectal cancers, head and neck cancers, and glioblastoma multiforme.153-157 The study of 
EGFR treatment resistance in PDAC is currently much more limited. 
In general terms, drug resistance is divided into primary resistance and acquired resistance. 
Primary resistance describes the de novo properties of cancer which predetermines 
resistance to a particular therapy, and this is often used as a “negative biomarker” to guide 
treatment. The definition of acquired drug resistance, on the other hand, is less clear. The 
most acceptable definition of acquired resistance is both molecular (previous treatment with 
single agent inhibitor with development of a new genetic mutation) and clinical (progression of 
disease whilst on inhibitor with no intervening therapy between cessation of inhibitor and 
initiation of new therapy).158 This distinction, although only widely adopted in the study of 
NSCLC treatment, is very important in translational research as well as clinical practice. This 
is because mechanisms of primary and acquired resistance are often very different, and 
strategies to overcome them may also vary.134,159 In lung cancer, primary resistance has been 
well described with common gene abnormalities such as EGFR, K-Ras and B-RAF mutations. 
Acquired resistance, on the other hand, can occur due to EGFR modification such as T790M 
(occurring in over 50% of acquired EGFR inhibitor resistance in NSCLC) and EGFR variant 
vIII; activation of alternate pathways such as MET, HER2, NF-, PI3K; or histologic 
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transformation such as small cell transformation and epithelial-mesenchymal transition (table 
1.4).132,134,160 Regardless of the cancer type, there is now increasing evidence that acquired 
resistance may be related to emergence of cancer stem cells.82 This complexity and diversity 
of acquired resistance probably reflects clonal evolution in the presence of drug pressure, and 
therefore requires novel strategies to overcome it. Some of these strategies include 
intercalating targeted therapies with other treatment modalities (such as chemotherapies) and 
combining targeted therapies to overcome targeted drug resistance.161,162  
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Table 1.4: Overview of EGFR resistance mechanisms. From Chong and Janne (2013) The quest 
to overcome resistance to EGFR-targeted therapies in cancer.134 
 
In PDAC, several in-vitro studies suggested that mesenchymal cell phenotype and loss of 
dependency on EGFR-HER3 to be major determinants of erlotinib resistance in PDAC.84,163,164 
However, due to the limited utility of erlotinib given its small clinical benefit in survival, much 
of the research on EGFR signalling and EGFR inhibitor resistance in PDAC has been 
neglected.165  
It is interesting to note that there appears to be subtle differences in the resistance 
mechanisms between EGFR inhibitors and antibodies. Some of the mechanisms described 
for EGFR inhibitors include change in conformation of EGFRvIII, heterodimerisation of surface 
receptors, and oncogenic shift to alternate pathways such as IGF1R and Akt/mTOR pathway; 
whereas mechanisms of EGFR antibodies include EGFR mutations, unbiquination and 
internalisation and altered VEGF expression.132 Among these, activation of IGF1R and 
Akt/mTOR pathways appears to be of particular relevance in EGFR TKI resistance. A number 
of studies have demonstrated in GBM and NSCLC that EGFR inhibitor resistant tumours 
express high levels of pIGF1R in association with PI3K, along with loss of IGF-binding protein-
3, which results in sustained signalling via PI3K/Akt and rpS6.153,155 The high rates of IGF1R 
and PI3K/Akt over-expression (50%, 70%) in PDAC suggest that the association between 
these and erlotinib resistance should be further explored.48,54,61 
Altogether, the study of EGFR therapy resistance in NSCLC and other cancer types have 
been instrumental, though the study in PDAC is still preliminary and limited at this stage.  From 
the current literature, it appears that there are mechanistic differences between primary and 
acquired resistance, EGFR treatment resistance in different tumour types, and even 
differences between EGFR TKI and antibody resistance. The oncogenic shift to IGF1R and 
PI3K/Akt/mTOR pathways is a major mechanism of resistance to EGFR TKI, and is of 
particular relevance for this thesis. Further examination of these pathways in PDAC is 
therefore warranted.   
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1.4 Strategies to improve targeted therapies efficacy  
1.4.1  Novel targeted therapies 
This thesis will focus on the pre-clinical assessment of novel targeted therapies in the MAPK, 
IGF1R and PI3K/Akt/mTOR (or PAM) pathways in addition to EGFR inhibitors in PDAC. Whilst 
the individual compounds will be introduced in section 2.1.4, here the history of pre-clinical 
and clinical development of these novel compounds is outlined. 
IGF1R inhibitors and antibodies: Insulin growth factor 1-receptor (IGF-IR), a 
transmembrane receptor like EGFR with tyrosine kinase activity, activates downstream 
phosphatidylinositol 3-kinases (PI3K) serine-threonine protein kinase (Akt) proteins resulting 
in cell proliferation and survival.166 IGF1R is expressed in 50% of pancreatic cancer and is 
also important in both its development and progression.63,167-169 Manipulation of the IGF-IR 
system is shown to inhibit pancreatic cancer cell growth both in-vitro and in-vivo.170,171 There 
are currently about 8 Insulin Growth Factor antibodies and 3 small molecule tyrosine kinase 
inhibitors produced by various pharmaceutical companies.172 Figitumumab (CP-751,871) is a 
selective fully human IgG2 monoclonal antibody and the first IGF1R targeted therapy to reach 
randomized phase III clinical trial. In Phase I and II setting, figitumumab showed promising 
results in NSCLC, prostate cancer and recurrent head and neck cancer.173-175 When added to 
carboplatin and paclitaxel, figitumumab resulted in overall response rate of 64% compared to 
41% in chemotherapy only arm, including 1 complete response and 7 with striking partial 
response (50-80% tumour reduction by cycle 2).175 However, in the phase III randomized 
controlled trial in NSCLC, the combination of chemotherapy and figitumumab was shown to 
be harmful 8.5m vs. 10.3m, HR 1.23, p=0.051), with serious adverse events including 
dehydration, hyperglycaemia and haemoptysis.176 Post-hoc analysis showed that patients with 
high pre-treatment IGF-1 level (IGF1 > 145 ng/mL) may have improved overall survival (OS) 
from chemotherapy + figitumumab (HR = 0.62, p = 0.13).177 Whilst this compound from Pfizer 
has been discontinued for clinical development, other companies have continued developing 
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their IGF1R inhibitor. Most notable example was the AMGEN compound Ganitumab, which in 
randomised phase II trial improved median PFS from 2.1 to 5.1 months, with borderline 
statistical significance P=0.072. 127,128 At the time of initiating this research project, the 
proposed phase III trial from AMGEN was one of the major drivers of our study of EGFR- 
IGF1R inhibition in pre-clinical study in PDAC. Unfortunately, the phase III trial was 
discontinued in Aug 2012, putting pressure on any other companies attempting to develop 
IGF1R targeted treatment further.129 
PI3K and AKT inhibitors: PI3K in an excellent actionable target, because it responds to 
EGFR, IGF1R and K-Ras signaling, and it in turn controls a wide range of cellular processes 
which are major driving forces in cancer progression.55,178,179 The first-generation PI3K 
inhibitors were widely used for many pre-clinical experiments. The pan-PI3K inhibitor LY-
294002 was able to induce apoptosis in-vitro and induce tumour shrinkage in-vivo.53 However, 
this and others such as GDC-0941 and XL-147 were limited by weak PI3K inhibition and off-
target effects.180 Over the last decade, major advances in biochemistry have resulted in 
discovery of new compounds such as PI-103, which is a highly selective Class I PI3K inhibitor 
with extreme potency but solubility limitations; and PI-520 and PI-620, which are Class I PI3K 
inhibitors with slightly less potency but better pharmacokinetics and pharmacodynamics 
properties.180 These inhibitors tend to be isoform specific: NVP-BYL719 has been developed 
as a class I PI3K inhibitor with a high selectivity of p110α, whilst CAL-101 is a p110 specific. 
These inhibitors are expected to produce greater target inhibition with fewer adverse effects.47 
Other inhibitors of this class in early development include allosteric AKT inhibitors (MK-2206) 
and catalytic AKT inhibitors (GDC-0068 and GSK-690693), with allosteric inhibitors appearing 
to be more AKT-specific (Figure 1.14).47 The side effects of these PI3K and AKT inhibitors 
appear to be manageable, including mild rash, diarrhoea, stomatitis and hyperglycaemia. 
However, the biggest hurdle in the clinical development of these drugs is the modest activity 
it has on cancer as monotherapy, as opposed to the use of EGFR, ALK or B-RAF inhibitors 
on tumours with these driver mutations (EGFR, B-RAF) or translocations (ALK). 
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Pharmacodynamics studies showed that these drugs are hitting the right targets. Currently, it 
is thought that their limited efficacy may be related to co-existing mutations relating to 
resistance such as K-Ras, intra-tumoural heterogeneity, or the use of non-standardized or 
unvalidated assays for alterations in this pathway.47 
mTOR and dual PI3K/ mTOR inhibitors: Rapalogues were the first mTORC1 allosteric 
inhibitors developed, and included everolimus and temsirolmus which had proven single-agent 
efficacy in renal cell carcinoma (both), neuro-endocrine tumours (everolimus) and mantle cell 
lymphoma (temsirolimus).47 The most impressive data on the rapalogues, however, came from 
combined strategy trial. BOLERO-2 was a randomised phase III trial examined the effect of 
exemestane plus everolimus or placebo in 724 women with oestrogen receptor (ER) positive 
recurrent or metastatic breast cancer who previously had a non-steroidal aromatase inhibitor. 
Median PFS was improved from 4.1 to 10.6 months with a substantial magnitude of effect of 
HR of 0.36 (P<0.001).181 In other words, the addition of everolimus to aromatase inhibitors 
appeared to reverse endocrine resistance at least partially, suggesting cross-talk signalling 
between ER and mTORC pathways.182  
More recently, the dual PI3K/ mTORC inhibitors were developed based on the structural 
homologies in the catalytic domain of mTOR and p110 subunit of PI3K, providing the 
advantage of vertical blockade of the PAM pathway at two levels.47 BEZ-235 is one of the first 
compounds of this class, showing good in-vitro and in-vivo anti-tumour activity in multiple 
cancer types including pancreatic cancer.183-186 Early pre-clinical data also suggests that dual 
PI3K/ mTORC inhibitors are capable of over-riding transfected breast cancer cells with EGFR 
inhibitor resistance, supporting PAM pathway as an escape route.187 Recently, there is also 
pre-clinical data suggesting synergistic effect of BEZ-235 with radiation in glioblastoma, 
suggesting a role of this drug as a radiosensitizer in the treatment of brain cancer.188 
Interestingly, these inhibitors are known for off-targets such as fatigues and liver dysfunction, 
but are not associated with the usual metabolic side effects of rapalogues such as 
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hyperlipidaemia as well as pneumonitis.47 The safety and efficacy of these drugs are currently 
investigated in early phase I and II clinical trials. 
 
Figure 1.14: Inhibitors of the PAM pathway. From Rodon et al. (2013): Development of PI3K 
inhibitors: lessons learned from early clinical trials47 
 
MEK inhibitors: Targeting MEK is especially useful in cancer therapy, since MEK is a major 
downstream component of the MAPK (Ras/RAF/MEK/ERK) cascade which is a convergent 
point of many upstream signalling pathways.56,189 Whilst MEK1 and MEK2 genes are rarely 
mutated, over-activation of MEK usually occurs in the setting of upstream gain-of-function 
mutation of Ras and RAF.190 In contrast to other inhibitors, MEK inhibitors are all non-
competitive inhibitors of the ATP binding pocket of MEK that confer higher specificity.189 
However, MEK inhibitors tend to be cytostatic rather than cytotoxic.191 PD-98059 and U0126, 
the first MEK drugs, predominantly prevent activation of MEK instead of inhibiting its activity 
directly. These drugs were limited to in-vitro mechanistic studies due to issues with solubility 
and potency.192 CI-1040 was the first MEK inhibitor to succeed in-vivo and was subsequently 
assessed in a phase I and II settings. Unfortunately, this drug- whilst relatively non-toxic, 
demonstrated little clinical efficacy and its development was therefore terminated.192 The 
second-generation MEK inhibitors PD 0325901 and AZA6244, produced from changes in the 
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side chains of the compounds, resulted in >90 folds increase in potency and around 30-fold 
improvement in in-vivo efficacy. Both these drugs have entered into clinical development, with 
promising clinical activity of 30-50% stable disease rate for a median duration of 3-5 months. 
At this stage, the dose limiting toxicities for these drugs appear to be grade 3 rash, diarrhoea 
and a small chance of congestive cardiac failure.192 
In recent years, oncogenic dependence of downstream MAPK pathways have been 
discovered in Ras and RAF- mutant tumours, which display enhanced sensitivity to MEK 
inhibitors compared to wild type tumours.193,194 Importantly, whilst the mechanism of Ras and 
RAF mutations are different, both are associated with activated state of MEK, which in turn 
can be exploited by novel MEK inhibitors.194 In clinical trials, many have examined the roles 
of combining MEK inhibitors with other cancer therapies. The most notable example is 
combined vertical blockade (upstream and downstream) of the MAPK pathways in B-RAF 
mutated melanoma. A phase II trial demonstrates remarkable response rate of 56% by 
combining RAF and MEK inhibitors (dabrafenib and trametinib), as well as superior efficacy 
compared to conventional chemotherapy decarbazine (median PFS 9.4 versus 5.8 months, 
HR 0.39, P<0.0001).195 In K-Ras mutated metastatic CRC, a phase I/II study combining MEK 
inhibitor pimasertib with standard FOLFIRI chemotherapy is ongoing.196 For pancreatic 
cancer, whilst there are yet to be clinical trials researching the role of MEK inhibitor, this is 
certainly recognized as an area of active ongoing research given that virtually all PDAC are 
K-Ras mutated.189 
 
1.4.2  Combined blockade targeted therapies 
The drug development of novel targeted therapies has been hampered by the complexity of 
molecular pathways and existence of escape or bypass pathways. Combining targeted 
therapies as a strategy has a number of advantages: firstly, by targeting similar cellular 
pathways synergy may be achieved, where the combined anti-tumoural effects of two agents 
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exceed the additive effects of each drug. Secondly, combined blockade may circumvent 
escape pathways that contribute to drug resistance. Thirdly, it may overcome intra-tumoural 
heterogeneity in advanced disease where there are multiple metastatic clones with different 
genomic profiles and molecular activity.197 Lastly, combined blockade may potentially take 
advantage of synthetic lethality in cancer cells.198,199 In synthetic lethality, one mutated gene 
is compatible with viability but two mutated genes result in death. By targeting a gene that is 
synthetically lethal in cancer cells that have already mutated one gene, the normal cells may 
be spared.200 As our understanding of cancer genetics and gene-gene interactions expand, in 
the future we may be able to identify drug targets which exploit synthetic lethality and design 
cancer-specific drug combinations with enhanced therapeutic indices.199  
Combined blockade can take one of three strategies: horizontal blockade (blocking parallel 
oncogenic pathways), vertical blockade (upstream and downstream of the same pathway), 
and the so-called “super-inhibition” (maximising blockade of single target).161,201 Horizontal 
blockade aims at achieving selective tumour cytotoxicity whilst minimising overlapping 
toxicities by using different classes of agents, whilst vertical blockade maximises pathway 
inhibition by shutting down regulatory feedback loops which may give rise to drug 
resistance.161 Super-inhibition aims at the complete inhibition of a single target thereby 
enhancing “on-target” effects, and is utilised in cancer types that are highly dependent on a 
single oncogenic driver.202 An example is HER2 antibody (Herceptin) plus EGFR/HER2 
dimerising antibody (pertuzumab) in HER2+ metastatic breast cancer (CLEOPATRA).203 
The strategy of combined therapies has actually existed for a very long time in oncology 
history. Many chemotherapy regimens have been designed by combining multiple cytotoxic 
agents with presumably different mechanism of action and non-overlapping toxicities.198 
Examples of these include most adjuvant chemotherapy regimes in solid cancer malignancies 
(FOLFOX in colorectal cancer, AC-T in breast cancer) and a wide range of regimens used in 
haematological malignancies. However, there are some notable differences in studying 
chemotherapy versus targeted therapy combinations (table 1.5). Firstly, chemotherapy 
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combinations are traditionally studied only after single agents have been assessed as having 
high clinical efficacy, whereas some targeted therapies have little single-agent efficacy but 
may be synergistic when combined.161 Secondly, chemotherapy combinations are limited by 
non-specific toxicities on rapidly cycling normal tissues (e.g. myelotoxicity), whereas targeted 
therapies offer greater biochemical selectivity. The potential benefit for this is that there may 
be fewer overlapping toxicities in targeted therapy combinations, such that therapeutic index 
is widened allowing for higher dose or more frequent schedules to be adopted.198 
 
Table 1.5: Combined cytotoxic and targeted therapy combination approaches. From Kummar et 
al. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent 
requirements (2010)198 
 
In view of hundreds of targeted therapies in development, there are essentially an unlimited 
number of targeted therapy combinations for investigation.198 In 2006, the US National Cancer 
Institute (NCI) proposed a set of strategies for development of targeted therapy combinations, 
and prioritised renal cell carcinoma, melanoma and glioblastoma as the three tumours for 
further development of this strategy. A total of 15 phase I and II trials were proposed as a 
result, and emphasis was placed on developing VEGF super-inhibition, VEGF/ mTOR and 
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VEGF/ EGFR horizontal blockades.198,199 After this, this approach has also been extended to 
colorectal and lung cancers.198 Of recent times, probably the most notable success of 
combined blockade strategy was the phase III CLEOPATRA trial, where super-inhibition with 
herceptin and pertuzumab along with docetaxel chemotherapy resulted in a significant 
improvement in PFS from 12.4 to 18.5m (HR 0.62, P<0.001) compared with Herceptin plus 
docetaxel and placebo in women with HER2 positive metastatic breast cancer.203 Another 
exciting development was the phase II study combining B-Raf and MEK inhibition in B-Raf 
mutated melanoma and the phase III RCT COMBI that followed.195 However, not all targeted 
therapy combinations trials are met with success. Both PAACE and CAIRO2 were phase III 
metastatic colorectal cancer trials that showed inferior PFS when standard chemotherapy 
(PAACE: oxaliplatin or irinotecan-based, CAIRO-2: CAPOX) plus VEGF antibody 
bevacizumab was combined with EGFR antibody (PAACE: pannitumumab, CAIRO-2: 
cetuximab) whilst increasing toxicity204,205 At this stage it is uncertain whether this unexpected 
result was due to reduced dose intensity of chemotherapy, excess toxicity or negative synergy 
between two targeted therapies.206 Clearly, empirical combinations have a fair chance of 
failure; a better understanding in the molecular cross-talks and escape pathways is therefore 
needed to design biologically rational targeted therapy combinations.198 
Combined blockade of the MAPK and PAM pathways present itself as an attractive strategy 
given their relatively high frequencies of gene alteration and extensive cross-talk between the 
two signalling cascades.47,207,208 In fact, the relative low potency of the PI3K inhibitors and the 
apparent cytostaticity of MEK inhibitors may be in part related to the cross-talks between these 
two pathways, suggesting benefits in the horizontal blockade strategy.191,207 Pre-clinical 
studies have already demonstrated synergy of combining Raf and Akt/mTOR inhibitors in B-
Raf mutated melanoma, as well as MEK and PI3K inhibition in K-Ras mutated CRC, PTEN 
deleted ovarian cancer, lung cancer and triple negative breast cancer;207 and this strategy has 
been shown to suppress feedback loop associated with reactivation of reciprocal pathway.208  
Ongoing clinical development for PI3K inhibitors is presently focused on combination 
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strategies, with targeted therapy, chemotherapy or hormone therapy (Figure 1.15).47 In 
pancreatic cancer, there is certainly a strong rationale to co-inhibit the MAPK and PAM 
pathways, given the extremely high rates of K-Ras mutation and its downstream signalling 
effects on both network.191 There is early pre-clinical evidence combining PI3K and MEK 
inhibition in this cancer, but further development for this combination is warranted.191 
 
Figure 1.15: Ongoing Clinical Trial strategies of PI3K inhibitors. From Rodon et al. (2013): 
Development of PI3K inhibitors: lessons learned from early clinical trials47 
 
Nevertheless, many challenges remain in the clinical development of drug combination trials, 
as suggested by the recent Institute of Medicine workshop. These include “developing and 
applying appropriate preclinical and clinical experiments, prioritising relevant drug 
combinations, identifying relevant biomarkers, avoiding or managing the overlapping toxicities 
of multiple agents, and overcoming legal, cultural, and regulatory barriers that impede 
collaboration of pharmaceutical companies, academia and government institutions.”197 In 
particular, defining optimal dosing and schedules for the drug combination whilst optimising 
metabolic interactions and minimising overlapping toxicities in clinical studies can be 
exceedingly complex, and frequently a phase I study may take more than a year and at 
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significant costs to complete.161 To address these challenges, drug combinations should be 
selected based on “known biologic mechanism for which an assay is available, with activity or 
target engagement at clinical relevant doses, and validated biomarkers for patient 
selection”.197 Pre-clinical evidence of a strong biological rationale of the specific drug 
combination is critical for it to be taken forward to clinical development. During early clinical 
development, novel combinatory designs such as flexible dose escalation and de-escalation 
rules, multiple parallel cohorts and Bayesian models of dose escalation should be adopted to 
reach an optimal recommend phase II dose (R2PD) efficiently.161 In addition, pharmacokinetic/ 
pharmacodynamics as well as biomarker studies should be incorporated early in phase I/ II 
studies. Finally, collaboration between regulatory authorities, pharmaceutical companies and 
academic institutions is paramount to co-develop multiple drugs from different origins whilst 
ensuring intellectual property and funding issues are dealt with appropriately.161  
 
1.4.3  Biomarkers in EGFR and PI3K inhibitor therapies 
A third general strategy to improve targeted therapy treatment is to discover positive predictive 
biomarkers which may identify patients who will benefit from these treatments. Of recent times, 
probably the most topical biomarker in PDAC is the Human Equilibrative Nucleoside 
Transporter (hENT-1)- a bi-directional transporter of pyrimidine nucleosides into cells, where 
low hENT-1 predicts for gemcitabine resistance and poorer survival.209-211 On the other hand, 
discovering biomarkers for targeted therapies in a disease with extensive genetic alterations 
proves most challenging, and genetic profiling is likely needed in early phase development of 
these drugs and combinations to enable researchers to tailor drug dosing for each patient.197 
Here current literature informing possible biomarkers in EGFR and PI3K inhibitor therapies is 
described. 
EGFR inhibitors:  In PDAC, the study of erlotinib and biomarkers are somewhat limited. Pre-
clinical studies implicate HER-3 mediated PI3K/ Akt pathway activation and quasi-
76 
 
mesenchymal status as negative predictive markers for erlotinib treatment.163,212 However, in 
clinical studies, Akt over-activation and K-Ras mutation are only recognized as negative 
prognostic markers at this stage, whilst their predictive values remained unproven.44,54 There 
are two translational studies based on large phase III clinical trials published to date. In the 
sub-study from the investigator of the PA.3 trial, K-Ras mutation status and EGFR gene copy 
numbers (by FISH) were retrospectively analysed.213 Unfortunately, as PA.3 trial did not 
mandate tissue biopsy in its eligibility criteria, only 32% patient samples (181/569) could be 
retrieved for further analysis, of which only 26% K-Ras mutation status and 15% EGFR FISH 
results were available. The result was inconclusive, with no significant interactions reported 
for K-Ras mutation (P=0.38) or EGFR high polysomy (P=0.32), and OS was not significant 
different between patients with K-Ras mutant and K-Ras wild type tumours (7.4 vs. 4.5m, 
HR=0.68, P=0.30) or between EGFR FISH positive and FISH negative tumours (6.7 vs. 5.3m, 
HR=1.07, P=0.83). As the investigators rightly pointed out, the study limitations (retrospective 
design and small sample size) may have influenced the potential prognostic and predictive 
values of individual markers.213 In the AIO-PK0104 study, the investigators prospectively 
collect tissue and analyse K-Ras mutations on fixed paraffin embedded tissue.121 They also 
retrospectively analysed EGFR over-expression, EGFR gene amplification, intron 1 and exon 
13 polymorphism and PTEN over-expression.60 To the credit of the investigators, they were 
able to collect tumour blocks in 74% (208/281) and successfully performed K-Ras mutation 
testing on 61% (173/281) cases. The prevalence of K-Ras mutation was lower than reported 
in literature (70%), whilst EGFR gene was found to be overexpressed in 46% by FISH, EGFR 
over-expressed in 49% by IHC and PTEN over-expressed in 18% by IHC. Patients with K-Ras 
wild type appear to have a longer OS than those with K-Ras mutated tumours (7.9 vs. 5.7 m, 
HR 1.68, P=0.005), but there is no correlation between K-Ras status and other study 
endpoints. Loss of PTEN was associated with shorter (Time- to- treatment failure) TTF1 and 
TTF2 (P=0.02, P=0.04), but none of the EGFR related markers are co-related with differences 
in any study endpoints, nor are they co-related with each other.60 From this analysis, K-Ras 
status and PTEN expression may represent important markers in PDAC, though whether they 
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have prognostic or predictive value remain to be seen. EGFR or EGFR gene have limited 
value, and the authors suggest that further translational research should focus on downstream 
signalling pathway networks PI3K-PTEN-AKT and RAS-MAPK-MEK-ERK.60 One other study 
examined EGFR mutation, copy number and K-Ras mutation in 66 consecutive patients with 
PDAC. Whilst presence of K-Ras mutation was adversely prognostic (P=0.03), EGFR 
mutation or copy number were not.214 
Despite the apparent lack of utility of EGFR as a predictive marker for erlotinib sensitivity and 
resistance in translational studies, there certainly appears that EGFR signalling continues to 
have a vital role in the tumour biology of PDAC. Although EGFR mutation is rare in PDAC 
(1.5%) and is typically silent, it can certainly co-exist with K-Ras mutation in PDAC.58,213-215 
EGFR gene is in fact over-amplified in 42% cases and EGFR tyrosine kinase is over-
expressed in 77% of cases.59 EGFR over-expression, whilst not shown to be prognostic, was 
strongly correlated with metastasis to lymph nodes and distant organs.165,216 A seminal paper 
in Cell found evidence through in vivo gene knockout models that EGFR signalling is 
absolutely vital for PDAC carcinogenesis and progression, and that K-Ras oncogenic driven 
lesions remain dependent on EGFR signalling.165 This stands in sharp contrast to our 
understanding of NSCLC and CRC tumours, where K-Ras and EGFR mutations are mutually 
exclusive.58,165 The group further found that EGFR co-operate with K-Ras by activating the 
AKT and STAT3 pathways, suggesting the need of compound inhibition of all 4 pathways to 
abrogate progression of PDAC tumours.165 Based on these findings, EGFR, Ras and PI3K/Akt 
signalling should all be evaluated as biomarkers in further translational studies, and this 
probably requires multiple platforms evaluating both genetic and molecular markers. 
PI3K/Akt inhibitors: PI3K/ Akt inhibitors have only just entered into early clinical development 
at this stage. There is active research into evaluating candidate biomarkers for PI3K/ Akt 
inhibitors; but suffice to say, there are much conflicting results in the early stages of this 
translational research. Biomarkers for the PI3K/ Akt inhibitors have generally been evaluated 
under three groups: pharmacodynamics (molecular) markers, metabolic markers and genetic 
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markers.47 Pharmacodynamic markers refer to indicators of whether the drugs are hitting the 
target, and current development focuses on testing phosphorylation of key molecular signals 
(e.g. Akt, S6, 4EBP-1) in surrogate tissue such as serum, skin or hair through serial sampling. 
Whilst the strategy appears innovative, this strategy is currently limited by variability in 
measurements and lack of correlation between surrogate and tumour tissue levels (table 
1.6).47 Metabolic markers are another interesting concept, given that PI3K is intricately 
involved in glucose metabolism.46 Attempts have been made to assess dose-response 
relationship with fasting serum glucose, insulin and C-peptide, but these are limited by normal 
diurnal variations.47 18F-flurodeoxyglucose (FDG)- PET scans appear to correlate strongly with 
PAM inhibitor treatment response in early pre-clinical studies, suggesting a role of PET as an 
imaging biomarker for PAM inhibitors treatment.217,218 This is now a focus of ongoing phase I 
trial research in this area.47 Lastly, genetic markers such as PIK3CA mutations and PTEN loss 
have been assessed in clinical trials with PAM inhibitors, in an attempt to identify predictive 
biomarkers that may be used to enrich future study populations.47 In a translational study of a 
phase I study of 217 patients with advanced tumours, Janku et al. found that PIK3CA was 
mutated in 11.5% of patients, with the highest frequency in endometrial cancer (21%), followed 
by ovarian (17%), colorectal (17%), breast (14%), cervical (13%) and lung (11%) cancers. 
Among the patients who received a PAM inhibitors as part of their treatment, response rate 
was significantly higher for patients with PIK3CA mutation than those without documented 
mutations (35% vs. 6%, P=0.001). Furthermore, the duration of response for these patients 
was at least 9 weeks, and as long as 59 weeks by censoring.219 Despite these encouraging 
results, identifying genomic markers for PI3K inhibitors prove more challenging than for EGFR 
or BRAF targeted therapies, due to coexistence of gene mutations (45% of patients with 
PIK3CA mutation also harbour K-Ras mutation), conflicting preclinical data on the activity of 
PAM inhibitors in specific molecular setting as well as continuing issues with assays detecting 
PI3K alterations.47,219 Certainly, more work is needed to validate these potential biomarkers 
and translate them into clinical practice.      
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Table 1.6: Pharmacodynamic markers of PI3K inhibitors. From Rodon et al. (2013): 
Development of PI3K inhibitors: lessons learned from early clinical trials47 
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1.5 Study Hypotheses and Aims 
To summarise, PDAC is a deadly disease that is often diagnosed late, and for which there are 
few treatment options available. Targeted therapies, whilst becoming an important 
armamentarium in a number of cancers such as NSCLC, CRC, breast cancer and renal cell 
carcinoma, have unfortunately little role in PDAC yet. The genetically heterogeneous nature 
means that clearly empirical testing of targeted therapy in unselected population will bound to 
fail;220 unless biological rational in vitro and in vivo combination treatment models are 
developed there is a high probability that the wrong drug/s will be tested in the wrong molecular 
setting.198 This current research program was designed 4 years ago, to dissect the tumour 
biology of EGFR inhibitor resistance, leading to in-vitro and in-vivo and clinical testings of 
EGFR/ PI3K combined blockade. The first 3 stages will be covered in chapter 3, 4, 5 of this 
thesis, and these findings are now leading to study proposal for a phase I/ II study. (Figure 
1.16).  
 
Figure 1.16: Summary of Methods in the Research Program. *ER denotes erlotinib resistant cell 
lines 
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The overall objective of this project is to establish pre-clinical evidence of combined blockade 
of co-dependent pathways to inhibit pancreatic cancer based on the concept of synthetic 
lethality, for it to be recommended for clinical development. The hypotheses and aims for the 
chapters to come are as follows (table 1.6 and 1.7), and will be developed at the beginning of 
the respective chapters. 
 
Table 1.6: Hypotheses of the research project 
  
Table 1.7: Summary of chapters and chapter aims  
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CHAPTER 2: 
 
MATERIALS AND METHODS 
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2.1 Materials 
2.1.1 Cell Lines 
BxPC-3 and CAPAN-2 were purchased from ATCC (Manassas, VA), CFPAC-2 and PANC-1 
were gifts from St George and MiaPACA-2 from Royal North Shore Hospitals. Cell lines were 
typed and they conformed to the ATCC reference standards (CellBank, Westmead, NSW). All 
5 cell lines except for BxPC-3 are K-Ras mutated. The genetic, phenotype characteristics and 
erlotinib sensitivities of these cell lines are illustrated in table 1. 
 
BxPC-3 (ATCC CRL-1687) (ATCC: the American Type Culture Collection, Manassas, VA, 
USA) is an epithelial type PDAC derived from the body of the pancreas from a 61 year-old 
female.221,222 It has a poorly differentiated grade and is known to have a rapid doubling time of 
24 hours.223 The tumorigenicity of this cell line was proven by xenograft in nude mice, and it 
differentially expressed carcinoembryonic antigen, human pancreas-cancer associated 
antigen and human pancreas-specific antigen.223 Unlike most PDAC cell lines, BxPC-3 is K-
Ras wild type. It is also wild type for p16, but is mutated for p53 (codon 220 Cys) and deleted 
for SMAD4/DPC-4.224 It has a 69% inhibition with erlotinib 10µM in-vitro,163 and is the most 
erlotinib sensitive among 12 PDAC cell lines studied in-vivo.84 
 
CFPAC-1 (ATCC CRL-1918) is derived from a PDAC liver metastasis of a 26 year-old 
Caucasian male with cystic fibrosis (CF).225 The cells show epithelial morphology and 
polarisation with apical microvilli. It is well differentiated, and has a doubling time of 32 hours. 
It has been stable for over 80 passages.225 CFPAC-1 is K-Ras mutated (codon 12 Val), p53 
mutated (codon 242 Arg), p16 methylated and SMAD-4/DPC-4 deleted.226 Additionally, it 
displays a phenylalanine-508 deletion, the commonest form of CF mutation.225 In-vitro, it is 
inhibited by 51% with erlotinib 10µM.163 In-vivo, it is found to be sensitive to erlotinib.84 
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CAPAN-2 (ATCC HTB-80) originated from a 56-year old male with PDAC, whose primary 
tumour involved the head of pancreas and invaded the duodenal wall distal to ampulla.227,228 
The allozyme phenotypic profile of CAPAN-2 was determined in eight genetically determined 
loci, and it showed characteristics of ductal epithelium ultrastructurally.139,222 CAPAN-2 has an 
exceedingly long doubling time of 96 hours. It is K-Ras mutated (codon 12 Val); but is wild 
type for p53, p16 and SMAD-4/DPC-4.228 It is inhibited by 50% with erlotinib 10µM in-vitro,163 
but is only moderately sensitive to erlotinib in-vivo.84 
 
MiaPACA-2 (ATCC CRL-1420) is a PDAC cell line isolated from a 65 year-old Caucasian 
male in 1975.229 The tumour was poorly differentiated and involved the body and tail of the 
pancreas that had invaded the periaortic area.228 This cell line has a mesenchymal morphology 
and displayed both mesenchymal and amoeboid motility.222,230 MiaPACa-2 was first reported 
to have a doubling time of 40 hours,229 but a doubling time as short of 19 hours has been 
reported.223 MiaPACA-2 is K-Ras mutated (codon 12 Cys), p53 mutated (248 Trp) and p16 
deleted, but it is wild type for SMAD-4/DPC-4.226 It is insensitive to erlotinib in-vitro with only 
9% inhibition with erlotinib 10µM and it is also insensitive in-vivo.84,163 
 
PANC-1 (ATCC CRL-1469) was from an epithelioid PDAC carcinoma from a 56 year-old male, 
whose primary tumour originated from the head of the pancreas, and invaded the duodenal 
wall and metastasized to peripancreatic lymph node.228,231 PANC-1 has a mixed population of 
epithelial and mesenchymal cell type,222,232 but is known only to express mesenchymal marker 
vimentin and not epithelial marker e-cadherin.84 It is poorly differentiated, has a doubling time 
of 52 hours and displays glucose-6-phosphate dehydrogenase deficiency (G6PD) activity of 
the B-type slow mobility.231 PANC-1 is K-Ras mutated (codon 12 Asp), p53 mutated (codon 
86 
 
273 His) and p16 deleted, but it is wild type for SMAD-4/DPC-4.226 Like MiaPACA-2, it is not 
sensitive to erlotinib in-vitro (8% inhibition with erlotinib 10µM) and in-vivo.84,163 
 
Cell Lines BxPC-3 CFPAC-1 CAPAN-2 MiaPACA-2 PANC-1 
Origin Body of 
Pancreas 
Primary 
Liver 
Metastasis 
Head of 
Pancreas 
Primary 
Body/tail of 
Pancreas 
Primary 
Head of 
Pancreas 
Primary 
Cell Type Epithelial Epithelial Epithelial Mesenchymal Mixed  
Doubling Time 24hr 32hr 96hr 40hr (18hr has 
been reported) 
52hr 
Differentiation Moderate Well Well Poor Poor 
E-Cadherin + + + - - 
Vimentin - - - + + 
K-Ras WT 12Val 12Val 12Cys 12Asp 
p16 WT WT WT del del 
p53 220Cys 242Arg WT 248Trp 273His 
SMAD-4* 1659del del WT WT WT 
ERLOTINIB 
SENSITIVITY 
VERY HIGH HIGH MODERATE LOW LOW 
 
Table 2.1: Genetic, morphological characteristics and erlotinib sensitivities of 5 PDAC cell line 
used for in-vitro experiments. Number denotes the position of the gene codon where the mutation 
occurs, resulting in the translation of an incorrect amino acid. WT- wild type. Del- deleted. Val- valine, 
Cys- cysteine, Asp- aspartic acid, Arg- arginine, Trp- tryptophan, His- histidine.84,226,228 
 
 
2.1.2 Media for Cell Culture 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
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DMEM medium (Hyclone, Thermo scientific Fisher, NSW, Australia) with 2mM L-glutamine, 
supplemented with 10% Fetal Bovine Serum (FBS) Ausgene X, QLD, Australia) and 1% L-
glutamine (Thermo Scientific Fisher) was used for cell culture for MiaPACA-2 and PANC-1 
cell lines. It was also used for PANC-ER, a cell line derived from PANC-1 and made resistant 
to erlotinib. 
 
RPMI 1640 Medium 
BxPC-3, CFPAC-1 and CAPAN-2 cell lines were cultured in RPMI 1640 solution (Thermo 
Scientific Fisher), supplemented with 10% FBS and 2mM L-glutamine. It was also used for 
BxPC-ER, a cell line derived from BxPC-3 and made resistant to erlotinib.  
 
2.1.3 Novel Tyrosine Kinase Inhibitors (inhibitor) 
Erlotinib (C21H21N3O4.HCl, MW 415.87) is an oral epidermal growth factor receptor/ human 
epidermal growth factor type 1 (EGFR/ HER1) tyrosine kinase inhibitor (TKI) with a half-life of 
36 hours.233 EGFR is expressed on cell surface of normal cells and epithelial type cancer cells; 
erlotinib inhibits phosphorylation of EGFR tyrosine kinase in these cells with nanomolar 
potency.233 It is currently TGA approved for the indication for the treatment of locally advanced 
or metastatic PDAC in combination with gemcitabine, first-line in NSCLC with EGFR mutation, 
and subsidised by the Pharmaceutical Benefits Scheme (PBS) for NSCLC after prior platinum 
based doublet chemotherapy due to progression or intolerance of chemotherapy.234 Erlotinib 
was used in both in-vitro and in-vivo studies in this project. For in-vitro experiments, erlotinib 
was purchased from Selleckchem, Houston, TX (cat no: S2205), and was diluted with 100% 
DMSO to 20mM stock. Final concentration tested for in-vitro experiments ranged from 5 to 
30µM, as initial optimisation experiments had found that erlotinib concentration higher than 
30µM could not be completely dissolved in medium resulting in crystallisation. For in-vivo 
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experiments, 150mg erlotinib tablets for clinical use (Roche) were homogenized in 6 mg/ml 
0.5% methylcellulose prepared fresh twice weekly for gavaging, and stored at -20oC for a 
maximum of 7 days. 
 
Gefitinib (C22H24CIFN4O3, MW 446.90) is an oral selective EGFR inhibitor with EGFR 
inhibitory IC50 of 0.03µM and a half-life of 41 hours.233,235 In-vitro, it has a cellular inhibitory IC50 
as low as 0.2 to 0.4µM in colon cancers, breast cancers and ovarian cancers, but only 
significantly reduces cell proliferation at concentration above 20µM in pancreatic cancer.236,237 
Although gefitinib is active across many tumour types in-vivo,235 gefitinib has only been 
extensively investigated in NSCLC clinical trials, and its clinical efficacy in PDAC is unproven. 
Gefitinib is used alongside erlotinib in in-vitro studies to assess sensitivities of cell lines to 
EGFR inhibitors. Gefitinib was purchased from Selleckchem, Houston, TX (cat no: S1025), 
and was diluted with 100% DMSO to 10mM stock. Final concentration tested for in-vitro 
experiments ranged from 5 to 30µM. 
 
NVP-AEW541 (C27H29N5O, MW 439.55) is an IGF1R inhibitor belonging to the pyrrolo [2,3-
d]pyrimidine class family of compounds, with equipotent inhibition activity against IGF1R 
(IC50=0.15µM) and Insulin Receptor (Ins-R) (IC50=0.14µM) on kinase activity assays, and 
highly specific cellular inhibitory activity for IGF1R (IC50 = 0.086µM) which is 27-fold higher 
than Ins-R and other kinases. It also has activity against Akt and MAPK signalling pathway.238 
It has in-vivo activity against various tumour types including pancreatic cancer, colorectal 
cancers and sarcoma, but has not yet been studied in clinical settings.238-240 NVP-AEW541 
was purchased from Selleckchem (cat no: S1034) used for in-vitro studies only. It was 
dissolved in 100% DMSO as a 2mM stock and frozen in -20oC refrigerator. 
LY-294002 (C19H17NO3, MW 307.34) has been extensively studied in preclinical studies as a 
pan-PI3K inhibitor with inhibitory IC50 of PI3K-p110α, p110δ, and p110β of 0.5, 0.57 and 
0.97µM, resulting in a dose-dependent inhibition of Akt.241,242 LY-294002 is in fact not a very 
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specific PI3K inhibitor, as it also binds to other non-lipid kinases such as CK2, mTOR and 
GSK3β, though all these kinases may indirectly relate back to PI3K.243 It is also not very potent, 
as it only inhibits PI3K with micromolar potency.180 LY-294002 has proven in-vivo efficacy in 
pancreatic cancers, colorectal cancers, hepatoblastoma and ovarian cancers among many 
others.53,242,244,245 In this project, LY-294002 was purchased from Selleckchem (cat no: S1106) 
and was used in-vitro to compare with specific PI3Kα inhibitor NVP-BYL719. It was dissolved 
in 100% DMSO as a 2mM stock and frozen in -20oC refrigerator. 
 
NVP-BYL719 is a novel specific class I PI3Kα inhibitor currently being developed by Novartis 
and donated by Novartis for these experiments (Basel, Switzerland). It has been tested in-
vitro, in-vivo with plans for clinical development.246 Due to privacy agreement with the pharma 
company, details of previous studies could not be provided in this thesis. NVP-BYL719 was 
used for both in-vitro and in-vivo studies. For in-vitro studies, it was dissolved in 100% DMSO 
as 2mM stock and stored in 4oC refrigerator upon advice from Novartis. For in-vivo studies, 
NVP-BYL719 was prepared fresh twice weekly and homogenized in 6 mg/ml 0.5% 
methylcellulose for oral gavaging, and stored at -20oC for a maximum of 7 days. 
 
NVP-BEZ235 is a novel dual PI3K/ mTOR inhibitor also currently developed by Novartis. It 
has an inhibitor IC50 of 75nM against Class I PI3K, and also has nanomolar potency against 
mTOR (IC50 =20nM). It has strong anti-proliferative activity with an average GI50 of 10 to 12nM, 
and also strong anti-tumour activity in-vivo at 25mg/kg twice daily.183  Whilst NVP-BEZ235 was 
only a recently developed inhibitor over the last few years, it already had established in-vivo 
activity against pancreatic cancers, ovarian cancers, renal cell carcinomas, and is now being 
developed in phase I clinical trial.184-186 NVP-BEZ235 was initially purchased from 
Biochempartner (Shanghai, China) and later supplied by Novartis. For in-vitro studies, it was 
dissolved in 100% DMSO as a 40µM stock and frozen in -20oC refrigerator. For in-vivo studies, 
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it was homogenized in 6 mg/ml 0.5% methylcellulose prepared fresh twice, and stored at -
20oC for a maximum of 7 days. 
 
PD-98059 (C16H13NO3, MW 267.28) is the first and oldest synthetic inhibitor of the MAPK 
pathway via selective MEK inhibition (IC50 =2µM).247 Over the years, it has been extensively 
studied in cancers in-vitro, predominantly to illustrate connections of MAPK/MEK/ERK 
pathways to other systems.248-251 More recently, it has been investigated in various 
combination strategies with chemotherapy, IGF1R inhibitors, mTOR inhibitors and PI3K 
inhibitors.252-255 PD-98059 was purchased from Selleckchem (cat no: S1177) and dissolved in 
100% DMSO as a 4µM stock and frozen in -20oC refrigerator for in-vitro experiments. 
 
Other targeted therapies used in this PhD project were IGF1R inhibitor OSI-906 (C26H23N5O, 
MW 421.49, Selleckchem) and IGF1R antibody Figitumumab (CP751,871; Pfizer, Conneticut, 
USA). These drugs were used initially in preliminary experiments, and were later superseded 
by the more potent NVP-AEW541. Data for these were not shown. 
2.1.4 Chemotherapeutic agents 
Gemcitabine (C9H11F2N3O4.HCl, MW: 299.66) is a pyrimidine analogue that is primarily 
cytotoxic for cell undergoing DNA synthesis (S-phase). It is given intravenously in patients with 
a half- life between 42 to 94 minutes. It is used clinically in a wide range of cancer types 
including breast cancers, lung cancers, pancreatic cancers and ovarian cancers.233 It was 
used predominantly in-vivo in the studies given that it is the standard first-line therapy in 
advanced and metastatic PDAC. Gemcitabine was purchased as powder (Hospira) and 
reconstituted in sterile normal saline 0.9% into 10mg/ml solution for intra-peritoneal injection 
in-vivo. 
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Mitomycin (C15H18N4O5. MW: 334.3) is an antibiotic that has cytotoxic properties. At low 
concentration, it inhibits DNA synthesis; and at high concentration, it also suppresses RNA 
and protein synthesis.233 It was purchased as powder (Bristol-Myers Squibb), reconstituted in 
sterile normal saline to produce 0.2mg/ml stock, and was used as a cytostatic agent in 
migration assays. 
 
2.1.5 Antibodies 
The primary antibodies p-EGFR, EGFR, p-IGF1R, IGF1R, p-Erk, Erk, p-Akt, Akt, p-S6, S6, p-
4EBP1, 4EBP1 and β-actin were purchased from Cell Signalling. Conventional secondary 
antibodies goat anti-rabbit, goat anti-mouse and human anti-goat, were from Santa Cruz. 
Fluorescent secondary antibodies goat anti-rabbit (733nM- red), goat anti-mouse (488nM- 
green) and human anti-goat (733nM- red) were from Cell Signalling. Antibodies were used for 
western blotting, immunofluorescence and immunohistochemistry experiment (Table 2a-c).  
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Western Blotting Experiments 
Primary 
Antibody 
Size (kda) Optimised Concentration 
for Primary Antibody 
Optimised Concentration 
for Secondary Antibody 
pEGFR Tyr1068 175 1:1000 1:1000 (anti-rabbit) 
pEGFR Tyr845 175 1:1000 1:1000 (anti-rabbit) 
EGFR 175 1:1000 1:1000 (anti-rabbit) 
pIGF1R Tyr1135 95 1:1000 1:1000 (anti-rabbit) 
IGF1R 95 1:1000 1:1000 (anti-rabbit) 
pERK Thr202/Tyr204 42, 44 1:1000 1:1000 (anti-rabbit) 
ERK 42, 44 1:1000 1:1000 (anti-rabbit) 
pAkt Ser473 60 1:1000 1:1000 (anti-rabbit) 
pAkt Thr308 60 1:1000 1:1000 (anti-rabbit) 
Akt  60 1:1000 1:1000 (anti-rabbit) 
pS6 kinase Thr398 70 1:1000 1:1000 (anti-rabbit) 
pS6 kinase 70 1:1000 1:1000 (anti-rabbit) 
p4E-BP1 Thr37/46 15-20 1:1000 1:1000 (anti-rabbit) 
4EBP1 15-20 1:1000 1:1000 (anti-rabbit) 
Cleaved Caspase-
3 
17, 19 1:1000 1:1000 (anti-rabbit) 
E-cadherin 110 1:1000 1:1000 (anti-mouse) 
Vimentin 58 1:1000 1:1000 (anti-goat) 
B-actin 45 1:3000 1:3000 (anti-mouse) 
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Immunofluorescence Experiments 
Primary Antibody Optimised Concentration 
for Primary Antibody 
Optimised Concentration 
for Secondary Antibody 
pERK (mouse) 1:125 1:1000 (anti-mouse) 
pERK (rabbit) 1:125 1:1000 (anti-rabbit) 
ERK 1:100 1:1000 (anti-rabbit) 
pAkt Ser473 1:125 1:1000 (anti-rabbit) 
Akt 1:125 1:1000 (anti-rabbit) 
Cleaved Capase-3 1:100 1:1000 (anti-rabbit) 
E-cadherin 1:150 1:1000 (anti-mouse) 
Vimentin 1:150 1:1000 (anti-goat) 
 
Immunohistochemistry Experiments 
 
 
Table 2.2 a-c) Optimised concentration for primary and secondary antibodies for Western 
blotting (WB), Immunofluorescence (IF) and Immunohistochemistry (IHC).  
 
  
Primary Antibody Optimised Concentration 
for Primary Antibody 
Optimised Concentration 
for Secondary Antibody 
Cytokeratin 7 1:100 1:1000 (anti-rabbit) 
Cytokerain 20 1:100 1:1000 (anti-rabbit) 
p-Akt 1:100 1:1000 (anti-rabbit) 
Akt 1:100 1:1000 (anti-rabbit) 
Ki-67 1:300 1:1000 (anti-rabbit) 
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2.1.6 Primers 
Table 3 shows the list of primers used for quantitative real time PCR (qRT-PCR). These 
primers cover for genes from the PI3K/ Akt pathways as well as alternate pathways such as 
MAPK, TLR-4 and HER3 pathways. All of these were kiCqStart pre-made sYBR Green 
primers (Sigma), with the exception of NF-kb1A, Rel and GAPDH which were TaqMan probes 
(Applied Biosystems). TaqMan probes were used for these because no suitable SYBR Green 
primers were found for NF-kb system for the PDAC cell lines in this study. GAPDH was used 
as the reference gene for Taqman assay, and 18S for SYBR Green assay. SYBR Green 
Primers were obtained in pairs (forward and reverse primers), and different variants of the 
same gene were obtained to improve the sensitivity of the results. The primer pair, reference 
codes, exon size, description, position and sequences are shown below: 
Primer Pair Unigene Ref Seq Exon Description 
Gene 
Position 
 Sequence (5’-3’) 
PIK3CA_1 Hs.553498 NM_006218 9-10 Phosphoinositide-3-kinase, 
catalytic, alpha polypeptide 
3q26.3 Forward: GAGTAACAGACTAGCTAGAGAC 
Reverse: AGAAAATCTTTCTCCTGCTC 
PIK3CG_1 Hs.32942 NM_002649 6-8 Phosphoinositide-3-kinase, 
catalytic, gamma 
polypeptide 
7q22.3 Forward: CAGATTCTACGAATCATGGAG 
Reverse: TCCTATTTTGTCACCAGTTG 
PIK3CG_2 Hs.32942 NM_002649 10-11 Phosphoinositide-3-kinase, 
catalytic, gamma 
polypeptide 
7q22.3 Forward: TCAGGACATCTGTGTTAAGG 
Reverse: GCATCCCGGATATATTCAATG 
AKT2_1 Hs.631535 NM_001243027 2-3 V-akt murine thymoma viral 
oncogene homolog 2, 
AKT2 
19q13.1-q13.2 Forward: CACCATGAATGAGGTGAATAC 
Reverse: CTACGGAGAAGTTGTTTAAGG 
AKT2_2 Hs.631535 NM_001243027 1-3 V-akt murine thymoma viral 
oncogene homolog 2, 
AKT2 
19q13.1-q13.2 Forward: GAAACACAAGGAAAGGGAAC 
Reverse: AGGTCTTGATGTATTCACCTC 
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MAPK1_1 Hs.431850 NM_002745 n/a Mitogen-activated protein 
kinase 1. ERK2 
22q11.21 Forward: TAACATCTGGAGACTGTGAG 
Reverse: TGAAGTTAGTGGTTTCATGC 
MAPK1_2 Hs.431850 NM_002745 n/a Mitogen-activated protein 
kinase 1. ERK2 
22q11.21 Forward: TACCAAAATAACACAGCACC 
Reverse: TAAACAAGTTACCACATGC 
ERBB3_1 Hs.118681 NM_001982 27-28 V-erb-b2 erythroblastic 
leukemia viral oncogene 
homolog 3, HER3 
12q13 Forward: ATACACACCTCAAAGGTACTC 
Reverse: ATCTTCTTCTTCAGTACCCAG 
FOS_1 Hs.728789/ 
Hs.731317 
NM_005252 3-4 FBJ murine osteosarcoma 
viral oncogene homolog. 
Fos 
14q24.3 Forward: GGAGACAGACCAACTAGAAG 
Reverse: GTTTTTCCTTCTCCTTCAGC 
TLR4_2 Hs.174312 NM_138557 1-2 Toll-like receptor 4 
9q33.1 Forward: TGGAGGTGTGAAATCCAG 
Reverse: CTTGARAGRCCAGAAAAGGC 
NF-kb1A Hs00765730_m1 n.a. n.a. Nuclear factor- kappa B 
P50 
 Not disclosed by company 
Rel-A Hs01042010_m1 n.a. n.a. Nuclear factor- kappa B 
P65 (Rel A) 
 Not disclosed by company 
18S X3205.1 HSRRN18S - Ribosomal 18S 
 Forward: GCCCGAAGCGTTTACTTT 
Reverse: TCCATTATTCCTAGCTGCGGTATC 
GAPDH Hs99999905_m1 n.a. n.a. glyceraldehyde-3-
phosphate dehydrogenase 
 Not disclosed by company 
Table 2.3 Primers used in qRT-PCR experiments 
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2.2 Methods 
2.2.1 Cell Culture Protocols 
BxPC-3, CFPAC-1, CAPAN-2 and BxPC-ER were cultured in T75 flasks with RPMI medium 
supplemented with 10% FBS and 1% L-glutamine. MiaPACA-2, PANC-1 and PANC-ER were 
cultured in T75 flasks with DMEM supplemented with 10% FBS and 1% L-glutamine. Every 3 
days old medium would be discarded and fresh medium added. When cells reached 80% 
confluence, cells were passaged into new T75 flasks. Briefly, cells were rinsed twice using 
Dulbecco’s phosphate buffer saline (dPBS, GIBCO, BRL), after which 2-4mL 0.25% (w/v) 
trypsin/0.03% (w/v) EDTA solution was added to the flask and incubated at 37oC for 5 to 10 
minutes. The cells were inspected under inverted microscope (x40, Olympus, Diagnostic 
Instruments, NSW, Australia) to check if the cell layer was detached. Once cells were 
trypsinized, the flask content was added aseptically to a new 15mL tube with 5mL growth 
medium with 10% FBS, and centrifuged at 1200g for 5 minutes (Eppdendorf Centrifuge 5702, 
NSW, Australia). After discarding the supernatant, 5mL of fresh medium with 10% FBS was 
added to the tube and the solution resuspended. At this stage, 10µL of mixture could be added 
to the haemocytometer for cell counting if new experiments were being set up. Otherwise, the 
cells were transferred to a new flask at a ratio of 1 to 3 and grown at 37oC in 5% CO2 in air 
atmosphere.  
Two erlotinib-resistant (ER) cell lines (BxPC-ER and PANC-ER) were subcultured from BxPC-
3 and PANC-1 respectively after prolonged treatment daily with graduating concentrations of 
erlotinib from 10µM to 30µM over a 10-month period, as per a protocol described previously.64 
Cells were not sub-cultured in erlotinib concentration higher than 30µM as crystallisation 
appeared above this concentration indicating saturation of the drug. Resistant cells were 
passaged approximately every 10 days with a seeding ratio of 1:2, with the aim of maintaining 
confluence at less than 20%. Each month after the 4th month, the IC50 to erlotinib for inhibition 
of cell proliferation was calculated, and a small portion of ER cells were cryopreserved as 
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reserve. At the completion of subculturing cell lines, both BxPC-ER and PANC-ER were tested 
against erlotinib and a wide range of inhibitor to assess erlotinib resistance and cross 
resistance to other inhibitors. They were also tested for any mycoplasma contamination and 
for stability, after which they were stored in liquid nitrogen as per cell storage protocol below. 
The progress results for the subculturing of ER cell lines were discussed further in Chapter 3. 
 
2.2.2 Cell Cryopreservation and Thawing Frozen Cells Protocols 
Cells were trypsinised and harvested at 3-5 x106 per mL of fresh complete medium with 10% 
FBS. After centrifuge, supernatant was discarded and an equal volume of complete medium 
and freezing solution containing 20% heat-inactivated FBS, 20% sterilised DMSO (Sigma-
Aldrich, NSW) and 60% appropriate medium was added drop wise with gentle mixing. Cells 
were aliquoted at 800µL each to pre-label sterile freeing vials, and placed in coolcell racks 
(Biocision, CA) in -80oC fridge overnight resulting in a rate of approximately 1oC drop per 
minute. The cells were then transferred to liquid nitrogen tank storage (-196oC). 
Frozen cells were removed from liquid nitrogen tank using full personal protective equipment 
(PPE). The vial was thawed in 37oC water bath by gentle agitation for one to two minutes, and 
sprayed and cleaned with 70% ethanol. The content of the thawed vial was transferred to a 
15mL tube containing 5mL of fresh growth medium with 10% FBS in cell culture cabinet, and 
then centrifuged at 1200g for 5 minutes. Supernatant was discarded and cells resuspended 
in 3mL medium, and then transferred to T75 flask with 7mL medium. The culture flask was 
incubated at 37oC with 5% CO2 in air atmosphere. 
2.2.3 Cell Proliferation (MTT Colorimetric Assay) 
The colorimetric MTT assay [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
was used to measure cell proliferation semi-quantitatively for cells on treatment compared to 
control. Cells were seeded at 2 x 103 density in 100µL final volume in 96 well plate. The next 
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day, old medium was discarded and cells were treated with varying concentrations of inhibitor 
in medium supplemented with 10% FBS in biological triplicates. Cells with complete medium 
and cells with complete medium plus 0.3% DMSO were used as controls in the initial 
experiments, since all drugs stock were dissolved with DMSO with final concentration up to 
0.3%. In the subsequent experiments, only cells with complete medium were used as control, 
since it was found that DMSO at 0.3% did not adversely affect cell proliferation. Initial 
optimisation tested treatment durations for 24, 48, 72 and 96 hours, and had found that 72 
hours of inhibitor treatment yielded the most optimal results. After completion of 72 hours 
treatment, 5mg/ml Thiazolyl Blue Tetrazolium Bromide (Sigma-Aldrich, NSW) was added to 
medium and results read after 2 hours with colorimeter at 570 (test) and 630nM (reference) 
wavelengths (Biotek synergy HT, VT, US) Absorbance was calculated as the difference 
between the test and reference wavelength values. All Cell Proliferation assays were 
performed in at least six independent experiments to allow for accurate statistical analysis. 
 
2.2.4 Cell Proliferation Assay (Incucyte) 
Incucyte Live Cell Imager is a combined incubator and imaging system (Essen Bioscience, 
VIC) developed to accurately produce semi-quantitative measure of cell proliferation. For 
these experiments, the Essen ImageLock 96-well plates (Essen Bioscience, VIC) were used 
as fiducial marks at the bottom of each well allowed the camera to lock on the same location 
of each well and capture accurate images. Cells were seeded in the same density and treated 
in the same way as in the MTT assay. The ImageLock plate was then transferred to the 
Incucyte Imaging System, which incubated the plate in 37oC and 5% CO2 in air atmosphere. 
Camera was set on phase contrast to capture images of each well every 2 hours for 72 hours. 
The absolute quantitative measure of confluence was calculated by the Incucyte system as 
the density of cells in a particular image. The results appeared as a plot of confluence against 
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time for each treatment. Each experiment was designed with biological triplicate, and four cell 
proliferation (incucyte) experiments were performed. 
 
2.2.5 Clonogenic Assay (anchorage dependent) 
The cell ability to form colonies after exposure to inhibitor was measured by anchorage-
dependent clonogenic assay, and the protocol has been described previously.256 Cells were 
seeded at 2 x 105 in 12-well plates. After 24 hours, these were treated with inhibitor for 72 
hours, trypsinised and counted on a haemocytometer. 2000 live cells were reseeded on a new 
6-well plate with complete medium (10% FBS). Every 4 days, medium was changed. The 6-
well plate was observed under inverted microscope daily, and colonies were defined as a 
group of more than 50 cells. When confluence reached about 10%, or when there were 
sufficient colonies observed under the microscopy (typically after 7-10 days of reseeding), 
0.05% crystal violet was added for 5 minutes after discarding medium. The plate was washed 
and air-dried, and images were taken on the LAS-3000 (Fujifilm, NSW). Colonies were 
counted using Colony v1.1 software (Fujifilm, NSW), and were represented as a percentage 
of colonies in untreated controls. Biological duplicates were performed in each experiment, 
and three independent experiments were performed for each comparison. 
 
2.2.6 Phospho- RTK Array 
Phospho-RTK array (Cell Signalling, QLD) is a slide-based antibody array kit that allowed 
simultaneous detection of 39 proteins (28 receptor tyrosine kinases and 11 important 
signalling nodes), and represents a rapid screening methods of differences in activated 
signalling pathways between several cell lines. In this study, phospho-RTK array was used to 
compare basal and EGF-stimulated pathways between ER and respective parent cell lines. 
For this experiment, 1 x105 cells for BxPC-3, BxPC-ER, PANC-1 and PANC-ER were seeded 
100 
 
in 12 well plates in duplicate. After plating overnight, old medium was discarded and serum 
free medium was added for at least 4 hours. One sample of each cell line was treated with 
EGF stimulation (10ng/ml) for 15 minutes, and the other untreated. All samples were 
harvested with Cell Lysis Buffer provided by the kit supplemented with 1mM 
phenylmethylsulfonyl fluoride (PMSF). Protein Concentration assay (Thermo Fisher Scientific, 
VIC) was used to equalise amount of proteins between samples and to adjust the final 
concentration to 0.5mg/mL. For the array procedure, the manufacturer’s instructions for the 
PathScan RTK Signalling Antibody Array Kit were strictly followed. The glass slide and multi-
well gasket were first assembled, followed by addition of array blocking buffer for 15minutes, 
diluted lysate for 2 hours, detection antibody cocktail for 1 hour, and HRP-Linked Streptavidin 
for 30 minutes, with washing procedures in between each step. For readout, the slide was 
dissembled and covered with LumiGlo/ peroxide reagent, and read on high-resolution setting 
on the LAS-4000 imaging system. Graphical representation of 39 phospho-proteins were 
tested. The chemiluminescence intensity was first quantified with Multigauge software 
(Fujifilm, NSW), adjusted to both negative and positive controls, and graphed as per 
manufacturer’s recommendations. Western blotting was used to validate phospho-RTK array 
results. 
2.2.7 Western blotting 
Western blotting experiments were conducted as previously described.257 All western blotting 
experiments were performed three times. Representative blots, and average and standard 
error of the mean (SEM) of triplicate experiments are provided. 
2.2.7.1  Preparing Cell Lysates 
As per phospho-RTK array, 1 x105 cells were seeded in 12-well plate per sample. All samples 
were conditioned with serum free medium for at least 4 hours after overnight set down. For 
drug inhibition studies, inhibitor was added for 60 minutes followed by 15 minutes of growth 
factor stimulation. For EGFR or MEK inhibitors studies, EGF (10ng/ml) was added. For IGF1R, 
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PI3K or mTOR inhibitors studies, IGF (50ng/ml) was added. For combined blockade studies, 
EGF, IGF or both were added in optimisation experiments. In subsequent experiments, EGF 
and IGF were added together whenever combined blockade (CB) was used to maintain 
consistency across all experiments. After inhibitor inhibition and growth factor stimulation, cells 
were washed twice with PBS and lysed with either RIPA buffer containing 1% NP-40, 0.1% 
Sodium doccyl sulphate (SDS, BDH), 150µL complete protease inhibitors (Roche) and 0.5% 
sodium deoxycholate (BDH) in PBS; or Laemmli buffer containing 62.5mM Tris, 2% SDS, 10% 
glycerol, 50mM DTT and 0.01% bromphenol blue. Laemmli buffer was preferred over RIPA 
buffer, and used whenever possible since the higher concentration of SDS ensured that all 
protein lysate could be detached from the well and collected. When protein concentration 
assay was needed as an additional step, however, RIPA buffer was used as Laemmli buffer 
dyed the lysate blue making it incompatible with protein concentration assay. Lysates were 
collected in 1mL microtubes and immediately placed on ice. They were then sonicated at 40% 
Amp for 30 seconds (Vibracell, CT, USA) and centrifuged at 8000g for 10 minutes at 4oC 
(Beckman Coulter, NSW, Australia). Lysates were stored in -20oC freezer until use. 
2.2.7.2  Adjusting Protein Concentration 
Protein concentration assay (Thermo Fisher Scientific, VIC) was used whenever western 
blotting experiments involved comparison across different cell lines or if inhibition studies more 
than two hours were performed. In the latter case, proteins needed to be adjusted between 
samples since cells began to die within two hours of inhibitors treatment. Instructions for the 
Protein Concentration Assay were strictly followed. Eight diluted BSA standards were first 
prepared from kit ranging from 0 to 200µg/mL. Micro BCA working reagent was prepared by 
mixing 25 part A with 24 part B and 1 part C. 100µL of lysates or BSA standards and 100µL 
of Micro BCA working reagent were added to a 96 well microplate in duplicate. After two hours 
of incubation in 37oC air atmosphere, the absorbance was measured on the plate reader at 
562nM. A standard curve was fitted by plotting the average BSA standard absorbance reading 
and the known concentration (Excel 2010). Protein concentrations of the unknowns were 
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estimated from the absorbance values on the fitted curve. This information was then used to 
dilute samples prior to electrophoresis.    
2.2.7.3  Electrophoresis 
The NuPAGE gels (Bis-Tris 12%, Invitrogen, NSW) were used for electrophoresis. 10-well, 
12-well and 15-wells were all used depending on the number of samples to be compared. 
After removing gel from packaging, the tape at the bottom of the cassette and the comb from 
the top of the cassette were carefully removed, and it was rinsed with 1x NuPAGE SDS 
running buffer (Invitrogen, NSW). The mini-cell gel apparatus (Invitrogen, NSW) was set up 
with both upper and lower chambers filled with 1x running buffer. 15-45µL of sample was 
added to the well depending on the size of the gel, with 5µL protein molecular weight pageruler 
(Invitrogen) added on either side of the gel. If protein concentrations needed to be equalised 
across samples, they were diluted with PBS according to the BCA protein concentration assay. 
Electrophoresis was run at 180V for 60-90 minutes when the pageruler was observed to reach 
full length down to the bottom of the gel. For longer gels (20 or 25 well), self-customised gels 
were used with the Galileo system. Resolving gel was made by combining 3.75ml 1M tris (pH 
8.8), 100μL 10% SDS, 4ml 30% 29:1 acrylamide, 100μL 10% APS, 10μL Temed and 2.05ml 
ddH2O to a final volume of 10mL. This was inserted between the glass apparatus and left to 
set for 5 minutes. Stacking gel was made by combining 1.25ml tris (pH6.8) 100μL 10% SDS. 
1.6ml 30% 29:1 arcrylamide, 100μL 10% APS, 10μL Temed and 6.95ml ddH2O to a final 
volume of 10ml. This was added on top of the resolving gel after it had set, and a 20-well or 
25-well comb was inserted between the glasses to create the well. After another 5 minutes of 
setting, samples could be loaded into these long gels. For these long gels, electrophoresis 
was run on the Galileo apparatus at 100V for 90-120 minutes. 
 
2.2.7.4  Preparing Various Buffers 
103 
 
Transfer Buffer 10x, TBS 10x were prepared in batches and stored in 4oC refrigerator. When 
a new western blotting experiment was run, transfer buffer 1x, TBST 1x and 5% Skim milk 
were prepared fresh. The buffer constituents were listed below: 
Transfer buffer 10x (1L): 14.4g Glycine/L, 3.03g Tris Base/L (BDH) in 1L Milli-Q water 
Transfer buffer 1x (1L): 100mL Transfer Buffer 10x, 200mL 20% methanol (BDH) and 
700mL Milli-Q water to make 1L of Transfer Buffer 1x 
Tris Buffered saline (TBS) 10x (1L): 2.42g Tris Base/L, 8.0g NaCl/ L (BDH) in 1L Milli-Q 
water, adjusted to pH 7.6 
TBS-Tween (TBST) 1x (1L): 100mL TBS 10x, 900mL Milli-Q water and 0.5mL Tween to 
make 1L of TBST 1x 
5% Skim milk in TBST: 5g skim milk powder in 100mL TBST 
2.2.7.5  Transferring Membrane 
After electrophoresis, the cassette was carefully opened and gel immediately placed in freshly 
prepared Transfer Buffer 1x. Polyvinylidene difluoride (PVDF) membrane (Millipore, MA) was 
wet in methanol for 1 minute and then transferred to Transfer Buffer 1x. Electroblotting 
apparatus was assembled from bottom to top with Sponge, 3x layers filter paper, NuPAGE 
gel, PVDF membrane, 3x layers filter paper and sponge. The apparatus was closed and 
sealed with white clasp. An ice pack was placed in the apparatus, and it was then filled with 
1L Transfer Buffer 1x up to the top of apparatus. The equipment was run at 85V for 2 gels for 
90 minutes at room temperature. Long gels were transferred with both gels and membrane 
placed in the Galileo Transfer system separated by 3x filer papers in a sandwich configuration.  
Current was set at 0.36mAmp for 120 minutes for a complete transfer. 
2.2.7.6  Immunoblotting 
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After transfer was completed, it was checked to see if Pageruler ladder appeared on either 
side of the PVDF membrane. This was further checked by placing the PVDF in Ponceau S 
solution 5% w/v (Sigma, NSW). With good transfer, dark bands representing different proteins 
should appear on the membrane upon Ponceau exposure. At this stage the membrane could 
be divided so that different portions of the membrane could be incubated with different primary 
antibodies simultaneously. The dark bands that appeared on ponceau X was easily reversible 
by washing the membrane a couple of times with TBST. Membrane was then blocked with 5% 
skim milk TBST for 1 hour, and then incubated with primary antibody. Primary antibody 
incubation was performed with 50mL tubes and a roller to conserve amount of antibody 
needed. For example, 5µL of primary antibody was added in 5mL of 5% skim milk, as 
according to the optimised primary antibody concentration listed on Table 2.2b. Different 
portions of the membrane were then inserted in the corresponding tubes with the correct 
primary antibodies. The tubes were then placed on the roller and incubated in the cold room 
(4oC). In this way, 2 membranes incubated with up to 3 primary antibodies (typically pEGFR 
at 165 dKa, pAkt at 60 dKa, and pERK at 42 and 44 dKa) could be read simultaneously the 
next day. After overnight primary antibodies incubation, the membranes were then washed 4x 
with TBST, and incubated with corresponding secondary antibodies in the same way for 1 
hour at room temperature. After 4x further washes with TBST, the membranes were ready to 
be exposed for imaging. 
2.2.7.7  Membrane exposure 
ECL (GE Healthcare Life Science, NSW) was used to bring out chemilluminescence of the 
membrane. All membrane portions were incubated with ECL mixture for 3 minutes in dark. 
Images were then taken with LAS-3000 at high resolution, with exposure time as determined 
by the camera.  
2.2.7.8  Membrane stripping 
105 
 
Since each membrane portion might have to be incubated several times with different primary 
antibody, all membrane portions were stripped with stripping solution (Invitrogen, NSW) for 15 
minutes in 37oC. After stripping, the membrane portions were washed at least 4x, after which 
primary antibody incubation could be repeated (2.2.6.5). Membrane portions could be stripped 
up to three times, after which the bands often became too faint on chemilluminescence to be 
reliable. If more information was required, a separate western blotting experiment would then 
need to be run. 
 
 
2.2.8 Immunofluorescence (Confocal Microscopy) 
Confocal Microscopy (Leica TCS SP5, NSW) was used for all immunofluorescence 
experiments as the tight control on laser emission microscope improved specificity and limited 
the amount of auto-fluorescence, while the tiny pinhole mounted on a 63x objective allowed 
cells to be scanned in cross sections down to a few microns thick.258  All experiments were 
performed in triplicates. Representative images, averages and SEM were provided, and 
additionally samples were statistically analysed with 2-sample t-test. 
2.2.8.1  Samples preparation and treatment duration 
Prior to cells seeding, 10mm diameter coverslips were placed at the bottom of each well in a 
12-well plate. 1.5 x 105 cells were seeded on top of the coverslips of each well. Serum free 
medium replaced old medium after cells set down overnight. For the studies of phosphorylated 
ERK and Akt, EGF stimulation (10ng/ml) was added for 15 minutes as in western blotting 
experiments. No growth factor stimulation was required if basal level of e-cadherin, vimentin 
or total proteins were studied. For caspase-3 inhibitor studies, inhibitor in 10% FBS serum was 
added to samples for various times from 6 to 36 hours after overnight plating, and later on at 
16-24 hours after the timing was optimised. 
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2.2.8.2  Fixing and Permeabilising 
Cells were washed with PBS twice, after which they were fixed with 3% formaldehyde and 
permeabilised with 0.2% Triton X-100 for 15 minutes each, with two PBS washings in between 
each procedure. 
2.2.8.3  Antibody Incubation 
The coverslips were lifted from the wells and transferred to a plastic wrap placed inside a 
cassette box. They were blocked with 2% BSA for 1 hour, and incubated with 60µL e-cadherin, 
vimentin (1:150); p-ERK, p-Akt (1:125); ERK, Akt (1:100); or capase-3 (1:100) in 2% BSA in 
dark at 4oC overnight, followed by incubation with secondary fluorescent antibody 1:1000 in 
dark for 1 hour at room temperature. PBS washings x3 were performed after antibody 
incubation. DAPI was added to slides, and the coverslips were placed face down on the slides 
and stored in dark at room temperature. Incubation with DAPI was for at least 30 minutes, but 
mostly the incubation was for overnight. For each experiment, a positive control and negative 
control were always included. 
2.2.8.4  Confocal Microscopy 
Before viewing slides under confocal microscopy, coverslips were sealed on the slides by 
applying acetone on the side for at least 30 minutes. 4 lasers from the Leica Confocal 
Microscopy system (blue diode, argon, DPSS, HeNe) were switched on at power of at least 
20% to allow for laser excitation to occur at a range from 405 to 633nM. Slides were viewed 
with x63 objective under oil immersion. All images were captured with the LAS-AF program 
(Leica). The anti-rabbit, anti-mouse and anti-goat secondary antibodies were of 633nM, 
488nM and 633nM respectively, and appeared red, green and red upon exposure to laser 
emission. Positive control and negative control were first viewed, so that gain parameters 
could be adjusted. To assess objectively, 5 random images were taken at the top right, top 
left, bottom right, bottom left and centre of the coverslips for each sample. After all images 
were captured, the 3 strongest signals of each image were measured for colour intensity, 
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expressed numerically as mean grey value (MGV) by the program. This means that for each 
sample 15 highest signals would be obtained in each experiment. As all experiments were 
repeated in triplicate, a total of 45 values were collected. This then allowed 2- sample t-test to 
be objectively performed between samples, in addition to providing the usual averages and 
SEM data. 
2.2.9 PCR Array 
PI3K PCR Array was a customised 384-well plate that allowed simultaneous analysis of 96 
genes (84 genes related to PI3K pathway, 5 housekeeping genes and 7 control genes) 
between 4 samples (Qiagen). It utilised the same equipment (7900HT) and methodology of 
qRT-PCR. This was performed twice to compare genetic differences in PI3K pathway between 
the two pairs of parent and ER cell lines (BxPC-3, BxPC-ER, PANC-1, PANC-ER). Standard 
RNA extraction, reverse transcription and mastermixes protocols from the company were 
strictly followed. 
2.2.9.1  RNA extraction and purification 
RNeasy Mini kit (Qiagen, VIC) was used for RNA extraction. 1.5 x 106 cells were seeded as a 
monolayer in T75 flasks and harvested at the log growth phase two days after seeding. They 
were first trypsinised and centrifuged in 15ml tubes at 1200g for 5 minutes; then washed with 
PBS. After second centrifuge, supernatant was discarded and 350µL of buffer RLT was added 
to lyse pelleted cells. Lysates were homogenised by brief vortexing, and then pipetted to 
QIAshredder spin column in 2ml collection tubes, before centrifuging at 12,000g for 2 minutes. 
Equal volume of ethanol was then added to the homogenized lysate for RNA precipitation, 
and the total volume was centrifuged in RNeasy spin column for 15s at 12,000g so that 
concentrated RNA was isolated at the spin column. At this stage, DNase digestion was 
performed as an additional step to remove foreign DNA and improve RNA purification. After 3 
washing steps with buffer RPE, 30µL water was added to the spin column and the RNA 
content was eluted into 1.5ml collection tube. RNAs were stored in -80oC freezer until use. 
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2.2.9.2  RNA Quantification and Quality Control 
Nanodrop spectrophotometer (Thermo Scientific Fisher, NSW, Australia) was used to assess 
the quantity and quality of RNA. After appropriate dilution, 1µL of RNA from each sample was 
added to the Nanodrop machine and compared to H2O blanks. Quantification of the RNA was 
calculated as an average of two consecutive measurement from Nanodrop after adjustment 
to the dilutional factor (ng/µL). Quality of the RNA was assessed by the A260:280 ratio 
(between 1.8 to 2.0 was optimal) and the shape of the mass spectrometry curve (only one 
peak with low baseline was optimal). 
2.2.9.3  Reverse Transcription 
Reverse Transcription (RT) was performed with RT2 First Strand Kit (Qiagen). After diluting all 
RNA samples to 400ng, the genomic DNA elimination mix of each sample was produced by 
mixing this with 2µL Buffer GE and making up to 10µL total volume with RNase-free water. 
After heating this at 42oC for 5 minutes using the Thermal Cycler (Biorad), 10µL of RT mix 
containing 4µL Buffer BC3 5x, 1µL Control P2, 2µL RE3 RT mix and 3µL RNase-free water 
was added to produce a 20µL mixture. RT reaction was conducted by incubating this mixture 
at 42oC for exactly 15 minutes and stopping reaction by 95oC for 5 minutes. Finally, 91µL 
RNase-free water was added to each reaction, and this was placed on ice for the PCR 
protocol. 
 
 
 
2.2.9.4  Quantitative Real Time PCR 
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1300µL of PCR component mix was produced by mixing 102µL of cDNA synthesis reaction 
with 650µL SYBR Green Mastermix and 548µL RNase-free water. The 384-well plate had the 
following configuration, and already had different primers preloaded in each well. 
 
Figure 2.1: Configuration of 384-well PCR array used in the PI3K array experiment 
Mastermix/ sample mixtures were robotically dispensed 10µL in each well for sample 1, 
followed by samples 2, 3 and 4 (EP Motion 5070, Eppendorf). The Qiagen primers were 
already preloaded in the 384-well array and came with the packing. ROX was built in as the 
reference dye. After sealing and centrifuging, qRT-PCR was run on the 7900HT system 
(Applied Biosystems, Australia) with the following cycling condition.  
 
Table 2.4: qRT-PCR cycling setup 
The Qiagen primers had undergone extensive Q.A., and claimed to be “internally validated”. 
As such, no technical replicates were needed. Instead, PCR array was performed on biological 
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duplicate (run on two independent experiments), and sought to validate the Genes of Interest 
(GOI) with standard qRT-PCR. 
2.2.9.5  Data Analysis 
After setting baseline and threshold for the qRT-PCR data at the exponential phase of the 
amplification plots, average Ct data for each experiment was exported in excel file and 
analysed with the web-based program provided by Qiagen. For quality control, RT efficiency 
as assessed by built-in controls, distribution of Ct ranges and melting curves of key genes 
were reported. The combined data of two experiments were compared between BxPC-3 and 
PANC-1, and between each pair of parent and ER cell lines. All results with greater than 3-
fold changes were reported. Additionally, scattergram, 3D-plots, clustergrams and histograms 
were used to present genomic differences between cell lines. 
 
2.2.10  Quantitative Real-time PCR (qRT-PCR) 
qRT-PCR was used to confirm results for the PI3K PCR array among the 2 pairs of parent and 
ER cell lines in the study of acquired erlotinib resistance, as well as to study key genes in the 
other ATCC cell lines that may be attributable to primary erlotinib resistance. The same 
method of RNA extraction and RNA quantification was used on all 7 cell lines (5 parent cell 
lines, 2 ER cell lines) as described in the previous section. For reverse transcription, the Sigma 
Reverse Transcriptase kit (ReadyScript™ cDNA Synthesis Mix) was used. This kit utilised a 
blend of oligoDT and random hexamers offering higher sensitivity. Since the predesigned 
SYBR Green primers may be less specific than Qiagen customised SYBR-based primers or 
Taqman probes, it was recommended to use this Reverse Transcriptase kit to optimise the 
cDNA product for qRT-PCR. 
2.2.10.2  Standard curve optimisation experiments for SYBR Green primers 
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For SYBR Green primers, specificity of the primers were tested first by standard curve 
experiments with 5 points of 10 fold dilution for samples. PCR efficiency was assessed by 
calculating for slope, efficiency [E= 10 (-1/slope)] and R squares of each standard curve, as 
previously described.259 Melting curves were also analysed to assess the specificity of the 
SYBR Green primers. Gel electrophoresis was not performed however, since melting curve 
analysis is a more accurate method for screening specificity of primers.260 Standard curve and 
melting curve analyses were not necessary for the highly specific Taqman probes. 
2.2.10.3  Quantitative Real Time PCR 
Real Time PCR for validation was conducted with 96 well plates in the same 7900HT system. 
This protocol was also slightly different than that for PCR array, in that 20µL total volume was 
used for 96 well plates. For SYBR green primers, each 20µL of PCR Master mix contained 
0.4μL (0.2µM) each of forward and reverse primer, 0.2μL SYBR Green primer 0.1x, 0.2μL 
(10nM) fluorescein as reference dye (BioRad, NSW, Australia), 10µL SuperMix-UDG 
Mastermix 2x (Invitrogen), 5µL of cDNA sample, and 3.8µL of RNA free water. 18S was 
chosen as the reference gene. The samples for 18S were diluted 10,000 fold, as 18S is a 
ubiquitous gene and serial dilutions were needed to bring Ct value back from 9-10 to 14-15 
cycles. For Taqman probes, each 20µL of PCR Master mix contained 9µL cDNA, 10µL of 
universal PCR mix (uPCR, Appied biosystems) and the respective Taqman probe. Standard 
cycling set ups were used for SYBR and taqman based probes. 
2.2.10.3 Data Analysis 
For the core experiments, Ct values were acquired and analysed and cross-validated with 
DataAssist 3.0 (SA Bioscience) and excel 2010 (Microsoft). Intra- and inter-assay precision 
[Coefficient of Variation (CV) <5%] were measured. Relative quantification (delta-delta Ct or 
Ct) method was used, where the calculations for the parameters are as follows:261 
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Delta Ct values (Ct) = Ct GOI – Ct Ref, where GOI and Ref are gene of interest and reference. In the case 
of SYBR Green assay, 18S was the chosen Reference Gene; in the case of Taqman assay, GAPDH was the 
chosen Reference Gene 
Ct = Ct Cell Line - Ct Ref Cell Line, in these experiments BxPC-3 was reference cell line 
Fold change = 2 ^ (-Ct) 
Standard error = (SD GOI2 + SD Ref2) 1/2 / n 
All results were reported as fold change to reference cell line BxPC-3, with standard error bars 
shown. Biological triplicate experiments are performed, and P-values calculated by two-way 
analysis of variance (ANOVA) of the delta Ct adjusted for experiments. All results showing 
greater than 2-fold change and P-value <0.05 were considered significant results.262 
 
2.2.11  Cell Cycle (Flow Cytometry) 
Cell cycle analysis was used to study the effect of different inhibitor and drug combinations on 
cell cycle arrests in cell lines.  Three independent experiments were performed for each 
comparison. 4 x 105 cells were plated on 6 well plates. After seeding overnight, cells were 
treated with various drugs for 24 and 48 hours. After treatment, cells were trypsinised, fixed, 
permeabilised and washed as previously described.263 300µL each of flow cytometry cell cycle 
mixture -consisting of 50 µg/ml of propidium iodide (PI), 25 µg/ml of fresh boiled RNase and 
0.2% Triton X-100 in PBS- was added to the samples once supernatants were discarded from 
centrifuged samples. The mixture was resuspended by vortexing, and incubated in dark at 
room temperature for 30 minutes, then on ice for another 30 minutes. After further vortexing, 
samples were transferred to FACS tubes, and analysed by the 2-laser 4-colour FACSCaliburs 
(BD Bioscience, California, USA) on the FL2-A channel (designated to DNA mass by PI). DNA 
histogram was constructed by Modfit (Verity, Topshem, USA). The endpoint for cell cycle 
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analysis was S-phase fraction (SPF) between treated cells and untreated controls,264 but any 
irregular changes in the DNA histogram were also reported. 
 
2.2.12  Apoptotic Assay (Flow Cytometry) 
A local protocol utilising DiLC5 and PI was used to study apoptosis due to various inhibitor or 
drug combinations.265 After seeding 2x105 cells in 12-well plates, they were treated with 
inhibitor for 48 and 72 hours from day 2. After treatment, the samples were trypsinised, 
centrifuged and resuspended in 300µL of PBS. To each sample 2µL of 2µM DiLC5 was added 
for 30 minutes to stain for mitochondria, followed by 2µL of 10mg/ml PI for another 30 minutes. 
Apoptotic Assay was read by FACSCaliburs and analysed on CellQuest (BD Bioscience, 
California). DiLC5 fluorescence was excited at 633nM laser and detected in the FL-4 channel, 
and PI was excited at 488 nm and detected in the FL-2 or FL-3 channel. Live cells were located 
on the upper left quadrant in the apoptotic scatterplot as they accumulated DiLC5 dye in the 
intact mitochondria but were not stained with PI because of intact membrane. Apoptotic cells 
had a clear loss of mitochondrial signal but retained an intact membrane, and were located on 
the lower left quadrant. Necrotic cells had lost mitochondrial signal and was stained with PI 
because of disrupted membranes, and were located in the lower right quadrant. Apoptotic and 
necrotic cells were analysed together in a cumulative column graph as they were usually found 
on a continuum of cell stress and cell death. To accurately estimate apoptosis and necrosis, 
five independent experiments were performed for apoptotic assay. To validate this particular 
apoptotic assay, caspase-3 western blotting and immunofluorescence were performed. 
 
 
 
2.2.13  Migration Assay (Incucyte) 
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Cells (8x105) were seeded in 96-well plates to achieve 100% confluence. After overnight 
plating, cells were first pre-treated with mitomycin (10µg/ml) as an anti-proliferation agent for 
at least 3 hours.266 Essen Bioscience 96-pin wound maker (Essen Bioscience) was then used 
on the plate to make a uniform scratch in each well. After three washings, the cells were 
incubated in a fresh medium mixture consisting of 10%FBS, 10µg/ml mitomycin and varying 
concentrations of inhibitor. The plate was inserted into the Incucyte Imager, where 
photographs were taken every 2 hours for 48 hours using high definition scratch wound phase-
contrast imaging. Cell migration kinetics was quantified using relative migration density as 
calculated by the software provided. Triplicate experiments were performed and results are 
presented as average time plots with SEM provided. 
 
2.2.14  General Methods of Animal Experiment  
Detailed methodology of the Animal Experiment will be described in Chapter 5. Animal 
experiments were undertaken as a group work (RS, SJ, AX, SS, MW), with tumour 
engraftment surgery and tumour harvest primarily performed by AX and SS to ensure quality 
control. For the core experiments sub-renal transplantation of first-generation xenograft were 
used. For supplementary experiments, a subcutaneous model of fourth to fifth generation 
xenografts was utilised. These methods and the rationales for each method will be discussed 
in more detail in chapter 5. 
 
Briefly, for sub-renal model, patient-derived tumour tissue (PDTT) was harvested from 
pancreatic cancer parenchyma in patients undergoing Whipple’s surgery, and engrafted under 
both renal capsules of NOD/SCID mice (male, 6-8 week-old; Animal Resources Centre, WA, 
Australia) in multiple 1 x 2 x 2 mm3 segments within 2 hours of tumour retrieval, as per 
methodology described previously.267,268 In pilot studies, this animal model was validated by 
demonstrating an engraftment rate >90%, similar histopathology and immunohistochemistry 
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between xenografts and original tissue, and confirming the effectiveness of standard intra-
peritoneal (IP) gemcitabine compared to control. For subcutaneous model, xenograft was 
passaged using sub-renal engraftment over several generations of mice- a group of 4-5 mice 
in each generation. The tumour that grew the fastest each time would be chosen and 
passaged to a new generation. After 4-5 generations, the tumours chosen by “natural 
selection” were highly pathogenic, and could thus be studied in mice using traditional 
subcutaneous methods. As with the sub-renal model, tumours were cut into multiple small 
segments, but were inserted subcutaneously after a small cut was made in the mice’s back. 
After tumour insertion, the edges of the skin were apposed and dermabond glue (Ethicon, 
NSW) applied. 
 
After engraftment in either model, animals were given standard post-op care for 4 weeks. 
Animals were then randomly divided into 3-4 treatment groups consisting of control and 
various drug treatments. Oral medications were gavaged, and IP medications were inserted 
aseptically with a 30-gauge needle. After 4 weeks of treatment, mice were sacrificed and the 
kidneys removed and weighed. Lymph nodes, lungs, livers, kidneys, spleens, and bone 
(femur) of the hosts were also removed, fixed and examined for metastases. The primary 
endpoint was tumour volume based on the modified ellipsoid formula ½ (Length × 
Width2),269,270 and secondary endpoints were kidney weight, metastatic disease and IHC of Ki-
67. Animal study was approved by local animal and human ethics committee at Northern 
Sydney Central Coast Area Health, Sydney, in April 2011 (Reference numbers:1011-015A, 
0909-227M) 
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2.2.15  Haematoxylin and Eosin Staining (H&E) and 
Immunohistochemistry (IHC) 
2.2.15.1 H&E Protocol 
H&E and IHC (Cytokerain 7, 20, Ki-67) were performed on all original tumour specimens as 
well as tumour xenografts upon animal sacrifice, according to standard methods.271 Tumour 
tissue was cut, preserved in formalin 10% overnight, and then 70% ethanol. For slide 
preparation, tissue was paraffin embedded (Leica EG1150H), prepared (Thermo Scientific 
Fisher), trimmed in 6 µm and then sectioned in 4µm slices (Leica RM2245), and then mounted 
on standard histology slides (HD scientific Supplies, NSW, Australia). Slides were dried at 
65oC for 30 minutes (Labec, Australia) and deparaffinised in two changes of xylene. This was 
followed by graded series of alcohol immersion (100%, 95%, 75%) and washing in distilled 
water for 2 minutes. The slides were stained in Harris Hematoxylin for 5 minutes and washed, 
followed by differentiation in 1% acid alcohol briefly. After this, the slides were stained with 
Scott’s blue and counter-stained with Eosin, with washings in between each procedure. After 
a series of dehydration in alcohol immersion (75%, 95%, 100%), the slides were again put in 
two changes of xylene, and further air-dried in 40oC incubator for 5 minutes. Finally, coverslips 
were mounted on the slide after oil immersion, and left overnight to dry. H&E slides were 
inspected on inverted microscope (Olympus BX60, NJ, US) to determine the existence of 
tumours on each xenograft, so that engraftment rate (%) could be determined. 
2.2.15.2 IHC Protocol 
IHC was performed on all xenografts with tumour present on corresponding H&E sections. 
New paraffin embedded slides were deparaffinised and immersed in graded series of alcohol 
as before. The slides were then boiled in buffer (pH 9) at 98oC for 20 minutes, cooled for 15 
minutes, washed then blocked with 0.3% H2O2 followed by 10% horse serum in slide 
cassettes. Overnight, slides were incubated with mouse anti-human cytokeratin 7, cytokeratin 
20 or ki-67 in humidifier chamber at 4oC (Thermoline Scientific, NSW). The primary antibody 
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concentration was optimised in initial experiments based on positive labelling of tumour cells 
against negative background of adjacent stromal tissue, and were listed in Table 2.2 c. The 
slides were washed three times with TBS the next day, and incubated with rabbit anti-mouse 
IgG-HRP (Dakopatts, Glostrup, Denmark) for 30 minutes at room temperature. After another 
two washings with TBS, the slides were developed with 3,3’ diaminobenzidine (DAB, 
Dakopatts) for 5-10 minutes. For negative control, primary antibody was omitted. Cytokeratin 
7 and 20 staining of slides were inspected under light microscopy to ensure that the staining 
patterns were similar between original tumour and xenograft tumour treated with control, so to 
validate the existing animal model. Ki-67 was expressed as a percentage of positively stained 
cells over all cells observed under 40x objective to the closest 5% by senior pathologist (AG) 
at Royal North Shore Hospital. pAkt was scored 0, 1+, 2+ or 3+. 
 
2.2.16  General Statistical Analysis 
For in-vitro experiments, raw results of all experiments were expressed as a percentage to 
untreated control, except for apoptotic assay where total % of necrosis and apoptosis was 
expressed (baseline apoptosis and necrosis rate were close to 0%), and in migration and cell 
proliferation incucyte experiments where absolute values (relative migration density and 
confluence) were measured by the program. These percentages were combined and 
expressed as average and SEM. In cell proliferation (MTT) and western blotting experiments, 
IC50 of cell were calculated and expressed as mean IC50, mean IC50 +/- SEM. Where 
appropriate, paired t-tests were performed with P-values calculated to assess for statistical 
significance. This primarily applied to qRT-PCR and immunofluorescence data, which were 
discussed in more detail in the relevant sections.  
Synergy of 2 inhibitors was studied by cell proliferation and western blotting experiments. 3-D 
dose reponse curve, synergy index and isobolograms were used.272 A 6x6 matrix of doubling 
concentration of drug A and drug B was performed in cell proliferation experiments. Three-
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dimensional dose-response curves were fitted with spline interpolation using SAS version 9.2 
as described previously (SAS, Cary, NC).272 A concave contour map with a steep slope from 
top left to bottom right suggests synergistic effect of the two drugs. A convex or flat contour 
map with small gradient suggests antagonistic effect. Synergy Index (S.I.) was calculated 
using PROC NLIN in SAS v.9.2 with the Bliss synergism/ antagonism formula.272 A S.I. >1 
indicates synergism, where the result was more than effects of each drug combined; and S.I. 
<1 indicates antagonism, where the result was less than effects of each drug combined. 
Isobolograms were used to assess synergy in western blotting experiments, where the 
placement of observed inhibitory IC50 of combined inhibitors below the estimated additivity line 
indicates synergy. These methodologies will be explained in more detail in Chapter 4. 
For in-vivo studies, tumour volumes between each treatment group were compared using two-
way analysis of variance (ANOVA) after adjusting for experiments (SAS v9.2), since tumours 
xenografts from one patient was used on all mice in each experiment. Tumour volumes data 
were log transformed as raw data did not conform to the normality assumption.273 Boxplots of 
tumour volumes from each group were presented. Ki-67% was categorised with standard 
quantitative scoring methods (<10%, 10-25%, 25-50%, 50-75%, >75%) prior to statistical 
analysis.274,275 
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CHAPTER 3: 
 
GENETIC AND MOLECULAR CHARACTERISATION 
OF PRIMARY AND ACQUIRED ERLOTINIB 
RESISTANCE 
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3.1 Introduction 
3.1.1  Chapter Background 
Erlotinib resistance is an unmet area in pancreatic cancer research. HER-3 mediated PI3K/ 
Akt pathway activation has been implicated in EGFR inhibitor resistance, and other pathways 
such as loss of IGFBP3 and MET amplification have also been speculated from studies of 
other cancer types.153,154,163,209 However, there is a dearth of research specifically for 
pancreatic cancer. In recent years, there has only been a small number of in-vitro studies on 
erlotinib resistance in pancreatic cancer,84,163 and only one translational study on investigating 
possible predictive biomarkers for this drug, based on a sub-study of the PA.3 phase III clinical 
trial.213 Further molecular characterisation of erlotinib resistance is therefore urgently needed 
in PDAC. 
This chapter explores the distinct molecular characteristics of erlotinib resistance. A specific 
distinction is made between primary (de novo) and acquired erlotinib resistance, because the 
two are not necessarily synonymous and they often harbour different genetic mechanisms.159 
This was achieved by comparing the molecular profiles of 5 PDAC cell lines stratified by 
erlotinib sensitivity and 2 cell lines made resistant to erlotinib. A particular focus was placed at 
the interaction of EGFR and IGF1R activity with the MAPK and PAM pathways (Figure 3.1). 
These two pathways are the principal mechanisms for controlling “cell survival, differentiation, 
proliferation, metabolism, and motility in response to extracellular cues”; and there are 
significant cross-talks between them.276 Importantly, in pancreatic cancer K-Ras is mutated in 
over 90%,20 whilst PI3K and Akt are overexpressed in 70% and 50% respectively,48,54 
suggesting that both pathways are active in this cancer.  
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Figure 3.1: EGFR/ MAPK and IGF1R/ PI3K/Akt/mTOR pathways: molecular cross-talks 
 
3.1.2  Chapter Aims 
1. To assess erlotinib sensitivity in 5 PDAC cell lines 
2. To develop PDAC cell lines with acquired resistance to erlotinib 
3. To study molecular properties for primary and acquired erlotinib resistance 
4. To propose treatment strategies that may exploit the knowledge of erlotinib 
resistance 
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3.1.3  Chapter Methods 
In the first part of this chapter, erlotinib sensitivity among 5 PDAC cell lines (BxPC-3, CFPAC-
1, CAPAN-2, MiaPACA-2 and PANC-1) is determined, with the aim of confirming earlier 
published reports.84,277 2 EGFR TKIs erlotinib and gefitinib with gemcitabine were used to 
assess if this was a class effect or a drug-specific effect.  Erlotinib sensitivity was studied by 
means of cell proliferation (MTT assay) and clonogenic assay. 
After erlotinib sensitivity was established in these cell lines, the most innately sensitive (BxPC-
3) and most resistant (PANC-1) cell lines were chosen and they were sub-cultured in condition 
with graduating daily erlotinib concentration from 10μM to 30μM, for a period of 10 months. 
The detailed methodology was already discussed in Methods 2.2.1. The complete change in 
the morphology of these cells (BxPC-ER, PANC-ER) signalled the completion of erlotinib 
resistant (ER) cell lines. These results for the progress are illustrated in section 3.3.  
To study primary or de novo erlotinib resistance, molecular characteristics of the 5 cell lines 
were compared, after stratifying into erlotinib sensitive and erlotinib insensitive groups. 
Western blotting, immunofluorescence and qRT-PCR were performed. To study acquired 
erlotinib resistance, the two pairs of parent versus ER cell lines (BxPC-3 and BxPC-ER; 
PANC-1 and PANC-ER) were compared. Phospho-RTK array and PCR array were first used 
for larger-scale molecular and gene discovery. Western blotting, immunofluorescence and 
PCR were then used to validate the findings. The specific mechanisms that will be focused 
include epithelial-mesenchymal status, EGFR, IGF1R, PI3K pathways.  
For the purpose of this thesis, erlotinib insensitivity (EI) was used interchangeably as primary 
erlotinib resistance. Erlotinib resistance (ER) was used to refer to acquired erlotinib resistance. 
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3.2 Measuring Erlotinib Sensitivity in 5 PDAC Cell Lines 
3.2.1 Cell Proliferation Results to Erlotinib and Gefitinib Single Agent 
Key Finding: Cell Proliferation differentiated two groups of cell lines (erlotinib sensitive 
and erlotinib insensitive), and erlotinib sensitivity closely correlated with pattern of 
sensitivity to MEK inhibition also. 
 
 
MTT assay is one of the most established method in studying cell proliferation, based on the 
cleavage of yellow MTT (tetrazolium) to a soluble blue formazan product by mitochondrial 
enzymes.278 However, several parameters have been found to affect cell metabolism and 
hence produced false positive and negative results.278 In addition, reporting of treatment 
concentration ranges (erlotinib 0- 100μM), treatment time (48- 96 hours), and cell numbers 
(2000- 20000 cells) in erlotinib and gefitinib cell proliferation assays were highly varied in 
current literature.164,237,279,280 Thus, before embarking in the main cell proliferation studies, five 
conditions needed to be optimised: treatment concentration ranges, DMSO concentration, 
treatment time, cell number and MTT incubation time.  
DMSO concentration was a crucial condition to be optimised, because all drugs were 
dissolved in 100% DMSO as per product information, making final DMSO concentration as 
high as 0.3% in complete medium. Since DMSO is potentially toxic to cells,281 and the DMSO 
concentration varied depending on how much drug working stock was added to the medium, 
it was pertinent to ensure there was no significant toxicity caused by DMSO. Optimising 
treatment time and cell number were also paramount, as suboptimal treatment time and cell 
number would profoundly affect cell proliferation results.  
MTT incubation time was also an important parameter that needed to be optimised.278  Since 
MTT assay is based on the mitochondrial metabolic activity of cell lines, the results for a slow 
growing cell line could be falsely over-estimated if the incubation of MTT was too short. 
Conversely, MTT results for a fast growing cell line may be falsely under-estimated if the 
incubation of MTT was too long.  
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The 5 PDAC cell lines varied immensely in their doubling times, from as short as 18 hours for 
MiaPACA-2 to 96 hours for CAPAN-2. Therefore, all 5 PDAC cell lines were tested 
independently for optimisation conditions. For brevity, only optimisation results of CFPAC-1 
and CAPAN-2 will be shown, since CFPAC-1 was a good representative of all 5 cell lines 
having an intermediate doubling time of 32 hours, and CAPAN-2 had the longest doubling 
time and was therefore good as a comparison. Optimisation experiments were performed in 
duplicate, and R2 statistics was used to assess the best optimisation condition based on 
goodness of fit in a log linear regression model. MTT assay results were presented as 
proportional viability, based on this formula282,283: 
Proportional Viability = Net Absorbancetreatment/ Net Absorbancecontrol x 100% 
   = (Abs630nM – Abs570nM) treatment / (Abs630nM – Abs570nM) control x 100% 
   Where Abs630nM and Abs570nM represents reference and test colorimetry values 
 
3.2.1.1  Optimising Cell number and Treatment Time 
Gefitinib was used to conduct cell number and treatment time optimisation experiments. Cell 
numbers of 2000 or 4000 were seeded in the 96-well plate, and they were treated with varying 
concentration of gefitinib for 24, 48 or 72 hours.  
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Figure 3.2: Cell Proliferation Assay optimising for treatment time 
 
Figure 3.2 shows the optimisation results for treatment time for CFPAC-1 and CAPAN-2. For 
the moderately fast growing cell line CFPAC-1, both 48 hour and 72 hour treatment appeared 
to show an excellent dose response to gefitinib. On the other hand, for the slow growing 
CAPAN-2, there was an unpredictable response at 24 hours and 48 hours treatment. Only at 
72 hours treatment was the cell viability proportional to the drug concentration. By fitting these 
dose response curves, both cell lines demonstrated a good fit at 72 hours treatment (R2= 
0.983 for CFPAC-1 and 0.845 for CAPAN-2). Thus, 72 hours treatment was chosen as the 
optimised condition for all cell lines in subsequent studies. 
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Figure 3.3: Cell Proliferation Assay optimising for cell number 
 
Figure 3.3 shows the optimisation results for cell numbers seeding. For CFPAC-1, the cell 
number of 2000 cells demonstrated a very slightly better fit than 4000 cells (R2 = 0.955). BxPC-
3, MiaPAC-2 and PANC-1 were also optimised for 2000 cells (not shown). On the other hand, 
4000 cells clearly demonstrated a better fit for slow-growing CAPAN-2 (R2 = 0.845). This was 
clear on visual inspection of the plate. At 72 hours, a plate seeded with 2000 CAPAN-2 cells 
only would show a very faint colour across the entire plate after MTT / DMSO addition, 
whereas a plate seeded with 4000 cells would showed a differential changes in colour from 
dark to faint with increasing drug concentration. Hence, for CAPAN-2 4000 cells were used 
and for other cell lines 2000 cells were used in subsequent experiments. 
3.2.1.2  Optimising Drug Concentration Ranges and DMSO Concentration  
127 
 
In the previous figures, gefitinib was tested in a range from 0 to 40μM. As is clear in figure 
3.2, the proportional viability for CFPAC-1 was almost equivocal and very low for gefitinib at 
20μM and 40µM. This most likely represented baseline detection threshold by the MTT assay. 
Similarly, for CAPAN-2 gefitinib 40µM resulted in a viability proportion of <10%, with a net 
absorbance <0.05, which probably passed the lower threshold of detection by this assay. And 
since previous reports had estimated PDAC cell lines to have gefitinib IC50 mostly between 
2.5 to 10µM,284 there was no need to increase gefitinib concentration above 20µM. Thus, for 
ongoing experiments a range of 0 to 20µM gefitinib was used. 
 
Figure 3.4: Cell Proliferation Assay Testing erlotinib concentration range 
Figure 3.4 shows the cell proliferation results of the two cell lines treated with erlotinib from 0 
to 40µM. Again, there appeared little difference between the result at the higher drug 
concentrations (erlotinib 30 and 40µM). Importantly, at concentration above 30µM erlotinib 
could not be fully dissolved in complete medium- it crystallised instead. The crystals were 
readily detectable under light microscopy, and could not be dissolved with heating or 
homogenising. The fact that erlotinib oversaturated above 30µM means that it could not 
produce reliable results for higher erlotinib concentration. Therefore, for ongoing experiments 
a range of 0 to 30µM erlotinib was used. 
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Figure 3.5: Cell Proliferation Assay Testing DMSO concentration. * P=0.02 
 
 
Next, it must be determined whether DMSO was actually toxic to the PDAC cells. As 
mentioned before, DMSO concentration up to 0.3% may be present with the higher 
concentration drugs being dissolved in medium. DMSO concentration was tested from 0 all 
the way to 1.0% (Figure 3.5). In both cell lines, there was no significant reduction in 
proportional viability with DMSO concentration below 1.0%. This optimisation experiment gave 
the reassurance that the cell proliferation results was due to the tested drug alone and not 
from other constituents. This result was also useful for other in-vitro studies that investigated 
the effect of drug inhibition- such as cell cycle assay or apoptosis assay, since all these assays 
utilised inhibitors dissolved in DMSO. 
 
3.2.1.3  Optimisation of MTT incubation time 
Finally, MTT exposure time needed to be optimised. MTT was the last step of the cell 
proliferation assay, and studies have shown that the duration MTT is added to the wells for 
oxidising reaction has a profound impact on results.278 To optimise MTT assay, cell lines were 
treated with gefitinib and erlotinib in graduating concentrations in the exact same way in 3 
separate plates. After MTT was added to the plates, the first plate was read after discarding 
medium and adding DMSO, in exactly 1 hour. The second plate was read after 2 hours, and 
129 
 
the third after 3 hours. For brevity, results for the cell line with fastest and slowest doubling 
times (MiaPACA-2 and CAPAN-2) were shown here: 
 
Table 3.1: MTT Timing Optimisation Experiments (CAPAN-2, MiaPACA-2) 
 
 
The absolute measures of absorbance for no treatment were fairly low in CAPAN-2 compared 
to MiaPACA-2, possibly due to a slower metabolic rate of this cell line. In both cell lines, 
however, the absorbance increased with time. Goodness of fit was very good (>0.90) for all 
incubation times in both cell lines. Of interest, the IC50 appeared to decrease for the slow-
growing CAPAN-2 with longer MTT incubation, and increase for the fast-growing MiaPACA-2. 
This was probably related to the mathematical artefact when calculating IC50, since IC50 was 
determined by log linear regression curve that was based on the PV against control at different 
concentrations. With a relatively low absorbance of 0.05 for CAPAN-2 at 1 hour, all PV would 
appear to be much higher %, thereby falsely predicting a higher IC50. Based on higher 
absorbance with control (NT) on longer MTT incubation, 2.5 hours was deemed to be 
appropriate as the optimal MTT incubation time. 
To sum it up, these experiments found that the optimal conditions were seeding 4000 cells 
for CAPAN-2 and 2000 for others, treating them with gefitinib 0-20μM and erlotinib 0-
30μM for 72 hours, and finally incubating with MTT for 2.5 hours before reading.  
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3.2.1.4  Erlotinib and Gefitinib Cell Proliferation Studies  
To study the effect of erlotinib and gefitinib on the 5 PDAC cell lines, 6 replicate experiments 
with biological triplicate were carried out for each experiment. The erlotinib treatment 
concentrations tested were 0, 5, 10, 20 and 30µM, and for gefitinib treatment concentrations 
were 0, 5, 10 and 20µM. Averages and Standard error of the mean (SEM) were presented 
below, with best regression line fitted for each cell line. 
 
Figure 3.6: Cell Proliferation Assay Proportional Viability Scatterplots for Gefitinib and 
Erlotinib 
 
From this figure 3.6, it was discernible that BxPC-3 and CFPAC-1 were much more sensitive 
to EGFR inhibitors than CAPAN-2, MiaPACA-2 and PANC-1. For gefitinib, there was even a 
clearer separation between the highly sensitive and highly insensitive cell lines. This result 
was in accordance to that reported by Buck et al.84, who assigned BxPC-3 and CFPAC-1 to 
erlotinib sensitive group, CAPAN-2 to intermediate sensitive group, and MiaPACa-2 and 
PANC-1 to erlotinib insensitive group. A similar trend was also observed in another study.277  
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To calculate for cytotoxic IC50, a log linear regression formula was calculated from the best 
fitted curve (SAS 9.2), and the drug concentration corresponding to the 50% proportional 
viability was extrapolated. 
 
Figure 3.7: Cell Proliferation Assay IC50 for Gefitinib and Erlotinib 
 
The cytotoxic IC50 of the 5 cell lines (Figure 3.7) confirmed the observation in figure 3.6, 
where there was a decreasing effect to EGFR inhibitors in the order BxPC-3 (most 
sensitive)>CFPAC-1>CAPAN-2>MiaPACA-2>PANC-1 (least sensitive). It also demonstrated 
that this was actually an EGFR inhibitor class effect, since the results were largely concordant 
between erlotinib and gefitinib, but followed a different pattern of sensitivity to gemcitabine 
chemotherapy. These results made sense because BxPC-3 and CFPAC-1 were known to be 
epithelial cell type, and epithelial tumours were known to have high EGFR expression,285 thus 
possibly making them more susceptible to EGFR inhibition.84 On the other hand, MiaPACA-2 
is a true mesenchymal cell type and PANC-1 has a mixed cell type.222,232 Interestingly, 
CAPAN-2 is reported to have an epithelial morphology,222 and yet is only moderately 
insensitive to EGFR inhibitor. However, as in section 3.4.1, a new finding in the epithelial-
mesenchymal status of this cell line could explain why this was so. 
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3.2.1.5  Cell Proliferation Studies on Other inhibitors 
Several inhibitors of other classes were tested on the 5 cell lines. This included IGF1R inhibitor 
NVP-AEW541 (AEW), pan-PI3K inhibitor LY-294002, PI3Kα inhibitor NVP-BYL719 (BYL), 
dual PI3K/mTOR inhibitor NVP-BEZ235 (BEZ) and MEK inhibitor PD-98059 (PD). These 
experiments were also repeated six times. 
 
Table 3.2: Cell Proliferation Assay IC50 for other inhibitors 
Whilst the sensitivities to inhibitors vastly differed between the 5 PDAC cell lines, three 
patterns were observed. Firstly, the pattern of sensitivities to MEK inhibition closely 
correlated to that of EGFR inhibition. That is, the erlotinib insensitive (EI) cell lines- CAPAN-
2, MiaPACA-2 and PANC-1, were also insensitive to PD-98059 (in red, bolded = most highly 
insensitive). This is comprehensible as MEK lies downstream of EGFR in the Raf-MEK-ERK 
cascade.56 It would seem to suggest that the basis of both primary EGFRi and MEKi resistance 
arose from molecular signals downstream of both EGFR and MEK, possibly ERK. Secondly, 
the IGF1R and PI3K inhibitor sensitivity followed a different pattern. CAPAN-2 and 
PANC-1 were insensitive (blue), but not MiaPACA-2. Thirdly, all cell lines remained 
sensitive to dual PI3K/mTOR inhibition with nanomolar potency. 
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3.2.2 Clonogenic Results to Erlotinib and Gefitinib Single Agent 
Key Finding: Clonogenic results were concordant with cell proliferation assay results 
 
Clonogenic assay was used as a second assay to confirm EGFR inhibitor sensitivity pattern 
of the 5 PDAC cell lines. Clonogenic assay was selected, because by the nature of this assay, 
it is measuring the after-effect of drug inhibition. Cells are treated for 3 days, and after 
harvesting, they are reseeded in a new plate with fresh complete medium without the drug.256 
Therefore, in essence this assay measures if there are any residual effects of the drug on 
colony formation. Thus, combining results from both cell proliferation assay and clonogenic 
assay, a clear distinction can be made between erlotinib sensitive and erlotinib insensitive cell 
lines in regarding to the immediate and delayed effects of these inhibitors. 
3.2.2.1  Optimising Cell Number, Treatment Concentration and Colony Size 
Again, before commencing on the core experiments, a number of conditions needed to be 
optimised. In the preliminary experiments, the cell numbers, treatment concentration and 
colony size were optimised using CFPAC-1, CAPAN-2 and PANC-1 given the varying 
differences between the doubling time and cell properties of these 3 cell lines. The problem 
with seeding too many cells is that there will be too many overcrowded small colonies instead 
of fewer but bigger colonies. This essentially defeats the purpose of clonogenic assay, which 
is to measure their ability of individual cells to build into big colonies. The best treatment 
concentration was also sought for testing clonogenic assay. Whilst clonogenic assay could 
technically be performed under several treatment concentrations, there would become too 
many permutations once several dual inhibitor combination treatments were planned. For 
optimisation, erlotinib 5M or 10M were tested for three days, after which 1000 or 2000 cells 
were seeded in 6-well plates. An attempt was also made to “optimise” colony size. Historically, 
a colony in a clonogenic assay is defined by a cluster of more than 50 cells.256 In reality, 
however, the plate was photographed under magnification (LAS 3000), and the colonies were 
automatically counted as pixel by an associated program (Fujifilm Colony) after setting density, 
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circularity and size of colonies. Clearly, it was impossible to correlate the exact locations of 
the colonies on a microscope to the crystal violet dots on the plate given the microscopic size 
of colonies. Thus, in order to make an association between identified pixels with colony size, 
the plate was viewed under light microscope at high objective (40x) after staining with crystal 
violet, and was then compared with the results obtained from Colony v1.1.  
 
 
 
Figure 3.8: Clonogenic assay optimising for cell numbers and erlotinib concentration 
 
 
Figure 3.8 shows the optimisation results of cell number seeding and erlotinib concentration. 
The number of colonies identified by seeding 2000 cells was clearly more than that by seeding 
135 
 
1000 cells. For example, given the same treatment with erlotinib 10M, 138 colonies were 
identified by seeding 2000 PANC-1 cells, compared to 73 colonies when seeding 1000 cells 
(not shown). Whilst this theoretically should not affect the results given all results were 
expressed as a percentage to control, the smaller number of colonies would make the results 
susceptible to larger errors of variation produced by the automatic pixel counting program. 
This is particularly the case for cell lines that are resistant to erlotinib. In this case, the error of 
variation had resulted in an overestimation of proportion of colonies in PANC-1 (PANC-1 
treated with erlotinib 10M having 179% colonies compared to control (Figure 3.8, arrow) - 
131 colonies compared to 73 colonies), which clearly does not make sense. Thus, from here 
on 2000 cells were reseeded after drug treatment. 
Clonogenic assay was also assessed with erlotinib 5 versus 10M for 72 hours, after 
reseeding 2000 cells. There was not much difference between the two drug concentrations, 
and here it was shown that at either dose, CFPAC-1 was highly sensitive, CAPAN-2 was 
moderately so, and PANC-1 was not. For the subsequent experiments, erlotinib 10M for 72 
hours was used since this dose was also used as a standard in other in-vitro assays. For 
experiments in Chapter 4 with combined blockade treatment, erlotinib 5μM and 10μM were 
both used as the dose response with low dose and moderate dose combined blockade 
treatment needed to be determined. 
 
Figure 3.9: Representative photos of clonogenic assay under light microscopy 
A general view of the clonogenic assay under light microscopy had shown only small clusters 
of cells for CFPAC-1 (which does not classify as a “colony” based on the definition of more 
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than 50 cells), intermediate colonies for CAPAN-2, and large colonies for PANC-1 (Figure 
3.9). This corresponded well with the results of optimisation experiments, that is, CFPAC-1 
was sensitive, CAPAN-2 was moderately insensitive and PANC-1 was insensitive to erlotinib. 
 
3.2.2.2  Erlotinib and Gefitinib Clonogenic Assay Studies 
Triplicate clonogenic assays were then performed for all 5 cell lines, after exposure of erlotinib 
or gefitinib 10M for 72 hours. Cells were harvested after 72 hours, and manually counted on 
haemocytometer. Since both cell proliferation and clonogenic assays exposed cells to 
inhibitors for 72 hours, the results from counting from 3 experiments were included as a 
secondary outcome, to assess whether this matched the cell proliferation assay results. 
 
Figure 3.10: Proportional Viability in response to erlotinib/ gefitinib, by manual counting. 
 
As expected, both BxPC-3 and CFPAC-1 were sensitive to erlotinib and gefitinib, CAPAN-2 
was only moderately sensitive, and MiaPACA-2 and PANC-1 insensitive to the drugs. Of note, 
the proportional viability for erlotinib and gefitinib followed very similar trend, further supporting 
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this observation as an EGFR inhibitor class effect. Overall, the manual counting correlated 
well with the cell proliferation (MTT) assay results. 
After 7-10 days of seeding and growing in new medium, crystal violet 0.025% was added after 
discarding the medium. After washing and air-drying, photos of the plate were taken on 
standard resolution setting on the LAS 3000. Figure 3.11 shows representative photos of the 
clonogenic assay of the 5 cell lines after erlotinib and gefitinib treatment. The colony size and 
numbers were clearly smaller with EGFR inhibitor treatment for BxPC-3 and CFPAC-1. With 
the other 3 cell lines, there were perhaps some minor reduction in the size and number of 
colonies, but this was not very obvious on visual inspection. 
 
Figure 3.11: Representative photos of the Clonogenic assay with erlotinib and gefitinib  
138 
 
 
Figure 3.12: Aggregate Clonogenic Assay results with erlotinib and gefitinib treatment  
Colony numbers were counted by Colony v1.1, and averages and SEM of triplicate biological 
experiments of two technical duplicates were presented. Clearly, erlotinib and gefitinib had 
prolonged effect on the first two cell lines, with colony numbers only 50-60% of control. In 
contrast, the last three cell lines were little affected by EGFR inhibitors, with only around 10-
20% reduction of colony numbers. In keeping with cell proliferation experiments, clonogenic 
assay also showed marked sensitivity of all cell lines to gemcitabine, at a dose as low as 0.05 
μM. Once again, this supports the sensitivity pattern observed for erlotinib as an EGFR 
inhibitor class effect. 
In summary, cell proliferation and clonogenic assays had identified two groups of cell lines 
(erlotinib sensitive – BxPC-3 and CFPAC-1; and erlotinib insensitive – CAPAN-2, 
MiaPACA-2, PANC-1). The effects of these inhibitors to the cell lines seemed to be prolonged, 
with definite inhibition of cell proliferation at 72 hours but also continual effect of the drug to 
colony numbers over 7-10 days after the drugs were withdrawn. 
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3.3. Sub-culturing acquired erlotinib resistance PDAC Cell 
Lines 
Key Finding: 2 ER Cell Lines showed significant erlotinib resistance compared to 
parent cell lines, and were cross-resistant to IGF1R and MEK inhibitors. 
 
The previous experiments differentiated erlotinib sensitive and erlotinib insensitive cell lines. 
To create cell lines with acquired erlotinib resistance (ER), the most erlotinib-sensitive cell line 
(BxPC-3) and most erlotinib-insensitive cell line (PANC-1) were treated daily with graduating 
concentration of erlotinib, from 10 to 20 to 30M over a period of 10 months. Three times a 
week old medium was removed and fresh medium supplemented with the drug was added. 
The highest subculturing erlotinib concentration was 30M, because above this dose erlotinib 
crystallised as previously described. The cells were passaged at a ratio 1:2 whenever 
confluence reached 10-20%, typically every 10-14 days. This occurred after 4 months of sub-
culturing, as discussed below. Below summarises the progress results. 
 
3.3.1  Change of Erlotinib IC50 and Morphology over Time 
The micrographs of the sub-cultured cell lines (BxPC-ER and PANC-ER) and the time plots 
of IC50% (compared to control) are presented here. 
 
Figure 3.13: Micrographs of subcultured cell lines (red arrows: mesenchymal cells) 
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Figure 3.14: IC50  time plot of the two sub-cultured cell lines 
Before sub-culturing started, BxPC-3 was identified as an epithelial cell type and PANC-1 as 
a mixture of epithelial and mesenchymal cell type (mesenchymal cells highlighted in red) 
(Figure 3.13), as previously described.221,232 In the first 4 months of sub-culturing, BxPC-3 and 
PANC-1 were treated with erlotinib 10-20M. The growth of BxPC-3 and PANC-1 were 
drastically suppressed by the erlotinib, to the point that no passage of cells was done or could 
be done during this initial period. This may seem somewhat surprising for the PANC-1 cell 
line, as previously this cell line was shown to be insensitive to erlotinib. However, one needs 
to make clear the distinction of “insensitivity” and “resistance” here. Even though PANC-1 was 
labelled as erlotinib insensitive, 40% of cells still died within 3 days of erlotinib exposure on 
cell proliferation assay (Figure 3.6). And this was an exposure of the drug for 3 days only. At 
prolonged daily exposure over months, it is perceivable that even erlotinib insensitive cell lines 
would succumb to the effect of the inhibitor. 
Despite the fact that most cells died at 4 months, there remained a small number of cells in 
both cell lines that appeared to survive under the drug pressure. These cells were very few in 
number, and they looked different in morphology than the parent cell lines (red arrows) (Figure 
3.13). They were bigger, irregular and more elongated in shape, and sometimes there were 
cells with axons that were branching out. At first, these were thought to be apoptotic cells that 
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were dying from erlotinib, but gradually these types of cells increased in number and actually 
started to form colonies. 
At 5th month, both cell lines finally started growing to a reasonable confluence (10-20%) that 
allowed them to be passaged. A small volume of cells were tested against parent cell lines 
BxPC-3 and PANC-1 in cell proliferation assay, and the rest were transferred to new T75 
flasks. As expected, there were relatively little changes of IC50 of both subcultured cell lines 
compared to parent cell lines (150% and 112% for BxPC-ER and PANC-ER) (Figure 3.14). 
Over the next few months, the cell lines continued to grow at a reasonable rate that allowed 
cell passage to occur every 10-14 days. This also meant that the cells could now be treated 
daily with the higher erlotinib concentration (30M). Monthly cell proliferation assay had 
demonstrated that the IC50 of the subcultured cell lines continued to increase gradually against 
control. 
At 7th month, the micrographs of the subcultured cell lines showed that these cells were able 
to withstand drug pressure and formed reasonable size colonies. The morphology of the cells 
had changed ever so slightly, with BxPC-ER looking slightly more elongated and irregular and 
the PANC-ER becoming more stallate in shape (red arrows). The IC50 ratio was 177% and 
171% for BxPC-ER and PANC-ER.  
From 7th to 10th month, there was a sudden change with both cell lines growing at a more rapid 
rate, necessitating cell passage every 7 days instead of 10-14 days. There was a sudden 
increase in IC50 of both cell lines, with BxPC-ER IC50 going above 30M and PANC-ER IC50 
going above 50M. There was also gradual replacement of epithelial to mesenchymal cell 
type (red arrows), and epithelial-mesenchymal transition (EMT) was suspected to have 
occurred. This initially occurred in the outer edges of the colonies for both cell lines. By 10 th 
month, there was a monoclonal population of mesenchymal cells taking over in both cell lines. 
At this stage, the sub-culturing process had completed and a large number of these cells were 
cryopreserved. The final cell proliferation assay was repeated three times, with the final IC50 
of 35.9M for BxPC-ER (349% to BxPC-3) and 66.9M for PANC-ER (273% to PANC-1). 
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BxPC-ER and PANC-ER were significantly resistant to erlotinib compared to parent cell lines 
in 6 independent cell proliferation experiments (both P<0.001) (Table 3.3). The cell lines were 
sent for typing, and also analysed for mycoplasma infection. It confirmed that both BxPC-ER 
and PANC-ER were derived from original cell lines by ATCC standards, and was negative for 
mycoplasma contamination.
 
Table 3.3: Cell proliferation IC50 of multiple inhibitor with t-test statistics 
 
 
3.3.2 Stability of Acquired Erlotinib Resistant Cell Lines 
Recent evidence is emerging that chemotherapy or drug resistance could be reversible in 
cancer, and epigenetic phenomenon is largely implicated for this reversible process.286 Was 
erlotinib resistance complete? Or was it reversible in the ER cell lines? This was a fundamental 
question that must be addressed in this project. If erlotinib sensitivity was indeed restored after 
drug pressure was removed, then genetic, epigenetic and molecular alterations may be all 
equally important. More importantly, if drug resistance was not static, then the results of these 
experiment results would no longer be consistent since it took about 12 months to complete 
the in-vitro work for the ER cell lines. 
To assess for stability of the cell lines, each ER cell line was cultured separately in two T25 
flasks, one continuing with daily treatment with erlotinib 30µM and one without. After 4 weeks 
of further culturing, the IC50 of parent cell lines, resistant cell lines with and without erlotinib 
143 
 
were assessed on three biological triplicate cell proliferation experiments. The ER cell lines 
were determined to be stable if the ER cell line that discontinued from erlotinib treatment 
remained resistant to erlotinib compared to parent cell line.  
Figure 3.15: Cell Proliferation Assay assessing stability of ER cell lines 
Averaging from triplicate experiments, both BxPC-ER and PANC-ER with daily erlotinib 
continued to display significant erlotinib resistance compared to respective parent cell lines 
(319% and 231% respectively). The BxPC-ER that discontinued erlotinib for at least 4 weeks 
was still 307% more resistant than BxPC-3. Likewise, PANC-ER that discontinued erlotinib 
was 268% more resistant than PANC-1. Both these were significantly resistant. Notice that 
the estimated IC50 was slightly higher for PANC-ER that discontinued erlotinib (64.0M) than 
PANC-ER that continued erlotinib (55.2M). Clearly, the graphs looked very similar between 
the two. This was likely an artefactual error from extrapolation of fitted curve, where the 
estimated IC50 was much higher than the highest erlotinib concentration being tested (30M). 
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In any case, both ER cell lines that discontinued erlotinib remained significantly resistant to 
erlotinib. In other words, the ER cell lines were stable. 
 
3.3.3 Cross Resistance to IGF1R and MEK inhibition 
Next, the ER cell lines were assessed for cross- resistance to other inhibitors. The inhibitor 
tested included IGF1R inhibitor AEW, pan-PI3K inhibitor LY-294002, PI3K-α inhibitor BYL, 
dual PI3K/ mTOR inhibitor BEZ and MEK inhibitor PD. These drugs were used to test the cell 
proliferation of 5 parent cell lines previously, and were also used in different combinations in 
other in-vitro studies, which will be the core subject of chapter 4. Cell proliferation inhibition 
IC50 of multiple inhibitors in acquired resistant cell lines versus parent cell lines is presented in 
table 3.3 and graphically in figure 3.16. 6 experiments were performed, and t-test statistics 
(paired) was calculated. 
 
 
 
Figure 3.16: Cell proliferation IC50 of multiple inhibitors 
 
As described before, both BxPC-ER and PANC-ER were made significantly resistant to 
erlotinib (BxPC-ER IC50 349% to BxPC-3 and PANC-ER IC50 273% to PANC-1, both P<0.001). 
In addition, both resistant cell lines showed significant cross-resistance to IGF1R inhibitor 
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NVP-AEW541 (BxPC-ER: 176% of IC50, P=0.037; PANC-ER: 184% of IC50, P<0.001) and 
MEK inhibitor PD-98059 (PANC-ER: 218% of IC50, P=0.006), with the exception of BxPC-ER 
reaching near statistical significance to MEK inhibitor resistance (BxPC-ER: 181% of IC50, 
P=0.053). Notably, there was no significant cross-resistance to either PI3K inhibitors or 
the PI3K/mTOR inhibitor. That is, the ER cell lines remained sensitive to PI3K inhibition. This 
therefore gave us the first impression of the involvement of PI3K/Akt/mTOR (PAM) pathway 
in erlotinib resistance, which will be studied in much greater detail in the section 3.5. 
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3.4 Molecular Characterisation for primary erlotinib 
resistance 
After the 5 PDAC cell lines were stratified into erlotinb sensitive group (BxPC-3, CFPAC-1) 
and EI group (CAPAN-2, MiaPACA-2, PANC-1), molecular characterisation of these cell lines 
was performed in an attempt to find distinct properties shared in each group of cell lines, that 
could possibly be attributable to primary or de novo erlotinib resistance. Epithelial-
mesenchymal status was briefly reviewed, after which the focus was placed on the gene and 
molecular studies of EGFR, IGF1R, MAPK and PAM related pathways. These findings were 
correlated with the cell proliferation and clonogenic assay results in section 3.4.2, and a 
detailed discussion will be presented in section 3.6. 
3.4.1 Epithelial-mesenchymal Status of 5 Cell Lines 
Key Finding: CAPAN-2 had mixed epithelial and mesenchymal properties. So all three 
cell lines with some mesenchymal properties (CAPAN-2, MiaPACA-2 and PANC-1) 
appeared erlotinib-insensitive. 
 
First, epithelial-mesenchymal status of the 5 cell lines is presented here. This is important 
mesenchymal morphology has been implicated as a mechanism of erlotinib resistance.84  
 
Figure 3.17: Micrographs and e-cadherin/ vimentin (immunofluorescence) of 5 cell lines 
147 
 
The micrographs showed that BxPC-3 and CFPAC-1 had predominantly epithelial morphology 
as described previously.221,225 MiaPACA-2 was true mesenchymal. PANC-1 was mixed, 
showing a mixture of epithelial and spindle-shaped cells.230,232 CAPAN-2 was reported to be 
an epithelial cell type,139  but on micrographs of CAPAN-2 showed a mixture of epithelial and 
mesenchymal cell types (red arrows) (Fig 3.17). The 5 cell lines had been typed (03/2012) 
and conformed to ATCC standards. This finding in CAPAN-2 did not necessarily contradict 
with literature, since epithelial-mesenchymal transition (EMT) is a reversible and transient 
process that allows for certain plasticity without full commitment to mesenchymal 
phenotypes.287 
To study epithelial-mesenchymal status in more detail, the cells were stained for epithelial 
marker e-cadherin and mesenchymal marker vimentin. On confocal microscopy, vimentin 
appeared red (633nM) and e-cadherin appeared green (488nM). As expected, epithelial cells 
BxPC-3 and CFPAC-1 had positive e-cadherin but no vimentin expression. Mesenchymal 
MiaPACA-2 had positive vimentin but no e-cadherin. PANC-1 was mixed, though it was only 
positive for vimentin and not for e-cadherin. By contrast, CAPAN-2 was positive for both e-
cadherin and vimentin (Fig 3.17).  
 
Figure 3.18 E-cadherin/ vimentin (western blotting) of 5 cell lines 
To confirm this, e-cadherin and vimentin were confirmed by western blotting.  This was 
consistent with the immunofluorescence findings, in that BxPC-3 and CFPAC-1 showed e-
cadherin alone; MiaPACA-2 and PANC-1 vimentin alone, and CAPAN-2 displayed both (Fig 
3.18).  
Altogether, cell lines with some mesenchymal properties (as demonstrated by high 
vimentin) were insensitive to erlotinib. This was consistent with the existing literature.84 In 
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reality, this is an over-simplification, since the EMT program is dependent on a large signalling 
network of proteins and factors in addition to e-cadherin and vimentin.69 Moreover, epithelial-
mesenchymal status is governed by a dynamic equilibrium of EMT and mesenchymal-
epithelial transition (MET).69 The full study of this process requires interrogation of TGF-
stimulated SMAD4 and various transcription factors like Snail, and was clearly beyond the 
scope of this PhD. Since this PhD focuses on the role of EGFR and PI3K co-inhibition in 
PDAC, a primary effort was placed on the examination of these signal transduction pathways. 
 
3.4.2 EGFR, IGF1R, PI3K related protein expressions (western blotting) 
Key Finding: The constitutively active Akt and ERK, the readily activated Akt by both 
EGF and IGF stimulation, and oncogenic shift of PI3K/Akt and MAPK pathways 
appeared to contribute to erlotinib insensitivity in PDAC. 
 
In this sub-section, EGFR, IGF1R, Akt and ERK protein expression were examined by means 
of western blotting. As discussed previously, Akt is a key regulator of the PI3K pathway, which 
is part of the larger IGF-stimulated PAM pathway. ERK1/2, on the other hand, is downstream 
of EGFR in the MAPK cascade. Both EGFR and IGF1R have input in these pathways. 43,288 
Current literature suggests significant cross-talk between these two pathways,43 and 
transactivation of EGFR or IGF1R by the other receptor via autocrine loop is also known to 
occur.289 Hence, to study the molecular mechanisms of these cell lines, the basal expression 
of these proteins was first assessed, followed by downstream activation by EGF/ IGF, and 
finally single blockade by EGFR, IGF1R and PI3K inhibitors. 
3.4.2.1  Basal Expression of EGFR, IGF1R, ERK and Akt 
In this duplicate experiment, the 5 cell lines and the supernatant from residual medium were 
lysed, adjusted with protein concentration assay, and then immunoblotted in 2 separate 12-
well gel, with markers on the last lanes from each side. Both total and phosphorylated proteins 
were assessed. Below showed the representative blot from one of the experiments: 
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Figure 3.19: Western blotting experiment of basal expression of EGFR, IGF1R, Akt and ERK1/2 
In regards to expression of the surface receptors (EGFR and IGF1R) in the 5 cell lines, the 
most erlotinib-sensitive BxPC-3 had the most constitutively active EGFR and IGF1R. On the 
other hand, the erlotinib-insensitive MiaPACA-2 and PANC-1 had the most attenuated EGFR 
and non-existent phosphorylation of IGF1R at baseline. By contrast, in regards to expression 
of downstream signals (ERK and Akt), these two cell lines and CAPAN-2 had high total and 
phosphorylated ERK compared to the other two cell lines. Moreover, PANC-1 appeared to 
have substantially higher expression of both total and phosphorylated Akt, indicating a basally 
active PI3K/Akt pathway. Also, not shown in the above figure were the blotting results of the 
supernatant (culture medium) of the 5 PDAC cell lines. EGFR and IGF1R could not be 
detectedin the supernatant of any cell lines, indicating that EGFR and IGF1R were indeed cell 
surface receptors and not present as circulating free receptors.  
 
3.4.2.2  EGF- and IGF- stimulated Downstream Signals 
The effect of EGF and IGF on downstream signals was studied next. Before this experiment 
was performed, the conditions for EGF and IGF stimulation needed to be optimised. EGF 
10ng/ml and IGF 50ng/ml were used based on literature and previous laboratory 
experience.64,289 The timing for growth factor stimulation should be optimised, so that the best 
signals for both surface receptors and downstream proteins could be achieved. The 
stimulation time of 5, 15 and 60 minutes was tested on BxPC-3 and CAPAN-2. These two 
were chosen because theoretically the rapid growth rate of BxPC-3 and the slow growth rate 
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of CAPAN-2 could result in different signalling rates between these two cell lines by growth 
factor stimulation. 
 
Figure 3.20: Western blotting experiment time optimisation for EGF and IGF 
Time optimisation experiments showed that the phosphorylated receptor signalled best at 5 
minutes for BxPC-3 and 5 or 15 minutes for CAPAN-2 (Fig 3.19). At 60 minutes, the signals 
were too attenuated for both cell lines. Interestingly, this optimisation experiment was the first 
of many to elicit “exclusive signalling” in erlotinib sensitive cell lines. In BxPC-3, EGF only 
activated pERK and IGF only activated pAkt. By contrast, in CAPAN-2 EGF and IGF both 
stimulated pAkt and pERK. Note that in this optimisation experiments protein concentration 
adjustment was not performed. Also, total proteins were not tested for this pilot study. This 
was not necessary, as it only sought to find the optimal time for the phosphorylated signal. 
Results from these cell lines were not directly comparable. Since downstream signals were 
strongest at 5 minutes for BxPC-3 and slightly stronger at 15 minutes for CAPAN-2, EGF and 
IGF stimulation for 10 minutes was chosen for subsequent studies. 
After optimisation, the downstream signals ERK and Akt were studied in more detail for the 5 
PDAC cell lines. This time protein concentrations were adjusted between samples. These 
were studied in a long 25-well gel that allowed for simultaneous immunoblotting and exposure 
of all 20 samples, with markers loaded at the end lane on either side. Phosphorylated and 
total proteins were both studied. This core experiment was performed 3 times, and below 
shows a representative western blot.  
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Figure 3.21: Western blotting experiment pAkt and pERK in 5 PDAC cell lines 
 
Two things were of particular interest in this EGF and/or IGF stimulation study. Firstly, erlotinib 
insensitive cell lines all seemed to have higher basal level of total and phosphorylated ERK 
(red arrows), suggesting that they had a constitutively active MAPK pathway. PANC-1 also 
had a more constitutively active pAkt compared to other cell lines, though the total Akt 
intensities were similar between the cell lines except for MiaPACA-2. Secondly, in 2 of the 3 
erlotinib-insensitive cell lines (CAPAN-2 and PANC-1) pAkt was readily activated by IGF as 
well as EGF (blue arrows), and pAkt signals of these 2 cell lines were also the highest when 
both EGF and IGF stimulation were applied. 
In the pooled analysis of quadruplicate experiments, pAkt and pERK were measured 
(multiguage v3.0), adjusted to total Akt and ERK protein respectively, and the summary 
statistics were then calculated. However, the nature of western blotting experiment did not 
allow for t-statistics to be performed as there was only one raw data per experiment (only 4 
data point for 4 experiments). Immunofluorescence experiment by confocal microscopy was 
used to study total and phosphorylated Akt and ERK, and comparative statistics were 
calculated based on those next results. These will be presented in the next section (3.4.3). 
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Figure 3.22: Western blotting experiment pAkt and pERK in 5 PDAC cell lines, average of 4 
experiments 
In the pooled results above, erlotinib insensitive cell lines were confirmed to have constitutively 
higher level of activation of both pAkt and pERK. EGF stimulated pERK in all cell lines (blue 
bars, right); but also pAkt in CAPAN-2 MiaPACA-2 and PANC-1 (red bars, left, figure 3.22). 
IGF strongly stimulated pAkt in all cell lines (green bars, left), but pERK in variable extents in 
the 5 cell lines (green bars, right). The combination of EGF and IGF had a profound effect of 
Akt and ERK to a lesser extent; and the proportion of pAkt to total Akt was the highest in the 
erlotinib insensitive cell lines (purple bars, left: black arrows). Therefore, by western blotting 
methods, erlotinib insensitive cell lines appeared to be characterised by a more basally 
active pAkt and pERK system, high pAkt activity upon dual EGF and IGF stimulation. 
 
3.4.2.3  Response to EGFR, IGF1R or PI3K single drug inhibition 
To study the effect of drug inhibition of these pathways, western blotting was performed on 
erlotinib-sensitive BxPC-3 and erlotinib-insensitive PANC-1 after treatment with EGFR 
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inhibitor erlotinib, IGF1R inhibitor AEW, pan-PI3K inhibitor LY and PI3K-α inhibitor BYL, in 
dose response studies. For erlotinib experiments, EGF stimulation was used. For IGF1R or 
PI3K inhibitor experiments, IGF stimulation was used. Total proteins were not blotted for this 
condensed experiment, as a more detailed experiment will be covered in subsection 4.2.3.2. 
This experiment had been performed in triplicate: 
   
 
 
Figure 3.23: Western blotting of BxPC-3 and PANC-1 after EGFR, IGF1R or PI3K inhibition 
A 
B 
C 
B 
A 
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Figure 3.24: Average and SEM of phosorylated/ total signals of BxPC-3 and PANC-1 in 
response to erlotinib and NVP-AEW541 (average of 3 experiments), * P<0.05, ** P<0.01 
 
 
Table 3.4: Western blotting estimated IC50 for erlotinib, NVP-AEW541, LY294002 and NVP-
BYL719 
 
ERL 
155 
 
EGF substantially stimulated pAkt in PANC-1 but not BxPC-3 (figure 3.23). For both cell lines, 
there were appropriate increases in pEGFR and pERK with exposure to EGF, and reduction 
in these signals with EGFR inhibitor erlotinib. The IC50 for pEGFR inhibition was estimated to 
be 4.0 µM (3.6-4.4 µM) for BxPC-3 and higher at 8.2 µM (7.9-8.6 µM) for PANC-1; and the 
IC50 for pERK inhibition was 15.7 µM (11.3-12.0 µM) and 15.6 µM (13.9-18.1 µM) for BxPC-3 
and PANC-1 respectively. Both cell lines, however, paradoxically increased pAkt with erlotinib 
suggesting oncogenic shift to the alternate pathway (both P<0.05). In BxPC-3, after the initial 
rise pAkt appropriately decreased from 1M erlotinib. In PANC-1, the trend only decreased 
from 10M erlotinib; implying a more resilient mechanism of oncogenic shift in this less 
sensitive cell line (figure 3.24). Note that all signals were adjusted to EGF-stimulated control, 
so for PANC-1 which had a much more highly EGF-stimulated pAkt, the relative fold-change 
with erlotinib inhibition appeared smaller than for BxPC-3. Averaged from three experiments, 
the IC50 for pAkt inhibition was estimated to be 39.3 µM (30.3-48.2) for BxPC-3 and 67.6 µM 
(28.1-106.9) for PANC-1 (Figure 3.23a).  
Next, the two cell lines were treated with IGF1R and PI3K inhibitors. pAkt inhibition IC50 for 
BYL [1.6µM (0.8-2.3) for BxPC-3 and 4.6µM (3.8- 5.3) for PANC-1] was 4-5 times more potent 
than LY [5.6µM (3.1-8.1) and 21.5µM (17.0-26.0) respectively]. On the other hand, the pAkt 
inhibition IC50 for AEW was the most potent, at 0.61µM (0.38-0.84) for BxPC-3 and 0.53µM 
(0.32-0.73) for PANC-1 (Table 3.4). Of interest, whilst AEW strongly inhibited pAkt and 
pIGF1R in both cell lines, there was a paradoxical increase in pERK with increasing 
concentration of AEW in PANC-1 (P<0.01) (Figure 3.23b). In BxPC-3, pERK appropriately 
decreased from 1M AEW whilst the trends only decreased from 2M AEW for PANC-1 
(Figure 3.24). pERK in PANC-1 also appeared to be unaffected by LY. Only BYL induced a 
reduction in p-ERK in both cell lines, with an IC50 of 25.3 µM (15.9-34.6) and 22.8 µM (21.3-
24.2) in BxPC-3 and PANC-1 (Figure 3.23c, table 3.4). The paradoxical increases in pAkt 
level in response to EGFR inhibitor and pERK level in response to IGF1R inhibitor suggested 
that there was significant cross-talk between MAPK and PI3K/Akt pathways. When a 
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stressor is applied to one downstream pathway, the cancer cells rapidly switch to an escape 
pathway, a process that has been termed “oncogenic shift”.132 This mechanism appears to be 
more resilient in the erlotinib insensitive PANC-1 cell line. 
 
3.4.3 ERK and Akt expressions in 5 Cell Lines (Immunofluorescence) 
Key Findings: All 3 erlotinib insensitive cell lines had significantly increased total and 
phosphorylated ERK or Akt at baseline, and higher EGF-stimulated pAkt signals. 
 
Confocal microscopy using Immunofluorescence was used to confirm the western blotting 
findings of activated downstream pathways and inter-pathway cross-talk. 
Immunofluorescence had enabled quantification of the intensity of signals, to measure this in 
multiple cells (and thereby allowing t-test statistics to be calculated), and to study total proteins 
independently. Immunofluorescence by confocal microscopy utilised laser emission and 
capture technique that enabled slide sections via ~0.2 micron pinholes, thus permitting high 
definition of intracellular signals and compartmentalising of cytoplasmic or nuclear signals.258 
In this sub-section, total Akt and ERK was first examined in the 5 cell lines, followed by 
phosphorylated ERK and Akt signals basally and with EGF. Quadruplicate experiments were 
performed to allow for robust statistical calculation. Since quantification could be subjected to 
a variety of measurement bias, a more stringent P-value of 0.01 was used. Exact P values 
down to 0.0001 were presented. 
3.4.3.1  Total ERK and Akt 
Total ERK was stained in fluorescent green (488nM) and total Akt in fluorescent red (633nM). 
The representative set of photos from confocal microscopy is shown below: 
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Figure 3.25: Representative photo of total Akt and ERK immunofluorescence in 5 PDAC cell lines 
 
For Akt, PANC-1 clearly expressed the highest signal, followed by MiaPACA-2, CAPAN-2 and 
CFPAC-1. BxPC-3 hardly expressed any Akt. For ERK, CAPAN-2 showed the highest signal, 
followed by MiaPACA-2 and PANC-1, CFPAC-1 and BxPC-3 (Fig 3.25). Summary statistics 
was calculated for 4 experiments, with t-statistics and trend statistics shown below: 
 
Figure 3.26: Immunofluorescence of total Akt and ERK in 5 cell lines, average of 4 experiments 
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Table 3.5: t-test statistics of total Akt and ERK expression between 5 PDAC cell lines 
Concordant to the representative photos, total ERK was highest in CAPAN-2 and total Akt 
highest in PANC-1. Student paired t-test showed that the erlotinib insensitive cell lines 
(CAPAN-2, MiaPACA-2 and PANC-1) had significantly higher pAkt than sensitive cell lines 
(BxPC-3, CFPAC-1) (all P<0.01). For ERK, each cell line was significantly different to another, 
with the exception of CFPAC-1 and MiaPACA-2 as well as CFPAC-1 and PANC-1. To further 
summarise these data, trend statistics was performed according to decreasing erlotinib 
sensitivity in the 5 cell lines after adjusting to each experiment. A significant trend was 
present for total Akt (t=2.76, P=0.006) but not in total ERK (t=1.47, P=0.14). 
 
3.4.3.2  pERK and pAkt at baseline and with EGF stimulation 
For phosphorylated signals, pERK and pAkt signals were studied at baseline and with EGF 
stimulation only; since EGF was the direct ligand of EGFR, and EGF-stimulated pAkt in 2 of 
the 3 erlotinib insensitive cell lines (CAPAN-2 and PANC-1) on western blotting was of 
particular interest from Fig 3.22. To achieve this, phosphorylated downstream signals upon 
EGF stimulation were compared with baseline signals.  
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Figure 3.27: Immunofluorescence of pAkt and pERK in 5 cell lines, at baseline and with EGF 
(10ng/ml, 10 minutes) stimulation. 
 
Again, pAkt was stained in fluorescent red like AKT, and pERK stained in the same fluorescent 
green as ERK, to maintain consistency. The results from immunofluorescence were very 
similar to western blotting. CAPAN-2, MiaPACA-2 and PANC-1 had visible pERK and pAkt 
signalling at baseline. Whilst EGF stimulated pERK and pAkt in all 5 cell lines, the signal 
intensity was clearly stronger in the latter 3 cell lines. In particular, PANC-1 had a propensity 
of activating pAkt (red) on EGF stimulation. Combining 4 experiments, the summary statistics 
and t-statistics are presented below. 
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Table 3.6: t-test statistics of pAkt and pERK expression at baseline and with EGF stimulation 
between 5 PDAC cell lines 
 
Figure 3.28: Immunofluorescence of pAkt and pERK in 5 cell lines, at baseline and with EGF 
stimulation, average of 4 experiments 
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For pERK and pAkt at baseline, CAPAN-2, MiaPACA-2 and PANC-1 had statistically different 
level of signals than BxPC-3 and CFPAC-1. Likewise, they also had higher levels of pAkt with 
EGF stimulation than the two erlotinib sensitive cell lines. Only pERK with EGF stimulation did 
not follow this pattern (Table 3.5). On the graphical representation, pERK was higher in the 3 
erlotinib insensitive cell lines, but the levels were similar between them. On the other hand, 
pAkt clearly followed the incremental erlotinib insensitivity of the 5 PDAC cell lines, at baseline 
and with EGF stimulation. The trend statistics showed pAkt followed a significant trend of 
erlotinib insensitivity at baseline (t=3.11, P=0.002) and with EGF (t=6.83, P<0.0001). 
However, pERK was not shown to follow a significant trend at baseline (t=2.29, P=0.023) and 
with EGF (t=1.48, P=0.14), using the stringent criteria of P<0.01 to demonstrate statistical 
significance. 
In summary, western blotting and immunofluorescence were largely consistent in showing that 
the 3 erlotinib-insensitive cell lines tended to have more highly activated downstream 
pathways. Both total and phosphorylated proteins were up-regulated. Importantly, total and 
pAkt followed a significant trend in erlotinib insensitivity, but not total and pERK. This 
implies that the PI3K/Akt system has a more crucial role in EGFR inhibitor insensitivity, as 
opposed to the MAPK pathways. Nonetheless, cross talk between the two pathways still 
takes a major role, as shown by the ability of “oncogenic shift” between MAPK and PI3K/Akt 
pathway in PANC-1 when put under drug pressure with low dose inhibitors. 
 
3.4.4 PCR of key Gene Expressions in 5 Cell Lines (qRT-PCR) 
Key Findings: EGFR and HER3 was significantly down-regulated and AKT-2 was 
significant up-regulated in erlotinib insensitivity 
qRT-PCR experiments were performed to assess the upstream and downstream-related 
genes of the two pathways among the 5 PDAC cell lines (3.4.3.3), and later to validate the 
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gene array results in erlotinib resistant cell lines (3.5.6). For simplicity, the optimisation studies 
of both experiments were presented below. 
3.4.3.2  Optimisation of SYBR Green Primers 
The genes of interest (GOI) for the erlotinib insensitivity and (later) erlotinib resistance 
experiments were EGFR, IGF1R, HER3 (ERBB3), MAPK1, PI3Kα, PI3Kγ, TLR4, Fos, NFkB 
and RelA. The control genes tested were 18S, B-actin and GAPDH. NFkB, RelA and GAPDH 
were taqman probes, whilst the others were SYBR Green-based primers. Taqman probes are 
internally validated, so optimisation experiments are generally not needed.   
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Figure 3.29: Examples of Amplification and Standard curve plots for different variants of AKT2 
and MAPK1 SYBR green primers 
 
Table 3.7: Slope, Efficiency and R squares for different variants of SYBR green primers 
SYBR Green technologies utilise DNA-binding as opposed to probe-based detection systems 
for Taqman probes, resulting in preferential binding of GC sequence and reduced 
specificity.290-292 The Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments (MIQE) regards PCR efficiency and primer specificity as essential information for 
publication.293 For the SYBR Green primers, 2 variants of each gene were purchased where 
available, with corresponding forward and reverse primers. These were mixed, diluted and 
frozen according manufacturer’s instructions. Altogether 2 variants of AKT2, 2 variants of 
MAPK1, 2 variants of PI3Kγ, 1 variant of PI3Kα, 1 variant of HER3, 1 variant of TLR4 and 1 
variant of Fos were obtained. EGFR and IGF1R primers were previously validated by the 
CanSur laboratory staff and used in prior publication.63 Standard curve experiments were 
performed with 5 10-fold dilution points on all variants, to determine the more specific primer 
of each gene to take into the core experiments. 
Figure 3.29 and Table 3.7 showed exemplary results of the optimisation experiments, in the 
study of PCR efficiency. In Figure 3.29, the amplification plots and standard curve plots are 
shown for the two variants for AKT2 and MAPK1. What is immediately obvious is that different 
variants of the same gene could produce very different efficiency. For AKT2, the FR1 variant 
164 
 
could not even detect the PCR product whereas the FR2 variant closely conformed to the 
standard curve. For MAPK1, the FR1 variant showed a good standard curve whereas there 
was an unacceptable level of variation in the FR2 variant.  Table 3.7 showed the estimated 
slope and efficiency for each primer. A good reaction should have a slope between -3.10 to -
3.58, equivalent to an efficiency between 90 to 110% and ideally as close to 100% as possible, 
as well as a correlation coefficient (R2) as close to 0.999 as possible.294 After these parameters 
were calculated, most primers were found to have very good efficiency. The final primers 
chosen for further study were AKT2 (FR2), MAPK1 (FR1), PIK3CA (FR1), PIK3CG (FR1), 
ERBB3 (FR1), TLR4 (FR1) and Fos (FR1).  
Next, the specificity of the primers were evaluated by means of melting curves. Melting curves 
plot the folded fraction of a structure vs. temperature, yielding important thermodynamic 
information. In highly specific PCR primers, Only one spike should be present for each melting 
plot, designated as the Temperature of melting (Tm).260 In Figure 3.30, the melting curve 
examples of 6 gene variant primers are shown. All of these primers showed a single spike 
indicating high specificity. With this information, it was deemed unnecessary to perform gel 
electrophoresis to assess primer specificity further. Finally, in this set of standard curve 
experiments, 18S and GAPDH were selected as the reference genes for subsequent 
experiments. B-actin, another possible reference gene, had a less specific melting curve plot 
than the other reference gene primers, so it was not used. 
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Figure 3.30: Examples of Melting Curves of SYBR green primers tested 
 
3.4.3.3  qRT-PCR results of EGFR and IGF1R/PI3K related genes 
The relative quantification method using Ct was used for qRT-PCR analysis, with the 
methodology and calculations already covered in methods (2.2.10.3). BxPC-3 was chosen as 
the reference cell line. As 18S was an abundant gene among these cell lines, samples were 
diluted 10,000 fold for 18S to achieve a Ct value of 14-15 (cycle 14-15). This allowed a 
calculation of fold –regulation with lesser degree of variance, as most other genes had a C t 
values from 20-25. This core experiment was performed with technical duplicate in biological 
triplicate experiments. Pooled results with higher than 2-fold difference (up- or down-
regulation) with a P-value less than 0.01 were considered statistically significant.262 To 
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evaluate the 5 PDAC cell lines for erlotinib insensitivity, the genes of interest (GOI) were 
EGFR, IGF1R, HER3, MAPK1, PI3KCA and AKT2. 
 
Figure 3.31: qRT-PCR results for EGFR and IGF1R/PI3K related genes in 5 PDAC Cell Line. *NE- 
not expressed. + P<0.01 
 
Table 3.8: Fold up- or down-regulation and P-values for EGFR/MAPK and IGF1R/PI3K related 
genes in 5 PDAC cell lines, with trend statistics. Genes with more than +/- 2 fold change AND P< 
0.05 are considered significantly different (coded in pink and blue for up and down-regulation). 
 
In 3 experiments, all 3 erlotinib insensitive cell lines was shown to have some degree of EGFR 
down-regulation (-1.5 to -2.5 fold, all P<0.01), accompanied by up-regulation of varying 
downstream targeting genes. For CAPAN-2, PI3KCA was found to be most strongly up-
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regulated among the PDAC cell lines (+4.13 fold compared to BxPC-3, P<0.0001); for 
MiaPACA-2, MAPK1 was up-regulated by 2.4 fold (P<0.0001); and for PANC-1, AKT2 was 
up-regulated by 20.8 fold (P<0.0001). Interestingly, the two most erlotinib insensitive cell lines 
also had a substantial down-regulation of HER3 (more than -13.5-fold, both P<0.0001). The 
standard errors of the gene expression were very acceptable, with an average CV of 1.4% 
and no CV above 5% across the gene tested. In particular, the CV for HER3 and AKT2 were 
fairly tight (1.1% and 1.9% respectively), suggesting that the substantial down- and up-
regulation of these 2 genes were valid results. Trend t-statistics was calculated after adjusting 
to experiments, with a similar statistical approach as in the immunofluorescence studies. A 
consistent pattern was observed in the direction of the trend. Upstream targeting genes 
(EGFR, IGF1R, HER3) tended to down-regulate, whereas downstream targeting genes 
(MAPK1, PIK3CA, AKT2) tended to up-regulate in decreasing erlotinib sensitivity. Moreover, 
a significant trend of EGFR and HER3 down-regulation and AKT2 up-regulation was observed 
(all P<0.0001) (Table 3.8). 
To sum up this section, erlotinib insensitivity is associated with downstream MAPK or 
PI3K/Akt over-activation. On the gene level, erlotinib insensitivity was correlated with down-
regulation of EGFR and up-regulation of PI3K/Akt and MAPK-related genes. Each erlotinib 
insensitive cell line was characterised by a different downstream gene over-expression. The 
highest gene signals for CAPAN-2, MiaPCA-2 and PANC-1 were PIK3CA, MAPK1 and 
AKT2 respectively. These gene over-expressions resulted in a higher total and 
phosphorylated Akt and ERK molecular signals on the molecular level, as demonstrated by 
western blotting and immunofluorescence. Importantly, a significant trend was observed for 
Akt but not in ERK. These results underline the importance of cross-talk of the 2 systems, and 
perhaps suggests a more critical role of PI3K/Akt in erlotinib insensitivity.  
  
168 
 
3.5 Molecular Characterisation of Acquired erlotinib 
resistance 
In this next section, the molecular characteristics between parent and acquired erlotinib 
resistant (ER) cell lines were compared. Technically, BxPC-ER and PANC-ER were the same 
cell lines as BxPC-3 and PANC-1, except that they were made resistant to erlotinib after 
chronic drug exposure. Thus, these two pairs of parent versus ER cell lines serve as a powerful 
tool in the study of acquired erlotinib resistance. One thing to note, however, is that even 
though both ER cell lines were produced in the same way, they may not necessarily acquire 
erlotinib resistance via the same mechanism. Furthermore, the driver mechanism of erlotinib 
could be multiple, and may lie anywhere upstream or downstream, and may even be attributed 
by entirely different signalling pathways, as already discussed in introduction (1.5). For this 
reason, after the study of epithelial-mesenchymal status of these cell lines was completed, 
phospho-RTK array and PCR array were performed as a mass screening of genetic and 
molecular signatures that determined or contributed erlotinib resistance. PCR, western blotting 
and immunofluorescence were then used to validate these biomarker discovery findings. 
 
3.5.1  Epithelial-mesenchymal Status of Parent versus ER cell lines 
Key Finding: Both ER cell lines had likely undergone epithelial-mesenchymal transition 
as demonstrated by increased vimentin.  
 
3.5.1.1  E-cadherin and Vimentin of Parent versus ER cell lines 
Previously, the micrographs of the two pairs of parent and resistant cell lines were shown, and 
demonstrated that BxPC-ER and PANC-ER had both transformed into a more mesenchymal 
phenotype, characterised by elongated and almost stellate morphology (Figure 3.13). To 
validate these findings, e-cadherin and vimentin were studied by immunofluorescence and 
western blotting. A representative set of photos are shown, where e-cadherin was stained in 
fluorescent green (488nm) and vimentin stained in fluorescent red (633nm), was shown below: 
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Figure 3.32: Representative photos of immunofluorescence of e-cadherin and vimentin in 
parent versus resistant cell lines by confocal microscopy 
 
BxPC-3 normally expressed e-cadherin but no vimentin. In the resistant sub-line BxPC-ER, 
there was a decrease in e-cadherin and corresponding increased expression in vimentin, 
consistent with the finding of mesenchymal morphology in this cell line. PANC-1 normally 
expressed vimentin but not e-cadherin. The PANC-ER showed increased expression in 
vimentin compared to PANC-1 (Figure 3.32). Interestingly, there was also a change in location 
of vimentin expression. Vimentin expression was scattered throughout PANC-1, which was 
consistent with its mixed epithelial and mesenchymal phenotype. In PANC-ER, on the other 
hand, vimentin was found at the edge of the colonies. This also appeared the case for BxPC-
ER. Light microscopy showed that mesenchymal cells of BxPC-ER were found at the edges 
of colonies. The above photo, too, was taken at the periphery of a large colony. Thus, there 
was a strategic relocation of mesenchymal cells in ER cell lines to facilitate invasion and 
migration.  
To quantitatively measure signal change in e-cadherin and vimentin, the signal intensity was 
again assessed by LAS3000 and the averages were compared in four experiments: 
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Figure 3.33: Immunofluorescence of e-cadherin and vimentin, average of 3 experiments (*** 
P<0.0001) 
Whilst there were no significant changes in e-cadherin expression between parent and 
resistant cell lines, there was a significant increase in vimentin expression in BxPC-ER and 
PANC-ER compared to BxPC-3 and PANC-1 (both P<0.0001). In addition, there was a large 
magnitude increase in vimentin expression from PANC-1 to PANC-ER (Figure 3.33). These 
results suggested that ER cell lines, like erlotinib insensitive cell lines, also acquired 
mesenchymal properties. It thus provided a good link between erlotinib resistance and EMT. 
3.5.2  Phosphorylated RTK Protein Discovery Array 
Key Finding: Acquired erlotinib resistance is characterised by the up-regulation of the 
PAM pathway, with increased pAkt and pS6 activity. 
To study acquired erlotinib resistance in detail, molecular profiling of BxPC-3, BxPC-ER, 
PANC-1 and PANC-ER was performed using the Phosphorylated Receptor Tyrosine Kinase 
array (phospho-RTK). The Pathscan phospho-RTK array (cell signalling) is customised for 39 
key targets from the EGFR/MAPK, IGF1R/PI3K, FGFR, HGFR, VEGF, PDGFR, EphR 
families, and is a useful tool for molecular screening between cell lines.295 The primary aim for 
this study was to characterise molecular mechanism of acquired erlotinib resistance, by 
comparing between the two pairs of parent and resistant cell lines (BxPC-ER versus BxPC-3, 
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and PANC-1 versus PANC-ER). As a secondary comparison. major differences between the 
molecular signatures of BxPC-3 and PANC-1 were also studied that may contribute to erlotinib 
insensitivity. However, the results for this secondary aim was understandably of low yield, 
since BxPC-3 and PANC-1 were two very different cell lines, and the many molecular 
differences between them may not be specifically related to erlotinib insensitivity.  
 
3.5.2.1  Basal phosphorylated RTK signals between parent and resistant cell 
lines 
The first set of experiment examined the 4 cell lines at baseline. For consistency, 2x105 cells 
were plated overnight for each cell line. They were washed and conditioned with serum-free 
medium before lysis using the kit lysis buffer provided. Protein concentrations were then 
adjusted using BCA assay (thermo scientific fisher) to 0.7mg/ml (array dynamic range: 0.125 
- 2 mg/mL) prior to performing array experiment. Below showed the phospho-RTK array set 
up for comparison of phosphorylated signals at baseline between the 4 cell lines (Figure 3.35), 
and the target map (Figure 3.36): 
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Figure 3.35: Target map of phosphorylated RTK tested in the phospho-RTK array. Courtesy of 
Cell Signalling © 2012 
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Figure 3.36: Representative phospho-RTK array blotting results (on high resolution) 
 
The above chemilumminescent images were taken on LAS-3000 on high resolution settings. 
To orientate the reading for the phosphorylated RTK array, one noticed the 10 highly intense 
(dark) signals in the same area of each array. These were the positive controls, and were 
located in a specific pattern to allow the correct orientation of other signals. The next highest 
signals were actually pS6 and pAkt (red and blue boxes: Figure 3.36). Importantly, pS6 and 
pAkt appeared higher in BxPC-ER and PANC-ER compared to BxPC-3 and PANC-1. S6 is 
one of the two major downstream effectors of mTOR whose activity is dependent of Akt (the 
other effector being 4E-BP1).49 This suggested that acquired erlotinib resistance appeared to 
be at least partly attributable to up-regulation of PI3K/Akt/mTOR or the PAM pathway. 
In order to quantify these results, each signal was measured by pixel density (multigauage 
v3.0) and then adjusted to both positive and negative controls, as per product instruction. The 
column graphs for BxPC-3 versus PANC-1, BxPC-3 versus BxPC-ER and PANC-1 versus 
PANC-ER are shown below. The axis scaling was kept the same for these and subsequent 
comparisons: 
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Figure 3.37: Phospho-RTK array result for parent and resistant cell line (baseline) 
 
Between BxPC-3 and PANC-1, there were many molecular differences as expected. However, 
the greatest differences were pAkt (Ser473) and pS6, which also happened to be the highest 
intensity signal in PANC-1 (arrows, figure 3.37a). This is consistent with the previous western 
blotting and immunofluorescence finding, that PI3K/ Akt pathway is highly regulated in this cell 
line. A comparison between BxPC-3 and BxPC-ER showed that pS6 was much more highly 
up-regulated in BxPC-ER, even above the level observed in PANC-1 (about 0.12 pixel density 
to positive control, figure 3.37b). Another signal that was more active in BxPC-ER was C-abl, 
a tyroinse kinase in the Abl family that was extensively studied in haematological malignancies 
including leukemia. Importantly, c-Abl could induce drug resistance by modulating DNA repair 
mechanism, and was directly activated by the PI3K/Akt pathway.296 Likewise, PANC-ER also 
increased pS6 and pC-Abl compared to PANC-1, and pAkt was also slightly increased as well 
(red arrows, figure 3.37c). In addition, PANC-ER also appeared more active in some of the 
C 
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surface receptors, including the HER, IGF and Fibroblast-growth factor (FGF) families (blue 
bracket). 
 
3.5.2.1  Phosphorylated RTK signals between parent and resistant cell lines upon 
EGF stimulation 
In the next set of experiment, the effect of 10 minutes of EGF stimulation (10ng/ml) was 
examined on the 4 cell lines. These samples had protein concentration adjusted together with 
the baseline samples, and were measured together in single run. Thus, the results for baseline 
and EGF stimulation were directly comparable:  
 
A 
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Figure 3.38: Phospho-RTK array result for parent and resistant cell line (with EGF stimulation) 
C 
B 
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With EGF stimulation, BxPC-3 preferentially activated ERK1/2 in a classical EGFR/ MAPK 
cascade (black arrow), whereas PANC-1 greatly increased the PAM system via Akt and S6 
(grey arrows, Figure 3.38a). The intensity for these signals (0.14 and 0.17 of positive control) 
was much higher than baseline (0.09 and 0.1). In the BxPC-3 versus BxPC-ER and PANC-1 
versus PANC-ER comparisons, there were further increases in pS6 and pAkt (Thr308 and 
Ser473) in BxPC-ER, and pS6 and pERK1/2 in PANC-ER (grey arrows). The highest signal 
and the greatest difference remained pS6, which was 0.12 of positive control in BxPC-ER, and 
up to as high as 0.22 of positive control in PANC-ER (Figure 3.38b-c). 
Hence, PI3K/Akt system was not only implicated in erlotinib insensitivity, but also further 
manipulated in erlotinib resistance, mediating via the mTOR system. In both ER cell lines, pS6 
and to a lesser extent pAkt was up-regulated at baseline. These signals were further increased 
with EGF stimulation. There were also a slightly more active pERK in the PANC-ER cell line, 
though this was a much smaller increase compared to the pS6. These findings were of major 
significance, since this was the first mass screening experiment to show the dominance of 
PI3K/Akt/mTOR or PAM over other possible molecular targets. In the next section, these 
findings need to be validated by western blotting and immunofluorescence. In chapter 4, the 
hypothesis of PI3K/ mTOR system up-regulation contributing to erlotinib resistance will be 
further tested, by means of single blockade and combined blockade studies using these 
inhibitors. 
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3.5.3 Validation for ERK, Akt and S6 of Parent versus ER Cell Lines 
(Western Blotting) 
Key Finding: Western blotting supported the findings of phospho-RTK array, in that 
pS6, pAkt and pERK were all found to be of higher intensity in ER cell lines compared 
to parent cell lines. In particular, the pAkt and pS6 were the highest in PANC-ER than 
the other 3 cell lines. 
Western blotting was used to validate the Pathscan phospho-RTK array results. Due to 
technical difficulties, repeated blotting for S6 on all 5 primary PDAC cell was not performed. A 
very long gel would need to be made to compare across 7 (5 primary + 2 ER) cell lines. Since 
the 4 cell lines used in phospho-RTK arrays were BxPC-3, BxPC-ER, PANC-1 and PANC-ER, 
western blotting was perform on these only. The molecular targets of interest were pAkt, pERK 
and pS6. Samples were loaded on a 20-well membrane with markers on each side. These 
were performed as 3 independent experiments.  
 
Figure 3.39: Western blotting results of ER versus parent cell line with EGF and IGF stimulation 
 
At baseline, all cell lines expressed pERK (red arrows) and pAkt (blue arrows) except for 
BxPC-3, though the pAkt signals were much fainter in BxPC-ER and PANC-1 than PANC-ER 
(Figure 3.39). In addition, both ER cell lines expressed more pS6 than the parent cell line 
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(green arrows). In Figure 3.21, PANC-1 was already shown to have high expression of pAkt 
at baseline. In this representative blot (Figure 3.39), PANC-ER had even higher pAkt than 
PANC-1. The exposure was 60 seconds on high exposure setting for the previous blot, but 
only 4 seconds on standard exposure for this experiment, indicating that PANC-ER had even 
more up-regulated PAM compared with its parent predecessor which was already active in 
this pathway. With EGF stimulation, BxPC-3 preferentially activated ERK1/2 in the MAPK 
pathway. BxPC-ER and PANC-1 possibly stimulated pAkt with EGF, but this was definitely the 
case for PANC-ER (orange arrows). PANC-ER also appeared to stimulate pERK with IGF 
(purple arrows). With EGF and IGF stimulation, both ER cell lines appeared to have higher 
pAkt and pS6 intensity as the parent counterpart (black arrows), and PANC-ER also appeared 
to have higher pERK than PANC-1 (white arrows). 
To sum it up, this representative blot had demonstrated that ER cell lines were more likely to 
have highly active PI3K/Akt/mTOR pathway as indicated by pAkt and pS6, basally and with 
growth factor stimulation. In addition, the PANC-ER cell line also had a highly activated MAPK 
pathway upon growth factor stimulation. These were almost identical results as the phosphor- 
RTK array.  
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Figure 3.40: Western blotting results of ER versus parent cell line with EGF and IGF stimulation, 
average of 3 experiments 
 
 
3 western blotting experiments were pooled together and presented as relative signal intensity 
to total proteins. After combining the three experiments, one could see graphically that ER cell 
lines had higher pERK, pAkt and pS6 than parent cell lines, basally as well as with growth 
factor stimulation. It was clear that the differences were very small for pERK, more prominent 
for pAkt, and most prominent for pS6- particularly after EGF and IGF dual stimulation (Figure 
3.40). EGF was slightly better at activating pERK in all 4 cell lines; IGF was slightly better at 
activating pAkt; and IGF was substantially better at activating pS6. The one exception to this 
rule was that EGF was actually better than IGF in stimulating pAkt in PANC-ER (black arrow), 
which was consistent with the representative blot above. Since S6 is an Akt-driven effector of 
the mTOR complex, PAM pathway was indeed the active mechanism of acquired erlotinib 
resistance, with the driving force down the mTOR complex through S6.  
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3.5.4 Validation of ERK and Akt of Parent versus ER Cell Lines 
(Immunofluorescence) 
Key Finding: ER cell lines had more highly active pAkt by immunofluorescence, both 
at baseline and EGF stimulation, and total Akt level was also over-expressed. 
The interaction between EGF and IGF with PAM and MAPK pathways was the central concept 
of this thesis. Given its relevance and significance, immunofluorescence was used as a 
second method of validation. Total ERK/ Akt and pERK/ pAkt were again assessed under 
confocal microscopy. Although S6 was another important signal by the RTK array, a primary 
pS6 antibody that would function well for immunofluorescence could not be obtained. Given 
S6 was primarily driven by Akt in the same PAM pathway, the emphasis was placed on Akt 
instead. Phosphorylated signals were studied at baseline and with EGF stimulation as 
previous experiments. IGF stimulation was deemed unnecessary given that IGF-pERK was 
not observed in substantial magnitude in Figure 3.40. Again, 4 experiments were performed 
to allow for statistical analysis. 
3.5.4.1  Total ERK and Akt 
 
Figure 3.41 Representative photos of immunofluorescence of total Akt and ERK in parent 
versus resistant cell lines by confocal microscopy 
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From the previous immunofluorescence studies on total Akt of 5 PDAC cell lines (3.4.3.1, 
figure 3.24), PANC-1 was already established as having high total Akt expression. PANC-ER 
appeared to have higher intensity in total Akt than PANC-1 still. BxPC-3 had little Akt 
expression, and BxPC-ER had slightly gained some Akt expression. Total ERK appeared to 
be somewhat more intense in BxPC-ER than BxPC-3. However, the difference between 
PANC-1 and PANC-ER was probably slight at best, and was not appreciated readily in the 
representative photos. 
 
Figure 3.42: Immunofluorescence of total Akt and ERK in parent versus resistant cell lines, 
average of 3 experiments (*** P<0.0001) 
Averaged from 3 experiments, total Akt was significantly highly expressed in ER cell lines than 
parent cell lines (both P<0.0001). Total ERK was also significantly more highly expressed in 
BxPC-ER than BxPC-3 (P<0.0001, Figure 3.42). These findings parallelled that observed in 
erlotinib insensitive cell lines. Phosphorylated ERK and Akt was studied next to see if they 
were also significantly over-activated, as suggested from phospho-RTK array and western 
blotting experiments. 
3.5.4.2  Phosphorylated ERK and Akt at baseline and EGF stimulation 
Again, pERK (green) and pAkt (red) were studied together, at baseline and with EGF 
stimulation. Below showed the low power and high power representative set of photos: 
184 
 
 
Figure 3.43: Representative photos of immunofluorescence of pAkt and pERK at baseline and 
with EGF stimulation in parent versus resistant cell lines by confocal microscopy 
The basal pERK and pAkt signals were fairly weak for BxPC-3 and BxPC-ER, though on 
higher power pERK was more detectable in a speckled configuration around the nucleus. By 
contrast, pAkt signal was high in PANC-1 and even more intense in PANC-ER, indicating that 
Akt (or PI3K pathway) was constitutively active in these cell lines (Figure 3.43). With EGF 
stimulation, it was observed that pERK signal increased in BxPC-3. In BxPC-ER, pERK signal 
increased, as did the pAkt signal. In PANC-1, pAkt (not pERK) was predominantly increased 
with EGF stimulation. Comparing PANC-1 with PANC-ER, pAkt was further and markedly 
increased by EGF stimulation, predominantly in the cytoplasmic region of the cells. 
185 
 
 
Figure 3.44: Immunofluorescence of pAkt and pERK at baseline and with EGF stimulation, 
average of 3 experiments * P< 0.05, *** P<0.0001 
Again, using the stringent criteria of statistical significance of P<0.01, a significant increase in 
pERK signalling was noted in PANC-ER compared to PANC-1, but only on EGF stimulation 
(P<0.0001; Figure 3.44). By comparison, pAkt signalling were significantly increased in both 
ER cell lines under both basal or EGF stimulation conditions (all P<0.0001). There was a 
particularly substantial increase in pAkt in PANC-ER compared to PANC-1 (65 and 80 mean 
intensity values in NT and EGF). Thus, western blotting and immunofluorescence results 
were concordant in showing that over-expression and over-activity of PI3K (not MAPK) 
pathway was associated with acquired erlotinib resistance. 
 
 
 
 
3.5.5 Gene Discovery by PI3K PCR Array  
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Key Finding: The two ER cell lines appeared to have derived erlotinib resistance from 
pathways downstream of PI3K/Akt, as opposed to AKT or S6 genes. NF-kb and c-fos 
could be the possible driver mechanism in BxPC-ER and PANC-ER respectively. 
In the experiments so far, Akt and S6 were established to be important factors in acquired 
erlotinib resistance. The drug inhibition and molecular characterisation studies so far have 
suggested a high possibility that the entire PAM pathway was involved in erlotinib resistance, 
particularly as ER cell lines remained sensitive to PI3K and PI3K/mTOR but not IGF1R or 
MEK inhibitors. Importantly, it appeared that it was both total Akt and phosphorylated Akt were 
increased in ER cell lines. In this case, one would expect that AKT or related genes to be over-
expressed resulting in the transcription of these proteins. To search for an answer, gene 
discovery study was the next step. 
Recent advances in gene technology have introduced methods such as next-generation DNA 
sequencing (NGS) and DNA microarray for the mass screening of whole human genome.297,298 
Whilst the costs of these techniques have dramatically reduced over the last decade, this was 
still a substantial cost to the project considering that these gene searching methods needed 
to be repeated twice at the very least. Since the genes of interest were highly likely located 
within the PI3K/ mTOR or other related pathways, a focused PI3K PCR array was used for 
the gene discovery experiment. The RT2 Profiler Array (Qiagen) is a 384-well plate intended 
for gene discovery of 96 customised genes for 4 simultaneous samples. Among the 96 genes 
were 84 genes related to PI3K pathway, 5 housekeeping genes and 7 controls. The primers 
are all preloaded in the array. The dye used is a highly sensitive sYBR green dye with ROX 
as a reference dye. Detailed methodology had already been described in subsection 2.2.9.  
In the array experiment, the 2 pair of parent and resistant cell lines (BxPC-3, BxPC-ER, PANC-
1, PANC-ER) were simultaneously tested in a single 384-well PCR array for two times, with 
qRT-PCR used to validate the genes of interest (subsection 3.5.6). Each experiment was 
independently performed. New cells were thawed, grown, RNA was then extracted, reverse 
transcribed, and PCR array performed, in two independent experiments.  
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3.5.5.1  Quality Control of RNA, DNA and PCR 
For conciseness, only the most relevant quality control results are shown. RNeasy mini Kit 
(Qiagen) was used for RNA extraction and purification from the 4 cell lines. The maximum 
binding capacity for the mini spin column was 100g. Below shows the RNA quantity extracted 
from each experiment, as measured on mass spectrometer: 
 BxPC-3 BxPC-ER PANC-1 PANC-ER 
Exp 1 23.8g 17.9g 22.3g 35.4g 
Exp 2 16.9g 20.4g 39.7g 48.7g 
Table 3.9: RNA quantity for two PCR array experiments 
Hence, the total RNA quantities from both experiments were well within the maximum capacity 
of the RNA extraction kit. Next, the RNA quality was assessed by the mass spectrophotometric 
curve, A260:A280 ratio, and A260:A230 ratios. UV absorbances at 280nM, 260nM and 230nM are 
used to measure aromatic amino acids, nucleic acid and contaminants respectively.299 Thus, 
A260:A280 and A260:A230 ratios were used to provide a measure of RNA purity, with acceptable 
A260:A280 ratio being 1.8-2.2 and A260:A230 ratio >1.7.293,299  
 BxPC-3 BxPC-ER PANC-1 PANC-ER 
Exp 1: A260:A280 1.95 1.92 2.05 2.01 
Exp 2: A260:A280 1.91 1.82 1.95 1.91 
Exp 1: A260:A230 2.03 2.08 2.17 2.17 
Exp 2: A260:A230 2.38 2.27 2.07 2.32 
Table 3.10: RNA quality for two PCR array experiments (A260:A280 ratio) 
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Figure 3.45: Example of a mass spectrophotometric curve in assessing RNA quality  
A260:A280 ratio, and A260:A230 ratios of the 4 cell lines in both experiments were within the 
acceptable ranges. Shown above was an example of UV absorbance curve for experiment 2. 
In this case each sample was tested twice; the absorbance curves for each pair were fairly 
close together. In all samples there was only one peak indicating high purity of RNA. The main 
disadvantages of using mass spectrophotometry to assess RNA purity are inaccuracy in 
measuring low-level samples and its inability to distinguish other nucleic acids such as dsDNA 
and ssDNA.299 Since the samples for both experiments were of appropriate quantity, and that 
DNAse was used as an additional step in RNA extraction, it was not necessary to further 
assess RNA quality by gel electrophoresis (RNA gel). 
After adjusting RNA quantity, 400ng of total RNA were reverse transcribed into DNA for each 
sample. Master mixes were then added to the cDNA, and these were dispensed to the PCR 
array by robotics. Quality of PCR was assessed a number of ways.  
As a screening test, before qRT-PCR was run for the PCR array, the 4 samples were run 
together with a control sample with known cDNA quantity, and were tested for 18s and β-actin 
control genes. The results showed that these samples had almost identical amplification rate 
to control and each other, thus supporting that all 4 samples had similar quantity of DNA. 
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qRT-PCR was then run on the 384-well plate, according to the protocol in subsection 2.2.9. 
Threshold was set at 10x the standard deviation of the fluorescent value of baseline. The 
amplification plot and distribution of threshold cycle (Ct) are shown below: 
 
Figure 3.46: Amplification plot for 96 genes * 4 samples in the 384 well PCR array 
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Figure 3.47: Distribution of Ct of 96 genes for 4 samples in 2 experiments 
As depicted above, most genes were at the steep part of the amplification by cycles 15-25. In 
the Ct distribution column graph, most Ct values were before 30 cycles. Only 5-10% of genes 
had Ct values after 30 cycles, which likely represented genes that were not expressed in the 
cell lines as opposed to artefactual errors. The average Ct values for each cell line in both 
experiments were very close together, with a range from 18.6 to 19.5 cycles, with standard 
deviation of only 0.45-0.59 between experiments. 4 of the 5 control genes tested (β-actin or 
ACTB, β2-microglobulin, GAPDH and ribosomal protein large P0 or RPLP0) had Ct values 
ranging from 16 to 20 cycles, while the less commonly used hypoxanthine control gene had 
Ct values between 23 and 24 cycles. Internal controls with reverse transcription control (<5Ct) 
and genomic DNA contamination (>35Ct) were also found to be acceptable. 
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Finally, the use of SYBR Green probes allowed melting or dissociation curve analysis to be 
performed. Melting curve analysis was programmed at the end of PCR experiment. Each 
primer has a temperature of melting (Tm); a melting curve plots the folded fraction of the 
structure versus temperature, and enables assessment of the specificity of the primers.260 
Clearly, it is impossible to show the melting curves of all 96 genes here. Melting curves of the 
key genes of interest are presented below: 
 
Figure 3.48: Melting curves of some of the key genes in PCR array 
In all these genes, melting curves showed only one peak- that is one product only. All 96 
melting curves had been checked, and they all showed equivalent results indicating the 
primers used in this array was specific. 
All in all, the quality of RNA, DNA and PCR were suitable for further analysis. Results of the 
PCR array experiment are now presented, as per the Minimum Information for Publication of 
Quantitative Real-Time PCR Experiments (MIQE) guidelines.293 
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3.5.5.2  PCR Array Results 
As a general overview, the clustergram or heat map of all 96 genes grouped in gene families 
are shown below. From left to right are PANC-1, PANC-ER, BxPC-3 and BxPC-ER. Green 
indicates down-regulation, red indicates up-regulation and black indicates average level: 
 
Figure 3.49: Clustergram or heat map for 96 genes on the 4 cell lines, average of 2 experiments 
(red = up-regulation; green = down-regulation)  
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Between parent and ER cell lines, most genes were concordant between the two pairs of cell 
lines. However, there were also distinct groups of genes that were differentially expressed 
(that is, up-regulated in one cell line and down-regulated in another). These were highlighted 
in red bracket (BxPC-3 versus BxPC-ER) and blue bracket (PANC-1 versus PANC-ER). 
Interestingly, these followed specific families of genes in a particular pattern. In BxPC-ER, the 
genes lying in mTOR to nuclear c-fos pathways were up-regulated, with accompanying down-
regulation of genes in the IGF1R – PI3K pathways. In PANC-ER, the genes in the NF-κB 
family appeared to be up-regulated, and the genes in the PI3K- mTOR pathway were down-
regulated. In both cell lines, there appeared to be a silencing of part of the PI3K/Akt/mTOR 
signals, but accentuation of nuclear or paranuclear signals parallel or downstream of mTOR. 
To explore erlotinib resistance in greater detail, two-way comparisons were first made between 
BxPC-3 and PANC-1; then BxPC-3 and BxPC-ER, and PANC-1 and PANC-ER for acquired 
erlotinib resistance. Scatterplots of 2^-delta Ct and 3 dimensional column graphs are shown 
below, with Ct values and fold changes listed in ascending order: 
 
Figure 3.50: Scatter plots of square root of –delta Ct between pairs of cell lines in PCR array. 
Boundary set at 3 fold difference 
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Figure 3.51: 3-dimensonal column graphs, Ct values and fold changes between cell lines 
B 
C 
A 
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The scatterplots and the 3-dimensional column graphs both showed many molecular 
differences between BxPC-3 and PANC-1, as to be expected from two completely different 
cell lines. Some genes were highly over-expressed in PANC-1 (+16 fold), while others were 
most likely not expressed at all (-135 fold). Consistent with the qRT-PCR findings previously 
(3.4.4), here it is also shown that PANC-1 was up-regulated in AKT-2 (+12.48 fold) and AKT-
3 genes (+3.33 fold) (Figure 3.51a).  
The two pairs of parent and resistant cell lines were much more similar, as expected. 
Importantly, there was a small number of genes of interest that were found to be different 
(Figure 3.50, 3.51 b-c). Two things were noted in these analyses. Firstly, the AKT genes were 
not up-regulated in either ER cell line. After two experiments, it was shown that BxPC-ER only 
had a +0.96, +0.82, and +1.22 fold up-regulation of AKT-1, -2 and -3 genes compared to 
BxPC-3, whilst PANC-ER had +1.49, +1.17 and +1.53 fold up-regulation (not shown). It was 
difficult at this stage to assess whether these were significant differences, but less than 2-fold 
change was not usually considered meaningful in any case.262  
Secondly, some genes were common between the BxPC-ER: BxPC-3 and PANC-ER: PANC-
1 analyses, but the direction of up-regulation and down-regulation were opposite. For 
example, GJA-1 was up-regulated in BxPC-ER compared to BxPC-3 (+6.04) and down-
regulated in PANC-ER compared to PANC-1 (-6.73). TLR-4, on the other hand, was down-
regulated in BxPC-ER compared to BxPC-3 (-3.01) and up-regulated in PANC-ER compared 
to PANC-1 (+17.13). The first column graph appeared to shed some light to this apparent 
paradox (figure 3.51 a), where it was shown that PANC-1 had much more highly up-regulated 
GJA-1 gene (+8.91) and down-regulated TLR-4 gene (-26.55) than BxPC-3. That is, it may be 
that the differences observed were simply due to some unique properties of a parent cell line, 
not the ER cell line. 
To address these issues and filter down the genes of interest in acquired erlotinib resistance, 
a 4-way comparison of these genes was presented to search for genes that were unique to 
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one ER cell line only and not the others. Below shows the column graphs of delta Ct, 2 to the 
power of (-delta Ct) and fold change of the 6 genes of interest revealed in the PCR array. Error 
bars of two experiments were shown for average delta Ct and (- delta Ct) squared. 
 
Figure 3.52: 4-way analysis of genes of interest in PCR array 
In the 4-way analysis, PI3KCG, TLR4 and CD14 gene expressions did not follow a predictable 
pattern. The average Ct was higher in BxPC-ER than BxPC-3, and lower in PANC-ER than 
PANC-1, but the highest average Ct was in PANC-1 (Figure 3.52, upper left). These therefore 
represented unique properties for PANC-1, and might possibly reflect the artefacts from 
environmental factors that had affected this cell line. Clearly, this was not the aim of this 
experiment. The aim here was to search for unique markers of ER cell lines. Instead, the gene 
of interest must be unique and differentially expressed in either or both ER cell lines, but not 
in the parent cell lines. 
To offset the variability, 2 to the power of –delta Ct was calculated as per product instructions 
and a column graph was produced. Two distinct markers were now apparent: NFκB1A was 
the highest in BxPC-ER and not the other three cell lines (Figure 3.52, bottom left, yellow 
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bars), and Fos was highest in PANC-ER and not the other three cell lines (blue bars). Finally, 
fold change was calculated by squaring negative delta-delta Ct, and here NFκB1A was up-
regulated by about 3 fold in BxPC-ER, and Fos was up-regulated by about 4 fold in PANC-
ER, compared to the other cell lines (Figure 3.52, upper right, yellow and blue bars, black 
arrow). 
Thus, PI3K PCR array found a propensity of ER cell lines to up-regulate alternate pathways 
further downstream to mTOR. It had also uncovered two possible markers, one for each ER 
cell lines. To validate this, qRT-PCR was performed to be discussed in the next sub-section.  
 
 
3.5.6 PCR Validation of Key Genes of Parent versus ER Cell Lines 
Key Finding: qRT-PCR had reproduced and validated the PCR array results 
In total, 12 genes were tested in this qRT-PCR validation study. Some of these genes had 
already been tested in the previous experiment on 5 PDAC cell lines (MAPK, PI3Kα, PI3Kγ, 
AKT2, ERBB3. PCR array genes of interest (GOI) were fos, TLR4, NFκB1a (P50) and Rel-A 
(P65), and these were also assessed in validation study. Rel-A is one of the key sub-unit of 
the NFκB family complex equipped with a non-homologous transactivation domain.300 Given 
its intricate association with NFκB1a, it was also studied here even though it was not included 
in the PI3K array. Taqman probes were used for NFκB1a and Rel-A- since there were no 
appropriate SYBR green primers found for these genes. Other GOIs were all detected by 
SYBR Green primers. The integrity of the SYBR Green primers had already been tested in 
standard curve experiments in 3.4.3.2. SYBR Green primers were corrected to 18S as the 
reference gene as before, and Taqman probes to GAPDH. As before, biological triplicate 
experiments with technical duplicate were performed. 
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Figure 3.53: qRT-PCR genes of interest results for ER versus parent cell lines 
 
Table 3.11: Fold up- or down-regulation and P-values for GOI in parent versus ER cell lines 
In this new set of qRT-PCR results, the axes were set at ± 40-fold, as opposed to ± 20-fold 
previously in Figure 3.31. As already observed, PANC-1 had substantially up-regulated AKT2, 
and down-regulated PI3Kγ and EGFR compared to BxPC-3. Here there were in fact many 
other significant genetic differences between these two cell lines, with a definite trend of up-
regulation of PI3Kα/ AKT2 but down-regulation in other pathways (Table 3.11). Between ER 
and parent cell lines, although both BxPC-ER and PANC-ER had significantly up-regulated AKT-
2 than parent cell line (P<0.05), the fold changes were relatively small to be considered 
meaningful (BxPC-ER: +1.4 fold, P=0.016; PANC-ER: +1.6 fold, P=0.005). Previous PCR 
array found other pathways to be active in ER cell lines. In here, the two isoforms of NF-κB 
(1A and c-rel) were probably up-regulated in BxPC-ER (+2.4 and 10.1-fold respectively, 
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0.01<P<0.05), whilst Fos was up-regulated in PANC-ER (+2.3-fold, P=0.002). TLR4 and 
PI3Kg were both down-regulated in BxPC-ER (from BxPC-3) and up-regulated in PANC-ER 
(from PANC-1), and were regarded as artefacts. All in all, these results were almost identical 
to the PCR array results. To sum it up, there was slight up-regulation in MAPK1 and PI3KCA 
in ER cell lines, which was somewhat surprising. AKT2 was further up-regulated in PANC-ER 
(more than +30-fold to BxPC-3), but the comparative fold change from each pair of ER: parent 
cell lines were short of 2-fold. Instead, two markers were identified- NF-κB1a and c-Fos - 
which was up-regulated in BxPC-ER (2.4-10.1 fold) and PANC-ER (2.3 fold) respectively. 
These, in turn, may represent the driver mechanism of erlotinib resistance in these two ER 
cell lines. Importantly, these genetic markers for erlotinib resistance appeared to arise further 
downstream to PI3K/Akt/mTOR. This certainly highlighted the exceeding complexity and our 
limited knowledge of drug resistance, though the above findings remained entirely plausible, 
given that feedback loops of both NF-κB and c-Fos had certainly been well described in 
literature and implicated in drug resistance.301,302 
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3.6 Discussion 
This chapter explores the mechanism of erlotinib resistance in detail. Although erlotinib is not 
routinely used in PDAC due to its high cost and marginal benefit in survival, erlotinib resistance 
remains an important area of research. It helps current understanding about the molecular 
biology of pancreatic cancer, and may lead to discover novel strategy to target this cancer and 
overcome drug resistance. A distinction was made between primary (de novo) resistance and 
acquired resistance, since there had already been examples of different mechanisms between 
primary and acquired erlotinib resistance in NSCLC.159 The results of chapter 3 are 
summarised in the following table (Table 3.12): 
 
Table 3.12 Summary of primary and acquired erlotinib resistance results in chapter 3. WB = 
western blot, IF = immunofluorescence 
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Whilst the experiments that were performed in chapter 3 may seem somewhat repetitive, these 
experiments in totality had provided an insight in the similar yet subtly different mechanisms 
of primary and acquired erlotinib resistance. These are illustrated in the next 2 figures under 
the two respective headings. 
3.6.1  Mechanisms of Primary Erlotinib Resistance 
 
Figure 3.54: Proposed molecular mechanism of erlotinib insensitivity in PDAC 
Primary erlotinib resistance or erlotinib insensitivity is characterised by an up-regulation of 
pathways downstream of EGFR. The predominant pathways studied are the direct 
downstream MAPK pathway and the PAM pathway, and both appear involved (Figure 
3.54). This is a class effect, since cell proliferation experiments showed a similar pattern of 
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drug sensitivity for gefitinib and erlotinib but not gemcitabine chemotherapy (section 3.2). At 
baseline, all 3 erlotinib-insensitive cell lines were found to be over-expressed in downstream 
pathways, with higher total ERK or AKT (IF) (Figure 3.25) and pERK and pAkt (IF and WB) 
(Table 3.6, Figure 3.22). Erlotinib sensitive BxPC-3, on the other hand, has up-regulated 
pEGFR and pIGF1R compared to other cell lines. This pattern of protein expression was 
closely associated with the gene expression. From qRT-PCR, erlotinib-insensitive cell lines 
had either up-regulated PI3Kα, MAPK1 or AKT2 genes (CAPAN-2, MiaPACA-2 and PANC-
1), accompanied by a down-regulation of EGFR gene (Figure 3.31). A significant trend of 
EGFR gene down-regulation was observed with incremental erlotinib insensitivity. AKT-2 also 
displayed a significant up-regulation trend, though the statistical significance was largely 
contributed from a 20-fold increase in AKT-2 in PANC-1 (Table 3.8). Interestingly, the 2 most 
erlotinib-insensitive cell lines MiaPACA-2 and PANC-1 had substantially down-regulated 
ERBB3 (HER3) compared to the reference standard. In gefitinib-sensitive lung cancer cell 
lines models, HER3 coupled with EGFR in the activation of the PI3K/Akt pathway; whilst in 
gefitinib-resistant cell lines MET amplification had a dominant role.154,303 The demonstration of 
HER3 down-regulation in the two highly erlotinib-insensitive cell lines appeared to be 
consistent with existing literature, suggesting HER3/ EGFR independent downstream 
activation of the PI3K/Akt axis in mediating de novo erlotinib resistance. 
One intriguing observation from these experiments was the responsiveness of PI3K/Akt and 
significant EGFR/ PI3K pathways cross-talk in erlotinib-insensitive cell lines. Through a series 
of immunofluorescence and western blotting experiments, erlotinib-insensitive cell lines were 
found to have equipped with higher total Akt and pAkt at baseline (Figure 3.26, Figure 3.28), 
pAkt was also more actively stimulated by EGF (Figure 3.22, table 3.6). Furthermore, from 
both here and in the next chapter, PANC-1 was shown to be able to paradoxically activate 
pAkt upon EGFR inhibition alone, and activate pERK upon IGF1R inhibition alone (Figure 
3.23, Figure 4.13). This indicates that erlotinib-insensitive cell lines are active in multiple 
pathways and is capable of mediating molecular signals via the pathway of the least 
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“resistance”, a process known as “oncogenic shift”. This agrees well with the observation of 
feedback activation of reciprocal pathway by Sos et al., where pERK and pAkt are 
paradoxically activated by PI3K and MEK inhibitors respectively;208 and an experimental and 
mathematical model by Lange et al. showing basal Akt phosphorylation and degree of EGF-
activated Akt and ERK as a determining factor of erlotinib sensitivity.304  
Finally, the studies of the 5 PDAC cell lines have yielded interesting observations on K-Ras. 
K-Ras mutant PDAC may act differently than in other cancer types. In K-Ras mutated 
colorectal cancer, there is a “constitutive activation of Ras/RAF/MEK/ERK pathway, with loss 
of EGFR signalling control, rendering EGFR inhibitors (cetuximab and pannitumumab) 
ineffective.”305 In BRAF mutated melanoma, there is also a constitutive activation of the 
MEK/ERK signalling pathway.306 As both K-Ras and BRAF lie further upstream than ERK and 
MEK, this may explain why K-Ras mutant colorectal cancers and BRAF mutant melanomas 
remain sensitive to MEK inhibitors.195,307 On the other hand, in this project K-Ras mutant 
pancreatic cancer was found to behave somewhat differently. Firstly, K-Ras wild type cell line 
BxPC-3 was much more highly up-regulated in EGFR, whilst all K-Ras mutant cell lines had 
significantly highly up-regulated PI3Kα (Table 3.7). In addition, cell proliferation experiments 
showed that erlotinib-insensitive PDAC cell lines (all of which are K-Ras mutant) also exhibited 
the same pattern of insensitivity to PD-98059, a highly specific tyrosine kinase inhibitor of 
MEK1/2;56 whilst remaining sensitive to dual PI3K/mTOR inhibitor NVP-BEZ235 (Table 3.2). 
Further, in chapter 4, by western blotting, pERK was inhibited by PI3K and PI3K/mTOR 
inhibitors in PANC-1, but ironically was not inhibited by the direct downstream MEK inhibitor 
(figure 4.13 and table 4.2). These findings in aggregate suggest that K-Ras mutant PDAC 
tumours have a propensity to act via PI3K/Akt/mTOR instead of the classical 
Ras/RAF/MEK/ERK pathway. Clearly, these experiments so far merely raise this as a 
hypothesis, which can only be proven in large scale patient tumour studies. In section 6, a 
study proposal for a clinical trial will be discussed as a future direction to prove this concept. 
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In summary, the current hypothesis is that erlotinib-insensitive tumours likely have high 
activity in both MAPK and PAM pathways, with either or both pathways efficiently 
switched on depending on the situation. This dynamic shift in molecular pathways of 
pancreatic cancer may potentially explain the heterogeneity in PDAC and why it has been so 
difficult to isolate a molecular marker. Based on this premise, the goal for overcoming primary 
erlotinib resistance is no longer simply finding a specific marker and using a novel targeted 
drug to inhibit it. Instead, one must think about combining targeted therapies of multiple 
pathways to achieve a complete blockade of the signalling pathways in PDAC, a strategy that 
has already been well established in many cancer types in trial settings and an approach that 
is in line with the general directions of American Society of Clinical Oncology 2012.161 Given 
the influence of MAPK and PAM pathways in erlotinib insensitivity, the effect of different 
upstream and downstream combined blockades of EGFR and PI3K pathways in PDAC cell 
lines will be explored in chapter 4. 
 
 
 
 
3.6.1  Mechanisms of Acquired Erlotinib Resistance  
In many ways, acquired erlotinib resistance appeared to be an extension of erlotinib 
insensitivity in this study. Erlotinib insensitive cell lines had various downstream target 
pathways activation, whilst erlotinib resistant cell lines further exploited the PI3K/Akt pathways 
(Figure 3.55). On close examination, 4 important characteristics were found to be unique to 
acquired erlotinib resistance. 
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Figure 3.55: Proposed molecular mechanism of acquired erlotinib resistance in PDAC 
Firstly, in both ER cell lines there was a dominant shift from the MAPK pathway to the PI3K/Akt 
pathway mediating through mTOR, as demonstrated by western blotting and 
immunofluorescence (Figure 3.40, Figure 3.44). Of interest, whilst PANC-1 already had up-
regulated PI3K/Akt pathway and PANC-ER simply took further advantage of this active 
system, BxPC-3 had low PI3K/Akt pathway activity to start off with. Yet, like PANC-ER, BxPC-
ER also up-regulated this pathway in mediating erlotinib resistance. In particular, Akt-driven 
pS6 within the mTOR complex was highly up-regulated, as opposed to the many other 
effectors of Akt (Figure 3.37, 3.38, 3.44). This therefore implies that PI3K/Akt/mTOR pathway 
confers a natural selective advantage under the erlotinib drug pressure, which in turn suggests 
a possible role of mTOR inhibition in overcoming erlotinib resistance. 
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Secondly, ER cell lines were characterised by epithelial-mesenchymal transition (EMT). 
Whilst BxPC-3 was epithelial and PANC-1 mixed epithelial and mesenchymal, a progression 
from epithelial to mesenchymal morphology was observed in ER cell lines. Of note, there was 
a strategic relocation of vimentin close to the edges of ER cell colonies. In PDAC TGF-β 
activates SMAD-4 pathway in mediating EMT, in the so-called “canonical EMT pathway”71,72 
However, BxPC-3 is known to be SMAD-4 deleted,228 implying that BxPC-ER probably 
mediated EMT via non-canonical pathways. In support of this, a series of preliminary western 
blotting experiments that SMAD4 protein was present in PANC-1 and PANC-ER but not BxPC-
3 and BxPC-ER. Comparing each ER cell line to parent cell line, pSMAD2/3 was more active 
in PANC-ER and less active in BxPC-ER. Recent evidence suggested that pathways such as 
MAPK pathway, c-jun N-terminal kinase (JNK) and PI3K may be involved in EMT.77 It is 
possible that EMT is driven by the up-regulated PI3K/Akt/mTOR pathway, such that it 
represents an “outcome” rather than the “cause” of acquired erlotinib resistance. Note that the 
focus of this project remains the study of interaction between EGFR, IGF1R, MAPK and PAM, 
and it is not designed to substantiate EMT and erlotinib resistance. A thorough examination of 
SMAD and EMT transcription factors (e.g. Snail, Trail) by TGF stimulation will be required for 
ongoing studies. 
Thirdly, the genetic drivers for acquired erlotinib resistance may possibly lie further 
downstream of PI3K/Akt/mTOR. In the case of BxPC-ER, the NF-κB system was involved; 
for PANC-ER, c-Fos was implicated (3.5.5 and 3.5.6). NF-κB has been found to activate 
PI3K/Akt as early as 2002, and is now known to stimulate PI3K/Akt through removal of a brake 
involving the mTOR/S6/IRS1 feedback and down-regulation of PTEN via an intermediary 
RIP1.301,308,309 c-Fos, on the other hand, is a transcriptional regulator of many genes, and is 
known to be induced by both ERK and PI3K/Akt via Elk1.309 That said, no current data exists 
that support negative feedback of c-Fos on PI3K/Akt. Whilst these current experiments were 
only hypothesis-generating at best, it nonetheless highlighted the extensive genetic 
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heterogeneity, alterations and complex pathway wirings observed in pancreatic cancer,20,29 
and provides a basis for ongoing sequencing experiments of these intriguing cell lines. 
Lastly, and importantly, the ER cell lines which were up-regulated in the PAM pathway became 
significantly cross-resistant to IGF1R and MEK inhibitors whilst remaining sensitive to PI3K 
and PI3K/mTOR inhibitors as single agents (Table 3.3). In a way this is counter-intuitive, since 
one would expect that over-activation of PAM pathway should lead to an increased resistance 
to drugs that are designed to block it. The current hypothesis is that erlotinib resistant cell 
lines have not only “shifted” but also become dependent in the PAM pathway. To 
investigate oncogenic dependence further, the differential response of ER and parent cell lines 
to PI3K and mTOR inhibitors across multiple functional assays needs to be studied. So far 
both figures 3.54 and 3.55 are incomplete, and have many unknown endpoints denoted by 
“?”. In chapter 4, the results of migration assay, cell cycle assay and apoptosis assay will be 
presented in addition to cell proliferation and clonogenic assay, and further information will be 
added to the existing diagrams of proposed molecular mechanisms. This discussion point will 
be revisited in the section 4.5. 
In summary, primary erlotinib resistance appears to be determined by active downstream 
signal activation and cross-talk between multiple pathways (notably EGFR/MAPK and 
PI3K/Akt pathways), whereas acquired erlotinib resistance results from a dominant shift to 
PI3K/Akt/mTOR pathway under constant drug pressure. In both cases, cancer cells remained 
sensitive to PI3K/mTOR inhibitor NVP-BEZ235 and PI3Kα inhibitor NVP-BYL719 to a lesser 
extent. The next chapter will examine the effect of these inhibitors, erlotinib, MEK inhibitor and 
IGF1R inhibitors, alone or in combination.  
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CHAPTER 4:  
 
COMBINED BLOCKADE VERSUS SINGLE 
BLOCKADE OF EGFR AND PI3K/MTOR IN-VITRO 
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4.1  Introduction 
4.1.1   Chapter Background 
In the previous chapter, genomic and molecular characterisation was performed on 5 PDAC 
cell lines and 2 ER cell lines. Primary or de novo erlotinib resistance was found to be 
contributed by constitutively active downstream signalling pathways and significant cross-talk 
between EGF/IGF and MAPK/PAM pathways; whereas acquired erlotinib resistance was 
characterised by an oncogenic shift to the dominant PAM pathway. Yet, at this stage only little 
was known about the end outcomes of erlotinib resistance, as cell proliferation and clonogenic 
assays were the only functional assays that were discussed in the last chapter. In the last 
chapter, there was early evidence that both primary and acquired resistant cell lines remained 
sensitive to dual PI3K/mTOR inhibitor (BEZ-235) with nanomolar potency. However, an in-
depth analysis of the optimal strategy to overcome erlotinib resistance had yet to be explored. 
Over the last few years, combined targeted treatment or combined blockade (CB) has rapidly 
gained momentum in pre-clinical and clinical studies, particularly with the aim of overcoming 
targeted drug resistance.310 The concept of CB is to improve the complete blockade of a target 
by inhibiting on multiple forms of the same target; or to produce complementary effect by 
blocking different targets in the same pathway”.198 This latter strategy is particular important 
for cancers with extensive molecular crosstalk- as demonstrated in the erlotinib insensitive 
PDAC cell lines, since these cancers are often equipped with redundant signalling pathways 
making them difficult to inhibit by single drug alone.160 Given the significant interaction between 
EGFR/ IGF1R/ MAPK/ PAM pathways, 4 horizontal combined blockade strategies ranging 
from dual upstream to dual downstream blockades were closely examined in their synergy as 
well as efficacy. The differential sensitivities between parent and resistant cell lines to CB were 
then scrutinised to explore the concept of oncogenic addiction, whereby cancer cells driven 
down a molecular pathway are preferentially killed by CB. 
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4.1.2  Chapter Aims 
1. To compare the effect of CB versus single blockade (SB), and to establish synergy 
2. To propose the “best” CB combination for pancreatic cancer to take to in-vivo study 
3. To explore onocogenic dependence by comparing differential response to CB 
between parent and resistant cell lines 
 
4.1.3  Chapter Methods  
In the first half of this chapter, various methods from pharmacology biostatistics are used to 
demonstrate the important concept of synergy between drug A and drug B. These are used to 
study the synergistic effect of 4 horizontal CB combinations covering the MAPK and PAM 
pathways: 1) erlotinib (ERL)* NVP-AEW541 (IGF1Ri: AEW)– both cell surface receptors (dual 
upstream); 2) ERL* NVP-BYL719 (PI3Kαi: BYL)– upstream plus “midstream” blockade, 3) 
erlotinib* NVP-BEZ235 (dual PI3K/mTORi: BEZ) – upstream plus downstream blockade; and 
4) PD-98059 (MEKi: PD)* BEZ – dual downstream blockades. “Cytotoxic synergy” and 
“molecular synergy” were studied by cell proliferation and western blotting respectively. In the 
second half of this chapter, CB versus SB and the test of 4 CB combinations were then carried 
out in a wide variety of functional assays, including cell cycle, apoptosis assay, clonogenic 
assay and migration assay. Finally, in the discussion, all results are pooled to make 
conclusions about the best combination to take to in-vivo study, and to generate some theories 
about molecular functions of erlotinib resistance and logical ways to overcome this. 
Building from the diagram from previous chapter, the designed targets of these inhibitors are 
illustrated in the figure below: 
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Figure 4.1: Drug Targets on EGFR, IGF1R, MAPK and PAM pathways 
The design of these CB combinations took into account that erlotinib resistance was found to 
be mediated via up-regulated downstream MAPK or PAM pathways with downstream mTOR 
being intricately involved. If this hypothesis was true, one would expect that combined 
downstream blockades would be more complete than upstream blockades. That is, the last 
combination would be more effective than third, than second, than the first combination. 
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4.2 Establishing Pharmacological Synergy 
4.2.1  Statistical analysis of pharmacologic synergy 
4.2.1.1  Definition of Synergy 
Drug combinations have been studied extensively in pharmacological investigations. The 
standard way of examining drug combination is the concept of dose equivalence or additivity, 
where the combined effect of two drugs are well fitted in the equation predicted by the 
maximum effect produced by each drug combined.311 Mathematically, this is expressed by the 
following formula: 
Eab = Emax(b + a/R) 
        (b + a/R) + CB 
where Eab denotes the effect observed when drug a and drug b are combined, R denotes the 
ratio of equivalent doses (R = CA/ CB) and Emax denotes the upper limit of effect observed in 
the system.311 In other words, additivity simply means that the less potent drug is acting as a 
diluted form of the other drug, and that there are no interactions between the two drugs.312 
Thus, by definition, synergy is more than expected for an additive effect and antagonism is 
less than expected for an additive effect. 
Whilst the combined effects of two drugs can be easily represented in column graphs, it is 
often important to quantify synergy mathematically, especially as several CB combinations will 
be compared against one another. The subject of synergy analysis is exceedingly complex, 
often requiring complicated mathematical algorithms and advanced pharmacological 
statistical analysis. In addition, there are in excess of 13 ways to quantify synergy, including 
isobolograms, combination index plots, combined dose effect curves and many others.313 As 
such, the subject of synergy analysis cannot be comprehensively covered in this thesis; nor is 
it necessary to do so. Instead, the concepts of the 3 most common ways of synergy analysis 
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(dose response surface plots, isobolograms and synergy index)  and their interpretations are 
described below. 
4.2.1.2  Three-dimensional dose response surface plot 
The combined dose response of drug A and drug B can be simply explored in a matrix of 
graded concentrations of drug A times drug B. This is particularly used for cell proliferation 
experiments, where responses are measured as proportional viability (%), as in this example: 
 Dose of NVP-AEW541 
Dose of erlotinib 0 M 1 M 2 M 4 M 
0 M 100% 78% 68% 54% 
10 M 40% 8% 7% 4% 
20 M 34% 6% 5% 5% 
30 M 31% 6% 5% 4% 
 
Table 4.1: Raw Data example of combined blockade cell proliferation experiments 
This data in Table 4.1 can then be plotted in a dose response surface plot, where x-axis 
represents dose of one drug, y-axis the dose of second drug, and z-axis the proportional 
viability (%). There are then three ways of producing the graph using SAS 9.2, as described 
elsewhere.272 
 
Figure 4.2: Different forms of dose response surface plots 
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In figure 4.2 (a), the raw proportional viability (PV) data is shown on the surface plot. Whilst 
all observed data in the 4x4 matrix are presented accurately, there is a lack of appreciation of 
the “contour” of the dose response because of the small number of data points. In the actual 
experiments, a 6x 6 matrix of graded concentrations of each drug was used, but despite this, 
36 observations were still too few to create a sense of contour. Figure 4.2 (b) uses log 
transformation on the observed data, as recommended by Whitehead et al.272 Presumably this 
is because tumour growth have been described in log linear models previously.314 However, 
the log transformation did not enhance the sense of contour in these experiments, and created 
unequal distance between each log doses. Figure 4.2 (c) shows a fitted curve based on the 
observed data. The values are fitted using spline interpolation with SAS 9.2, and the resulting 
curve comprises of 50 x 50 = 2500 expected data points. This closely resembles the raw data 
surface plot in figure 4.2 (a), and also creates a contour shape that can be easily appreciated. 
 
Figure 4.3: Interpretation of fitted dose response surface plots 
In terms of the interpretation of fitted dose response surface plots, figure 4.3 (a) shows a cell 
line that is sensitive to both drugs, with PV reduced to more than 50% with each drug alone (x 
and z-axis).The combination of two drugs at high dose essentially suppress the cells to 0%. 
This is therefore a synergistic combination, and the resulting surface plot tends to be concave, 
slanting from the top left corner to the bottom right in a steep slope. On the other hand, an 
antagonistic combination is usually flat or even convex, with the proportional viability remaining 
high even at the highest concentrations of both drugs as in figure 4.3 (b). The left and right 
figures represented the actual experiment results of ERL* AEW combination in BxPC-3 and 
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PANC-1 respectively. From these results, it is appreciated that this combination is synergistic 
in BxPC-3 but not in PANC-1. 
4.2.1.3  Isobolograms 
A very common way of representing drug synergy graphically is isobologram. This is a graph 
of equally effective dose pairs called isoboles, and is particularly effective in conditions where 
two agonists have varying potency.312 Below is an example of isobologram: 
 
Figure 4.4: Example of an isobologram 
A particular effect level is first selected, such as IC50. The doses of drug A and drug B to 
produce the IC50 are plotted on the X and Y-axis. A straight line connecting the two intercepts 
represents all the possible dose pairs that produce the effect in an additivity combination. This 
line is called the additivity line, and is expressed by this equation: 
      a  + b = 1 
Ai   Bi                
where Ai and Bi represent the IC50 of each drug, and all (a,b) points represent the dose pairs 
that lie on the additivity line.315 
The observed dose pairs to achieve IC50 are then plotted on the same graph. A dose pair that 
lies below the additivity line represents a synergistic or supra-additive combination, whereas 
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a dose pair that lies above the additivity line represents an antagonistic or sub-additive 
combination.312 
4.2.1.4  Synergy Index 
The above two methods only qualitatively assess synergy. It is useful for assessing whether 
a CB combination is synergistic, but is less useful for comparing whether one CB combination 
is more synergistic than another. To quantitatively measure synergy, the Bliss synergism/ 
antagonism model, one of the most popular and robust model for measuring synergy, was 
implemented.316 The Bliss model essentially predicts if each individual drug cause growth 
inhibition by 50%, then two drug combined decrease growth by 1–0.5*0.5, or 75%.317  
In the modelling part, a four-parameter model was programmed on SAS 9.2 and this model 
was fitted using PROC NLIN (non-linear regression). This formula has been published 
elsewhere, but is not included here because of its complexity.272 The results will be presented 
in the following way: 
 
 
 
 
Table 4.2: Interpretation of Synergy Index 
Synergy Index (S.I.) equals to 1 when the observed effect of the dose pair is exactly the same 
as the combined effect of each drug alone, that is the combined effect is additive only. A S.I. 
>1 indicates that synergy is present, with higher values representing more synergy. A S.I. <1 
indicates that antagonism is present, with lower values (>0) representing less synergy. A 95% 
confidence interval (C.I.) is calculated. A 95% C.I. that crosses 1 indicates the result is non-
significant, whereas a 95% C.I. that excludes value of 1 indicates significant result. That said, 
a non-significant result did not necessarily exclude synergy, since type II error was high with 
 Bliss Synergy/ antagonism model  Departure from model Conclusion 
Cell line n S.I. 95% C.I. t-value P-value  
BxPC-3 4 1.99 1.43 2.76 t= 0.00 1.00 Significant synergy 
PANC-1 4 0.96 0.68 1.37 t = 0.07 0.94 Possible antagonism 
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this model. Finally, the residuals are used to assess departure from the Bliss model, and the 
formula had been previously described.272 A significant P (<0.05) suggests heterogeneous 
data, resulting from poor iterations and unreliable data. In this case, synergy index cannot be 
interpreted with confidence. In the above example that studied ERL*AEW combination, the 
CB was significantly synergistic for BxPC-3 as the 95% C.I. did not cross the null value of 1, 
and possibly slightly antagonistic for PANC-1 since the C.I. crossed 1. 
 
 
4.2.2  Study of Cytotoxic Synergy by cell proliferation assays 
As described previously, a 6x6 matrix of graded concentration of two drugs from 4 CB 
combinations (ERL*AEW, ERL*BYL, ERL*BEZ, PD*BEZ) were tested on the 5 PDAC cell 
lines. For erlotinib, the 6 doses ranged from 0, 5, 10, 15, 20 and 30M; for NVP-AEW541, this 
ranged from 0, 0.5, 1, 2, 3 and 4M; for NVP-BYL719, this ranged from 0, 0.5, 1, 2.5, 5 and 
10M; for NVP-BEZ235, this ranged from 0, 0.01, 0.025, 0.05, 0.1 and 0.2M; and for PD-
98059 this ranged from 0, 5, 10, 20, 30 and 40M. Biological triplicates were performed for 
each dose set. Synergy experiments were repeated in at least 4 times, to provide enough 
statistical power for performing synergy analysis.  
 
4.2.2.1  Synergy analysis of 4 CB combinations in 5 PDAC cell Lines 
Key Finding: EGFR and IGF1R are synergistic for cell lines with active upstream 
receptors; whilst EGFR and PI3K are synergistic for cell lines with active downstream 
pathways. 
Before analysing synergy with the methodologies above, the raw values of an ERL*AEW 
synergy experiments for 2 combination dose sets are presented as an illustration. 
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Figure 4.5: An example of raw data for an erlotinib* NVP-AEW541 synergy experiment 
In the figure above, the raw data of erlotinib 10 and 20M, crossed with IGF1R inhibitor AEW 
1 and 2M respectively, are shown for the 5 cell lines. First of all, the most obvious finding 
was that the responses of these 5 cell lines to CB (dark blue, dark green bars) followed a 
similar pattern to single drug alone. It roughly followed that BxPC-3<CFPAC-1<CAPAN-2 
<MiaPACA-2<PANC-1 in insensitivity. As for synergy, a simple calculation using the bliss 
model could be done manually. The Bliss synergy/ antagonism model simply predicts that 
synergy occurs when the observed effect of two drugs combined is more than the product of 
the expected effect of each drug, as discussed previously. Thus, as an example, the 
proportional viability (PV) from the effect of ERL 10M * AEW 1M on BxPC-3 should be at 
least 70%*47% = 33%. In this case, the observed PV of erlotinib 10M * NVP-AEW541 1M 
was 10%. In other words, the cell suppression effect of the combination was actually 90%, 
which was far greater than the expected 1-33%= 67%. Therefore, synergy was likely present 
for this combination at this dose for this cell line. After simple multiplications, the expected 
combined PV for ERL 10M * AEW 1 M were 33%, 40%, 50%, 46% and 77% for BxPC-3, 
CFPAC-1, CAPAN-2, MiaPACA-2 and PANC-1; whereas the observed PV were 10%, 25%, 
41%, 48% and 68%. At this dose, then, synergy was present for BxPC-3, CFPAC-1, CAPAN-
2 and PANC-1 since the observed CB PV was smaller than the expected CB PV (or the 
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observed cell proliferation suppression effect was greater), whereas antagonism was present 
for MiaPACA-2 as the observed PV (or the observed cell proliferation suppression effect was 
smaller). For ERL 20 M * AEW 2 M the expected combined PV were 22%, 28%, 36%, 25% 
and 46%; whereas the observed PV were 6%, 16%, 31%, 38% and 48%. Thus, at a higher 
dose this combination was synergistic in BxPC-3, CFPAC-1 and CAPAN-2. This time, this 
combination was antagonistic for both MiaPACA-2 and PANC-1.  
Of course, this illustration was far from complete, since only 2 combination dose sets were 
represented here, and as many as 25 dose sets should be assessed in a 6x6 matrix 
experiment. Also, as was becoming clear in this illustration, 2 drugs could be synergistic for 
one dose set and antagonistic in another for the same cell line (PANC-1 in this example). A 
more robust way of combining these data is needed rather than averaging or performing 2-
sample t-test. This is why synergy index is much more powerful to statistically analyse for 
synergy. Below, the dose response surface plot is presented first before the S.I. data. 
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Figure 4.6: Dose response surface plots of 4 CB combinations in 5 PDAC cell lines  
Firstly, examining the first column from the left, ERL* AEW CB appeared to be synergistic for 
BxPC-3, CFPAC-1 and CAPAN-2, consistent with the raw data. In all three surface plots, the 
contour appeared concave, and there was a steep gradient from the top left to the bottom 
right. Importantly, the PV at the highest dose set almost reached zero baseline for BxPC-3, 
indicating that the two drugs together at this dose (ERL 30M and AEW 4M) nearly 
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completely eliminated all cells. For MiaPACA-2 and PANC-1, however, the shapes of the 
surface plots were clearly different. There was a convexity in the middle of the surface plots 
for both cell lines (arrows), indicating an unexpectedly high PV (or low effect) as would be 
predicted by additivity. In addition, for MiaPACA-2 there were many irregular contour “terrains” 
in addition to the central convexity in PANC-1, and this was reflected in the lower S.I. value 
(higher antagonism) which is discussed in the next section. 
As the surface plots of all 4 CB combinations were examined in all 5 PDAC cell lines, it was 
clear for most combinations there was a steep concave slope suggesting synergy. The 
exceptions to this are MiaPACA-2 and PANC-1 for the ERL*AEW combination as discussed 
above; and PANC-1 for the ERL * BYL (PI3Kα inhibitor) combination (arrows). In all three 
cases, the apparent convexity appeared at mid-range dose sets, indicating where the 
antagonism was observed. Importantly, on closer examination, the last 3 cell lines (CAPAN-
2, MiaPACA-2 and PANC-1) were relatively insensitive to ERL or PD (MEK inhibitor), as 
indicated by the small gradient on the z-axes (z-axis corresponds to ERL in the first 3 
combination, and PD for the 4th combination). Despite this, the use of BYL and in particular 
the dual PI3K/ mTOR inhibitor BEZ was mostly capable to reduce the PV synergistically. 
Synergy index with 95% confidence interval and statistical testing of model departure was 
shown below for all 4 CB combinations in 5 PDAC cell line: 
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Table 4.3: Synergy Index (S.I.) for 4 CB combinations in 5 cell lines with 95% confidence 
interval (C.I.) and statistics for model departure provided. 
 
For easier inspection, S.I. >1 indicating synergy was coded in red, and S.I. <1 indicating 
antagonism was coded in blue. A significant result with 95% C.I. not crossing 1 was bolded 
(Table 4.3). From these analyses, the following observations could be made: 
1) The results of S.I. analysis closely corresponded to the dose response surface plots, with 
synergy indicated for all cell lines except for MiaPACA-2 (ERL*AEW) and PANC-1 (ERL*AEW, 
ERL*BYL) (blue). 
2) For the erlotinib sensitive cell lines, ERL* AEW combination was highly synergistic for 
BxPC-3 (S.I. = 1.99, 1.43-2.76) and CFPAC-1 (S.I. = 1.55, 1.14-2.14). Other combinations 
remained synergistic for these 2 cell lines, but were clearly less synergistic than this CB. 
3) For the erlotinib insensitive cell lines, ERL* AEW combination was non-significantly 
antagonistic for MiaPACA-2 (S.I. =0.84, 0.67-1.05) and PANC-1 (S.I. =0.96, 0.68-1.37). 
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However, ERL* BYL was possibly synergistic for MiaPACA-2 (S.I. = 1.15, 0.98-1.35); and 
when combined with BEZ, both 3rd/4th CB were highly synergistic, with S.I. from 1.27- 1.44. 
4) For the moderately insensitive CAPAN-2, all CB combinations were equally synergistic.  
5) Comparing the 4 CB combinations, ERL and BEZ were significantly synergistic with 4 of 
the 5 cell lines. Significant results could not be demonstrated for CAPAN-2 using any CB 
combination, since CAPAN-2 was a slow-growing cell line with inherent issues of 
underestimating the true PV as discussed in chapter 3. 
6) None of the results had significant departure from the model, and were all valid results. 
Finally, isobolograms were constructed for all 4 CB combinations on the 5 cell lines. However, 
since the results were largely concordant with the two previous methodologies, only the ones 
for the most erlotinib-sensitive BxPC-3 and most erlotinib-insensitive PANC-1 are presented 
here. 
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Figure 4.7: Isobolograms of 4 CB combinations in BxPC-3 and PANC-1  
In figure 4.7, the IC50 additivity line was the bolded straight line, and the IC75 line was the 
dotted black line. The circles and stars represented the observed dose sets that were 
predicted to achieve the same IC50 and IC75. They had to be below the bolded straight line and 
dotted straight line respectively to establish synergy. The black arrows indicated the dose sets 
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that lied above the additivity line, suggesting antagonism. Notice that the axes are different 
between BxPC-3 and PANC-1. The Y-axes go up to 40 M for BxPC-3 and up to 80 M for 
PANC-1. The X-axes are also doubled for PANC-1 for the first 2 CB, but are the same for both 
cell lines for the last 2 BEZ-235 based CB combinations. This is because BEZ remain potent 
in both cell lines, such that the additivity lines lie appropriately within the axes ranges.  
For BxPC-3, the ERL *AEW were very highly synergistic. The observed dose sets were 
located virtually on the Y-axis. This meant that when this cell line was treated with erlotinib, 
only very minimal AEW was needed to reach the same IC50 that was achieved by SB. Other 
CB remained synergistic for BxPC-3, since the circles lie below the straight line and stars lied 
below the dotted line. However, the magnitude of synergy was clearly less than that of the first 
combination, with these symbols lying further away from the Y-axis. 
For PANC-1, the first 3 CB resulted in outlier symbols (above the additivity line) indicating 
antagonism. The first two isobolograms corresponded well with the S.I. analysis. There was 
only 1 circle lying above the additivity line for ERL* AEW (S.I. =0.96, just below), whereas 
there were 2 outliers for ERL* BYL (S.I. =0.85). ERL* BEZ were significantly synergistic in S.I. 
analysis (1.27), but the isobologram indicates otherwise. PD and BEZ were synergistic for 
PANC-1 (1.44), which was consistent with the isobologram results. 
Overall, then, isobolograms appeared to correspond well with the previous two methodologies 
with the exception of ERL *BEZ for PANC-1. Here, it must be pointed out that isobologram 
has a major limitation. Like the raw data first presented, isobolograms here only present a 
limited view of all the possible dose sets. In this figure, IC50 and IC75 lines were arbitrarily 
chosen, but in reality there is an unlimited number of additivity lines that can be selected. S.I. 
analysis, however, accounts for all possible values, and produces a statistics of significance. 
Thus, the S.I. remains the most valid and reliable methods of the three. 
In summary, the three synergy analyses methods employed were largely concordant, and 
showed that ERL and IGF1R inhibitor AEW were highly synergistic for BxPC-3 and CFPAC-
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1, the two erlotinib-sensitive cell lines. Conversely, these were antagonistic for the highly 
erlotinib-insensitive MiaPACa-2 and PANC-1. However, when combinations involving 
downstream PI3K and PI3K/mTOR inhibitors were used, the reverse was true. These 
combinations were still synergistic for BxPC-3 and CFPAC-1, although less so. On the other 
hand, these combinations were increasingly synergistic for the erlotinib-insensitive cell line. 
As discussed previously, the erlotinib-sensitive cell lines – particularly BxPC-3- had a more 
active upstream receptors (EGFR, IGF1R), whereas MiaPACA-2 and PANC-1 had a highly 
active downstream MAPK and PI3K/Akt system (section 3.4). This may explain why the 
downstream CB combinations were much more synergistic in inhibiting the latter two cell lines. 
From these results, positive interactions between EGFR and IGF1R were observed in 
erlotinib-sensitive cell lines, and between EGFR and PI3K or PI3K/mTOR in erlotinib-
insensitive cell lines. 
 
4.2.2.2  Synergy analysis of 4 CB combinations in parent vs. resistant cell lines 
Key Finding: EGFR and PI3K inhibitors became more synergistic in ER cell lines, 
suggesting a dominant shift from EGFR-IGF1R interaction to EGFR-PI3K interaction. 
In this next section, the same 6x6 matrix in biological triplicates were performed on ER cell 
lines, in 4 independent experiments. Synergy of parent versus erlotinib-resistant (ER) cell lines 
were examined by dose-response surface plots and synergy index only. Isobolograms were 
not includedin this analysis. ER cell lines, though stably drug-resistant, were subjected to more 
variability than PDAC cell lines. They were more senile than PDAC cell lines, as they had been 
sub-cultured over 10 months before frozen, and there was plenty of manipulation and 
disruption to the environment where these cell lines are grown (changing of medium and drug). 
In fact, this variability of the ER cell lines between proliferation experiments was reflected by 
the wide C.I. in the S.I. as shown below. Given all the limitations of isobolograms already 
discussed, such as variations in assessing synergy based on a number of arbitrary additivity 
levels, isobolograms are too unreliable to be applied to analysis of ER cell lines. Instead, the 
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more robust S.I. analysis and the dose response surface plots are presented here (Figure 
4.8): 
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Figure 4.8: Synergy Index and Surface plots for 4 CB combinations in parent versus ER cell 
lines 
 
First of all, the effect of single drug on ER cell lines can be examined by inspecting the gradient 
of each axis. By definition, ER cell lines were more resistant to erlotinib compared to parent 
cell line. This was particularly noticeable in the BxPC-3 versus BxPC-ER comparison, where 
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the gradient of Z-axis was flat and PV remained high at erlotinib 30M in BxPC-ER. ER cell 
lines were also cross-resistant to MEK inhibitor PD and IGF1R inhibitor AEW; but remained 
moderately sensitive to PI3Kα inhibitor BYL and dual PI3K/mTOR inhibitor BEZ. As for synergy 
analysis, the S.I. of each pair of parent and resistant cell line was compared. ERL and AEW 
were synergistic in BxPC-3 [S.I. = 1.99 (1.43-2.76)] and not in PANC-1 [S.I. = 0.96 (0.68-
1.37)], as shown previously. The S.I. decreased for both ER cell lines [BxPC-ER: S.I. = 1.85 
(0.46-7.61); PANC-ER: S.I. = 0.69 (0.37-1.31)] compared to their parent cell lines. ERL and 
BYL were synergistic in BxPC-3 [S.I. = 1.34 (1.17-1.55)], but not in PANC-1 [S.I. = 0.85 (0.68-
1.07)]. The S.I. for both resistant cell lines increased markedly, with S.I. for BxPC-ER at 1.71 
(1.00-2.89)] and for PANC-ER at 1.44 (0.81-2.56). For the last two combinations involving the 
use of BEZ, both combinations were synergistic across the two pairs of cell lines, and the S.I. 
were relatively unchanged between parent and ER cell lines. Note, too, that the confidence 
intervals were much wider in the ER cell lines than the parent cell lines. This reflects the larger 
inter-experimental variability due to reasons stated above, which was accounted for by the 
robust S.I. regression model. 
To summarise, EGFR and IGF1R inhibitors became less synergistic in the erlotinib resistant 
cell lines. Conversely, EGFR and PI3K inhibitors became more synergistic. CB using dual 
PI3K/ mTOR inhibitor were synergistic in ER cell lines, but were not any more or less so than 
parent cell lines. Thus, it appears that there was a dominant shift from EGFR-IGF1R 
interaction to EGFR-PI3K interaction in both acquired erlotinib resistant cell lines. The 
fact that the last two CB combinations were equally synergistic in all 4 cell lines, and the fact 
that CB effect was only slightly more than BEZ-235 alone (X-axes in the last 2 CBs), suggest 
that it was the main component that exert effect in either CB combination. This drug was likely 
to be sufficient as a single drug alone, as the dual mechanisms of action in BEZ (PI3Kα and 
mTOR inhibition) were probably “internally synergistic” in the same drug. Since BEZ was 
already effective on its own, any drug added to NVP-BEZ235 could only make it a little more 
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effective. This supports the nanomolar potency observed for this drug on all PDAC and ER 
cell lines in chapter 3 (Table 3.2).  
 
4.2.2.3  Confluence % by cell imaging proliferation experiments 
Key Finding: PI3K inhibitors were effective in erlotinib insensitive and resistant cell 
lines; ER cell lines became “hypersensitive” to PI3K-inhibitor based combined 
blockade 
The previous synergy analyses, although detailed, were based on one type of experiment- the 
MTT cell proliferation assay. MTT assay is a widely used cell viability assay, but results can 
be potentially interfered by compounds that contain polyphenolic hydroxyl groups, culture 
media types and filter sets.318 Furthermore, the results of MTT are only semi-quantitative, 
expressed as proportional viability percentage to control; and are based on measurement of 
a single time point (72 hours).319 Since synergy analysis is one of the vital components of this 
project, a second method was used to validate the MTT assay. The confluence study by the 
incucyte live imager (Essen Bioscience) was chosen, as this is essentially a time-lapsed 
microscopy system that allows semi-quantitation of proliferation based on confluence. This 
system has been increasingly used in cancer research in the last few years.320-322 
In this experiment, one dose set was selected for each combination, based on the relative 
equipotency between each drug alone as measured by the MTT assay: ERL 10M and AEW 
1M (designated as E10A1), ERL 10M and BYL 5M (E10Y5), ERL 10M and BEZ 0.1M 
(E10B0.1) and PD 10M and BEZ 0.1M (P10B0.1). The first set of experiment compared 
single blockade (SB) versus CB for the first two combinations. The second set of experiment 
compared all 4 CB combinations. The cell lines tested were the two pairs of parent versus 
resistant cell lines. Confluence was measured over 70 hours in 4 experiments; the trend of the 
average values and its standard errors are presented below. 
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Figure 4.9: Confluence % as measured by Incucyte for erlotinib, NVP-AEW541 and NVP-
BYL719, alone or in combination in parent versus resistant cell lines. 
In this first set of experiments, a differential response to SB and CB was immediately obvious 
in the ER compared to parent cell lines, as demonstrated by the divergent plots (Figure 4.9). 
BxPC-3 had high sensitivity and PANC-1 had low sensitivity to erlotinib as a single drug. Upon 
treatment with erlotinib 10 µM, there was marked reduction in cell density of BxPC-3 compared 
to control (orange versus red lines), but no reduction for PANC-1. Importantly, BxPC-ER 
showed resistance to erlotinib, and PANC-ER was actually growth-stimulated by erlotinib 
compared to control. In response to other single agents, PANC-1 as well as both acquired ER 
cell lines showed cross-resistance to AEW (green), but was moderately sensitive to BYL 
(blue). Whilst both CB (purple and grey) were more effective than SB, in both ER cell lines 
ERL* BYL showed the most substantial suppression in cell proliferation, and was the only 
treatment strategy that was clearly cytostatic in all four cell lines.  
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Figure 4.10: Confluence % as measured by Incucyte for 4 CB combinations in parent versus 
resistant cell lines. 
In the second set of experiments, the 4 CB combinations were compared. Although ERL and 
AEW were previously shown to be more synergistic than other combinations in BxPC-3, the 
absolute measure of confluence% was completely suppressed by all 4 combinations in BxPC-
3. This suggested that synergy is merely a measure of interaction, not efficacy. For PANC-1, 
there were some increase in confluence with all 4 combinations over 70 hours, but the change 
was still less than that of control. Whilst all 4 combinations exhibited a similar pattern of cell 
proliferation suppression in the parent cell lines, the ER cell lines responded to the CB 
combinations in a different pattern. Once again, both ER cell lines were only moderately 
sensitive to the EGFR and IGF1R co-inhibition (orange lines), but were sensitive to the other 
3 combinations that utilised a PI3K inhibitor or dual PI3K/mTOR inhibitor (blue, purple and 
grey lines). Importantly, whilst these 3 combinations had a suppressed proliferation in PANC-
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1 compared to control, these induced complete cytostaticity on BxPC-ER and PANC-ER. This 
indicates that ER cell lines exhibited a hyper-sensitivity to CB based on a PI3K or PI3K/mTOR 
inhibitor. 
In summary, PI3K or PI3K/mTOR inhibitors were clearly active in both erlotinib insensitive or 
resistant cell lines. While ER cell lines became moderately insensitive to IGF1R plus 
EGFR inhibitors, they remained sensitive or even became hypersensitive to PI3K based 
combined blockade. This is supported by the synergy analyses that dmonstrated a shift from 
dominant EGFR/ IGF1R interaction to EGFR/ PI3K interaction in ER cell lines. Therefore, 
these results validated and reinforced the results of the MTT assay.  
So far, only cytotoxic synergy was explored at this stage. To fully understand the mechanism 
of this synergy, the molecular mechanisms of action of this synergy needed to be examined. 
In the next sub-section, the western blotting results of PDAC cell lines in response to combined 
blockade are described. 
 
 
4.2.3  Study of Molecular Synergy by western blotting 
In this part of the project, the differential response of PDAC cell lines to combined blockade 
(CB) versus single blockade (SB) was first established, and then the 4 CB were compared. 
The membranes were blotted for key tyrosine kinase receptors/ signalling proteins of the 
EGFR, MAPK and PAM pathways, as suggested from the results in chapter 3. These included 
EGFR, ERK, Akt, S6 and 4EBP1, the second effector of mTOR (the first being S6). Both total 
and phosphorylated proteins were studied. Three independent experiments were performed 
for each comparison unless otherwise specified. 
 
PD-98059 * BEZ-235 
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4.2.3.1  Optimisation of EGF/ IGF stimulation in BxPC-3 and PANC-1 
Key Finding: Significant cross talk of EGF- Akt and IGF- ERK in the erlotinib-insensitive 
PANC-1 
In the initial optimisation experiment, it needed to determine if drug inhibition studies should 
be accompanied by EGF, IGF or both. ERL* BYL was used as the CB combination in these 
optimisation experiments. Cell lines were treated with inhibitor SB or CB for 60 minutes and 
then stimulated with EGF or IGF alone for 10 minutes, so that the effect of a particular growth 
factor could be easily discerned. The cell lines used for optimisation were BxPC-3 and PANC-
1. Protein quantification was not done so the two cell lines were not directly comparable. This 
experiment was repeated twice. 
 
 
Figure 4.11: Optimisation of EGF or IGF growth factors stimulation in SB and CB 
studies 
BxPC-3 
PANC-1 
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Consistent with the previous findings in sub-section 3.4.2, extensive cross-talk was found 
between EGF-pAkt and IGF-pERK with PANC-1 but not in BxPC-3. BxPC-3 followed a strict 
classical cascade, where EGF predominantly stimulated ERK and IGF predominantly 
stimulated Akt. PANC-1, on the other hand, was capable of stimulating ERK and Akt in 
response to either EGF or IGF. Erlotinib was able to strongly inhibit ERK and also EGF-
stimulated Akt, but was not so good in inhibiting IGF-stimulated pAkt. BYL was also able to 
suppress its intended target Akt as well as IGF-stimulated pERK, but was less potent in 
inhibiting EGF-stimulated pERK. SB inhibition of downstream targets was therefore 
incomplete. The two drugs together were able to inhibit both ERK and Akt more strongly than 
either drug alone, even at erlotinib 5M plus BYL719 2.5M (low dose), suggesting positive 
interaction or “molecular synergy” in both cell lines. Thus, in this optimisation experiment EGF 
appears to have a stronger influence on pERK, and IGF on pAkt. In subsequent 
experiments, the cells were stimulated with EGF if they were treated with EGFR or MEK 
inhibitor; IGF if they were treated with PI3K or PI3K/mTOR inhibitor; and both EGF and IGF 
for CB treatment. This was done so that there would remain strong signals for different CB 
combinations to be compared with each other. Also, there was an early indication that 
regardless of the cross-talk mechanism of the two cell lines, CB appeared to be an effective 
strategy that was superior to single agent alone.  
 
4.2.3.2  Combined blockade of 4 inhibitor Combinations in BxPC-3 and PANC-1 
Key Finding: CB was able to prevent paradoxical activation of alternate pathways that 
was observed in SB. CB combinations that included the dual PI3K/mTOR inhibitor NVP-
BEZ235, appeared to be more effective than other combinations. 
To compare between the 4 CB combinations, cell lines were treated with erlotinb (0, 5, 10, 
20M), NVP-AEW541 (0, 0.5, 1, 2M), NVP-BYL719 (0, 2.5, 5, 10M), NVP-BEZ235 (0, 0.05, 
0.1, 0.2M), and PD-98059 (0, 5, 10, 20M), alone or in combination. These doses were 
chosen based on previous western blotting experiments on single drug alone. Each cell line 
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was loaded in a 15-well gel for ERL* AEW and ERL* BYL and 12-well gel for ERL* BEZ and 
PD* BEZ. For consistency, the samples were loaded in the following way for the first two 
combinations: no treatment, EGF alone followed by graded concentration of drug A with EGF, 
IGF alone followed by graded concentration of drug B with IGF, and then EGF plus IGF 
followed by both drugs in the same graded concentration with EGF and IGF. For the latter two 
combinations, the experiment was abbreviated (only BEZ SB was tested against ERL* BEZ, 
and only PD was tested against PD* BEZ) to avoid repetition. All membranes were 
immunoblotted for phosphorylated and total EGFR, ERK, Akt and S6. In addition, the ERL* 
AEW was also blotted for IGF1R, since NVP-AEW541 was an IGF1R inhibitor and it needed 
to be shown whether the inhibitor was acting on its intended target. 
Because of the sheer number of permutations of drug inhibition and stimulation combination 
experiments, it was not possible to test CB on all 5 PDAC cell lines. Instead, BxPC-3 was 
chosen to represent erlotinib sensitive cell lines, and PANC-1 to represent erlotinib insensitive 
cell lines. Representative blots of 3 experiments each were shown below: 
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Figure 4.12: Representative blots for SB versus CB for 4 combinations in BxPC-3 and 
PANC-1 
 
To summarise the exceedingly large amount of information from these 8 representative blots, 
emphasis was first placed on two dose-response experiments for ERL, AEW and BYL, alone 
or in combination. In BxPC-3, ERL, AEW and BYL appropriately reduced EGF-stimulated 
pERK and IGF-stimulated pAkt signals as single agents. CB using either drug in combination 
with ERL on this cell line was capable of near-complete inhibition of pERK and pAkt in the 
presence of both EGF and IGF. In PANC-1, however, pAkt was either unaffected or 
paradoxically increased by ERL, whereas pERK increased after exposure of higher dose of 
AEW (2M) (red arrows). Only BYL appropriately decreased downstream signals. The 
paradoxical effects observed in this cell line were abolished by CB with either AEW or BYL 
together with ERL, resulting in monotonic inhibition of both pERK and pAkt. Both CB 
combinations also diminished pS6 in both cell lines; but the ERL* BYL CB appeared to be 
superior in complete inhibition of this signal. Yet, even at the high dose of ERL 20M and BYL 
10M, downstream signals did not completely disappear, but were only attenuated.  
The last two combinations were interesting because both consisted of the dual PI3K/ mTOR 
inhibitor BEZ. This drug certainly appeared to hit the intended targets PI3K and mTOR, 
resulting in diminishing of AKT and disappearing of S6 (downstream of mTORC1) at a dose 
as low as 10nM. On the other hand, PD was not a very good MEK inhibitor. It only began to 
decrease ERK (downstream of MEK) at 10 M for BxPC-3, whilst PANC-1 was completely 
resistant to its effect on ERK. Despite the fact that PD was inferior to erlotinib in inhibiting the 
downstream MAPK pathway, either drug combined with BEZ resulted in some reduction in 
pERK signals in addition to disappearing of pAKT and pS6 in both cell lines. This confirmed 
the potency of BEZ by itself or in combination with EGFR or MEK inhibitor. Thus, this 
experiment established the CB as a strategy to overcome cancer cells that have significant 
cross talk and multiple active pathways, and demonstrate the superiority of CB of downstream 
targets of EGFR/ MAPK and PAM pathways. 
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4.3.2.3   Synergy Analysis of 4 CB Combinations in BxPC-3 and PANC-1 
Key Finding: EGFR and PI3K inhibitors positively interact at the level of S6, downstream 
of PI3K/mTOR, particularly in ER cell lines. This confirms the up-regulation of PAM 
pathway in ER cell lines, and supports the strategy of CB to overcome erlotinib 
resistance. 
Raw data are particularly difficult to interpret in western blotting experiments, because no two 
blots are the same, and it is difficult to visually detect small differences in signals. To attempt 
at synergy analysis on western blots, the signal changes were first quantified using multigauge 
v3.0 a pixel density calculator. Phosphorylated signals were measured in 3 independent 
experiments, and corrected against total protein (or β-actin in the setting where total protein 
exposure was inadequate). Since these experiments were performed in a dose response 
configuration, an IC50 for protein inhibition could be calculated by fitting a regression curve 
after pooling all experiments (SAS 9.2). IC50 of CB was calculated in the same way as SB, 
since both drugs doubled in dose in each dose escalation, but was reported as drug A [X M] 
+ drug B [y M]. The averages of all IC50 for the key downstream signals pERK, pAkt and pS6 
(in M) for SB and CB as dosing sets were shown below:  
 
Table 4.4: IC50 of single blockade and combined blockade in BxPC-3 and PANC-1. E+A denotes 
ERL*AEW; E+Y  ERL* BYL; E+B ERL* BEZ; P+B PD* BEZ,. NR “not reached”. 
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While there was too much data here to go through one by one, there were a number of general 
observations that could be made. Firstly, in general, each inhibitor was the most potent for 
inhibiting its direct downstream target (red bolded), as indicated by the lowest IC50. The 
notable exceptions were AEW, which appeared to reduce pS6 (further downstream) more 
effectively than pAkt; and PD, which was not able to suppress pERK signal at all in PANC-1 
(NR), as mentioned previously. Secondly, PANC-1 was more resistant to have off-targets 
inhibited than BxPC-3. For example, the IC50 of Akt inhibition by erlotinib was estimated to be 
39.3 M in BxPC-3 but 67.6 M in PANC-1. This also occurred in other inhibitors including 
pERK for BEZ (0.586 vs. 0.286 M) and pAkt for PD (15.19 vs. 49.17 M). This supported the 
previous study of PANC-1 as a cell line with multiple switched-on pathways and significant 
cross talks between pathways. Thirdly, regarding combined blockade, the effect of combined 
treatment was not very effective for EGFR/ IGF1R co-inhibition, but progressively became 
more effective with downstream inhibitions in the other combinations. For instance, in BxPC-
3, the pERK inhibition IC50 for erlotinib was 17.06M and for AEW 3.91M, but the combined 
IC50 dosing set was only erlotinib 13.03M and AEW 1.3M. That is, the CB had only dropped 
IC50 of erlotinib by 25%. By combining erlotinib with BYL or BEZ, the IC50 of the erlotinib 
component in the CB was able to be reduced by 32% (erlotinib 11.67M plus 5.83M BYL) 
and 47% (erlotinib 9.13M plus 91nM BEZ) respectively (red arrows). In other words, less 
erlotinib was required when combined with downstream inhibitors to achieve the same IC50. 
That said, this occurred in BxPC-3 but did not appear to be the case for erlotinib insensitive 
PANC-1. Hence, the presence of a inhibitor of downstream targets appeared to assist erlotinib 
in gain better control of its key targets in cell lines already sensitive to erlotinib, but was not 
able to do so for erlotinib insensitive cell line. To confirm these findings, synergy analysis of 
these molecular signals was measured. 
 
In assessing synergy for western blotting experiments, it needs to be noted that it was 
impossible to design a 6x6 matrix as in the case for cell proliferation experiments. Also, the 
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only quantitative data attained in western blotting was IC50. For these reasons, isobolograms 
were the only appropriate method for assessing synergy here. There were, however, some 
minor differences between these isobolograms to the ones shown in cell proliferation. Firstly, 
only one estimated dose set for CB was produced from these western blotting experiments. 
Secondly, synergy was suggested when estimated dose set lay below the additivity line; but 
antagonism was not necessarily suggested when observed dose set lay above the additivity 
line. This is because of the difference in growth factor stimulation between SB and CB. In SB, 
either EGF or IGF stimulation was used; in CB, both EGF and IGF stimulation were used. 
Thus, the estimated dose sets could be above the additivity line simply due to more growth 
factor stimulation, instead of antagonism between two drugs. With this in mind, the 
isobolograms are now presented for pERK, pAkt and pS6 inhibition: 
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Figure 4.13: Isobolograms for 4CB combinations in BxPC-3 and PANC-1 
Regarding to SB of individual drugs, AEW and BEZ were more potent than ERL, PD and BYL. 
The IC50 axes of the former 2 drugs ranged from 0.6 to 5 M, whereas the latter 3 drugs ranged 
from 30 to 60 M. Yet, this could simply relate to the potency of the drugs and affinity to the 
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targets, and did not necessarily indicate drug resistance. What was more suggestive of drug 
resistance was when the additivity line appeared as either vertical or horizontal lines, as in the 
case of the pERK line on PANC-1 for the PD* BEZ isobologram. In this example this means 
that all tested doses of PD did not inhibit pERK, and IC50 for pERK could not be reached for 
this drug. 
The CB isoblograms were studied next. For the ERL* AEW combination, all estimated IC50 
dose sets for both cell lines lied above the respective additivity line. As discussed before, 
synergy was not present, but this did not necessarily indicate antagonism. That said, 
comparing between pERK, pAkt and pS6 isobolograms, the estimated dose sets for pERK 
were closer to the additivity lines than pAkt and pS6 signals. In the second combination (ERL* 
BYL), pERK estimated IC50 point was also much closer to the additivity line than the pAKT 
estimated IC50 point. In addition, the two drugs were synergistic for inhibiting pS6 signal in 
both cell lines. In the third combination (ERL* BEZ), the two drugs were also synergistic for 
inhibiting pS6 signal. Further, the observed IC50 point also moved much closer to the additivity 
line than the previous combinations, suggesting greater synergism. Finally, in the fourth 
combination, “molecular synergism” was particularly difficult to assess since PD was found to 
inhibit pS6 much more strongly than erlotinib as a single agent, but was unable to suppress 
its intended pERK target in PANC-1. Taken altogether, pS6 appeared to be the point of 
synergism for ERL plus BYL or BEZ. 
To assess the previous speculation about the synergistic role of downstream inhibitors with 
erlotinib in overcoming basal autonomic downstream MAPK pathway activation in erlotinib 
sensitive cell lines, pERK synergism among the first three combinations was studied in greater 
detail. In contrast to ERL plus AEW, ERL plus BYL or BEZ were indeed synergistic in BxPC-
3 (indicated by the red circle below red line). This, however, did not occur in PANC-1, as all 
estimated IC50 dose sets lied above the additivity line. Overall, this is consistent with the 
analysis of the crude analysis of the raw data in Table 4.4.  
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In conclusion, erlotinib was more synergistic with downstream than upstream inhibitors. ERL* 
BEZ was the most synergistic, followed by ERL* BYL, and lastly the ERL* AEW. Synergism 
of PD plus BEZ235 could not be formally assessed, since PD-98059 behaved as a very 
different inhibitor than erlotinib. The level of interaction was located downstream at Akt-
driven S6 for both cell lines, and also at ERK for the erlotinib-sensitive BxPC-3. 
Altogether, cell proliferation and western blotting experiments demonstrated synergistic 
activity between erlotinib and PI3K or PI3K/mTOR inhibitors; suggesting the important 
interaction of EGFR and PI3K/ mTOR in PDAC cell lines. 
 
 
 
4.3.2.3  Comparison of CB combinations in parent versus resistant cell lines 
Key Finding: CB appeared more effective in inhibiting downstream signals in ER cell 
lines compared to SB. In particular, CB using PI3K or dual PI3K/mTOR inhibitor 
appeared more effective in ER cell lines. 
In the previous sub-sections, there was a heavy emphasis on using synergy analysis. 
However, synergy analysis was not possible in comparing CB combinations between parent 
and ER cell line. To obtain isobolograms in a way that could be comparable between parent 
and resistant cell lines, each pair of the parent and ER cell lines needed to be loaded in the 
above format (14 samples each) in one single gel, so that IC50 for SB and CB could be 
simultaneously produced for both cell lines. To do this, a 29 sample loading gel (including 1 
lane for marker) would be required as a minimum, but there were no customized gels that had 
this many loading wells. If the cell lines were loaded in different gels, even if the protein 
concentration was adjusted, the signals between each cell line pairs may remain incomparable 
due to inter-blot variability. 
Thus, rather than insisting on performing synergy analysis with the associated issues, two 
simple experiments for CB combination were performed instead. In the first set of experiment, 
the effect of SB versus CB was examined in a chosen combination (ERL * BYL). In the second 
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set of experiment, the different CB were compared in the ER versus parent cell lines. To allow 
for SB and CB to be compared, cell lines were all treated with EGF alone without IGF. The 
order for the sample loading was no treatment (NT), EGF alone, Erlotinib 20M, BYL-719 10M, 
and combined erlotinib and BYL-719 (5 samples) in the first experiment. Each pair of parent 
and resistant cell lines were loaded together (total 10 samples) in a 12-well gel (2 markers on 
the side) to allow for valid comparisons. All previous downstream signals (ERK, Akt, S6) plus 
another mTOR1 target (4E-BP1) were explored: 
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Figure 4.14: Representative blot of CB versus single blockade in parent versus resistant cell 
lines 
Comparing parent and ER cell lines at baseline, there appeared higher pS6 signals in BxPC-
ER and PANC-ER than BxPC-3 and PANC-1, though the signals were very faint indeed. On 
the other hand, p4EBP1 appeared lower in BxPC-ER and PANC-ER. This confirmed  
phospho-RTK array results earlier that the ER cell lines transduced PI3K/Akt growth signals 
down S6, and here it was shown that it was likely pS6 that was active in ER lines, as opposed 
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to the other mTOR effector p4EBP1. In all cell lines, EGF stimulated pEGFR and pAkt (slightly) 
but was unable to stimulate ERK in this representatibe blot. This was because the EGF 
stimulation was longer than usual (20 minutes- by accident) in this particular experiment, and 
previous optimisation experiments (3.4.2.2) had shown that EGF-stimulated pERK was short-
lived, between 5 to 15 minutes. All cell lines responded to erlotinib with decreased pEGFR, 
and responded to BYL719 with decreased pAkt, which were the intended target. Paradoxical 
activation representing alternate pathway escape was again observed with SB alone. This 
time, this occurred in BxPC-ER, where erlotinib paradoxically increased pAkt (dotted black 
arrow). The effect of CB was intriguing in this particular blot. CB with erlotinib and BYL-719 
reduced pERK and pS6 signals much more in ER cell lines than parent cell lines, though in 
this particular blot the signal for S6 was much too faint to be appreciated (straight black 
arrows). To quantify and compare signal changes, the phosphorylated signals were measured 
and corrected to total protein in three experiments. The NT signals of the parent cell lines were 
set at 100%, and relative signals to this were shown (Figure 4.15): 
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Figure 4.15: Combined blockade versus single blockade in parent versus resistant cell lines in 
3 experiments. E20 denotes erlotinib 20M, and E20Y10 denotes erlotinib 20M * NVP-BYL719 10M  
 
Comparing each pair of parent and ER cell line at baseline, both ER cell lines had up-regulated 
pAkt and pS6 but substantially down-regulated p4EBP1 (straight black arrows). In particular, 
BxPC-ER had a 50% relative increase in pAkt and pS6 than BxPC-3. From previous 
experiments, PANC-1 had high absolute pAkt and pS6 signals to start off with, and PANC-ER 
further increased this. EGF also appeared to increase pAkt more than pERK in the ER cell 
lines, as demonstrated before (3.4.2.2). Comparing between CB and SB, there was a clear 
trend of reduction in all phosphorylated signals in all 4 cell lines. Furthermore, PANC-ER 
appeared slightly more sensitive to CB than PANC-1. After averaging 3 experiments, both 
pERK and pS6 were more highly suppressed in PANC-ER than PANC-1 (dotted black arrows). 
The second set of experiment sought to compare the efficacy of signal inhibition with 3 CB 
combinations: ERL* AEW, ERL* BYL and ERL* BEZ. PD* BEZ was not tested here, since 
erlotinib was the constant here, and this experiment aimed to test the effect of IGF1R, PI3K 
or PI3K/mTOR inhibitor in combination to erlotinib. To maintain consistency, EGF stimulation 
only was used. However, 20ng/ml EGF was used here instead of 10ng/ml, such that weaker 
signals such as pS6 could become strong enough to be accurately detected. p4EBP1 was not 
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displayed here, since in the last figure it was already shown that the absolute signalling level 
was too low to be compared between the 3 CB. 
 
Figure 4.16: Representative blot comparing 3 CB combinations in parent versus resistant cell 
lines 
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Firstly, the higher dose of EGF had resulted in more visible signals in pS6. The most striking 
differences between the three CB was that pAkt and pS6 were attenuated but still present with 
EGFR/ IGF1R co-inhibition, as compared with complete disappearing of these phosphorylated 
signals with EGFR/ PI3K and EGFR/ PI3K/ mTOR co-inhibitions. pERK remained present in 
all 3 CB combination with 20ng/ml EGF stimulation, but again the second and third CB 
appeared to inhibit it more than ERL* AEW. Interestingly, when comparing between parent 
and resistant cell line, it was noted that ERL* AEW inhibited downstream signal pAkt less in 
ER than parent cell lines (straight black arrows). In addition, the CB combination utilising 
downstream combined blockades were not only able to abrogate pS6 and pAkt, but were also 
able to attenuate pERK in PANC-ER more strongly than PANC-1 (dotted black arrows). Thus, 
ERL* AEW was less effective, and ERL* BYL or BEZ were more effective in inhibiting 
downstream signals in ER cell lines. To summarise these data, phosphorylated signals from 
the three CB combinations were corrected to EGF stimulation, and the averages and SE were 
presented below (Figure 4.17). 
 
Figure 4.17: Comparison of CB combinations in parent versus resistant cell lines 
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For BxPC-3, ERL* BEZ was slightly more effective in inhibiting pERK. However, the effect of 
the 3 CB on pAkt and pS6 signals was difficult to assess. These signals were only weakly 
activated by EGF in BxPC-3, since there was little EGF-Akt cross-talk in this cell line as 
described earlier. When the pAkt and pS6 signals in response to CB were compared, the 
resultant proportion to EGF stimulation was all close to 1 for BxPC-3. For the other cell lines, 
certainly CB appeared to suppress pAkt signals more than pERK and pS6, in keeping with the 
direct downstream targeting of PI3K/Akt. Comparing the 3 CB, BxPC-3 appeared to have a 
much lower pERK and pS6 in response to ERL* BEZ, followed by ERL* BYL (straight black 
arrows). PANC-ER also appeared to respond markedly in response to ERL* BEZ, with much 
lower signals for pERK, pAkt and pS6 (dotted black arrows). This suggested a differential 
sensitivity of PANC-ER to dual PI3K/mTOR inhibition combined with erlotinib. In other words, 
there appears to be a dependency of this cell line on the PAM pathway through mTOR. 
All in all, then, CB was better at inhibiting downstream signals than SB, particularly in ER cell 
lines. Among the CB combinations downstream ERL* BEZ was especially effective in erlotinib 
resistance, followed by ERL* BYL. This observation was consistent with the cell proliferation 
experiments, where a dominant shift to EGFR-PI3K interaction was established. These results 
were counter-intuitive yet intriguing. In chapter 3 ER cell lines were found to have higher Akt 
and S6 than parent cell lines. The highly up-regulated in PI3K/Akt/mTOR pathway probably 
contributed to the erlotinib resistance. If that were the case, one would normally expect ER 
cell lines to be more resistant to PI3K/mTOR inhibitor and CB involving these drugs, since 
they were more active in PI3K/mTOR pathway. However, what was observed was the reverse. 
These cell lines became more strongly inhibited in downstream signals by PI3K and 
PI3K/mTOR inhibitors, and that these inhibitors were more synergistic with EGFR in these ER 
cell lines. The only explanation to this was that ER cell lines became dependent to an 
obligatory PI3K/mTOR pathway, a process known as “oncogenic addiction”. To prove this 
hypothesis, the absolute effects of these CB on ER cell lines must be studied by a variety of 
functional assays. 
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4.3 Functional assays of CB and SB 
In the first half of this chapter, positive interaction or synergy between various CB 
combinations was demonstrated. However, as already alluded to, synergy is not necessarily 
same as efficacy. To examine efficacy of CB and to prove the concept of “oncogenic 
addiction”, various functional assays including clonogenic, migration, cell cycle and apoptosis 
key assays were explored. These assays were chosen because PAM pathway has a direct 
role in cell cycle progression, modulating anti-apoptosis signals and colony formation, and an 
indirect role in cancer cell migration together with transcription factors, EMT status and 
molecular signals of other pathways.45,180,323,324 Importantly, if ER cell lines had onogenic 
dependence to the PAM pathway, one would expect to see a higher sensitivity of ER cell lines 
to PI3K- or PI3K/mTOR-based CB treatment, across all types of functional assays. Due to the 
large number of variable conditions for CB experiments, only 2-3 CB doses were selected for 
each assay, performed on a selection of primary cell lines, then ER vs. parent lines. 
4.3.1  Clonogenic Assays 
Key Finding: Downstream CB caused highly significant inhibition in colonies in ER 
compared to parent cell lines, with near-complete loss of colony formation 
Clonogenic assay results for erlotinib and gefitinib single drug treatment have been presented 
in chapter 3. In this sub-section, the effect of CB versus SB was first examined, and the best 
of 4 CB combinations in 3 primary lines was then evaluated. After that, CB between parent 
and ER cell lines was tested to assess any differential responses. Two dosing levels with 
erlotinib (5μM and 10μM), together with low and medium dosing of other inhibitors, were 
tested. These doses were decided based on potency observed from CB cell proliferation 
experiments (4.2.2). Each set of experiment was performed three times. In the first set of 
experiments, BxPC-3, CAPAN-2 and PANC-1 were chosen among the 5 PDAC cell lines to 
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represent erlotinib-sensitive, moderately insensitive, and erlotinib-insensitive cell lines 
respectively. 
4.3.1.1   Four CB Combinations in PDAC cell lines 
These initial experiments examined combined blockade versus single blockade inhibition. The 
cells were set up in a consistent pattern with 2 no treatment, 1 drug A, 1 drug B, and 2 drug 
A*B on each 6 well plate. Low doses and moderate doses treatment were tested in 2 separate 
plates. All 4 CB combinations were tested against the SB that made up the combination. For 
brevity and to illustrate a point, the following representative photo showed two sets of CB only 
(ERL* AEW and ERL* BYL with moderate dosing): 
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Figure 4.18: Representative photos of CB Clonogenic Assay: E10A1 denotes erlotinib 10μM * 
NVP-AEW541 1μM, and E10Y5 denotes erlotinib 10μM * NVP-BYL719 5μM. 
Here, combined blockade worked better than single blockade. CB with either combination 
appeared to reduce number of colonies markedly in BxPC-3, and in CAPAN-2 to a lesser 
extent. However, there was a clear difference between the two CB combinations in PANC-1. 
In PANC-1, there remained a large formation of colonies after treatment with E10A1, which 
was not smaller in number than either SB or control. By contrast, the colony size and numbers 
were evidently suppressed after treatment with BYL 5μM, and even more so for E10Y5 (black 
arrows). In other words, the EGFR/ PI3K co-inhibition was superior to EGFR/ IGF1R co-
inhibition in the erlotinib-insensitive PANC-1.  
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In determining the best of the 4 CB combinations, the summary results of 3 experiments for 
the 4 CB combinations in these 3 cell lines are illustrated next, in 4 sets of column graphs. In 
each set, CB and the SB that makeup the combinations are presented as percentages to 
control, and low dose and moderate dose SB/CB are presented adjacent to each other: 
 
 
Figure 4.19: Summary results of the 4 CB Clonogenic Assay, average of 3 experiments. 
257 
 
 
Two patterns have emerged from the dense column graphs above. First of all, in all 4 
combinations, a dose response pattern was followed, in that the higher dose of single or 
combined blockade treatment generally resulted in greater suppression of colony suppression. 
Secondly, the BxPC-3 and CAPAN-2 followed a different pattern of suppression as PANC-1. 
In the first two cell lines, EGFR/ IGF1R or EGFR/ PI3K co-inhibition were superior to SB and 
resulted in dramatic suppression of colony formation down to 10%, while the more 
downstream CBs with ERL or PD * BEZ resulted in slightly less marked suppression down to 
30%. Conversely, PANC-1 was essentially resistant to the colony suppression effect of EGFR/ 
IGF1R co-inhibition, moderately resistant to EGFR/ PI3K co-inhibition (down to 60-70%), but 
much more sensitive to downstream blockades (down to 40-60%). These intriguing results 
may be explained by the constitutively active surface receptors (EGFR and IGF1R) in BxPC-
3, and highly active PI3K downstream (especially Akt) observed in PANC-1 (section 3.4). The 
observation that CAPAN-2 followed the same pattern as BxPC-3 was an interesting one. 
Although CAPAN-2 also had up-regulated PI3K/Akt pathways, this was nowhere as prominent 
as PANC-1 on gene and molecular levels, and pS6 expression was much higher in PANC-1 
than CAPAN-2 in western blotting experiments. In summary, BxPC-3 and CAPAN-2 depend 
on upstream IGF1R and PI3K in mediating colony formation, whereas PANC-1 transduced 
this signal further downstream to PI3K, at the Akt and mTOR levels. The clonogenic assay 
results followed closely that of proliferation assay, suggesting that the effect of these CB to be 
long lasting, affecting cell lines long after the treatments were withdrawn. 
4.3.1.2   CB combinations in Parent versus ER Cell Lines 
Next, the four CB combinations were examined on the 2 parent and 2 ER cell lines. A 
representative photo is shown below: 
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Figure 4.20: Representative photos of 4 CB combinations in parent versus ER cell lines. 
E10B0.1 denotes erlotinib 10μM + BEZ-235 0.1μM, and P10B0.1 denotes PD-98059 10μM + BEZ-
235 0.1μM 
As before, BxPC-3 was very sensitive to the effect of E10A1, whereas PANC-1 was very 
resistant. As they progressed from upstream to downstream CB, the colony suppressing effect 
of PANC-1 increased and BxPC-3 decreased. At P10B0.1, the colony numbers for BxPC-3 
and PANC-1 were roughly similar (dotted black arrows). Comparing the ER cell lines with the 
respective parent cell lines, they also responded better with downstream combined blockades. 
Importantly, they had dramatically decreased size and numbers of colonies compared to the 
parent counterparts upon exposure to E10B1 and P10B0.1 (straight black arrows). Results 
were summarised and statistics were shown in the next graph: 
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Figure 4.21: 4 CB combinations in parent versus ER cell lines, average of 3 experiments 
 
Table 4.5: Differential sensitivity between ER and parent cell line to CB, clonogenic assay 
The reciprocal relationship between BxPC-3 and BxPC-ER was noted. BxPC-ER had 
significantly more colonies with E10A1 and E10Y5, and fewer colonies with P10B0.1 (all 
P<0.05). While PANC-1 and PANC-ER were resistant to E10A1, both were sensitive to PI3K 
or PI3K/mTOR-based CB. Intriguingly, like BxPC-ER, PANC-ER was increasingly more 
sensitive to progressive downstream CB compared to its parent counterpart (P=0.014, 0.004 
and <0.0001). All in all, these provocative results fitted well with the synergy analysis that there 
was increased dependence of ER cell lines to PI3K/mTOR, and demonstrated EGFR/ PI3K 
co-inhibition as an effective strategy of colony suppression in these cell lines. 
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4.3.2  Cell Cycle Assay 
Key Finding: PDAC cell lines depended on PI3K/Akt/mTOR in mediating multiple cell 
cycle checkpoints. PANC-ER was significantly hyperactive to this treatment than 
PANC-1 
Much attention was focused on cell cycle assay by flow cytometry, since it has been known 
for some time that the PI3K/Akt/mTOR/S6 pathway mediates G1 cell cycle progression in 
various cancer types.325,326 Two methods were attempted to study cell cycle in pancreatic 
cancer: conventional propidium iodide (PI) assay and the more sophisticated BrDU/7AAD 
assay, which also allowed the study of cell cycle kinetics. Unfortunately, the BrDU/7AAD assay 
could not be optimised in these cell lines after multiple (>5) attempts. The PI assay, on the 
other hand, produced good and consistent results. In this sub-section, the focus is on the 
results produced from the PI assay. In the first set of experiments, 3 PDAC cell lines (BxPC-
3, CAPAN-2, PANC-1) were tested for all 4 CB combinations and SB drugs that made up 
those combinations, with two dosing levels (low, medium) and two treatment times (24 hours, 
48 hours). In the second set of experiments, the 4 CB and SB were performed simultaneously 
on BxPC-3, BxPC-ER, PANC-1 and PANC-ER, mostly on the optimal dosing and time point. 
Biological triplicate experiments were performed for each set. 
After collecting information from the flow cytometer (on FLA-2 channel), DNA histograms were 
constructed and analysed using standard methods by Modfit.327 Given the sheer amount of 
data, DNA histograms were only shown for noteworthy changes for illustration. A coefficient 
of variation (C.V.) <5% was considered acceptable for each histogram. Most results were 
summarised in column graphs or tables. The primary endpoint for cell cycle assay was the % 
of cells in S-phase or S-phase fraction (SPF), as it closely correlates with the actual 
proliferative behaviour of the cell population.328 In each experiment, the SPF of each treatment 
was adjusted to control. The adjusted SPFs of three experiments are averaged, and where 
appropriate, paired t-test statistics iscalculated.   
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4.3.2.1  CB and SB on cell cycle for BxPC-3, CAPAN-2 and PANC-1 
For illustration, CB /SB for the first combination ERL* AEW was shown for BxPC-3 and 
PANC-1. These DNA histograms were extracted from the low dose at 24 and 48 hours: 
 
Figure 4.22: Representative DNA histograms forBxPC-3 and PANC-1 in response to Erlotinib 
and NVP-AEW541 SB and CB, 24 and 48 hours treatment 
DNA histograms plot the DNA mass against event counts. The first taller peak corresponds to 
cells in G1 phase, the second shorter peak corresponds to cells in G2/ M phase, and the 
middle plateau section represents cells undergoing S phase. For BxPC-3, the relatively wide 
S-phase portion with control had become suppressed upon treatment with ERL or CB, 
accompanied by a taller G1 peak. This occurred in both 24 and 48 hours (Figure 4.22, left, 
straight arrows). In this particular experiment, there was also a large accumulation of cells 
lying to the left of G1 phase (Sub G1 Fraction). These cells had smaller DNA mass than cells 
in G1, and might represent cells undergoing aneuploidy or apoptosis (dotted arrows). IGF1R 
inhibitor did not cause any obvious suppression to S-phase compared to control. For PANC-
1, neither SB nor CB caused a suppression of S-phase portion compared to control.  
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 Figure 4.23: Cell Cycle analysis for BxPC-3, CAPAN-2 and PANC-1 with Erlotinib and NVP-
AEW541 SB/CB 
 
Next, the combined results of low dose CB for the 3 cell lines was analysed (Figure 4.23). 
The same pattern emerged in BxPC-3 for either treatment time point. At 24 hours, the SPF 
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decreased from 42% to 30% and 30% with Erlotinib 5μM and low dose CB. This was 
accompanied by an increase of cells in G1 phase, indicating that cells were prevented to enter 
from G1 into S-phase- G1 arrest. IGF1R inhibitor, on the other hand, did not cause any change 
in SPF. Thus, the active drug in this CB combination was clearly erlotinib in this cell line. In 
CAPAN-2, little changes were observed at 24 hours; at 48 hours of treatment, CB had reduced 
SPF from 32% to 21%. Lastly, in PANC-1, there was very slight decrease by CB at 24 and 48 
hours. Clearly, BxPC-3 was a sensitive cell line whose cell cycle could be arrested by erlotinib 
alone. CAPAN-2 remained sensitive to CB but not SB alone, and PANC-1 was likely mediating 
its cell cycle further downstream of EGFR and IGF1R. Below is the analysis between the 4 
CB combinations. The 48 hour (best) treatment time is shown, though both 24 and 48 hour 
treatments were performed: 
 
Table 4.6: Cell Cycle analysis for BxPC-3, CAPAN-2 and PANC-1 with 4 CB combinations at 48 
hours. CB-L denotes low dose CB, and CB-M denotes medium dose CB. Bracket shows % to control. 
Bolded indicates SPF less than or equal to 50% of control 
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G1 and S phase fractions were summarised in Table 4.6 above. BxPC-3 and CAPAN-2 
responded better with medium than low dose of ERL* AEW CB (10 and 1μM), with adjusted 
SPF 54% vs. 63% and 53% vs. 66% respectively. On the other hand, PANC-1 remained fairly 
resistant with a SPF 77% and 80% of control (low, medium CB). With downstream blockades, 
BxPC-3 and PANC-1 became increasingly susceptible. The adjusted SPF was 48% and 27% 
on medium dose of ERL* BYL, and both BEZ235-based CB were capable of reducing adjusted 
SPF to between 50-70% of control. This was almost invariably associated with increase in G1 
fractions suggesting G1 arrest, and this increase was most prominent with PD *BEZ235 for 
these 2 cell lines. Interestingly, CAPAN-2 was only slightly affected by any CB combination, 
with the lowest adjusted SPF being 53% NT (ERL* AEW mod dose). However, one needs to 
be mindful that the S-phase fraction at control (NT) in CAPAN-2 was consistently lower than 
that for BxPC-3 and PANC-1. This was likely a technical artefact, relating to the the slow 
growing nature of CAPAN-2. The lower SPF at baseline might therefore underestimate the 
true effect of CB on cell cycle in this cell line.  
 
4.3.2.2  4 CB Combinations on cell cycle in parent versus ER cell lines 
CB and SB were performed on parent versus ER cell lines. All 4 CB and single agents that 
made up the CB were tested. For brevity, below shows a set of representative histograms for 
the 4 cell lines in response to Erlotinib (E10), Gemcitabine as a positive control (G0.05) –at 
48 hours; and the 2 CB (E10Y5, E10B0.01) at 24 and 48 hours. The representative histograms 
for CB at were magnified for clarity. Reference to other CB and SB was made accordingly. 
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Figure 4.24: Representative DNA histograms for ER and Parent cell lines with CB at 24/ 48 
hours 
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In all 4 cell lines, gemcitabine caused a complete S-phase arrest. Cells were prevented to 
enter into G2-phase, resulting in the disappearance of G2 peak (straight arrows). This closely 
reflects the mechanism of gemcitabine, an analogue of deoxycitidine that incorporates into 
DNA and prevents further DNA synthesis once phosphorylated into its active form.329 While all 
4 CB predominantly caused a G1 arrest in the 4 cell lines, PI3K or PI3K/mTOR inhibitor based 
CB also caused a variety of other disruptions to cell cycles. In a representative experiment, 
ERL*BYL and ERL*BEZ caused predominantly partial S phase or G2/M arrests in BxPC-3/ 
BxPC-ER. Partial S-phase arrest was evident with the greatly diminished G2 peak hiding in a 
plateau of S-phase (dotted arrows, BxPC-3), or a disappearance of G2 by 48 hours (dotted 
arrow, BxPC-ER). G2/M arrest appeared as a tight bottleneck just after G1 phase followed by 
a gradually rising slope into a larger G2 peak (dashed arrows, BxPC-ER). In the case of S-
phase arrest (BxPC-3), this resulted in a G2 fraction reducing from 12.5% to 3% and 4% for 
BYL-719 and BEZ-235 combinations at 48 hours. In either cell line, this disruption in cell cycle 
resulted in accumulation of cells in pre-G1 phase more in 48 hours than 24 hours, which were 
likely apoptotic cells (shaded in dark grey). For PANC-1 and PANC-ER, a more common 
pattern was observed- G1 cycle arrest. Whilst it was harder to appreciate this given that DNA 
histograms were magnified, for PANC-1 G1 fraction increased from 53% to 68% (E10Y5) and 
69% (E10B0.1) at 48 hour, accompanied by decrease of SPF from 32% to 17% (E10Y5) and 
14% (E10B0.1). For PANC-ER, the changes were even more prominent. G1 fraction increased 
from 52% to 62% (E10Y5) and 73% (E10B0.1), with SPF decreased from 33% to 16% (E10Y5) 
and 5% (E10B0.1). In multiple experiments, G2/M and S-phase disruptions appeared to occur 
sometimes in ERL*BYL and frequently in ERL*BEZ or PD*BEZ, but were never evident in 
ERL*AEW. In all cases, SB with BYL-719 or BEZ-235 caused similar but lesser changes, 
implying that PI3K/Akt via mTOR was important in regulating multiple checkpoints in cell cycle. 
Finally, SPF was compared between ER and parent cells for the 4 CB at 48hr in 3 experiments:  
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Figure 4.25: SPF% in parent versus ER cell lines for 4 CB combinations (48 hours) 
 
Table 4.7: Differential sensitivity between ER and parent cell line to CB, cell cycle  
BxPC-3 was sensitive to erlotinib 10μM (E10) alone, with SPF reduced to 28% compared to 
control (P<0.0001). The cell cycle progression was unaffected by E10 in the three other cell 
lines, indicating erlotinib insensitivity/ resistance. In figure 4.26 and table 4.7, all 4 CB were 
more or less equally effective in BxPC-3 (40-41% SPF, -26 to -28% from NT). With the other 
3 cell lines, downstream was more effective than upstream CB. This was particularly the case 
for PANC-1 and PANC-ER, where SPF was reduced by 10%, 14%, 21%, 25% (PANC-1) and 
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10%, 23%, 30% and 30% (PANC-ER) with E10A1, E10Y5, E10B0.1 and P10B0.1. To assess 
if there was a differential response between ER and parent cell lines to CB, t- statistics was 
calculated between each pair (ER: parent) after adjusting for each of the three experiments 
performed. There was a hint of higher efficacy on BxPC-ER than BxPC-3 for each CB, but the 
differential sensitivity between them was not significant (all P>0.05). On the other hand, 
PANC-ER was clearly more suppressed by BYL or BEZ-based CB compared to PANC-1 (-23 
vs. -14%, -30% vs. -21%, -30% vs. -25%), and there was a significant difference between 
these lines in response to these 3 CB (all P<0.05).  
Overall, downstream CB utilising PI3K or PI3K/mTOR inhibitors was especially effective 
causing a variety of G1, S or G2/ M arrests. In addition, there was a more effective cell cycle 
inhibition by these downstream CB on ER cell lines, and significantly so in PANC-ER. 
Thus, ER cell lines appeared to be dependent on the PAM pathway in cell cycle progression 
via multiple checkpoints, and these in turn appeared to be “actionable targets”. A Pre-G1 
subpopulation with CB could represent apoptotic cells, but formal apoptotic assays are needed 
to assess for necrosis and apoptosis. 
  
269 
 
4.3.3  Apoptotic Assays 
Key Finding: mTOR is important in regulating anti-apoptosis signals. PI3K /mTOR-
based CB (+EGFR or MEK inhibition) were very effective in inducing necrosis and 
apoptosis, particularly in ER cell lines 
Apoptotic assays were studied next, since Akt is known to modulate anti-apoptosis and 
survival signals through Forkhead and BAD via Bcl-2 and FasL,45 and a large fraction of cells 
were observed at pre-G1 phase in cell cycle assay when treated with CB, which was 
suggestive of apoptosis. An in-house protocol with PI and DiLC5 dye by flow cytometry was 
adopted.265 All 4 CB were studied along with SB that made up the combinations. These drugs 
were first studied in BxPC-3 and PANC-1, with two treatment times (48, 72 hours) and 3 dosing 
levels (low, medium, high). Each experiment used negative (no treatment) and positive 
controls (super-saturated erlotinib 80 μM). The differences between parent and ER cell lines 
were studied, after choosing the optimal treatment time and dosing level. The endpoint was a 
cumulative measure of necrosis and apoptosis %, since dying cancer cells usually lied in a 
continuum from apoptosis to necrosis, and they were best studied together. Quadruplicate 
experiments were performed, to allow for paired t-test statistics to be calculated. For 
confirmation, cleaved caspase-3 was studied by western blotting and immunofluorescence.  
Shown below is a set of apoptotic plots for the two cell lines with ERL and/or AEW, at 48 hours. 
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Figure 4.26: Representative Apoptosis plots for ERL* NVP-AEW541 CB in BxPC-3 and PANC-1 
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4.3.3.1  CB and SB on apoptosis and necrosis on BxPC-3 and PANC-1 
DiLC5 is a mitochondrial dye that stains positive in live cells, whereas propidium iodide (PI) 
stains DNA when it is allowed to enter in a disrupted membrane. In the apoptosis plots, then, 
live cells are located on the upper left quadrant in the apoptotic scatterplot as they accumulate 
DiLC5 in the intact mitochondria but are not stained with PI because of intact membrane. 
Apoptotic cells have a clear loss of mitochondrial signal but retain an intact membrane, and 
are therefore located on the lower left quadrant. Necrotic cells have lost mitochondrial signal 
and are stained with PI because of disrupted membranes, and are hence located in the lower 
right quadrant. Finally, cells located at the upper right quadrant may be under “stress”; they 
have leaky membrane but remain active in their cellular machinery.265  
For illustration, the apoptotic plots at 48 hour treatment were first shown above. In BxPC-3, 
both ERL and AEW SB alone were cytotoxic, with increasing necrosis (bottom right quadrant) 
proportional to dose response (Figure 4.26). For all dosing levels, CB was superior to either 
drug alone, with necrosis rate of 20%, 21% and 29% for low, medium and high combined 
dosing respectively (bottom right quadrant, top figure). PANC-1, on the other hand, was very 
resistant to either SB or CB, at all dosing levels. Although there appeared a sub-population of 
cells that were under stress (upper right quadrant, bottom figure), there were very few cells 
that had undergone apoptosis (1-3%) or necrosis (6-7%). Thus, it appeared BxPC-3 was 
sensitive to dual upstream blockades, but not PANC-1.  
Next, examples of 48-hour and 72-hour treatment in both cell lines in response to the other 
(downstream) CB are shown below. It was impossible to include all apoptotic plots for all 
treatments at both time points in this thesis. The following were included to illustrate some 
interesting mechanisms on apoptosis and necrosis by these downstream CB.  
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Figure 4.27: Representative Apoptosis plots of BxPC-3 and PANC-1 after 48 and 72 hours CB 
In the first example, three subpopulations of cells were identified after 48 hours treatment of 
high dose CB with E20B0.2 on BxPC-3. By 72 hours, the middle cell population moved to the 
necrotic quadrant. In the second example, PANC-1 was treated with medium dose CB 
P10B0.1. At 48 hours, there were also 3 cell subpopulations, spreading over live, apoptotic 
and necrotic quadrants. By 72 hours, the apoptotic portions moved to the necrotic quadrant 
resulting in an increase from 22 to 54% necrosis. In the third example, PANC-1 was treated 
with low dose CB involving the PI3K inhibitor BYL719. In this case, 2 subpopulations 
separated early at 48 hours with no cells in apoptosis and necrosis; but by 72 hours, these all 
returned to the live quadrant. From these examples, 4 general observations were made: firstly, 
cells were affected by inhibitor as early as 48 hour treatment. Secondly, not all cells were 
equally affected by inhibitor combinations, resulting in different cell subpopulations in the 
apoptotic plots. Thirdly, whilst cell subpopulations separated early, not all were destined to 
273 
 
become apoptotic or necrotic. In the case of low dose combination in PANC-1 (example 3), 
cells under stress at 48 hours actually returned to the live quadrant at 72 hours. Finally, cells 
that were destined to die appeared to move down diagonally from upper left to bottom right, 
losing mitochondrial activity as well as increasing membrane permeability resulting in PI 
uptake. Whilst they might sink down to the apoptotic quadrant first (example 2), this was not 
always the case (example 1). Given the reasons above, the 72 hour treatment results were 
considered more reliable and was primarily presented in subsequent series, and the 
cumulative measure of necrosis and apoptosis % were used as the study endpoint. 
The summary results for the 4 CB combinations in 4 experiments were shown below. Statistics 
were calculated between SB and CB, but not between CB and controls since nearly all 
treatment significantly induced necrosis and apoptosis compared to controls: 
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Figure 4.28: Summary Results of 4 CB on BxPC-3 and PANC-1 at 72 hours. * P<0.05 
Here, all CB induced numerically higher necrosis and apoptosis than SB alone, and a dose 
response was observed for all SB and CB. Since each CB was analysed alongside the SB 
that made up the combination, the following important observations about SB could be made. 
In BxPC-3, ERL was probably the active drug of the first 2 CB, and is responsible for the 
significant differences between CB and SB observed. On the other hand, ERL was clearly the 
least active in PANC-1. Both AEW and BYL contributed little to apoptosis and necrosis, but 
they still produced slightly more apoptosis and necrosis in PANC-1 than ERL. BEZ had a 
substantial impact on apoptosis and necrosis in both cell lines (up to 60%); and was superior 
to ERL even in the erlotinib-sensitive BxPC-3. As for CB, the first two combinations (ERL* 
AEW, ERL* BYL) were effective in BxPC-3 (up to 70%), but not so effective in PANC-1 (only 
30% maximum). The last two combinations (ERL* BEZ, PD* BEZ) were effective in both cell 
lines. In particular, PD*BEZ CB was statistically superior to PD alone in BxPC-3 for all doses 
and in PANC-1 for 2 of the 3 doses, inducing necrosis and apoptosis up to 90% in BxPC-3 
and 70% in PANC-1. Thus, BEZ-235 the dual PI3K/mTOR inhibitor was the active drug 
causing apoptosis and necrosis in both BxPC-3 and PANC-1, as was erlotinib in BxPC-
3. CB was better than SB in inflicting necrosis and apoptosis, with dual downstream inhibition 
(MEK and PI3K/mTOR) causing near-complete annihilation of cancer cells by 72 hours of 
treatment.  
 
4.3.3.2  4 CB Combinations on apoptosis / necrosis in parent versus ER cell 
lines 
Next, the 4 CB were compared between parent and ER cell lines together in 4 biological 
quadruplicate experiments. Below showed the representative apoptosis plots of the highest 
dose at 72 hr. 
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Figure 4.29: Representative Apoptosis plots for 4 CB combinations in ER versus parent cell 
lines 
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Shown above was the experiment with the extreme cases of apoptosis and necrosis on the 
highest dosing CB combinations. In this example, the highest dosing level of 4 CB were 
extremely effective against BxPC-3 and perhaps even slightly more so in BxPC-ER, with 
cumulative apoptosis and necrosis rate ranging from 81-99% in BxPC-ER compared to 85-
93% in BxPC-3. For PANC-1 and PANC-ER, E20A2 appeared to be the least potent, inflicting 
a combined necrosis and apoptosis rate of 28% in PANC-1 and 37% in PANC-ER. The other 
three CB combinations were more cytotoxic, with the combined dual downstream blockade 
PD*BEZ being the most potent. There was also a suggestion that these three CB worked more 
effectively in PANC-ER (57-71%) than PANC-1 (48-56%). 
4 experiments were also completed for the moderate dose of CB and SB. To maintain 
consistency with the cell cycle analysis (table 4.7), this dosing was selected for statistical 
analysis for the parent and ER cell lines below, after adjusting to the 4 experiments. 
 
Table 4.8: Differential sensitivity between ER and parent cell line to CB, apoptosis assay 
 
In BxPC-3, all moderate dose of CB appeared to cause similar amount of cumulative apoptosis 
and necrosis% (48-51%). BxPC-ER, on the other hand, showed increased sensitivity to each 
CB progressively downstream, with the greatest susceptibility for P10B0.1 (68%, P=0.0001). 
Statistically, there was a significant difference between BxPC-3 and BxPC-ER in their 
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responses to the last two combinations (P<0.05). PANC-1 was more sensitive to the last 2 CB 
than the first 2 CB, as described previously. PANC-ER showed higher resistance to E10A1, 
but E10Y5, E10B0.1 and P10B0.1 were all able to cause more necrosis and apoptosis, with 
the greatest susceptibility also for P10B0.1 (57%, P<0.0001). All of these three CB were 
significantly more effective in PANC-ER than PANC-1 (P<0.05) (table 4.8). Therefore, along 
the same theme as cell cycle assays, apoptosis assays had demonstrated that EGFR/MEK 
and PI3K/mTOR cooperatively mediated anti-apoptosis signals. In particular, mTOR 
appeared to be paramount to the regulation of this cellular function. Both ER cell lines 
became highly dependent on PI3K/Akt/mTOR resulting in increased apoptosis and 
necrosis with PI3K/mTOR-based combinations.  
 
 
4.3.3.3  Validation of Apoptosis Assay (microscopy and western blotting) 
Apoptosis Assay was an in-house protocol that has been widely used in the Kolling Institute 
for many years. Since it was an unpublished protocol and the findings from the apoptosis 
assay were crucial for the purpose of this thesis (discussion 4.5), apoptosis needed to be 
validated by a number of standard methods. Western blotting and immunofluorescence of 
cleaved (activated) caspase-3, a protein that was intimately involved in the apoptosis process, 
were used as surrogate endpoints of apoptosis. Since the 4 CB had already been explored in 
detail in apoptosis assay, the aim of the validation was to demonstrate the superiority of CB 
over SB. ERL* BYL was chosen as the CB by default, as this was the main combination 
selected to take forward to in-vivo study. 
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Figure 4.30: Cell microscopy of BxPC-3 and PANC-1 under E20Y10 CB. LP denotes low power; 
HP denotes high power  
First, the time-lapsed response of cells under E20Y10 CB was studied under light microscopy 
(Figure 4.33). 12 hours into treatment, cells were relatively intact for both cell lines. After 24 
hours of treatment, some cells were clearly detached from the flask (straight arrows), though 
morphology of these cells were difficult to appreciate since they were floating in the medium 
and became out of focus. By 48 hours, majority of cells that remained attached on the flask 
became shrivelled up with dense nuclei (dotted arrows) or disintegrated and formed debris 
(dashed arrows). These microscopic images were very typical to PDAC cell lines treated with 
PI3K or PI3K/mTOR-based CB. It often occurred with ERL* BYL and frequently occurred with 
BEZ or ERL* BEZ. However, it never occurred with CB involving IGF1R inhibitors.  
Next, cleaved caspase-3 was examined using western blot. Shown below was one of two 
western blotting experiments optimising the treatment time for the study of cleaved caspase-
3. This simple optimisation experiment involved treating BxPC-3 and PANC-1 with ERL or 
ERL* BYL at high dose, 24 and 48 hours. Protein concentrations were adjusted between cell 
lines, and they were blotted in two 10-well gels (Figure 4.31). 
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Figure 4.31: Cleaved caspase-3 treatment time optimisation (24 and 48 hours) 
In both cell lines, cleaved caspase-3 intensity was higher with CB than SB, and was higher in 
the 24 hour than 48 hour treatment time point. Of note, the intensity of cleaved caspase-3 was 
higher in BxPC-3 than PANC-1, possibly suggesting that PANC-1 activated a different 
caspase for apoptosis or that this particular antibody was not ideal for wetern blotting study. 
The 4 cell lines were examined for cleaved caspase-3 with 24 hour treatment of CB and SB, 
and EGFR/IGF1R and EGFR/PI3K combinations were tested, in 2 experiments. Protein 
concentration was also adjusted, and each pair of parent and ER cell lines were studied 
together in the same blot (Figure 4.32). 
 
Figure 4.32: Cleaved caspase-3 treatment ERL*AEW and ERL*BYL CB/SB (24 hours) 
In this representative blot, the signals for PANC-1/ PANC-ER were indeed much weaker than 
BxPC-3/ BxPC-ER, resulting in the detection of excessive background. Comparisons were 
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therefore difficult for PANC-1 and PANC-ER on western blotting given the weak caspase-3 
signal. In BxPC-3 and BxPC-ER, CB generally appeared superior to SB. Erlotinib activated 
cleaved caspase-3 by 24 hour in BxPC-3, and the signal was less strong for BYL and not 
present for AEW. In BxPC-ER, a background cleaved caspase-3 signal was present at NT. 
Both ERL and BYL had similar levels of cleaved caspase-3; suggesting BYL had a stronger 
effect in BxPC-ER than BxPC-3. Whilst both CB showed strong cleaved caspase-3 signal in 
BxPC-3, ERL*AEW elicited a weaker signal in BxPC-ER. ERL* BYL, on the other hand, elicited 
the strongest signals in BxPC-ER implying superiority.  
Unfortunately, the western blotting results were too weak, and microscopy results could only 
be regarded as supportive at best. In any case, these were insufficient as validation tools since 
the nature of these experiments could not allow for statistical analyses to be made. Cleaved 
caspsase-3 had to be studied by immunofluorescence instead. 
4.3.3.4  Validation of Apoptosis Assay (immunofluorescence) 
One of the difficulties studying cleaved caspase-3 by immunofluorescence was that individual 
cells activated caspase-3 at different treatment time points. To obtain caspase-3 staining in 
the largest number of cells under a high power field (63x by default), optimisation studies had 
to be carefully planned for the best treatment time. To do this, cleaved caspase-3 was 
examined over 5 treatment time points (6, 12, 18, 24, 30 hrs) based on the results of western 
blotting and microscopy. All 4 cell lines were independently optimised for the best condition. 
Higher dose - ERL 20 M and BYL 10 M – was chosen for confirmatory study. 
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Figure 4.33: Optimisation experiment of activated caspase-3 immunofluorescence under 
E20Y10 CB treatment 
Shown above were representative images of three optimisation experiments. Cleaved 
caspase-3 was essentially absent 6 hours into treatment, started to appear at 12 hours, was 
of the highest intensity from 18-24 hours, and disappeared altogether at 30 hours. This 
confirmed previous western blotting results of a higher cleaved caspase-3 expression at 24 
hours. For subsequent experiments, immunofluorescence was tested at 20-24 hours 
treatment. In contrast to the weak signals in western blotting experiments in PANC-1/ PANC-
ER, the same antibody produced good immunofluorescence signals for these cell lines. Thus, 
it was likely PANC-1/ PANC-ER also mediated apoptosis via caspase-3, only this particular 
antibody was better detected on immunofluorescence than western blotting. 
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Figure 4.34: Activated caspase-3 immunofluorescence with E20 and E20Y10 at 20-24 hours  
Representative photos of ER and parent cell lines treated with E20 and E20Y10 were shown 
(Figure 4.34). Negative control (no treatment) were done for each experiment, but were not 
shown here since they essentially showed no staining. With E20, cleaved caspase-3 was of 
the highest intensity in BxPC-3, as expected. There were little caspase-3 staining in PANC-1 
and essentially no staining for the ER cell lines. Conversely, the cleaved caspase-3 staining 
was much higher after treatment of E20Y10 CB in the ER cell lines than parent cell lines. 
These were in concordance with all the results observed thus far. 
As per previous immunofluorescence studies, 4 independent experiments were performed 
and intensity was averaged from the 3 highest signals in each high power field taken from 5 
random areas from each corner and the middle of the slides. Summary statistics and paired t-
test were performed between ER and parent cell lines (Figure 4.35). 
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Figure 4.35: Summary statistics with E20 and E20Y10 at 20-24 hours treatment, 4 experiments, 
** denotes P<0.001 
Comparing between E20Y10 CB and E20 alone, cleaved caspase-3 activity was generally 
higher in CB than SB. Cleaved caspase-3 activity was significantly higher in E20 than control, 
but only for the BxPC-3 cell line. Cleaved caspase-3 was also significantly higher in CB than 
control, for the two ER cell lines. Comparing between ER and parent cell lines, paired t-test 
statistics showed that CB was significantly more effective in PANC-ER than PANC-1 
(P=0.0001).  
In summary, apoptosis assay and immunofluorescence showed high efficacy of PI3K inhibitor-
based CB in inducing apoptosis and necrosis, whilst results of western blotting and microscopy 
were supportive. Additionally, interpreting these results together, the mechanism of apoptosis 
by these CB treatments was better understood: CB was cytotoxic to cancer cells, activating 
caspase-3 as early as 12 hours of treatment, with maximal signals at 20-24 hours (Figure 
4.33). Cell morphology began to change from 24-48 hours, with shrivelling of cells and 
condensation of nuclei (Figure 4.30). Cells gradually shut down their mitochondrial activity at 
48 hours, and finally approached the irreversible process of necrosis which was maximal by 
72 hours (Figure 4.27). 
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4.4.4  Migration Assays 
 
Key Finding: All CB were equally effective in inhibiting migration, and there were no 
differential responses between ER and parent cell lines. 
 
Finally, the effect of CB combinations on cancer cell migration was studied. Cell migration was 
analysed in the incucyte imager after a uniform scratch wound was made on a 96 well plate. 
Mitomycin (10ug/ml) was previously optimised as an anti-proliferation agent, and was used to 
pre-treat and treat cells undergoing the migration process. Photos were taken at 2-hour 
intervals for 40-44 hours, and relative migration density was measured as the quantitative 
endpoint. A detailed methodology was described in chapter 2. 
Cell imaging migration assays were performed for BxPC-3, BxPC-ER, PANC-1 and PANC-
ER, in biological triplicate in each set of experiments. The first set of migration experiments 
compared all SB and CB between BxPC-3 and PANC-1. The second set of experiments 
compared the selected SB and CB combinations between parent and ER cell lines. Migration 
assays were not performed on the other 3 primary cell lines as the natural properties of these 
cell lines made them unsuitable for migration assay experiments: CFPAC-1 was too easily 
detachable, such that a uniform scratch could not be made; CAPAN-2 and MiaPACA-2 
migrated way too slowly for meaningful migration density to be measured.  
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4.4.4.1  Migration Assays comparing all SB/ CB between BxPC-3 and PANC-1 
 
Figure 4.36: Representative photos of BxPC-3 undergoing SB and CB treatment (0-24hr) 
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The migration assay photos were converted into .avi movie files running at 2 frames per 
second for 40-44 hours. Excerpts of the movie of BxPC-3 undergoing ERL 10μM SB and 
E10Y5 were shown above to illustrate notable findings (Figure 4.36). 
Above, the migration rate for BxPC-3 in the absence of any inhibitor was exceedingly fast in 
the presence of mitomycin as an anti-proliferation agent. Cancer cells were well on their way 
of migrating towards each other by 6 hours, and at 12 hours the scratch wound had nearly 
closed in. With the addition of ERL 10 μM, the migration rate was retarded, but the migration 
process continued and was appreciated by 24 hours. Not shown here, the edges of the wound 
became apposed by 30 hours. For BxPC-3 undergoing E10Y5, the migration process was 
completely halted. There was no appreciable migration even at the termination of experiments 
(40 hours). Relative migration density is presented next: 
 
 
Figure 4.37: Migration Assay with SB and CB (mod dose) treatment in BxPC-3 and PANC-1 
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For brevity, only moderate inhibitor dosing results are shown since the low dosing results 
followed similar patterns. For BxPC-3, PD-98059 10 μM (P10) was the most effective in 
delaying and reducing relative migration density compared to control (Figure 4.37, top left 
diagram, orange and black lines compared to red line). IGF1R inhibitor (A1), PI3K inhibitor 
(Y5) and PI3K/mTOR inhibitor (B0.1) were less effective in reducing migration in this cell line 
(green, blue, purple lines). For PANC-1, all SB were similar in efficacy (bottom left diagram). 
Although it looked as though the migration density of treated cells was similar between BxPC-
3 and PANC-1, these drugs were in fact more effective in BxPC-3 since BxPC-3 migrated 
much faster than PANC-1 at baseline (red lines, top left and bottom left diagrams). In BxPC-
3, the best drugs E10 and P10 were able to reduce migration from 90% to 30% (33% of 
control); in PANC-1, the best drug Y5 was able to only reduce migration from 70% to 33% 
(47% of control). The different rates of migration between BxPC-3 and PANC-1 simply 
reflected the natural migration properties of the two cell lines, since optimisation experiments 
showed that the results at baseline remained the same regardless of whether mitomycin was 
added (not shown). 
In BxPC-3, CB appeared more effective than SB (top right diagram). All CB reduced migration 
in a similar rate (down to 10-20%). CB was slightly more effective than SB (down to 20-40%). 
In both cell lines dual downstream blockades with PD-98059 plus NVP-BEZ (P10B0.1) were 
only slightly more effective (purple lines). Importantly, the contour of the trend was different in 
BxPC-3. CB completely retarded the migration rate in BxPC-3, resulting in almost flat migration 
curves. 
Thus, it appeared that all pathways are involved in migration, with MAPK pathway (MEK) 
having a slightly more active role in BxPC-3. CB is effective in reducing migration in both cell 
lines compared to SB, especially in BxPC-3. 
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4.4.4.2  Migration Assays comparing SB/ CB between parent and ER cell lines 
Migration assay was performed for SB and CB, and compared between parent and ER cell 
lines. Shown below are the results of 3 experiments ERL, AEW and BYL, as SB or CB (Figure 
4.38): 
 
Figure 4.38: Migration Assay with E10A1 and E10Y5 SB/CB in parent versus ER cell lines  
Comparing ER and parent cell lines, the trends showed BxPC-ER had a higher migration rate 
than BxPC-3 at baseline, whilst both PANC-1 and PANC-ER migrated at a similar rate (red 
lines). BxPC-ER had increased erlotinib resistance compared to BxPC-3, and both PANC-1 
and PANC-ER were clearly resistant to the migration inhibitory effect of erlotinib (E10: orange 
lines). BYL (Y5: blue) was better than erlotinib and AEW (A1: green) in inhibiting migration in 
all 4 cell lines. Both E10A1 and E10Y5 CB (purple and grey) were equally effective. E10A1 
was superior to ERL and AEW alone in all four cell lines. E10Y5 had similar effect of migration 
inhibition to BYL in all four cell lines, implying that this was the active agent. Different to the 
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clonogenic assay results, both CB were just as effective and there appeared little suggestion 
that ER cell lines were more hypersensitive to the effects of PI3Ki-based CB than parent cell 
lines. The 4 CB combinations were then compared side by side among the 4 cell lines (Figure 
4.39). 
 
Figure 4.39: Migration Assay with 4 CB in parent versus ER cell lines  
In all 4 cell lines, all 4 CB were equally effective in inhibiting the migration process down to 
30% with variation of ±10%. This inhibition was very prominent in BxPC-3 and BxPC-ER, 
where the baseline migration rates were particularly high. There were no noticeable 
differences between parent cell lines and ER cell lines in their responses to a particular CB 
combination, suggesting that the cancer migration is a complex process dependent on all 
molecular pathways at many levels, rather than on a specific molecular signal. 
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4.4 Discussion 
After discovering the important roles of downstream pathway up-regulation and in particular 
PI3K/Akt/mTOR activation in primary and acquired erlotinib resistance in chapter 3, this 
chapter set out three aims: 1) to study the effect of co-inhibition of the EGFR / MEK and PAM 
versus SB, 2) to find the most optimal combined blockade (CB) combination to take to in-vivo 
experiments, and 3) to explore oncogenic dependence of PI3K/Akt pathway – a concept that 
was suspected but largely left untouched in the previous chapter. To answer these 3 aims, 3 
comparisons were made: 1) between CB and single blockade (SB), 2) between the 4 CB, and 
3) examined any different responses to CB between parent and ER cell lines. This chapter 
was divided into two main sections: the study of synergy, and functional studies of combined 
blockade. For the purpose of discussion, results from these sections are combined, and 
presented under the two following headings. 
4.4.1  Efficacy of Combined blockade Combinations in-vitro  
The first aim was achieved relatively easily. By combining various inhibitors of EGFR /MEK 
and PAM pathways, CB was found to be generally more effective than SB alone. By 
complex mathematical and statistical approaches, cytotoxic and molecular synergy was 
demonstrated between erlotinib/ PD-98059 and BYL-719/ BEZ-235 in most cell lines. The 
endpoints, as measured by confluence (cell imaging proliferation assay), relative migration 
density (cell imaging migration assay), S-phase fraction (cell cycle assays) and cumulative 
apoptosis and necrosis rate (apoptosis assay) unanimously demonstrated superiority of CB to 
SB. In some cases, the effect of one agent dominated the combined effect of CB. For example, 
erlotinib caused a much higher necrosis and apoptosis rate than NVP-AEW541. Even so, 
ERL*AEW was slightly more cytotoxic than erlotinib alone, in all dosing levels (Figure 4.27).  
The second aim, to find the most optimal combined blockade in PDAC, was clearly a much 
more challenging task than the first. With so many possible targets in each respective 
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signalling pathway, there were innumerable drug combinations that could be tested. To 
systematically address this question, 4 CB combinations were scrutinised. The first two 
combinations (EGFR*IGF1R, EGFR*PI3K) were compared to determine the exact cross-talk 
mechanisms between IGF1R versus PI3K and EGFR. The third and fourth combinations 
(EGFR*PI3K/mTOR, MEK*PI3K/mTOR) covered further downstream signalling pathways, 
and were crucial in determining the exact role of the dual PI3K/mTOR inhibitor and which 
partner/s it interacted with. Given the large amount of data from the various assays, a table is 
constructed below to attempt to summarise the key findings: 
 
Table 4.9: Comparison of 4 CB in various in-vitro assays 
Whilst these experiments could not be performed on all PDAC cell lines given the immense 
work needed for each assay in optimising and adjusting for multiple variable factors (dose, 
293 
 
treatment time etc.), a number of general conclusions could be made nonetheless. Firstly, the 
best combination could be different depending on the cell lines. Given the vast genetic and 
molecular differences between PDAC cell lines, one would anticipate that one cell line would 
be more susceptible to one CB, and a different cell line to another. This was indeed the case: 
PANC-1 and the ER cell lines that had highly up-regulated PI3K were much more susceptible 
to dual downstream blockades PD*BEZ-235. On the other hand, for BxPC-3 - a K-Ras wild 
type cell line with up-regulated EGFR and IGF1R, co-EGFR-IGF1R inhibition by ERL*AEW 
was highly synergistic. Yet, even in this case, functional assays showed that this combination 
was only most active in inhibiting colony formation and causing necrosis/ apoptosis, but other 
CB combinations were superior in cell cycle disruptions, migration and proliferation 
(confluence) in this cell line (Table 4.9). This suggests that multiple pathways remained at 
play even in the most erlotinib sensitive cell line.  
Secondly, synergy is clearly not equivalent to superiority. Although not all data was shown, 
BEZ-235 was a very active agent on its own, in cell cycle disruptions and colony inhibition, as 
well as inhibiting migration and causing necrosis/ apoptosis. However, synergy indexes were 
only 1.12-1.50 when BEZ-235 was combined with Erlotinib or PD-98059, compared to 1.99 
when erlotinib was combined with AEW541 in BxPC-3 (Table 4.3). Synergy simply refers to 
positive interaction. If one drug is a highly potent drug on its own, it may not necessarily be 
synergistic when combined with another drug, since it would be difficult to demonstrate 
potency higher than an already high potency. Cell proliferation synergy experiments were 
carefully planned and executed with multiple equipotent dosing levels in a 6x6 matrix, but BEZ-
235 remained such an active drug with nanomolar potency that it was hard to elicit synergy. 
Thus, synergy relates to mechanism, while superiority refers to efficacy- which was the focus 
for finding the optimal CB. 
Thirdly, in terms of efficacy, any CB combination that included PI3K or PI3K/mTOR inhibitor 
(2nd, 3rd, 4th combinations) appeared to be at least moderately to highly active to all cell lines 
tested, including erlotinib-sensitive (BxPC-3), insensitive (PANC-1) and resistant (ER) cell 
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lines alike. These 3 combinations were all equally and highly effective in inhibiting cell 
proliferation, cell cycle and migration; and there was a further increase in apoptosis/ necrosis 
and colony inhibition when comparing ERL*BYL to ERL*BEZ to PD*BEZ. In addition, the 
findings of multiple cell cycle arrests (G1, G2/M, S) and the shrivelled cells with dense nuclei 
on light microscopy were especially significant. These changes occurred mostly in BEZ-235 
based CB, often in ERL*BYL, but never in ERL*AEW541 CB. This implies that PI3K is vital in 
proliferation and migration processes, whilst PI3K via downstream mTOR signalling is closely 
involved in the colony formation, survival/ anti-apoptosis and cell cycle functions via multiple 
checkpoints. This was illustrated with the figure below (Figure 4.41), which added new 
information to the existing diagram Figure 4.1. By blocking both MAPK and PAM pathways 
downstream, reciprocal activation of collateral pathways was minimised. This, in turn, 
suggests that multiple pathways in fact converge rather than diverge at the level close to the 
nucleus. 
Taking all the functional studies together, combined downstream blockade with PD-98059 and 
BEZ-235 was the most effective CB combination, affecting a variety of cellular functions in 
all cell lines. This appears consistent with current literature reporting strong synergy between 
MEK and PI3K in various cancer types.191 Although this was considered the best of 4 CB, this 
did not end up being the CB combination used in-vivo. There were other considerations to the 
final choice such as toxicity, costs and drug availability. This will be discussed in more detail 
in the next chapter (Chapter 5). 
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Figure 4.40: Cellular functions inhibited by CB in PDAC cell lines 
 
4.4.2   Oncogenic Dependence to PI3K/Akt/mTOR pathway  
Importantly, this study illustrates the possibility of oncogenic addiction/ dependence in 
pancreatic cancer, the third aim of this chapter. That is, cancers become dependent on the 
activity of specific oncogenes and hence display higher sensitivity to drugs targeting that 
particular cancer circuitry.330 In the in-vitro model, the fact that both ER cell lines up-regulated 
the PAM pathway, made them susceptible to the effect of NVP-BYL719 or NVP-BEZ235 
based treatment. The evidence for this was based on multiple functional studies and 
summarised in the table below: 
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Table 4.10: Summary of 4 CB in various in-vitro assays. ^ Cell Proliferation assay was a crude 
measure of net cell proliferation minus cell death 
Of note, the pattern of susceptibility correlated closely with the known normal cellular functions 
of the PI3K/Akt/mTOR system. BYL-719 or BEZ-235 based CB caused significant arrest in 
G1, a checkpoint normally regulated by Akt-driven cyclin D1. This combination also caused 
high levels of apoptosis and necrosis, and Akt is known to modulate anti-apoptosis and 
survival signals via Forkhead and BAD via Bcl-2 and FasL.45 Lastly, it also substantially 
inhibited colony formation and cell proliferation, which depend on a number of pathways 
including Akt-driven mTOR, GSK3, p21 and p27.45,178,323 These effects on ER cell lines in 
proliferation assays, cell cycle, apoptotic assays and clonogenic assays were above what was 
observed in the parent cell lines, and significantly so for PANC-ER (Table 4.5, 4.7, 4.8). In 
contrast to proliferation and survival, migration was equally affected by all 4 CB, and there was 
no differential sensitivity observed between parent and resistant cell lines. Whilst the PI3K/Akt 
pathway has been linked to migration,324 this is a complex process of cell-matrix-stroma 
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interaction orchestrated by many autocrine factors including stromal-cell-derived factor (SDF-
1) and hepatocyte growth factor (HGF).331 Possibly since migration is in part driven by other 
molecular pathways, oncogenic addiction of PI3K/Akt/mTOR pathway by erlotinib resistant 
cell lines did not display hyper-sensitivity to PI3K inhibitors (Figure 4.40).  
The study of oncogenic dependence was therefore a significant one, because like synthetic 
lethality, it provided a conceptual framework for developing cancer-specific cytotoxic treatment 
strategy, by exploiting the weakness of cancer cells to go down a specific pathway in the face 
of drug pressure.200 Simply put, this study had found that despite all the complex networks 
in PDAC cells, there was a single obligatory pathway of “least resistance” that was 
exploited by these cells to escape drug pressure (the PI3K/Akt/mTOR), which in turn 
make them targetable by combined targeted drug blockade strategies. From this 
paradigm, there are multiple implications to ongoing research for pancreatic cancer, and these 
will be discussed in greater detail in Chapter 6. 
In conclusion, combined blockade of the closely connected EGFR/MEK and PI3K/Akt/MAPK 
pathways were more effective than single blockade alone, and dual downstream blockade 
with MEK and PI3K/mTOR inhibitors appeared the most effective in all cell lines. Erlotinib 
resistant cell lines that were driven down this pathway became dependent on this for survival, 
making them hyper-sensitive to these treatments. 
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CHAPTER 5:  
 
EGFR AND PI3K INHIBITORS CB IN-VIVO 
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5.1  Introduction 
5.1.1   Chapter Background 
So far, chapter 3 and 4 focused on in-vitro experiments and had elicited two intriguing 
properties about erlotinib resistance and pancreatic cancer: firstly, primary and acquired 
erlotinib resistance were both associated with downstream signalling pathway activation, 
especially via the PAM pathway. Secondly, erlotinib resistant PDAC cell lines were dependent 
on this obligatory pathway, making them highly susceptible to EGFR and PI3K co-inhibition. 
Putting these two concepts together, the hypothesis for translational study is that erlotinib 
resistance and/or PI3K/Akt over-activation may be potential predictive biomarkers for erlotinib 
plus PI3K inhibitors combined blockade. Therefore, initially the aim of this section was to study 
erlotinib resistance in-vivo. However, these objectives could not be definitively achieved in-
vivo due to the challenges of developing an of erlotinib resistance animal model as well as 
statistical considerations. On the other hand, these objectives could be more easily and 
decisively studied in human studies. Since patient-derived xenograft model is an established 
method of testing anti-cancer drug activity, and has been shown to closely recapitulate clinical 
trial situation if developed appropriately,332 the efforts were turned to developing and validating 
a suitable animal model and using it to establish in vivo efficacy of CB (Chapter 5). The CB 
selected were ERL* BYL and ERL* BEZ. Although PD * BEZ was previously shown to be the 
most potent combination, PD-98059 was only used in vitro due to solubility issues,192 and an 
appropriate MEK inhibitor could not be secured in vivo from pharma. As for the development 
of an in-vivo erlotinib resistant model and biomarkers for CB, these were attempted 
nonetheless with preliminary results presented in section 5.4. The ultimate proof of concept, 
however, will have to wait for human studies, whose study design is outlined in Chapter 6.  
 
5.1.2  Chapter Aims 
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1. To establish and validate a pancreatic cancer xenograft model for drug testing 
2. To test the in-vivo efficacy of EGFR and PI3K combined blockade 
5.1.3  Chapter Methods- summary 
The general animal study methods and design had been summarised in section 2.2.14 and 
will be covered in more detail in the next section. Briefly, Patient-derived tumour tissue (PDTT) 
fresh from patients who underwent Whipple’s surgery (JS) for resectable pancreatic cancer 
were removed, and transplanted in non-obese diabetic/severe combined immunodeficiency 
(NOD/SCID) mice. Whilst metastatic PDAC specimens would more closely resemble the in-
vitro models of metastatic PDAC cell lines, this was not feasible as most metastatic PDAC 
patients only have fine-needle aspirate biopsies, and there would not be sufficient tissue for 
our animal model. Two models (sub-renal, subcutaneous) were established and validated 
independently for drug testing. Sub-renal was selected as the core model for the reasons 
described below. 2 drug combinations were used (ERL* BYL, ERL* BEZ); and these were 
compared against control, SB or gemcitabine (standard). BYL and BEZ were either purchased 
or provided for by Novartis Pharmaceuticals. MEK inhibitor such as PD-98059 was 
unfortunately not available in sufficient quantity for in-vivo testing. The primary endpoint for 
the core study was tumour volume. The secondary endpoints were kidney weight, metastatic 
disease and IHC of Ki-67. I had major involvement in the overall study design and methods, 
and the execution of the project was undertaken as a group work (RS, SJ, AX, SS, myself). 
The animal experiments were carried out conforming the Australian code of practice for the 
care and use of animals for scientific purposes (2004),333 and were approved by local area 
ethics committee. 
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5.2  Study Methods and Design 
5.2.1   Study Methods 
5.2.1.1  Animals 
NOD/SCID mouse is the most common murine xenograft model.334 6-8 week-old male 
NOD/SCID mouse were obtained from the Animal Resources Centre, Perth; and were housed 
at the Kearns Facility in the Kolling Medical Research Institute, Royal North Shore Hospital. 
They were housed for a week to familiarise with new environments before surgery. 
5.2.1.2  Patient tumours 
Patients were consented by the surgical team for donation of part of their cancer tissue for 
research. The donor tissue was obtained from patients with resectable pancreatic cancer 
undergoing Whipple’s surgery in Royal North Shore Hospital. Within 30 minutes of surgical 
removal, the tumour specimens were preserved in DMEM supplemented with FBS and 
immediately transported in standard sterile transplant containers. Under sterile hood each 
tumour tissue was divided into two parts. One part was fixed in 10% formalin for histological 
analysis. The other part was cut into multiple 1 x 1 x 2 mm3 pieces, and was kept in medium 
on a sterile petri dish at 4 ºC. Xenografts experiments were performed fresh on NOD/SCID 
mice inside Kearns facility within 2 hours. The tumours were examined and diagnosed 
independently by 2 senior pathologists (AG, CT).  
The demographic details and histopathology of the tumours are presented in Table 5.1, In 
total, 21 human pancreatic cancer specimens were obtained. Median age was 59.5 years 
(range 49-79 years). 62% (13/21) were male. 6 patients had high grade (G3/G4) 
adenocarcinomas, and 15 patients had moderate grade adenocarcinoma (G2). 15 patients 
had pancreatic ductal adenocarcinoma. Among these, one tumour specimen (P009E7) was 
obtained from a pancreatic cancer metastatic lesion to the ribs. 4 patients had ampullary 
adenocarcinoma, 1 had duodenal cancer and 1 had gastric cancer. Since tumour biology of 
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these cancers could be very different to pancreatic cancer, these specimens of other 
pathologies were only used to develop the animal model. 18/21 patients were treatment naïve 
prior to surgery and had received gemicitabine treatment only after surgery. Only one patient 
(P010E8) received neoadjuvant gemcitabine and radiotherapy prior to tumour removal.  33% 
(7/21) had incomplete resection (R1), and would be expected to have poorer prognosis.335 
 
Table 5.1: Patient characteristics. Abbreviation:  G2: Moderately differentiated. G3: Poorly 
differentiated. G4:  Undifferentiated. M: male. F: female.N/A. Amp: Ampullary adenocarcinoma. PDAC: 
Pancreatic ductal adenocarcinoma. a:WHO classification.  b: TNM grading system. c:pTNM, AJCC 7th 
edition 2009. *Resection Margins: R0, resection is defined as a grossly complete resection with 
microscopically negative margins; R1, resection is defined as a grossly complete resection with 
microscopically positive margins; and  R2 resection is defined as a grossly incomplete resection N/A: 
no resection margin. RT: radiotherapy 
 
 
5.2.1.3  General care of animals 
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In accordance to the Australian Government National Health and Medical Research Council 
(NHMRC) Guidelines to promote the wellbeing of animals used for scientific purposes,336 
meticulous attention was given to apply high standards of quality and safety while ensuring 
animal rights of individual animal. Sterility was especially important for NOD-SCID 
immunocompromised mice.337 This was controlled by providing ultra-violet sterilised water and 
food, completing procedures in clean and hooded work area, cleaning cages or transferring 
animals to new cages weekly, and using sterilised or pre-packaged instruments. Pain 
assessment and management was paramount, as disruption of animals’ well-being frequently 
leads to variability and uncertainty of results.336 Mice were evaluated for general appearance, 
ability to move normally around cage and reach food and water, ability to eat and drink, 
grooming habits, skin colour and lethargy. In addition to the standard monitoring, care was 
also taken to monitor signs of pilorection, hunched posture, changes in group behaviour and 
responses upon handling; as these could all represent signs of pain or distress. General 
anaesthetics 2% isoflurane mixed with NO2 was used for all procedures including drug 
gavaging, to ensure the anaesthesia was quick and not distressing. Analgesia with pethidine 
was given post-op. Where mice were found to be dehydrated, nutrition gels were provided in 
the cages. Each week mice were weighed, and a log was kept for their serial weight and any 
concerning symptoms. Mice with loss of 20% body weight were euthanized. This was relatively 
uncommon, as mice at this age were observed to gain around 10% body weight per week, 
and cancer engraftment for 9 weeks caused cachexia unusually.  
5.2.1.4  Surgical procedure 
NOD/SCID mice were individually weighed and anesthetized with isoflurane, Nitrous oxide 
and Oxygen (2:1:1). The surgical field was cleaned with 70% alcohol and draped with sterile 
cloth, and surgical standard personal protective equipment (PPE) and instruments were used.  
Sub-renal capsule grafting procedure was well established by Wang et al in Canada.338 Whilst 
technically more challenging, this method was chosen as the core methods over 
subcutaneous model, since it resulted in high engraftment rate, allowed for quick assessment 
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(6-8 weeks) and resembled more closely to tumour histology and biology.268,339 After prepping 
with betadine and shaving the dorsal surface of the back of the skin, a small incision was made 
along the midline. The back skin was lifted with a pair of sterile blunt forceps and the posterior 
body wall was cut with a pair of scissors creating an incision approximately 2 cm in length 
(Figure 5.1). Each kidney was popped out by applying gentle pressure on either side of the 
abdomen using the forefinger. A pocket was then created between the capsule and kidney 
parenchyma by blunt dissection, and 1 - 2 grafts were inserted in the sub-renal capsule using 
a polished sterile glass pipette. The kidneys were gently eased back into body cavity. The 
abdominal wall and skin were closed with staples after both sides were completed. 
 
Figure 5.1 Sub-renal xenograft transplantation procedure. 
Subcutaneous xenograft models were performed as previously described methods.340 A 
smaller skin incision was made in the same way, and the adventitious tissue was dissected 
down by blunt forceps to create a subcutaneous pocket. Xenografts pieces were transplanted 
in the subcutaneous pockets on each side. Because of the smaller incisions, the skins were 
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apposed and glued instead of stapled. The mice were observed to recover more quickly post-
operatively with this procedure than the sub-renal transplantation. 
5.2.1.5  Post- operative Care and Monitoring 
Standard post-operative care was provided for the animals. After surgery, the mice were 
allowed to recover under the warm condition (with heated mat) with one mouse per cage and 
free access to food and water. Pethidine 10-20mg/kg subcutaneously was given post-op. The 
animals’ health was monitored daily after surgery for the first 5 days and then every second 
day until the wounds were healed. Twice weekly after operation, the wounds on the animals 
were examined and dressed with betadine. 10 days after surgery, staples were removed. 
5.2.1.6  Drug Treatment 
PDTT experiments were shown to be predictive of chemotherapeutic activity in humans, 
provided pharmcokinentically clinically equivalent doses were used.332 Erlotinib 50mg/kg/day 
was used, as this in-vivo dose was expected to yield plasma concentrations near the clinically 
therapeutic levels in humans without causing cardiovascular and renal toxicities.341 Intra-
peritoneal injection of gemcitabine 100mg/kg twice weekly was the standard dose for 
pancreatic cancer in-vivo study, supported by a number of publications.342,343 BYL-719 and 
BEZ-235 25mg/kg/day were chosen after demonstrating dose limiting toxicities with higher 
doses, and this was consistent with recommendations of the investigators’ brochures. All 
inhibitors were homogenized in 6 mg/ml 0.5% methylcellulose prepared fresh twice weekly, 
whilst gemcitabine was diluted by sterile 0.9% normal saline into 10mg/ml solution. These 
dilutions were made based on the maximum gavage volume of 10ml/kg and maximum 
intraperitoneal bolus injection volume of 1% of animal weight.336  
Gavaging of oral drug solution ensured the swallowing of drugs by animals. Standard 18-20 
gauge plastic feeding tubes 1.5 inches long were used. The animal was first anaesthetised, 
restrained and gavaged by feeding tube using the other hand, after gently extending the 
neck.344 Intraperitoneal (IP) injection was performed by holding the anaesthetised mouse in 
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the supine position with its posterior end slightly elevated. The needle was kept parallel to the 
vertebral column, and the injection was given at the abdominal surface of the lower quadrant 
of the abdomen at approximately 10o.345 Pre-packaged needles were used once only. All mice 
were monitored daily during drug treatment until termination of experiment.  
5.2.1.7  Sacrifice of Animals 
All mice will be euthanized on 60 days post grafting or 30 days post treatment. The last dose 
of treatment was given on day 28, and animals were given 2-day drug free holiday before 
sacrifice. The animals were killed by carbon monoxide inhalation instead of cervical dislocation 
to ensure a comfortable death.  
5.2.1.8  End-of-study assessment and Tissue Collection 
Animals were weighed at end of study. Kidneys were removed and also weighed. Tumours 
were directly visualized, photographed and measured using standard callipers. The tumours, 
lymph nodes, lungs, livers, kidneys, spleens, and bone (femur) of the hosts were removed, 
fixed and examined for metastases. Histopathology and IHC were performed on paraffin 
embedded slides using standard methods as described (sub-section 2.2.15), and were 
reviewed and scored by a senior pathologist (AG).  
5.2.1.9  Animal Ethics and Human Ethics Approval 
All animal care and experiments were carried out in accordance with the guidelines of the 
Australia Council on Animal Care and the Royal North Shore Hospital Animal Care & Ethics 
Committee (Protocol number 1011-015A, Sydney, Australia). Pancreatic tumour surgical 
specimens were obtained from either Royal North Shore Hospital or North Shore Private 
Hospital (Sydney, Australia) following protocols approved by the Northern Sydney Health 
Human Research Ethics Committee (Protocol number: 0909-227M, Sydney, Australia). 
5.2.2   Study Design 
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5.2.1.1  Development and validation of sub-renal model 
For each experiment, one patient pancreatic cancer specimen could be dissected into 
sufficient graft pieces for 20 mice. 28 days after tumour engraftment, mice were randomised 
to IP gemcitabine or normal saline treatment for another 28 days. The primary objective of 
the study was to demonstrate superiority of standard gemcitabine over control in end-
of-study tumour volume. The secondary objective was to elicit similar histopathology 
and immunohistochemistry of proteins that were not expected to change with 
treatment, between pre-graft and post-graft tumour specimens. Cytokeratin 7 and 20 
(CK7) and (CK20) immunohistochemistry was selected, since the expressions of these 
markers were generally associated with specific cancer type, and pancreatic adenocarcinoma 
typically stained CK7+ and CK20+ or focally positive.346 Two senior post-doc scientists (AX, 
SJ) had the principal roles in the development and validation of the sub-renal model. They had 
many years of animal study and immunohistochemistry experience. Other parts of the in-vivo 
project were undertaken by the research group (RS, SJ, AX, SS, myself) as described. 
5.2.1.2  Drug testing using sub-renal model 
For the ERL* BYL combination, this experiment was performed in 2 phases. In the first phase 
(pilot), animals were randomised to control, BYL and ERL* BYL. This was to establish 
superiority of CB over control that was not due to BYL alone. Importantly, The pilot study was 
also used to attain means and standard deviation statistics in order to calculate for the sample 
size for the core experiment. In the second phase (core), animals were randomised to 4 
treatment arms: control, gemcitabine, ERL and ERL* BYL (Figure 5.2).  There was no BYL 
alone arm, since PI3K inhibitors were shown to produce modest single-agent efficacy at best.47 
The primary objective was to demonstrate superiority of CB over control and non-
inferiority of CB against standard gemcitabine. The secondary endpoints were kidney 
weight, metastatic disease and IHC of Ki-67 activity index. 
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Figure 5.2: Study Design of the core sub-renal model experiments 
For the ERL* BEZ combination, preliminary pilot experiments were performed for 4 treatment 
arms. Mice were randomised to control, gemcitabine, ERL and ERL* BEZ. This was different 
from the ERL* BYL study design, as there was difficiulty in the acquisition of sufficient BEZ 
drug for in-vivo testing. The study was closed early after only 2 experiments, due to a lack of 
efficacy observed and importantly, a safety issue of grade 5 toxicity as a result of ERL* BEZ 
CB. This will be discussed in detail in the results section. 
 
5.2.1.3  Development and validation of subcutaneous model 
Subcutaneous models have the advantage of being visible from the outside, thereby allowing 
direct visual monitoring and serial measurements.347 Yet, the engraftment rate for 
subcutaneous model is typically low (40-60%), and it only succeeds in growing highly 
advanced malignancies, since it does not simulate the tumour microenvironment as the sub-
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renal or orothotopic model do.339 To circumvent this issue, serial transplantation of tumour 
xenograft was first performed in the sub-renal model to establish stable engraftment rate.348,349 
For each generation of mice, the tumour was divided and passaged to 3 to 4 mice at a time, 
and selected the mouse with the highest tumour burden for subsequent passages. In this way, 
the issue of tumour heterogeneity was overcome by means of natural selection. After serial 
passaging, the established xenograft was transplanted to the subcutaneous model. The 
primary objective was to establish a xenograft which could grow and was measurable 
in the set timeframe of 28 days of study, with a high engraftment rate >75%. The 
secondary objective was to ascertain that tumours had not changed in morphology, by 
examining the pre- and post-graft tumour histology of each new generation xenografts. 
5.2.1.4  Drug testing using subcutaneous model 
Once the tumour xenograft was validated for use in subcutaneous model, subcutaneous 
transplantation was performed and the mice were randomised to control, ERL, BYL and ERL* 
BYL. The primary objective was to confirm sub-renal core study, and secondary 
objective was to demonstrate synergy with CB. Thus, both ERL and BYL were studied as 
SB, but gemcitabine was not included. During the 28 days of study, tumour xenografts were 
palpated and measured by standard calipers weekly initially then twice weekly. The average 
tumour volumes for each group against time of study were presented as line graphs. The 
primary endpoint was comparison of tumour volume trends between CB, SB and control. 
Statistical analysis was performed but was limited by sample size. 
5.2.1.5  Statistical and other Study Considerations 
The 3 R’s of code of practice in animal research (replacement, reduction, refinement) were 
advocated throughout the statistical considerations of our in-vivo study.333 At each decision 
point, alternative study designs were considered to minimise the number of animals used. As 
mentioned, the sub-renal model experiments were divided into pilot and core studies. The pilot 
studies aimed to use a minimum number of animals to look for signals of efficacy and safety. 
310 
 
This had helped us apply early stopping of the ERL* BEZ experiments, after observing in 
excess of 2 deaths of animals due to CB toxicity. This pilot study design had also allowed for 
accurate statistical calculations to be made for the core study. For ERL* BYL, based on a  
(effect size) of -0.35,  (standard deviation) of 0.55, standard  and  of 0.05 and 0.8, and a 
paired analysis, 21 animals were needed for each of the 4 treatment arms. This totalled to at 
least 84 animals in the core study (PS, version 3, 2009), and 90 animals were used. The 
subcutaneous model experiments used up 3-4 animals for each generation of passage, and 
it was meant to only complement and support the sub-renal model, particularly as statistics 
could not be performed for this study design. Therefore, the minimum number of animals (5 
per treatment arm = 20 animals) was used to test the subcutaneous model. For statistical 
analysis, the data was log transformed since they did not conform to the normality assumption. 
Two-way ANOVA was used to analyse tumour volumes between treatment groups after 
adjusting to experiments (SAS 9.2), since the same xenograft was used for each experiment.  
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5.3   Study Results 
5.3.1  Development and validation of sub-renal model: results 
The sub-renal model was established from 21 patients, including 19 with pancreatic ductal 
adnocarcinoma. Of the total of 420 first-generation tissue implantations in 210 mice, 357 post-
grafts were successfully grown under the sub-renal capsule, giving a net xenograft rate of 
85%. Figure 5.3 shows pancreatic tumour tissue xenografts after 8 weeks of growth in 
NOD/SCID mice. All grafts started as tiny 1x 1x 2 mm3 grafts. By the end of 8 weeks, these 
successful grafts typically occupied 1/3 or 1/2 of the murine kidneys (~12mm3, or 600% of 
original size), established neovascularisation and became locally invasive into the kidneys. 
 
Figure 5.3: Sub-renal xenografts showing neovascularisation (black arrows) 
The histopathology between the original tumours (pre-grafts) and the post-graft tissues were 
compared using H&E. Of the 21 pancreatic tumour specimens, 18 showed concordant 
histological morphology between the pre-graft and post-graft tissues. 3 of them only grew 
fibrous tissues. Among the 18 evaluable tumours, 12 were moderately differentiated (G2), 5 
poorly differentiated (G3) and 1 undifferentiated (G4). In addition to grading and differentiation, 
the post-graft also carried over distinct morphological features such as ductal structures, loss 
of nuclear polarity, nuclear crowding and variation in nuclear size (Figure 5.4). These 18 cases 
were further evaulated with immunohistochemistry (IHC). 
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Figure 5.4: Similar histopathology between pre-graft and post-grafts tumour, in moderately 
differentiated (P006E5), poorly differentiated (P004E3) adenocarcinoma and metastasis lesion 
(P009E7). 
 
The IHC of CK7, CK20 and Ki-67 were compared between pre-grafts and post-grafts tissue of 
animals undergoing gemcitabine versus control treatments. CK7 and CK20 are cytokeratins 
that define intrinsic properties of specific cancer types, so they were expected to be similar 
between pre-grafts and post-grafts with control.346 Less is known about the changes of CK7 
and CK20 with gemcitabine treatment, due to the paucity of literature. On the other hand, Ki-
67 is a tumour activity index that has been shown to decrease with treatment in pre-clinical 
and clinical (mostly neoadjuvant) studies.1,350,351 Indeed, no substantial differences in the IHC 
staining patterns was found between pre-grafts and post-grafts of animals treated with saline 
control, in all of the 18 specimens, indicating retention of tumour characteristics and 
reproducibility of this current sub-renal model. Moreover, post-grafts of animals treated with 
gemcitabine demonstrated reduced expression of Ki-67, CK7 and CK20 in 5 cases (P006E5, 
P012E9, P021E15, P029E21 and P030E22) (Figure 5.5). Accordingly, in these cases the 
H&E showed low grade cells with less pleomorphism in these gemcitabine treated tumours. 
Importantly, these also happened to be the cases where there was a significant reduction in 
tumour volume in the gemcitabine treatment arm compared to control (Figure 5.6, Table 5.3). 
Thus, these results supported the use of these IHC markers as surrogate endpoints of 
response in the subsequent core experiments. 
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Figure 5.5: Representative IHC and H&E showing similarity of pre-grafts and post-grafts control, 
and response to gemcitabine 
 
Figure 5.6: Significant responses in tumour volumes in 5 of 18 cases of sub-renal xenografts 
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Tumour area (mm2) after treatment 
Patient ID Control Gemcitabine Inhibition%* P value 
P002E1 6.81±10.47 3.58±2.64 47.43 0.290 
P004E3 41.64±15.57 17.25±7.43 58.57 0.092 
P005E4 7.79±1.70 5.62±2.38 28.85 0.134 
P006E5 11.66±6.03 1.36±0.72 88.34 0.021 
P007E6 2.27±2.45 0.68±0.27 70.04 0.155 
P009E7 7.83±7.18 9.81±12.75 -25.29 0.413 
P012E9 10.69±7.01 3.96±3.74 62.96 0.032 
P014E11 6.29±6.28 5.67±0.58 9.86 0.436 
P021E15 84.3±28.81 21.2±9.65 75.90 0.011 
P022E16 2.83±2.02 4.48±3.28 -58.01 0.250 
P025E17 9.92±8.23 5.14±1.66 48.19 0.110 
P026E18 19.06±4.86 14.00±5.66 26.55 0.220 
P027E19 13.88±12.76 2.00±1.37 85.58 0.079 
P028E20 3.79±0.36 2.33±3.18 38.52 0.255 
P029E21 80.13±22.01 17.96±28.56 77.59 0.004 
P030E22 54.42±23.5 0.58±0.20 98.90 0.001 
P023E23 1.916±2.04 1.75±1.88 9.70 0.453 
P024E24 1.92±4.99 6.39±6.57 -0.07 0.255 
 
Table 5.2: Tumour area inhibition rate in-vivo among 18 cases 
 
In summary, the current sub-renal model was established with 21 xenografts (n=420). It 
produced a high engraftment rate of 85%, on par with other successful sub-renal models 
published in literature.267,338 Importantly, it demonstrated high concordance in histology to the 
original tumour tissue. In this model, a response rate of 28% (5/18) to gemcitabine was 
demonstrated. This was slightly more than the 8-12% response rate observed in clinical 
studies,108,109 but it certainly was within the expected range. Of interest, all 5 gemcitabine-
responsive tumours consistently showed reduced Ki-67 with this treatment; suggesting a role 
of this as a surrogate marker for tumour response endpoints. 
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5.3.2  Drug testing using sub-renal model 
5.3.2.1  ERL* BYL Combined blockade – Pilot study 
In the pilot study involving 34 NOD/SCID mice in 3 separate PDTT experiments, animals 
treated with ERL 50 mg/day plus BYL 25 mg/day had smaller tumours (E50Y25) (8.0mm3, 
95% CI: 4.3-14.8; n=11) compared with control (11.4mm3, 6.0-21.7; n=10) and BYL alone 
(10.4mm3, 6.2-17.4; n=12) (Figure 5.7). The differences were not statistically significant due 
to the small sample size, but numerically there was a small increase in SB (Y25) versus control 
but a noticeable decrease in tumour volume in CB (E50Y25). This generated a hypothesis that 
PI3K inhibition alone was not sufficient to overcome pancreatic cancer, and supported the 
concept of CB as established by the in-vitro models in Chapter 4. In view of these results, BYL 
was therefore omitted but ERL was retained as a SB treatment arm for subsequent core 
studies. 
 
Figure 5.7: Boxplots of mean tumour volumes in control, Y25 and E50Y25 (Pilot sub-renal study) 
This pilot study also provided the necessary statistical data for sample size to be calculated 
for the core experiment. Using the log transformed tumour volume data, a parameter estimate 
of 0.65 and standard error of 0.55 was estimated. The calculated sample size to demonstrate 
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a significant difference was at least 21 animals per treatment arm, or a minimum of 84 for 4 
treatment arms in the core study. 
 
5.3.2.2  ERL* BYL Combined blockade – Core Study 
Dual treatment was further evaluated in six experiments, and compared with control, 
gemcitabine 100mg/kg twice weekly (G100) and ERL 50mg/day (E50) (n=90). The 
engraftment rate was 80%. Tumours treated with E50Y25 appeared to be smaller, flatter and 
less bulky than tumours treated with control vehicle, G100 and E50 (Figure 5.8a). The 
adjusted mean tumour volumes for animals treated with E50Y25 was 3.5mm3 (95% CI: 2.2-
5.8 mm3), compared to control (14.7 mm3, 9.9-21.9 mm3), G100 (2.6 mm3, 2.0-3.4 mm3) and 
E50 (5.8 mm3, 4.0-8.4 mm3) (Figure 5.8b). Tumours in animals treated with E50B25 were 
significantly smaller than control (by 11.2 mm3, P=0.005). Tumours in gemcitabine-treated 
animals were also significantly smaller (by 12.7 mm3, P=0.001); and importantly, CB was non-
inferior to standard G100 (P=0.54) (Table 5.3a). The kidney weights for animals treated with 
E50Y25 and G100 were significantly lower than control (by 66 mg, P=0.002; by 70mg, 
P=0.002), and there were no significant differences between CB and G100 (P=0.86) (Table 
5.3b). The close correlation between tumour volume and kidney weight suggests the presence 
of a growing xenograft tumour had a significant impact on the weight of the organ on which it 
was engrafted. None of the animals had distant metastases on macroscopic inspection by the 
end of experiments (after 8 weeks of engraftment).  
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Figure 5.8: (A) Representative photos of tumours of animals undergoing treatment.  (B) Boxplots 
of mean tumour volumes between control, Gem, E50 and E50Y25 (Core sub-renal study);  
 
Table 5.3: 2-way ANOVA statistics of (A) tumour volumes and (B) kidney sizes in 4 treatment 
arms in core sub-renal study (ERL and BYL) 
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Histologically, the xenograft tumours of mice treated with E50Y25 appeared of lower grade 
with less Ki-67 and CK7 staining in 4 of the 6 experiments, compared with E50 and control 
(Figure 5.9). In 2 other experiments, a small tumour subclone was more intensely stained for 
Ki-67 and CK7 in CB compared to control or G100, possibly reflecting tumour heterogeneity 
and/or early resistance to CB in these 2 cases. Nevertheless, there was intense staining to 
cleaved caspase-3 with CB, reinforcing the apoptotic or cytotoxic mechanism of these drugs. 
(Figure 5.10). In all cases, pEGFR was decreased by erlotinib and more so with CB, indicating 
that the targeted drug treatment was hitting the target of interest. 
 
Figure 5.9: H&E and IHC between control, E50 and E50Y25 in a representative of 4 experiment 
responsive to CB 
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Figure 5.10: H&E and IHC between control, E50 and E50Y25 in a representative of 2 experiments 
unresponsive to CB  
18 largest tumours representative of treatment arms (NT, erlotinib and CB) were stained with 
Ki-67 and cleaved caspase-3 IHC, and were analysed categorically in statistical analyses. 
Consistent with in-vitro studies, cleaved caspase-3 activation was significantly increased by 
CB (33.9% vs. 7.0%, P=0.049) whilst Ki-67 was unchanged (44.8 vs. 40.9%, P=0.63), 
indicating that this CB acted via cell apoptosis instead of reduced tumour proliferation (Table 
5.4).  
 
Table 5.4: 2-way ANOVA statistics of Ki-67% and caspase-3% grading between 4 treatment arms 
in core sub-renal study (ERL and BYL), as per standard grading classification1  
5.3.2.3  ERL* BEZ Combined blockade – Core study 
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BEZ, the dual PI3K/mTOR inhibitor, demonstrated superiority to BYL in in-vitro studies 
(Chapter 4), particularly when combined with MEK inhibitor PD. Since PD or other MEK 
inhibitors were not available for in-vivo studies, ERL* BEZ was the next CB tested. Dosing 
was as per recommended doses in the investigators’ brochure. Animals were randomised to 
control, G100, E50 and E50B25. Unfortunately, after 2 experiments it was found a high 
proportion of mice on E50B25 with moderate diarrhoea, and 3 mice were suspected to have 
died from the CB (2 from sepsis, 1 from severe diarrhoea). The study was stopped prematurely 
due to serious adverse events (SAE), but the data was analysed nonetheless. In 2 
experiments (n=26), there was no significant differences in the 4 treatment groups, and the 
magnitude of effect of E50B25 on tumour volume and kidney weights was very small (-
1.88mm3, -7.14mg). Based on this and the SAE, a decision was made not to continue study 
of this drug on a lower dose. 
 
Table 5.5: 2-way ANOVA statistics of (A) tumour volumes and (B) kidney sizes in 4 treatment 
arms in core sub-renal model study (ERL and BEZ) 
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In conclusion, the core sub-renal xenograft study fulfilled its primary endpoint, demonstrating 
pre-clinical efficacy of ERL* BYL CB in reducing tumour volumes and providing a strong 
rationale for clinical development of BYL and ERL CB in pancreatic cancer. There was no 
early signal that BYL alone was effective in the pilot study, whilst erlotinib reduced tumour 
volume with borderline significance in the core study as a single agent (P=0.067). This implies 
that erlotinib remains the active agent in pancreatic cancer, with BYL producing additional 
benefits (or synergy) when added to erlotinib. BEZ, on the other hand, was found to have only 
a small non-significant effect on tumour volume. Whilst this may be due to inadequate sample 
size as a consequence of early stopping of the study, the significant toxicity of this drug 
hindered further drug development in the current study. Interestingly, the H&E and IHC results 
suggested a different mode of mechanism with these targeted therapies. There was a 
statistically significant increase in cleaved caspase-3 with CB (P=0.049), whilst Ki-67 
remained unchanged. This suggested that CB was cytotoxic rather than cytostatic, and was 
certainly supported by the in-vitro apoptosis assay results (Section 4.3.3). In 2 of 6 core ERL 
plus BYL experiments, a small sublone of aggressive dysplastic tumour cells was found even 
in CB treatment. This aligned with the current concept of tumour heterogeneity and acquired 
resistance to these drugs, and reinforced the need for treatment selection based on 
biomarkers to maximise effects. 
 
5.3.3  Development and validation of subcutaneous model: results 
The subcutaneous model was used to validate the sub-renal model results. Serial 
transplantation using 4 generations of sub-renal xenografts were performed, 3-4 mice per 
generation. Because of tumour heterogeneity, the small pieces of grafts (1x2x2 mm3) used for 
each transplantation, and the slight differences in microenvironment of each NOD/SCID 
mouse, some variation in tumour sizes was anticipated in the same generation of mice. For 
each generation, the largest tumour for subsequent generation of xenografting was chosen. 
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After 4 generations of xenografts, the engraftment rate reached almost 100%. Comparing 
several generations of sub-renal xenografts upon sacrifice, the later generation grafts grew 
faster, and were larger and more solid or “fleshy” (white arrows, Figure 5.11). Specifically, the 
3rd and 4th generation grafts were composed of more solid tissue, were more vascular and 
heterogenous in consistency and colour. In these examples, the 3rd generation graft on the 
right kidney was very locally aggressive and was wrapping around the kidney, though the one 
on the left kidney still remained small. On the other hand, all 4th generation grafts were large 
and invasive. This 4th generation graft even destroyed a kidney such that only liquefactive 
necrosis was found on dissecting this tumour (not shown). 
 
Figure 5.11: 1st versus 3rd versus 4th Generation sub-renal xenografts 
The 3rd generation sub-renal xenograft on Figure 5.11 was used to develop the subcutaneous 
model, whilst the remainder was passaged to the 4th generation sub-renal grafts in preparation 
of the core subcutaneous experiment. Tracking the 4 mice over 8 weeks post-transplantation, 
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the 4th generation subcutaneous tumour became palpable by 2 weeks and visible by 4 weeks 
(Figure 5.12). By 6-8 weeks, the tumour was certainly measurable even after the fur had 
grown back (red circles). Upon sacrifice of the mice after 8 weeks, the tumour palpated on 
examination corresponded well to the tumour found on dissection. In both examples on Figure 
5.13, the subcutaneous tumour measured 10mm (note 1:5 ruler was used in the top and 1:1 
ruler used in the bottom). The histology of several generations of xenografts tumour was 
compared: the ductal structures and morphology were similar between original tumour and 
the subsequent generation xenografts, except that tumour differentiation appeared of much 
higher grade in the 4th generation (black arrow, Figure 5.14). All in all, subcutaneous model 
was established and validated, with good engraftment rate and growth rate to allow us perform 
drug testing in the core experiments. 
 
Figure 5.12: 4th generation subcutaneous model over 8 weeks post-transplantation 
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Figure 5.13: 4th generation subcutaneous xenografts models at end-of-study 
 
Figure 5.14: Histology comparison over 4 generations of xenografts tumour 
 
5.3.4  Drug testing using subcutaneous model 
The observation that the 4th generation tumour was more de-differentiated than xenografts 
from previous generations was somewhat beyond expectation, but it provided confidence of 
the utility of the 5th generation xenografts in the core subcutaneous model. The bulky tumour 
shown from Figure 5.11 was dissected, and subcutaneous transplantation was performed on 
17 mice simultaneously. The engraftment rate was 78%. This highly selected tumour was 
much more aggressive than the one in the pilot study, resulting in measurable tumours of an 
average 100mm3 for nearly all animals only 4 weeks after transplantation. This was set as the 
baseline before treatment randomisation (control, E50, Y25 and E50Y25) (Figure 5.15), All 
animals had fur reshaved as this point, and tumours were measured with calipers weekly in 
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the first 14 days and twice weekly thereafter. Overall the next 4 weeks of treatment, the tumour 
of mice receiving control treatment continued to grow exponentially (3000 mm3 at 4 weeks). 
The tumours in animals receiving single agent treatment also grew in size – with BYL (1400 
mm3) much less effective than ERL (500 mm3 at 4 weeks), as expected from the low single 
agent efficacy for PI3Ki. The tumours in animals treated with CB did not grow (still 100 mm3 
at 4 weeks) (Figure 5.15). Multiple regression statistics showed significantly different trends 
between each treatment (Table 5.5, A). The tumour doubling times for NT, Y25 and E50 were 
7.1, 8.4 and 14.8 days respectively, and not reached for E50Y25. Figure 5.16 showed the 
sizes of the tumours of mice two weeks into treatment. Mice on control treatment had very 
large tumours protruding from the skin with areas of necrosis and ulceration. Tumours on the 
Y25 mice were slightly smaller, and on the E50 mice were smaller still. In all 4 mice treated 
with CB, the tumours were as small as before treatment, and in 1 of 4 mice there was a 
complete response where the tumour completely disappeared.  
 
Figure 5.15: Tumour volumes over experiment time of core subcutaneous experiment 
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Table 5.5: (A) TREND statistics at multiple measurements and (B) ANOVA statistics of LOG 
tumour volume at necropsy between control, E50, Y25 and E50Y25 in the core subcutaneous 
study  
 
Figure 5.16: Representative of photos of animals treated with 4 treatment arms after 2 weeks in 
core subcutaneous study 
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In their weeks 8-12 of life during treatment, it was expected that mice would increase their 
body weight approximately 1 g per week.352 In the control and SB treatment arm, the body 
weight of mice did not change. This was because the tumours had grown in size and weight, 
whilst the animals were observed to become more cachectic. The body weight of mice treated 
with CB paradoxically decreased, about 3g over 4 weeks (Figure 5.17). There could be 
several reasons to this. These mice were fed 300 uL of drug solution each day, more than 
other mice, and this could result in lesser food intake. In 1 or 2 mice there was some 
intermittent mild diarrhoea from the CB treatment which could have resulted in dehydration. 
Also, the xenograft tumours did not grow, and did not contribute to increase in weight. In any 
case, where mice of the other 3 treatments were more hunched, slower and had lost their 
natural shine; the animals treated with CB were certainly much healthier despite loss of weight. 
1 mouse treated with E50 died at day 24, without any obvious source of sepsis. This mouse 
had a 15% weight loss before it died, and it was concluded that it died from cancer 
complications.  
Figure 5.17: Animal weight over experiment time of core subcutaneous study 
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At necropsy, the subcutaneous tumour sizes on dissection corresponded to the measurement 
by external examination. The tumours were very large in control, still big in Y25, smaller in 
E50, and the smallest with E50Y25. In addition, the tumours on control treatment and SB were 
hyper-vascular and solid, compared to the small pale necrotic tumour in mice treated with 
E50Y25 (Figure 5.18), The end-of-study tumour volume of tumours in the 4 treatment arms 
were analysed further with ANOVA after log transformation, to evaluate if this supported the 
statistical findings in the sub-renal model. The statistics in table 5.5 (B) had to be presented 
in log transformed values because of the vast differences in volumes between control (3000 
mm3) with E50Y25 (100 mm3) as described earlier. In this small study of 17 mice, animals 
treated with SB alone had no significant reduction in tumour size than NT (E50: P=0.24, Y25: 
P=0.49). Yet, despite this small study, animals treated with E50Y25 had significantly smaller 
tumours than control (P=0.003), E50 (P=0.014) and Y25 (P=0.003). 
 
Figure 5.18: Representative end-of-study photos of animals treated with 4 treatment arms in 
core subcutaneous study 
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The objective of the core subcutaneous model was thus achieved; the superiority of 
CB over control was validated in the sub-renal model, and demonstrated its superiority 
over even SB alone.  Further study of this model was deemed unnecessary and not indicated, 
given the highly significant results, the number of animals needed to sacrifice for serial 
passaging (15-20), and the distress caused by the highly selective and invasive tumour on 
these animals. 
 
5.4   In-vivo Sub-studies 
Given the theme of this thesis on erlotinib resistance and PI3K/Akt driving mechanism in 
PDAC, it was desirable to study these topics further in-vivo. These were attempted, basing 
the study design from previously reported models. There are, however, specific challenges 
associated with developing in-vivo resistant model and in-vivo study of PI3K/Akt markers. In 
particular, the statistical power required to draw definitive conclusion in-vivo is too large to be 
accomplished through in-vivo study alone, and is best studied in clinical trials. Whilst proposals 
for these will be explored further in chapter 6 ongoing studies, the preliminary in-vivo results 
for erlotinib resistant model and PI3K/Akt/mTOR biomarkers are presented here. 
 
5.4.1  Biomarkers in erlotinib insensitive and resistant tumour 
In-vivo, there are many ways to study biomarkers of the PI3K/Akt/mTOR pathway, including 
phosphorprotein array, western blotting, immunohistochemistry, qRT-PCR, and fluorescence 
in situ hybridization (FISH).353-355 However, in clinical practice biomarker assay methods are 
much more limited. For example, the routine testing of standard biomarkers EGFR, K-Ras, B-
raf mutations and HER2 amplification are essentially limited to slide-based IHC, FISH and 
qRT-PCR methodologies due to their convenience and reproducibility.356-358 To complicate 
matters further, bringing biomarkers from bench top to bedside has been hampered by the 
exceedingly complex biology and roadmap of PI3K/Akt/mTOR. A large number of genes 
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including PIK3CA, PTEN, PDK1, AKT1,2,3, TSC1,2, mTOR, Rheb genes; as well as PTEN, 
PIK3CA, pAkt and pS6 proteins have been implicated as key potential biomarkers of this 
pathway. Aside from these, mRNA and epigenetics may also be involved.359,360 There is 
currently no consensus of the approach of development of these novel biomarkers.359  
The objective in this in-vivo sub-study was to study key molecular differences between animals 
that had good and poor response to erlotinib (that is, erlotinib insensitivity); as well as between 
erlotinib resistant and primary tumour (erlotinib resistance). For erlotinib insensitivity, this 
study was underpowered. Due to the study design using patient-derived xenografts, only 6 
primary tumours were used in sub-renal transplantation and subsequently studied of 90 
animals in the core study. From discussion with biostatistician, at least 15 primary tumours (or 
225 mice) would be required to show statistical significance. For erlotinib resistance, the 
preliminary experiments were unfortunately unsuccessful (Sub-section 5.4.2). The 
development of further resistant tumours was limited by the expense of continued supply of 
the drug and the lack of tumour monitoring by imaging. It was therefore impossible for any 
statistically meaningful conclusions to be drawn from this study. 
Here the preliminary findings of this sub-study focusing on the PI3K/Akt pathway is reported; 
but due to the lack of statistical power, this could only serve as a proof of principle. In chapter 
6 the clinical trial proposal to answer this research question definitively will be discussed. 
5.4.1.1  Study of AKT/ pAkt and EGFR/ pEGFR in Erlotinib insensitivity 
From the in-vitro studies, a consistent correlation of phosphorylated Akt and S6 protein to 
erlotinib resistance was found. From the gene expression point of view, downstream gene 
signals including NF-B1A and c-fos were found up-regulated in PCR array. However, none 
of the aforementioned biomarkers were found to be correlated to erlotinib resistance except 
for AKT-2, which was only modestly up-regulated (sub-section 3.5.6). Whilst the focus had 
been immunofluorescence and western blotting for the assessment of the total and 
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phosphorylated proteins in-vitro, these methods are operator-dependent, inconvenient and 
not always reproducible. They are also not standard methods for ongoing human studies. IHC, 
on the other hand, is a common and standard way of evaluating molecular markers, and is 
highly reproducible. A variety of stains including p/EGFR, p/AKT, p/S6, SMAD4, vimentin and 
FAP was used, in consultation with a senior pathologist. Like in immunofluorescence, S6 and 
pS6 antibodies were inconsistent in IHC. For other stains, no consistent patterns were found 
except for p/EGFR and p/Akt. The results for these markers will be presented here. 
Based on previous studies, AKT/ EGFR and pAkt/ pEGFR primary antibodies were tested at 
dilutions of 1:200-800 and 1:50-200 respectively.54,354 After optimisation, the best dilution for 
all 4 markers was chosen to be 1:150. The results of p/EGFR were illustrated already in figure 
5.10. For p/Akt, The original tumours (pre-graft) of experiments E11 and E15 were first stained 
(Figure 5.19). IHC for AKT was not useful because of the abundance of tissue AKT and the 
non-specific staining pattern of cancer versus normal tissues. Similar to other publications, 
abundant total AKT was found in both tumour and the adjacent normal tissues,361 and there 
were no differences in total AKT expression between E11 and E15 pre-grafts. Phosphorylated 
Akt, on the other hand, had more specific staining pattern in tumour tissue. Of interest, the 
tumour with low erlotinib response (E11) tended to have higher pAkt than tumour with higher 
response (E15). 
Currently, there is no standard of biomarker cut-offs for AKT and pAkt. Various research 
groups attempted to categorise IHC scoring, using a composite score called the H- score. 
360,362 This equals to percentage of positive cells (PP) by staining intensity (SI) on a high-power 
field: SI was scored 0 = negative, 1 = weak, 2 = moderate, and 3 = strong. The H-score value 
ranges from 0 to 300%; and a H-score more than 50% is considered positive. Based on the 
IHC scoring system, the pAkt H-score was 110% (/300%) for the low erlotinib response E11 
and 13% (/300%) for the high erlotinib response E15. This suggests that basal or pre-
treatment AKT activity (pAkt), but not total AKT, appeared to be associated with erlotinib 
insensitivity. This is in concordance in the in-vitro study results. 
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Figure 5.19: AKT and pAkt IHC on erlotinib-sensitive and less sensitive tumour (pre-graft) 
pAkt and pEGFR were then examined in the primary tumours and correlated with tumor 
responses for each of the 6 xenograft experiments (Figure 5.20). By RECIST 1.1,363 partial 
response was observed in only 2 of the 6 experiments with erlotinib alone, but was observed 
in all 6 experiments with E50Y25, with the highest tumour response observed in experiment 9 
(E9) (-66%) (Figure 5.20). pEGFR was scored 2+ and 3+ in E9 and E15, whilst pAkt was 
scored 2+ and 3+ in the primary tumours of E19 and E11 respectively (Figure 5.21). Of 
interest, E9 and E15 were among the experiments with the highest magnitude of response to 
both SB and CB, whereas E11 and E19 were among the lowest responses. That said, E11 
and E19 showed equivocal tumour responses (stable disease) with erlotinib alone (-3% and -
9%), but partial responses with the CB (-32% and -38%). The differential responses to SB and 
CB for these two experiments were among the highest with an absolute difference of 29% in 
both cases (Figure 5.20). This study therefore suggests the roles of pEGFR as positive and 
pAkt as negative predictive biomarkers for erlotinib SB or erlotinib plus BYL CB. This supports 
the concept that Akt over-expression as a negative prognostic factor,54 as well as a negative 
predictive factor for single blockade of EGFR.132 Importantly, despite pAkt being a negative 
predictive factor of erlotinib, this can still be overcome by EGFR-PI3K co-inhibition.  
333 
 
 
Figure 5.20: Tumour responses to SB and CB by RECIST 1.1 
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Figure 5.21: pEGFR and pAkt staining for all 6 experiments 
To study the downstream effects of in-vivo drug inhibition further, two experiments were 
stained and stained the end-of-study tumour xenografts treated with control, E50 and E50Y25, 
with AKT and pAkt for 2 of the experiments. Total AKT IHC slide photos were not shown as 
these showed abundant staining similar to pre-grafts. For both E11 and E15, pAkt was 
different among tumours undergoing different treatments, even though they originated from 
the same pre-grafts. This suggested that pAkt staining pattern was affected by residual 
treatment effect. All mice were off-treatment for at least 3 days before necropsy, but since the 
half-life of erlotinib was 36 hours, it was likely that the treatment still exerted some systemic 
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effect at necropsy. In both high-response and low-response experiments, the pAkt activity was 
increased for tumours undergoing SB (E50), but decreased for tumours undergoing CB 
(E50Y25) (Figure 5.22). The pAkt H-scores were 12% (NT), 33% (E50) and 1% (E50Y25) for 
E11; and 19% (NT), 35% (E50) and 11% (E50Y25) for E15. This preliminary experiment 
suggests that erlotinib alone increases pAkt, possibly similar to the oncogenic shift mechanism 
observed in in vitro studies, but that CB reduces pAkt expression. Importantly, the experiment 
that showed low response to erlotinib had the complete disappearing of pAkt signal with CB, 
supporting the concept of PI3K/Akt oncogenic dependence. 
 
 
Figure 5.22: pAkt IHC response on erlotinib-sensitive and less sensitive tumours 
 
In conclusion, there is suggestion that tumours that have up-regulated pAkt confer resistance 
to single agent erlotinib, whereas up-regulated pEGFR conversely confers sensitivity. 
Regardless, there was an improved response rate observed for CB versus SB in all 
experiments. Interestingly, there were substantial differences in the magnitude of response for 
the two experiments with strong pAkt staining, suggesting that CB could overcome this 
negative predictive marker. From another point of view, pAkt could therefore act as a 
differential biomarker for CB treatment selection over SB. 
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5.4.2  In-vivo Erlotinib Resistant Model 
The study design for this sub-study was based on a research paper on developing an erlotinib 
resistant orthotopic lung cancer murine model.364 In this study, the authors produced 
transgenic mice models using using vectors transfection or transgene insertion (EGFR, K-Ras 
mutation, P53 loss), and treated a total of 13 mice with several treatment regime of erlotinib 
25 mg/kg/day 5 days a week. They examined continuous versus intermittent protocol, the use 
of doxycycline to ensure continued expression of transgene, and treatment from 5 to 8 months. 
To confirm the presence of lung tumour and to monitor tumour growth, they used MRI on the 
mice every 4 weeks. The authors found that the intermittent protocol supplemented by 
doxycycline on “off-treatment” period was the best strategy, with most apparent tumour growth 
from 4 months onwards. 
One major hurdle in developing the erlotinib resistant model was the inadequate imaging 
modality for monitoring tumour growth in our animal house facility. Based on the group’s 
experiences and results with both subcutaneous and sub-renal models, sub-renal model with 
the higher engraftment and growth rates was chosen for development of erlotinib resistant 
moddue to its high vascularity. Whilst tumours that were passaged a number of generations 
would be aggressive enough to be palpable even as sub-renal xenografts, the concept of 
developing a drug resistant model was to simulate the human environment as closely as 
possible, and in this sense only first-generation xenografts should be employed. Thus, the 
only way to monitor tumour growth internally was to perform regular imaging as the previous 
study described. 
Unfortunately, the animal house was not equipped with a PET or MRI imaging facility. Whilst 
our group has affiliations with CSIRO and a number of nuclear medicine physicians, the rule 
from our animal house is that animals once taken outside cannot be brought back to the facility. 
Our animal house was equipped with the Carestream in-vivo MS FX PRO (Carestream, 
Toronto), a multispectral fluorescent, luminescent and radioisotopic high-resolution x-ray 
system which are increasingly used in in-vivo studies.365,366 A fluorescent dye (DID) was used, 
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and multiple attemps were made to optimise conditions for the best imaging results. Briefly, 
varying concentration of the dye, varying times of tail injection and imaging (4, 24, 48 hours) 
was explored, and both in-vivo and ex-vivo studies undertaken. A multimodality animal rotation 
system was utilised to generate 3-dimensional pictures.  
Below showed a montage of x-ray images taken 48 hours after injection of DID dye on 3 mice 
that had sub-renal tumours xenografted 8 weeks prior. On necropsy, all 3 mice had viable 
tumours. In 1 of the 3 mice, the tumour was localised well (white arrow) where it was 
transplanted, but this did not display on the other 2 mice (Figure 5.23). Thus, although the 
carestream imaging system was specific in tumour localisation, the sensitivity rate was too low 
to be used for routine tumour monitoring in the erlotinib resistant model. Attempts are made 
to combine DID dye with over-expressed proteins in pancreatic cancer, and this is a current 
subject of another student’s PhD.  
 
 
Figure 5.23: Carestream imaging for tumour localisation 
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Due to the uncertainty of current imaging for tumour monitoring, and the drug expense for 
long-term animal feeding of erlotinib, a pilot study of only 3 animals was performed, where 
sub-renal transplantation was used for two mice (M1, M3); and subcutaneous approach was 
used in another (M2) (Figure 5.24). The mice were allowed to grow for 8 weeks (sub-renal) 
and 12 weeks (subcutaneous) respectively before starting erlotinib treatment. M1 was treated 
with erlotinib 25 mg/kg/day, and M2 and M3 treated with 50 mg/kg/day. An on-off schedule 
was implemented as recommended to allow for tumour regrowth.364 For M1 and M2 
Doxycycline was supplemented with food in the off-treatment period. This was used to ensure 
expression of the transgene.364 M1 and M2 had a 4-week-on 4-week-off schedule, whereas 
M3 had a 4-week-on 2-week off schedule.  
 
Figure 5.24: Erlotinib resistant xenograft models- study design 
M2 was a mouse that had subcutaneous transplantation of xenografts. The tumour did not 
grow and was not present when the study was terminated at 3 months. The tumour did grow 
in M1 and M3, but M1 unexpectedly died at 2 months. It was on its treatment-off period, and 
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no other interventions were given at the time except for doxycycline. No sources of sepsis 
were found on the animal at autopsy. Doxycycline was not gavaged in mice, and was merely 
supplemented in the water. It was possible that by chance the mouse drank excessive water 
supplemented doxycycline and became overdosed. M3 was different to the other 2 mice where 
doxycycline was not given, and only a 2-week treatment-off period was allowed. The tumour 
on this mouse was palpable by 3 months, with ulcerations by 4 months. This tumour was 
removed upon necropsy 3 days after stopping treatment and fixed for histopathological 
diagnosis. Unfortunately, there were extensive necrosis but no viable tumours were identified 
in M3 (Figure 5.24). 
All in all, development of in-vivo model was not successful. It was limited by the absence of 
tumour imaging for monitoring, the lack of continued supply of the erlotinib targeted therapy 
and the underpowered statistics. Overall it was deemed too high a risk and costs to continue 
undertaking this sub-study in animal experiments. Instead plans are made to study this in the 
setting of a clinical trial. 
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5.5   Discussion 
Following the success of combined blockade in-vitro in pancreatic cancer in chapter 4, this 
was further evaluated in-vivo in this chapter. The objectives here were to develop and validate 
an animal model for drug testing, and then to use this to evaluate a number of CB 
combinations. Other sub-objectives of the in-vivo study were to develop an erlotinib resistant 
animal model and to assess for candidate predictive biomarker/s for erlotinib resistance and 
for CB combination. A full assessment would not be possible for this thesis, and thus these 
were only intended as preliminary assessments (sub-studies) foreshadowing larger clinical 
confirmatory trials, to be discussed in chapter 6. 
5.5.1  Patient derived tumour tissue model (PDTX) 
Patient derived tumour xenograft (PDTX) model is more demanding and requires close 
collaboration between surgeons, pathologists and scientists to ensure immediate 
transplantation of fresh viable tumour tissue into immunocompromised mice. However, there 
are many advantages of over traditional cell line in vivo model. Cell line in vivo models have 
long been criticised for not “sufficiently representing clinical cancer characteristics, especially 
with regard to metastasis and drug sensitivity”.339 PDTX model, on the other hand, better 
reflects human tumour biology, can be transplanted in various modes, and through 
generations of passaging provides a virtually unlimited source of tumour tissue for therapeutic 
testing.339 Whilst not perfect or standard by any means compared to patient study, PDTX 
models have significant roles in drug sensitivity screening, biomarker developments, and can 
also produce useful pharmacokinetic/ dynamic and resistance models (Figure 5.25, 
5.26)367,368. In this project, a close resemblance of PDTX to patient histology was found, and 
sufficient tissue were generated to evaluate drug testing in vivo as well as attempt at biomarker 
discovery and generation of a drug resistance model. 
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Figure 5.25: Characteristic of PDTX model 
 
Figure 5.26: Uses of PDTX model in drug development. Courtesy of Tentler et al. 2012.367 
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5.5.2  Sub-renal versus subcutaneous transplantation models 
Two models were used to evaluate drug efficacy in this project: sub-renal and subcutaneous 
models. Orthotopic models had also been considered, but xenograft transplantation directly 
into the pancreas of small mice only 30g in weight proved exceedingly difficult. The pros and 
cons for the sub-renal and subcutaneous models are listed below: 
 
Table 5.6: Comparison between sub-renal and subcutaneous models for our in-vivo studies. ^ 
Engraftment rate improved to 80%, and * growth rate improved to 8 weeks with 4-5 passages of 
first generation primary tumour 
 
There were several reasons for choosing both models: sub-renal was an efficient and cost-
effective model. Due to the high vascularity in the sub-renal capsule, the engraftment and 
growth rates were consistently high, and robust statistics could be calculated. However, only 
one measurement could be used in the absence of adequate imaging: the end-of-study 
measurement of tumour volume. Subcutaneous model, on the other hand, allowed multiple 
measurements of tumour by calipers once established. This allowed for tumour doubling time 
and growth trend statistics to be calculated.273 However, it required several generations of 
tumour passaging to establish a stable engraftment and growth rate. Even then, the 
engraftment rate was inferior to that of sub-renal model. This resulted in missing values, and 
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the statistical power was thus relatively lower for the same number of mice to be used. As our 
group constantly sought to comply with the NHMRC code of practice for minimisation and 
refinement of animal studies, the sub-renal model was chosen as the primary model based on 
the smaller number of animals required, and subcutaneous model as a supportive method. 
 
5.5.3  Combined blockade efficacy in-vivo 
Table 5.7 below summarised the sample sizes and statistical findings of the sub-renal and 
subcutaneous experiments. The P-values were calculated by 2-way ANOVA after adjusting 
for each experiment (SAS 9.2). Both erlotinib plus BEZ-235 and erlotinib plus BYL-719 CBs 
were tested, but the former was abandoned due to high levels of toxicity, which was also 
reported by other research groups in our institution. Possibly due to premature study 
termination, no significant differences were observed between E50B25, E50 and NT. The pilot 
study for the latter CB (E50Y25) was also not significantly different to E50 and NT; but the 
magnitude of difference was greater than that between E50 and NT. This pilot study therefore 
showed some early signs of efficacy, and provided the effect estimate that was used to 
calculate the true sample size for an adequately powered study. After 6 experiments with 90 
animals, the sub-renal core study achieved its objective by showing superiority over control 
(P=0.0005) and non-inferiority over gemcitabine (P=0.54). A subsequent follow-up 
subcutaneous study not only confirmed superiority of E50Y25 over NT (P=0.003), but also 
superiority over E50 (P=0.014) and Y50 (P=0.003). CB essentially halted tumour growth, such 
that the tumour doubling time was not reached in CB. Interestingly, BYL was not as effective 
as ERL as single agent, echoing current literature that these drugs are best used in 
combination with other targeted therapies for continuing clinical development.47  
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Table 5.7: Summary of P-values from ANOVA statistics of sub-renal and subcutaneous 
experiments. * based on end-of-study measurement. ^part of a larger study that established our 
current sub-renal model 
 
There is now therefore sufficient pre-clinical evidence (both in-vitro and in-vivo) to take the 
concept of combined blockade with erlotinib plus PI3K inhibitor NVP-BYL719 to clinical trials. 
The abbreviated findings of this combination were presented in a National meeting 
(Australasian Pancreatic Club 2013) and now published (CCR. 2014), and the proposal for 
clinical trials submitted to the two respective pharamaceutical for global evaluation. I believe 
that co-targeting MEK and PI3K warrants further evaluation given its strong in-vitro data and 
emerging clinical profile in other cancer types.207 One approach for further in-vivo and clinical 
development may be combining a novel MEK inhibitor such as AZD-6244 with BYL-719 in the 
future. 
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5.5.4  Biomarkers for erlotinib resistance and CB response 
Current literature implicates Akt over-activation and K-Ras mutation as negative prognostic 
markers,44,54 and quasi-mesenchymal status as negative predictive markers for erlotinib 
treatment.212 In chapter 3 and 4, erlotinib resistance is shown to be associated with up-
regulation of PI3K/Akt pathway via mTOR. This in-vivo study, though by no means definitive, 
suggests the roles of pEGFR as positive and pAkt as negative predictive biomarkers for 
erlotinib SB or erlotinib plus BYL CB. This is consistent with the current PDAC literature since 
mutant K-Ras still employs EGFR to some extent, and it is also shown to increase GSK-3 of 
the PI3K/Akt system contributing to tumor cell proliferation and survival.65,212 Although tumours 
with high pAkt immunostaining were correlated with lower response to CB compared to 
experiments with primary tumours expressing 0/1+ pAkt, partial responses were nonetheless 
observed in CB whilst no response was evident in SB. Hence, pAkt may also have a differential 
role in guiding CB treatment over SB. Whilst preliminary results were supportive of current 
literature, the clinical development of these biomarkers remained challenging, and a number 
of ongoing issues must be addressed in ongoing studies:  
1)  Target selection: pEGFR and pAkt were chosen as the candidate biomarkers for response 
for erlotinib and BYL-719, given the previous in-vitro studies and that it is directly downstream 
of PI3K. However, EGFR and PI3K/Akt pathways are exceedingly complex and multiple 
targets may be involved. At present, no single gene or molecular target has been 
demonstrated to predict efficacy for PI3K inhibitors reliably in published literature, which may 
be because of co-existing alterations in this pathway.47 Whilst phospho-RTK or PCR array 
may be of some use in biomarker discovery, genome wide screening platform will likely be 
required to look for genetic signatures predicting the efficacy of this treatment in clinical 
studies.359 
2) Combined platforms: Current approaches to biomarker development are “one-
dimensional” relying on single modality assay such as IHC, FISH or mRNA profiling. Early 
346 
 
biomarker studies on the PAM inhibitors are unfortunately flawed by improper, inappropriate 
or insensitive assays.47 In the PI3K signalling pathway where multiple mechanisms may be 
dysregulated, an integrated approach with combined analysis of DNA, RNA, protein and 
epigenetics is recommended.359 For further development of pAkt or pEGFR as biomarkers, 
this target must be tested on other platforms to correlate gene, molecular levels with patient 
outcomes. 
3) Study Design: One of the most frequently overlooked aspects of biomarker study by 
researchers is statistical power. In particular, two common errors are seen: arbitrarily setting 
biomarker cut-offs, and performing multiple testing without adjustment.359 Current practice in 
IHC is to score staining patterns in a dichotomous covariate (0, 1+, 2+, 3+).369 However, it is 
increasingly recognised that biomarkers should be evaluated as a continuous outcome in 
multivariate analyses in research setting, rather than as a dichotomous outcome in univariate 
analysis. Studies that are inappropriately designed based on unadjusted dichotomous 
statistics are often underpowered, and resulted in false acceptance of insignificant biomarkers 
(type II error).359,369 This sub-study attempted to utilise H-score, developed by McCarty and 
modified by Allred,370 and validated in 137 breast cancer patients.360 H-scores have been 
evaluated in PDAC in the study of SGLT1, Bcl-2 and p53 as prognostic markers and hedgehog 
as predictive markers.371,372 Although currently not specifically validated in PAM pathway in 
PDAC, it should be optimised in ongoing studies. 
In conclusion, this chapter has succeeded in achieving the aims that were set out: to develop 
2 animal models for drug testing and establish the in-vivo efficacy for PI3K/ EGFR co-inhibition 
in pancreatic cancer. The findings of the last three chapters (3, 4, 5) have together put forward 
a strong case for clinical development of this combination in pancreatic cancer. Nonetheless, 
additional translational research is still urgently needed to develop “robust biomarkers for 
clinical decision making and for patient selection”.373 The implications of these results are 
discussed in the next chapter, and the study design for an ongoing clinical trial will also be 
presented. 
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CHAPTER 6: 
 
THESIS DISCUSSION 
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6.1  Summary of Thesis backgrounds 
6.1.1  Background of the thesis 
This thesis was planned in 2010 and undertaken from 2011 to 2013. At the time FOLFIRINOX 
and gemcitabine-abraxane data had not been published yet, and gemcitabine was the only 
standard of care for advanced or metastatic pancreatic cancer. The only positive phase III 
drug combination clinical trial was the PA.3 in 2007, demonstrating that gemcitabine plus 
EGFR inhibitor erlotinib improved survival compared to gemcitabine.108 At the time, the PA.3 
trial was strongly criticised for its limited clinical significance (improving survival of only 10 
days) despite its statistical significance. Our group identified the importance of combining 
targeted therapies and identifying biomarkers in pancreatic cancer, before the embarrassment 
of the riches in literature over the last 3-4 years. 
Until mid-2010, there was a high level of enthusiasm with IGF1R antibody in the treatment of 
cancer. IGF1R antibodies have nanomolar potency, long half-lives allowing for 3-weekly 
infusion and have relatively few side effects except for hyperglycemia.374 In addition, there 
was a strong rationale combining IGF1R antibodies with chemotherapy, and this strategy has 
been shown to have activity in NSCLC in phase I and early phase II studies.374 From 2008 to 
2010, there had been a series of pre-clinical studies demonstrating synergy of EGFR and 
IGF1R inhibitors in various cancers.86,375,376 Later, it was also shown that IGF1R antibodies 
plus chemotherapy were active even in gastrointestinal carcinomas with K-Ras mutation.377,378   
My interests in experimenting with IGF1R inhibitors stemmed from pre-clinical studies 
establishing the role of IGF1R over-expression in mediating proliferation, survival, 
angiogenesis and invasion in pancreatic cancer.379,380 One of our prior studies of EGFR, 
IGF1R and urokinase pathways in 46 pancreatic cancer specimens also found an importance 
of IGF system in tumour progression. In addition, it also demonstrated significant association 
between EGFR and IGF1R-related genes, suggesting extensive cross-talks between the 2 
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pathways.63 I therefore made a hypothesis that erlotinib insensitivity or resistance in pancreatic 
cancer may be overcome by adding IGF1R inhibitors to erlotinib. 
In 2010, I attended the Australia and Asian Pacific Clinical Oncology Research Development 
Workshop (ACORD), and designed and completed a 100-page phase II clinical trial protocol 
with the aim of randomising 42 patients to erlotinib or erlotinib plus IGF1R antibody CP-
751,871 (figitumumab). This was the first manufactured antibody, and was also the drug with 
the highest level of evidence. I also designed a translational component with our proposed 
study, with mandatory collection of tissue for gene and IHC analysis of IGF-related biomarkers. 
At the time, combined blockade strategy was not yet popularised, and the study design was 
therefore considered novel. The proposal was endorsed by the Australasian Gastro-Intestinal 
Trials Group (AGITG) and submitted to Pfizer for consideration.  
Unfortunately, in the American Society of Clinical Oncology (ASCO) meeting in mid-2010, a 
large international phase III clinical trial NSCLC (n=820) was stopped early after showing 
chemotherapy plus figitumumab resulted in significantly worse survival compared to 
chemotherapy alone (HR 1.6, P=0.006). Combination therapy resulted in serious adverse 
events including dehydration, hyperglycemia and haemoptysis, and no subgroups had been 
found to derive more benefits from combination therapy.176 Subsequent studies showed 
conflicting data of whether IGF-1 or IGF1R was predictive to IGF1R combination 
therapies.177,381 The significantly harmful findings of this study had essentially closed off further 
development of this class of agents in various companies over the next 2 years. My proposal 
of phase II trial was rejected in early 2011. I received figitumumab from Pfizer for pre-clinical 
studies, though the preliminary studies in-vitro also showed limited activity of this drug in 
pancreatic cancer. 
Due to these unforseen circumstances, I had to radically alter my PhD research project in 
early 2011. I performed a literature review, and found a number of interesting molecular 
biology facts of the EGFR and IGF1R pathways, including the role of downstream PI3K 
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pathways over-activation in cancer progression in pancreatic cancer, and cross-talks between 
downstream EGFR/ MAPK and PI3K pathways. These will be discussed further in the next 
section. In contrast to the comprehensive development program of IGF1R inhibitors, PI3K and 
PI3K/mTOR inhibitors drug development were very new at the time, and little clinical data of 
these drugs existed at the time. Despite several discussions with managing directors and 
international experts, I could not acquire the drugs or funding for a clinical trial without further 
pre-clinical evidence. I therefore changed from clinical trial and translational research to basic 
science research.  
Initially, we purchased our own drugs from manufacturing companies. Later, when I had 
established effects of these drugs, I requested BYL-719 and BEZ-235 from Novartis. In the 
first year of my research project, I explored the mechanisms of erlotinib resistance and initially 
tested drug combinations of IGF1R inhibitors (NVP-AEW541, OSI-906) or PI3K inhibitors 
(BYL-719) and erlotinib in-vitro (Chapter 3, part of chapter 4). In my second year, I 
progressively studied the synergy and effects of downstream blockade using 4 CB 
combinations (chapters 4), after demonstrating superior effect of PI3K inhibitors over IGF1R 
inhibitors. With the encouraging results, I requested Novartis for BYL-719 and BEZ-235 for in-
vivo testing, and carried out the in-vivo experiments between 2012 and 2013 (chapter 5).  
 
6.1.2  Summary of known facts and evidence  
The facts and evidence have been comprehensively described in Chapter 1: introduction. 
Below is a summary of known facts, and the research questions that arise. 
The hypotheses or research questions for the research project were based on a number of 
scientific facts. Mechanistically, PAM pathway is often over-expressed in PDAC. In contrast to 
NSCLC, EGFR mutations in pancreatic cancer are rare and typically silent, and EGFR tyrosine 
kinase activity is highly conserved.58,213 Whilst EGFR gene may be up-regulated in 50%, EGFR 
protein is only over-expressed in 30% of PDAC.213,382 On the other hand, IGF1R, PI3K and 
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Akt proteins are found to be over-expressed in 50%, 70% and 50% by IHC.61 Cross-talks 
between EGFR and IGF1R are known to exist for various cancer types.86 In PDAC, significant 
cross-talks also exist between downstream signalling pathways. For example, oncogenic 
activation of Ras has been demonstrated to increase PI3K and GSK3 beta (downstream of 
Akt),65,68 and the Ras-induced PI3K/ mTOR signal transduction is shown to be sufficient to 
lead to tumourigenesis in pancreatic cancer.80 Since K-Ras mutation is highly prevalent in 
PDAC,20 and K-Ras mutation is associated with EGFR antibody resistance at least in 
colorectal cancer,137,305 the obvious question is whether erlotinib resistance in PDAC is also 
mediated by over-activation of PAM pathway, possibly by K-Ras. 
Therapeutically, there are to date no current clinical data of PI3K inhibitors in pancreatic 
cancer. Two clinical trials exist exploring the effect of erlotinib and EGFR antibody cetuximab. 
The marginal benefits of erlotinib in improvement of overall survival have already been 
described numerous times in this thesis. Yet, it is important to note the disease control rate 
(58%) and improvement in PFS (HR 0.77, P=0.0004) exceeded that may be expected from 
an absolute survival benefit of 10 days.108 This same pattern was also noted in another 
targeted therapy trial randomising patients to gemcitabine plus cetuximab versus gemcitabine 
alone, yielding a disease control rate of 51% and highly significant improvement in PFS 
(P=0.006).124 Despite the effect of EGFR inhibition in disease stabilisation and delay in 
progression the absolute benefit in survival is small. Given the extensive molecular cross-talk 
in pancreatic cancer, the therapeutic question proposed is whether dual targeting of EGFR 
and IGF1R or PI3K may be more effective than EGFR inhibition alone. 
Translational data based on clinical trials is extensive in metastatic NSCLC and CRC. EGFR 
mutation and K-Ras wild type have long been established and now adopted in clinical practice, 
as predictive factors for EGFR inhibitors and EGFR antibodies.137,138,144,145 Biomarkers for the 
use of erlotinib have not been fully established in PDAC however, with K-Ras mutation status 
implicated in one study but not the other.121,213 One of the research questions was to explore 
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predictive biomarkers for sensitivity to SB versus CB. Given the limitation in statistical power 
in in vivo study design, the aim here is proof of concept to take to clinical translational study. 
Mechanistic Therapeutic Translational 
Summary of known facts 
EGFR is over-expressed in 
30% of PDAC61 
Gem+ Erlotinib  > Gem in 
overall survival (HR 0.82, 
P=0.038) (PA.3) 
In mNSCLC, EGFR mutation was 
predictive of EGFR TKI 
response144,145 
K-Ras is mutated in 90% of 
PDAC20 
The absolute benefits was 
only 10 days (PA.3) 
In mCRC, K-Ras wild type was 
predictive of EGFR antibody 
response137,138 
PI3K and Akt are over-
expressed in 70% and 50% 
respectively48,54 
Gem + Erlotinib > Gem in PFS 
(HR 0.77, P=0.0004) (PA.3) 
K-Ras may be negative predictive for 
erlotinib response in PDAC121 
Multiple levels of interactions 
exist (EGFR/IGF1R, K-Ras/ 
PI3K)68  
Disease control rate with dual 
agent =58% (PA.3)108 
Only positive predictive “marker” for 
erlotinib appeared to be grade 2-3 
rash (PA.3)108  
Research Questions arisen  
What is/ are the key driver/s 
for erlotinib resistance? (Ch 3) 
Can combined blockade 
strategy increase efficacy of 
targeted treatment (Ch 4, 5) 
Can a marker be identified for dual 
targeted therapy strategy? (Ch 5, 6) 
Table 6.1: Summary of known facts and research questions  
 
6.1.3  Summary of aims and methods 
The chapters and chapter aims are summarised below. Chapter 3 and 4 are in-vitro studies 
and chapter 5 continues onto in-vivo studies. Chapter 3 aims to characterise the genetic and 
molecular profile or primary and acquired resistance by means of 5 PDAC cell lines and 2 
pairs of parent and ER cell lines. Chapter 4 aims to compare CB versus SB, and to test the 
best of 4 upstream/ downstream CB combinations. Chapter 5 aims to take the two best CB 
combinations into animal studies, after establishing and validating a xenograft model. Note 
that the translational sub-studies (e.g. pAkt/ AKT and in-vivo resistance model) were not 
included in part of the chapter 5 aims. These preliminary studies were only meant to 
demonstrate feasibility but could not be definitively studied in-vivo. 
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Table 6.2: Summary of chapters and chapter aims  
The summarised methods were illustrated below. This was divided into initial stages, testing 
stages and validation stages. Ongoing experiments will comprise of clinical and translational 
stages (Figure 6.1). 
 
Figure 6.1: Summary of Methods in the Research Program 
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Briefly, in the initial stage, 5 PDAC cell lines which differ in their sensitivity to erlotinib were 
used. The most erlotinib sensitive (BxPC-3) and insensitive (PANC-1) were used to develop 
2 erlotinib resistant cell lines (BxPC-ER, PANC-ER). Phospho-RTK and PCR arrays were 
used on the 2 pairs of parent and ER cell lines to compare their molecular and genetic 
differences that attributed to erlotinib resistance (acquired resistance). qRT-PCR, western 
blotting (WB) and immunofluorescence (IF) were used to study the EGFR, IGF1R and 
MAPK/PAM pathways that attributed to erlotinib insensitivity (primary resistance) in the 5 
PDAC cell lines, as well as to validate the screening array results. After demonstrating stability 
of erlotinib resistance, the differences between each pair of cell lines were assessed based 
on the status of erlotinib resistance only, thus making it a powerful model. 
In the CB testing stage, 4 CB combinations were used (EGFR/ IGF1R, EGFR/ PI3K, EGFR/ 
PI3K/mTOR, MEK/PI3K/mTOR) and compared these to single agents that made up the CB. 
6 in-vitro assays (cell proliferation assays, confluence/ incucyte study, clogenic assays, 
apoptosis assays, cell cycle assays, wound healing/ migration study) were used to study 3 
cellular functions- cell proliferation, cell function and migration. These are particularly 
important functions in tumour progression and metastasis. Both synergy and efficacy of these 
drugs were studied. These experiments allowed us to fully assess the effects of CB, and to 
interrogate the roles of upstream and downstream MAPK and PAM pathways in PDAC.  
The in-vivo studies were regarded as the validation stage. Due to the expense and complexity 
of in-vivo experiments, it was not possible to test all 4 CB combinations in animal study. Two 
models (sub-renal, subcutaneous) were used to evaluate two best CBs (ERL+ BYL, ERL+ 
BEZ), and studied the primary endpoint of tumour volumes and secondary endpoints of kidney 
weight, H&E and IHC (Ki-67). The sample sizes were based on a 2-sided  of 0.05,  of 0.8 
and an expected 36% decrease in tumour volumes by CB from pilot study. The objectives 
were to demonstrate superiority of CB over control and non-inferiority (or equivalence) to 
standard gemcitabine chemotherapy. 
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The thesis currently ends with the validation stage, having confirmed the efficacy, safety and 
dosing of erlotinib plus BYL-719 CB pre-clinically. The next phase will be clinical and 
translational stages in a first-in-man phase I/ II trial. The concept has been submitted to 
Novartis for further review, and the proposal was presented in the AGITG/ Australasian 
Pancreatic Club Workshop (Oct 2013). This will be discussed further in section 6.3. 
 
6.2  Results and Clinical significance 
Whilst the results and discussion have been described at the end of each chapter, the 
pertinent findings and the significance or implications for the thesis as a whole are presented 
here. The research project combines mechanistic, therapeutic and translational findings to 
answer the research question, and is illustrated in the same way as the background facts. 
Mechanistic Therapeutic Translational 
Results 
Downstream pathways 
are up-regulated in 
erlotinib insensitivity 
In-vitro, dual PI3K/mTOR 
and MEK blockade was 
most effective 
In-vitro, pAkt up-regulation 
predicts EGFR/ PI3K/ mTOR CB 
efficacy 
PI3K/Akt via mTOR is 
“exploited” in erlotinib 
resistance 
In-vivo, dual PI3K/mTOR 
and EGFR blockade was 
too toxic 
In-vitro, oncogenic dependence to 
pAkt is demonstrated in erlotinib 
resistance 
NF-kb and Fos genes 
over-expression are 
implicated in erlotinib 
resistance 
In-vivo, dual PI3K and 
EGFR blockade was 
superior to control and 
equivalent to gemcitabine 
chemotherapy 
ER cell lines were hyper-sensitive 
to PI3K-based CB 
Erlotinib insensitivity 
and resistance are 
likely associated with 
EMT 
In-vivo, CB appeared more 
cytotoxic ( tumour vol, ↑ 
cleaved caspase-3 ) than 
cytostatic ( Ki67) 
In-vivo, preliminary results showed 
pEGFR to be positive predictive  and 
pAkt as negative predictive; pAkt 
may act as differentiating biomarker 
of CB over SB 
Significance 
Significant cross-talks 
exist between MAPK 
and PI3K/Akt 
pathways in PDAC 
Combination strategy, e.g. 
Erlotinib plus BYL-719, 
should be evaluated in 
PDAC in clinical trial 
pAkt and pEGFR may be  
candidate predictive biomarkers, 
and should be further evaluated in 
translational study 
Table 6.3: Summary of chapters results and significance 
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6.2.1  Mechanisms of erlotinib resistance 
6.2.1.1  Mechanisms of primary erlotinib resistance  
Primary erlotinib resistance is associated with increased expression of downstream pathways, 
in PI3K/Akt (CAPAN-2, PANC-1) more so than MAPK (ERK) (MiaPACA-2) in PDAC cell lines. 
There also appears to be significant interaction between the EGFR/ ERK and IGF1R/PI3K 
(sub-section 3.4.3, 3.4.4). This is demonstrated by activation of downstream Akt and ERK by 
either EGF or IGF stimulation, and paradoxical increases in pAkt in response to erlotinib, and 
pERK in response to AEW in PANC-1. When a stressor is applied to one downstream 
pathway, cancer cells can rapidly switch to an escape route, a process that has been termed 
“oncogenic shift”.132  There is a trend of MAPK1, PIK3CA and AKT-2 gene up-regulation in 
concordance to molecular over-activation in erlotinib insensitive cell lines (table 3.8). Vimentin 
is also implicated in primary erlotinib resistance, being expressed in all 3 erlotinib-insensitive 
cell lines CAPAN-2, MiaPACA-2 and PANC-1, though only MiaPACA-2 is truly mesenchymal 
in morphology (sub-section 3.4.2).  
6.2.1.2  Mechanisms of acquired erlotinib resistance  
For acquired erlotinib resistance, there appear to be at least three mechanisms at play. Firstly, 
as demonstrated by phospho-RTK screening array and validated by western blotting and 
immunofluorescence, erlotinib resistance is associated with further exploitation of PI3K/Akt 
pathway, mediating via mTOR (sub-sections 3.5.2-3.5.4). This shift to the dominant PAM 
pathway may enable cancer cells to escape the EGFR blockade by erlotinib. Secondly, ER 
cell lines also activate the downstream ERK pathway, though not as strongly as PI3K/Akt 
(sub-sections 3.5.3-3.5.4). This would explain why PANC-ER showed especially high levels 
of cross-resistance to MEK inhibition, upstream of ERK (table 3.3). Finally, both ER cell lines 
had likely undergone EMT into mesenchymal morphology, and characterised by a significant 
increase in vimentin expression (sub-section 3.5.1). EMT results in decreased cell-cell 
adherence, increased motility, invasiveness and anchorage-independent survival.160 This is 
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particularly important as PI3K/Akt axis activation is emerging as a central player in EMT.383 
These observed mechanisms are likely related and together they confer a survival advantage 
for acquired ER cell lines when treated with erlotinib alone. 
Of interest, PI3K/Akt molecular over-activation in erlotinib resistance is not necessarily 
associated with the over-expression of these genes. screening PCR array found that only 
several gene expressions were different between parent and ER cell lines. Among these, NF-
B and Fos genes were the most highly over-expressed genes in BxPC-ER and PANC-ER 
respectively (sub-sections 3.5.5-3.5.6). Both these genes lie further downstream to 
PI3K/Akt/mTOR, almost to the nuclear levels. Yet, they were associated with up-regulation of 
PI3K/Akt upstream molecular pathway. These findings therefore suggest a negative feedback 
mechanism of downstream genes to PI3K/Akt molecular signalling. 
All in all, in this study of primary and acquired erlotinib resistance, the two are thought to be 
fairly similar. In either setting, PI3K/Akt has a dominant role, and there is an intricate cross-
talk between Ras/RAF/MEK/ERK and PI3K/Akt/mTOR pathways are involved, likely on 
several levels, with inputs from both EGFR and IGF1R. These cross-talk pathways were 
examined further with single and combined blockade therapeutic strategies. 
6.2.2  Single and Combined blockade therapeutic strategies  
6.2.2.1  Single targeted blockade 
Single targeted blockade yielded valuable information about these pathways in pancreatic 
cancer. Whilst erlotinib and AEW are potent EGFR and IGF1R inhibitors respectively, the use 
of these drugs alone resulted in paradoxical activation of the reciprocal pathway in erlotinib-
insensitive PANC-1 (sub-section 3.4.2.3). Likewise, pan-PI3K inhibitor LY-294002 also 
resulted in paradoxical activation of pERK, whereas class I PI3K inhibitor NVP-BYL719 was 
able to appropriately attenuate both pAkt [IC50 4.6M (3.8-5.3)] and pERK signals [IC50 22.8M 
(21.5-24.2)] (table 3.4). Importantly, BYL is a potent PI3K inhibitor with high affinity to P110 
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subunit (IC50 = 5nM), which is 50-fold more specific than other subunits.384 In contrast, LY is 
much less specific and less potent, with an IC50 range of 1-50 M for all PI3K-kinase 
subunits.385 In these experiments, BYL was shown to be 4 times more potent than LY in pAkt 
and pERK inhibition in both erlotinib sensitive and insensitive cell lines (table 3.4). Class I 
PI3K is highly over-expressed in 70% of PDAC, and is known to interact with Ras and p85 
regulatory units to activate Akt.48 My observation of paradoxical activation with erlotinib, AEW 
and LY, but not BYL which has an extremely high affinity to PI3K, suggests a crucial role of 
PI3K in the cross-talk mechanism. It supports the theory of K-Ras driven PI3K/Akt over-
activation via the -subunit as a mechanism of oncogenic shift in these K-Ras mutant cancers 
(Figure 6.2).386,387 
 
Figure 6.2: K-Ras to PI3K  interaction leading to oncogenic shift with single blockade of 
EGFR, IGF1R or PI3K, but not with specific PI3K inhibitors 
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BEZ-235 is an interesting drug with dual properties of PI3K and mTOR, with IC50 of 5nM to 
P110 subunit of PI3K and 6.5nM to RPS6, the effector of mTORC-1 complex. It is also 
important to note that BEZ-235 is only specific to these 2 molecular signals but inactive to 
most other kinases.183 In western blotting, BEZ-235 was shown to abrogate pERK, pAkt and 
pS6 signals as a single agent (Figure 4.13). In the comparison of BYL-719 with BEZ-235, 
BEZ-235 was found to be 88-fold, 7-fold and 260-fold more potent than BYL-719 in inhibiting 
pERK, pAkt and pS6 in BxPC-3, and 39-fold, 41-fold and 118-fold more potent in PANC-1 
(table 4.2). Given that both drugs have similar nanomolar potency to PI3K and only differ in 
the dual activity to mTOR for BEZ-235, the only logical conclusion appears to be that mTOR 
is also involved in cross-talks between pathways as well as negative feedback to upstream 
signalling pathways. Together with the previous results, these findings challenge the “classical 
cascade” transmitting molecular signals from surface receptors (e.g. EGFR, IGF1R) to 
downstream effectors (ERK, Akt, mTOR). Instead, these suggest that each molecule has 
positive and negative feedbacks to both upstream and downstream targets. The analogy is 
that of a complex metro network where commuters can take many different routes across 
different train lines to arrive from A to B. Given this intricate molecular network in pancreatic 
cancer, the hypothesis is that dual targeted therapy blockade will likely be superior to single 
therapy, and the research question hence becomes whether there is significant difference 
between upstream and downstream combined blockades. 
6.2.2.2  Combined blockade versus single blockade 
When comparing dual to single blockade, the effect of two drugs together is assumed to be at 
least as good as the combined effects of each drug alone (additivity effect). To concretely 
prove the hypothesis, multiple assays were undertaken to evaluate two endpoints: synergy 
(section 4.2) and efficacy (section 4.3). The synergy studies were dividd into “cytotoxic 
synergy” cell proliferation assays and “molecular synergy” western blotting analyses, and 
examined these by means of well-grounded statistical models such as contour plots, 
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isobolograms and bliss formula (synergy index). In the cytotoxic synergy studies, EGFR- 
IGF1R co-inhibition was found to be highly synergistic for erlotinib sensitive cell lines such as 
BxPC-3 and CFPAC-1 but antagonistic for erlotinib insensitive cell lines including MiaPACA-
2 and PANC-1. On the other hand, PI3K/mTOR inhibitor was synergistic with either erlotinib 
or MEK inhibitor PD-98059 for all 5 parent cell lines (table 4.1). Of particular interest, erlotinib 
and AEW-541 became less synergistic, and erlotinib and BYL-719 became more synergistic 
in both BxPC-ER and PANC-ER cell lines (figure 4.9). This reinforced the findings of high 
EGFR-PI3K and low EGFR-IGF1R interaction in erlotinib insensitive or resistant cell lines. 
Importantly, western blotting demonstrated BYL and BEZ were capable of effective inhibition 
of both PI3K/Akt/mTOR and EGFR/ERK pathways when combined with erlotinib, with near-
complete abrogation of pAkt, pERK and pS6. The molecular synergy analysis by isobolograms 
revealed that the highest level of synergy was located at the pS6 level for BYL-719* Erlotinib 
and at pAkt and pS6 levels for BEZ-235-based combinations (figure 4.14). To establish 
efficacy of CB, parent cell lines were tested with ERL* AEW and ERL* BYL as representative 
combinations, and demonstrated that CB was indeed far superior to the effect of single agent 
alone, in confluence studies (figure 4.10), clonogenic assays (figure 4.19), cell cycle assays 
(figure 4.23), apoptosis assays (figure 4.27), caspase-3 studies (figure 4.35-36) and 
migration studies (figure 4.37). Taken together, both synergy and efficacy of CB were proven, 
and the results confirmed the important role of pS6 and pAkt in the EGFR- PI3K pathway 
cross-talks. 
6.2.2.3  The best combined blockade combination/s 
To understand more about the mechanism of the EGFR/PI3K pathways cross-talks and to 
select the best CB combinations for in-vivo studies, 4 upstream versus downstream CB 
combinations were systematically studied on 2-3 parent cell lines, using clonogenic assays 
(figure 4.20), cell cycle assays (table 4.4), apoptosis assays (figure 4.29) and migration 
assays (figure 4.40). In these experiments, the overall pattern was that CBs involving PI3K 
or PI3K/mTOR inhibitors were more effective. Downstream CB appeared more effective than 
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upstream CB, and MEK/ PI3K/mTOR inhibition appeared the most potent. The exception to 
this rule was migration assay, where all CB were equally effective (figure 4.40).  
After establishing the superiority of PI3K or PI3K/mTOR-based CB, ERL * BYL-719 and ERL 
* BEZ-235 CB were taken into in-vivo study with patient-derived tumour xenograft. The 
development and validation of the two models (sub-renal, subcutaneous) were described in 
section 5.3.1 and 5.3.3, and the drug doses were taken from the Novartis’s investigator 
brochure based on previous publications. Unfortunately, the study on ERL * BEZ-235 had to 
be discontinued as this combination caused excessive treatment-related deaths in animals. 
ERL * BYL-719, on the other hand, was better tolerated and was superior to control (P=0.005) 
and non-inferior to standard gemcitabine chemotherapy (P=0.542) in the sub-renal study 
(Table 5.3). In subcutaneous xenograft experiments, this combination was also shown to be 
far superior to control or single drugs alone for the 28-day duration of treatment (Figure 5.15). 
Of interest, whilst this CB significantly reduced tumour volumes, it had no effect on tumour 
activity as measured by Ki-67, as opposed to chemotherapy (Table 5.4). This suggests that 
CB is cytotoxic but is not as effective as chemotherapy in halting DNA synthesis and cell 
proliferation. 
The results in totality comprehensively explored the mechanism of EGFR – PI3K pathways 
cross talks and the pre-clinical efficacy of CB drug combination. It demonstrates that 
downstream CBs are more synergistic and effective in pancreatic cancer, although all CB 
involving PI3K appeared effective. In-vivo, ERL + BYL significantly reduced tumour volumes. 
In particular, this TKI may have a different focus of action to standard chemotherapy, with 
more focus on apoptosis/necrosis than proliferation. This study thus provides a strong 
rationale for clinical development of BYL-719 and erlotinib combination for the treatment of 
pancreatic cancer. 
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6.2.3  Candidate biomarkers for combined blockade treatment 
Using targeted therapies in unselected cancer population has limited success. Enriching 
treatment population based on clinical biomarkers (e.g. young, Asian female non-smoker in 
NSCLC) saw the beginning of personalising medicine, whilst the effects of treatment selection 
based on molecular biomarkers (e.g. EGFR mutation in mNSCLC patients treated with EGFR 
inhibitors, or K-Ras wild type status in mCRC patients treated with EGFR antibodies, or B-Raf 
mutation in melanoma patients treated with B-Raf inhibitors) were far reaching.138,144,149,388 A 
comprehensive biomarker study could not be properly conducted in small-scale pre-clinical 
studies, but a search for early signals was attemped anyway in the preparation of launching 
CB strategy to clinical trial phase. 
6.2.3.1  Erlotinib resistance and pEGFR / pAkt as biomarkers to CB  
The first “biomarker” that was discovered was, in fact, erlotinib resistance. In the in-vitro model, 
both ER cell lines were more sensitive to EGFR/ PI3K-based CB than parent cell lines. A 
molecular screening approach using phospho-RTK array identified pS6 and pAkt as the 
differential factors (figure 3.35, 3.36). In other words, the fact that ER cell lines upregulated 
the PI3K/Akt/mTOR pathway made them susceptible to the effect of BYL-based treatment. Of 
note, the pattern of susceptibility correlated closely with the known normal cellular functions 
of the PI3K/Akt/mTOR system (figure 4.22, figure 4.26, figure 4.30). These effects, observed 
in proliferation, cell cycle, apoptosis and clonogenic assays, were greater than those in the 
parent cell lines, significantly so in one of the two ER cell lines studied (PANC-ER) (tables 
4.3, 4.5, 4.6). In contrast to proliferation and survival, migration was dramatically but equally 
affected by all 4 CB, and no differential sensitivity was observed between parent and ER cell 
lines (figure 4.40). Whilst the PI3K/Akt pathway has been linked to migration, this is a complex 
process of cell-matrix-stroma interaction orchestrated by many autocrine factors.331 Possibly 
since migration is driven by many molecular pathways, these PI3K-dependent ER cell lines 
did not display hyper-sensitivity to PI3K inhibitors in migration inhibition.  
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To study this further in-vivo, 2 sub-studies were conducted: developing in-vivo erlotinib 
resistance model, and to explore pEGFR and pAkt as an IHC marker (subsections 5.41 and 
5.42). Unfortunately, as already mentioned, the development of in-vivo resistant model was 
unsuccessful. The IHC study, while preliminary, showed that xenograft with high basal pEGFR 
had high tumour response to erlotinib alone. Tumours with high pAkt tended to have tumour 
response to erlotinib * BYL-719 CB but not to erlotinib alone. Therefore, this suggests that 
subjects treated with erlotinib will probably do well if tumour had high basal pEGFR. 
Conversely, subjects with tumour high in basal pAkt should probably be treated with EGFR/ 
PI3K CB. 
From the mechanistic point of view, these data suggested oncogenic dependence of PI3K in 
PDAC. That is, cancers become dependent on the activity of specific oncogenes and hence 
display higher sensitivity to drugs targeting that particular cancer circuitry.330,389 In this case, 
pancreatic cancer cell lines that are chronically exposed to erlotinib shunt its molecular signals 
down the PI3K/Akt pathway (oncogenic shift), and even relying on it thus making them highly 
susceptible to EGFR /PI3K co-inhibition (oncogenic dependence or addiction). This, therefore, 
challenges the complexity posed by the concept of genomic heterogeneity, in that there 
remains obligatory pathways operating in a predictable pattern in cancer despite extensive 
genetic alterations in cancers, and these pathways as a whole (not single signals) are in turn 
actionable. It therefore supports a strategic use of combined horizontal blockade of multiple 
obligatory pathways for pancreatic cancer. 
6.2.2.3  K-Ras mutation as a biomarker? 
It is possible that mutated K-Ras gene is the marker that precedes these other surrogate 
markers mentioned above. As outlined before, K-Ras functions upstream of PI3K by directly 
binding the catalytic subunit p110 of PI3K 68, and K-Ras mutant tumors have been implicated 
in resistance to EGFR and MEK inhibition via PI3K activaton 53,387. This could not be 
determined in the current study, as sequencing studies had not yet been performed. However, 
364 
 
circumstantial evidence from the experiments seemed to support this hypothesis. CAPAN-2, 
MiaPACa-2 and PANC-1- all of which are K-Ras mutant,228 behaved very differently to BxPC-
3 which is K-Ras wild type. Also, a slightly higher susceptibility of PANC-ER to EGFR-PI3K 
or EGFR-PI3K/mTOR co-inhibition than BxPC-ER was observd. And lastly, as already 
discussed, oncogenic shift occurred in PANC-1 with EGFR, IGF1R and PI3K single blockade, 
but not in specific PI3K blockade (figure 6.2). If indeed K-Ras mutation is the driver mutation 
and predictive marker for CB, this may have significant implications to the treatment over 90% 
of pancreatic cancer patients with K-Ras mutated tumour. 
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6.3  Future directions 
After completing in-vitro and in-vivo study of MAPK and PI3K/Akt/mTOR pathways blockades 
in pancreatic cancer, essentially we have come back a full circle to where I started my project, 
only this time my clinical research proposal is that for erlotinib plus BYL-719 instead of erlotinib 
plus IGF1R inhibitor figitumumab. With the strong pre-clinical evidence, I am proposing a 
phase I and II clinical trial with a built-in translational sub-study. The proposal has already 
been submitted to pharma company (Novartis) on the global level, and has been presented 
and endorsed by Australian Pancreatic Club and Australasian Gastro-Intestinal Trial Group 
(AGITG). Minor changes has been made to the proposal since. Briefly, the original research 
trial protocol and proposal are summarised below: 
6.3.1  Clinical Trial- Aims  
1. To assess safety of dual inhibitors in pancreatic cancer, to establish recommended 
phase II dose (phase I) 
2. To assess an early efficacy signal of erlotinib plus BYL-719 in pancreatic cancer 
(phase II) 
3. To evaluate pAkt, K-Ras mutation and other biomarkers that may predict good 
outcomes for this treatment (translational sub-study) 
4. To evaluate quality of life of patients on single-blockade or dual-blockade or best 
supportive care (quality of life sub-study) 
6.3.2  Clinical Trial- Methods 
6.3.2.1  Phase Ib clinical Trial 
Phase I cohort utilizes a fixed standard dose for erlotinib (100mg daily), and a Beysian 
approach to dose-escalation of BYL-719, with starting dose chosen based on pharmaceutical 
IB recommendations for patients with advanced biliary and pancreatic cancers. Patients will 
be studied in classic n=3 cohorts. Dose escalation will occur if 0 out of 3 patients reach dose-
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limiting toxicity (DLT), stop if more than 2 out of 3 reach DLT and expanded to 6 patients if 1 
out of 3 reach DLT. Erlotinib will be started at 100mg daily, the standard dose in clinical 
practice in pancreatic cancer. BYL-719 will be started at 90mg daily. The n+1 dose-escalation 
is ERL 100mg/d, BYL 180mg/d; n-1, n-2 and N-3 dosing de-escalations are ERL 100mg/d, 
BYL 60mg/d; ERL 75mg/d, BYL 60mg/d; and ERL 75mg/d, BYL 30mg/d respectively). 
Recommended phase II dose (RP2D) is determined as the next lower dose level from DLT 
(Figure 6.3). This model ensures safety while maximises study efficiency. 
 
Figure 6.3: Proposed phase I clinical trial design- Beysian model for dose escalation. 
6.3.2.2  Phase II clinical Trial 
The phase II study randomises patients to second or third-line erlotinib plus BYL-719 or 
placebo in a 2:1 ratio, with a planned cross-over of patients on placebo to combined blockade 
upon progression. Patients will be stratified by known prognostic factors in pancreatic cancer: 
age, ECOG; and lines of therapy. The primary study endpoint is progression-free survival. The 
secondary endpoints are 3 month PFS rate, response rate, overall survival, toxicity and quality 
of life (Figure 6.4). Patient will be followed up every week with routine bloods for 
chemotherapy, every 4 weeks with examination and tumour marker CA19.9; and CT imaging 
every 6 weeks for 12 months. Estimated accrual period is 12-18 months. Other study details 
including study screening, inclusion and exclusion criteria are illustrated in figure 6.5. There 
are a number of features in this study design that are of importance: 
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1) Second or third-line study: gemcitabine-based chemotherapy (gem-abraxane) or 
FOLRINOX remains the standard first-line treatment. On the other hand, no standard second-
line treatments currently exist. 118,119 Patients have a 2:1 chance to be randomised to the active 
treatment, with planned cross-over of patients who progressed on placebo.  
2) Placebo control: Measurement bias is inherent for endpoints of AE and QoL, and may 
also bias investigator-rated PFS and RR. It is therefore important that patients on control arm 
be offered an identical placebo. Since both targeted therapies are oral drugs, it is more feasible 
and ethical to offer oral placebo than if it were IV placebo. 
3) PFS as primary endpoint: a phase II study with its limited sample size will not be powered 
sufficiently to study overall survival (OS). In contrast to OS, progression-free survival (PFS) is 
less affected by cross-over and subsequent treatments. This is why PFS should be the primary 
study endpoint in this study. 
4) Secondary endpoints: Most patients will be expected to progress in the first 3 months. 
Since CT scans will only be performed every 6 weeks unless there is clinical progression, the 
proportion of patients who have not progressed by 3 months serve as a good surrogate marker 
for PFS. Other endpoints are typical for pancreatic cancer trial: response rate (expected to be 
at least 10% in unselected population, similar to gemcitabine), CA19.9 response (>50% 
decrease), overall survival, adverse events and quality of life as measured by the FHSI-18. 
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Figure 6.4: Proposed randomised phase II trial study design 
Figure 6.5: Proposed randomised phase II trial study details  
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6.3.2.2  Translational sub-study 
The translational sub-study aims at confirming the roles of pAkt, pEGFR over-expression and 
exploring K-Ras mutation as predictive markers for dual targeted therapies. Biopsy is 
mandated before enrolment in study, but a practical approach is adopted to ensure feasibility. 
For most patients initially diagnosed with metastatic pancreatic cancer, FNA or endoscopic 
ultrasound (EUS) biopsy of primary or metastases will be available for tissue collection. Both 
FNA and core biopsies are allowed. For practical reasons, the study also allows for previous 
whipple’s surgical specimen if the metastatic disease progresses recently (within last 3 
months), since patients in this situation are assumed to have progressed from pancreatic 
cancer and tissue biopsy is not required.  
Based on the preliminary studies, both pAkt and pEGFR genes and proteins will be studied 
as potential markers. In humans, pEGFR protein over-expression could be studied with IHC, 
and appeared to correlate with EGFR gene amplification with FISH and PCR.390,391 IHC for 
demonstrating pAkt activation and FISH for demonstrating AKT related genes amplification 
appear to be the most robust techniques studied.54,355,361 Conversely, PCR studies of AKT 
related genes in human studies are based on older techniques and may not be 
reproducible.392,393 For K-Ras mutation testing, current standard PCR techniques use probes 
that detect common mutations on codon 12 and 13, but may miss other variant mutations. 
Direct sequencing, on the other hand, is capable for detecting all possible mutations in exons 
2 and 3 but lack sensitivity.394 In order to fully capture the role of K-Ras mutation, both standard 
PCR and direct sequencing will be used. Other biomarkers that have been studied for PI3K 
inhibitors include PIK3CA mutation and PTEN loss, which will also be included here. For core 
biopsies where more tissue are available, patient consent will be requested to archive tissues 
for gene sequencing later on. 
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6.3.2.3  Quality of Life sub-study 
Quality of Life (QoL) is an important endpoint, as survival of patients with metastatic PDAC is 
short (6-10 months) and quality of life with or without treatment is paramount. QoL will be 
assessed every 4 weeks for the duration of the study, and every 8 weeks after second 
progression (PFS2). The 18-item FHSI-18 index is derived from FACT-G and FACT-H sub-
scales and developed by the FACIT group; it has been validated for patients with pancreatic 
and hepato-biliary cancers with high internal validity and reliability.395-397 It is easily 
administered (only 5 minutes for patients), and the item wording is of a 12 year-old reading 
level. It has a standard scoring system, making it well suited for administration in this setting. 
6.3.3  Clinical Trial- statistical considerations 
For the phase I study, between 9-18 patients will be recruited. For the randomized phase II 
study, prior data indicates that the median PFS on the best-supportive care (BSC) in second-
line setting is 1.5 months.398 The proposed treatment should have comparable rate of PFS to 
the “standard” second-line OFF (fluouracil and oxaliplatin) regimen, with the median survival 
times of 3.5 months.118,119,398 To demonstrate a change from median PFS from 1.5 to 3.5 
months in this single arm phase II study, 60 subjects will be needed with an alpha of 0.05 and 
power of 0.8 and allowing for 10% drop out rate. 
6.3.4  Clinical Trial- feasibility 
The phase I study will be undertaken in Royal North Shore Hospital (RNSH), a tertiary cancer 
care hospital. The primary investigator (PI) will be myself and phase I expert medical 
oncologist A/Prof Nick Pavlakis. The aim for phase II is a multi-centred clinical trial with RNSH 
and Gosford Hospital as lead sites. The translational sub-study will be undertaken in the 
Cansur Group, Kolling Institute (headed by Prof Ross Smith). The study proposal has been 
submitted to Novartis and Roche, and funding is requested from the pharmaceutical 
companies as well as NHMRC. 
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6.4  Thesis Conclusion 
 
The MAPK (RAS/ RAF/ MEK/ ERK), and PAM (PI3K/Akt/mTOR) signalling cascades are 
integral pathways with strong input from EGFR and IGF1R, and they together mediate cancer 
cell growth, survival and progression. This research project has demonstrated extensive 
cross-talks through multiple levels, and established the involvement of PI3K/Akt/ mTOR on 
multiple levels in the mechanism of both primary and acquired erlotinib resistance. Further, 
this cross-talk was shown to be disrupted by dual targeting of both pathways, and downstream 
combined blockade was more effective and synergistic than upstream combined blockades. 
In-vivo, erlotinib plus BYL-719 significantly reduced tumour volumes in both subcutaneous 
and sub-renal tumour model. Importantly, pancreatic cancer was shown to develop 
onocogenic dependence to PI3K/Akt pathway, and pEGFR and pAkt in turn may both act as 
surrogate markers predicting efficacy of single and combined blockade strategy. Thus, this 
pre-clinical study shows strong biological rationale to the clinical development of co-inhibition 
of EGFR and PI3K in phase I and II trials, and suggests the evaluation of pAkt, pEGFR over-
expression; and K-Ras mutation as potential biomarkers. It also suggests that MEK and PI3K 
co-inhibition warrants further evaluations. It is anticipated that the results of this project will 
rekindle interests of studying targeted therapies in pancreatic cancer, and assist in developing 
the personalising treatment strategy in this deadly disease. 
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